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Prologue 
Among the countless molecules that form the mystery of life there is one particular 
structure standing out literally and figuratively, one molecule that plays a leading role 
in viral and bacterial infections, cancer, autoimmune diseases and supports longevity 
both of proteins and whole organisms. This highly underestimated molecule might be 
the closest approximation to the alchemistic panacea, a lead structure to develop a 
universal cure for all diseases known to humanity. This molecule is sialic acid.  
Before I came in contact with sialic acids, my former work with real patients in a 
hospital strongly influenced my general interest in chemical biology. This experience 
had drawn the focus of attention towards the development of therapeutic drugs and 
this interest is reflected throughout all chapters of my thesis. Impressed by the 
versatility of sialic acids, I dedicated this thesis to further explore the potential of sialic 
acid derivatives for analytical purposes but also as medication.  
While it is impossible to discover all possible applications of sialic acid derivatives in 
one thesis, the research covers diverse fields including antibacterial therapies, viral 
immunity, cancer-therapeutics and auto-immune diseases. With my research, I hope 
to draw more attention towards sialic acids as possible therapeutics. 
  
Outline of the thesis 
Aim of this research is to apply sialic acid derivatives to target diseases or unravel 
biological processes. The most relevant foundation for this approach are the chemical 
reactions to synthesize those derivatives. Chapter 1 of Part 1 discusses the synthetic 
challenges in detail and compares literature approaches towards modified sialic acid 
mimetics. Examples and applications of these sialic acid mimetics towards Siglec 
binding are discussed in Chapter 2. Following the introduction, Part 2 shows the 
development of a new sialic acid derivative applied to detect a genetic disease in 
Chapter 3. On cell synthesis of further sialic acid mimetics in Chapter 4 aims to discover  
high affinity Siglec ligands to attenuate an inflammatory response as model for e.g. 
immune diseases. Derivatization of other sialic acid positions is explored in Chapter 5. 
The effect on viral infections is described in Chapter 6. Part 3 continues with the 
development of new inhibitors, first in Chapter 7 with improved sialic acid inhibitors 
on human cells thereby potentially enabling cancer-treatment, and then switches to 
bacterial infections in Chapter 8 by developing a potential antibacterial agent. This part 
concludes with the antibiotic development by investigating derivatives of the bacterial 
sugar KDO. Part 4 shortly summarizes the results and gives an outlook on future 
developments.   
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Part 1 
 
Introduction 
 
 
“The Nobel Prize is fine, but the drugs I've developed are rewards in themselves.” 
Gertrude B. Elion (1918-1999), revolutionized the field of medicine and drug 
development by designing drugs based on knowledge of the disease rather than 
trying natural substances. Invented drugs against leukemia, malaria, herpes, gout 
and general infections. 
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1 
Recent Advances in the 
Chemical Modification of 
Sialic Acid 
 
“In the course of the next 25 years, various laboratories attempted to determine the 
structure of the simplest of the sialic acids, N-acetylneuraminic acid. It was so 
difficult to work with, that 11 structures were proposed.” 
Saul Roseman (1921-2011) discovered the structure of sialic acid. 
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Abstract 
Sialic acid is a nine-carbon keto sugar that is universally presented at the cellular 
surface, responsible for a variety of different functions including cell-cell 
communication, immune regulation, fertilization, embryogenesis and brain 
development. To regulate this incredible amount of functions, small modifications at 
the multiple functional groups present on sialic acids are used to steer biological 
events. The precise function of many modifications is however still unknown. This is 
partially caused by the challenge to synthesize specifically modified sialic acids. Here, 
recent advances to chemically modify sialic acid in a site-specific manner are 
presented. 
 
 Heise T; Moons S; Boltje TJ. Recent Advances in the Chemical Modification of 
Sialic Acid. Manuscript in preparation. 
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Introduction  
All living organisms depend on carbohydrates as one of the four major classes of 
biomolecules,1 not only as energy-source but also as structural component of cells and 
macromolecules, for communication and interactions between cells and organisms. 
Glycans are made-up of very diverse combinations of monosaccharides forming 
complex structures that are commonly linked to proteins or lipids. Their high diversity 
and non-template based complexity hampered the study of glycans compared to other 
biomolecules but got more attention in the last years resulting in glycobiology being 
one of the most quickly growing research areas.2 This attention is well deserved given 
the high proportion of glycans compared to other biomolecules found in and on living 
cells. Especially the surface is covered with a thick layer of glycoconjugates forming the 
so-called glycocalyx which is even visible under an electron microscope. On top of the 
glycocalyx, the monosaccharide sialic acid resides as the most prominent residue that 
caps the termini of long glycan chains.2 
 
Every human cell is covered with several million sialic acids per µm2 surface area and 
also secreted glycoconjugates are often found to be sialylated.3 The sialic acid 
abundance in humans emphasizes their importance even more, as their biosynthesis 
is uncommonly energetically expensive by requiring two instead of the usual one-
nucleotide sugars as precursors.4 Sialic acids e.g. increase the life-time of biomolecules 
by capping the underlying monosaccharides such as galactoses.2 Their unique 
positioning on the terminal end of branched O-glycans, N-glycans and gangliosides 
enables sialic acids to be the first molecules encountered in biological interactions.5 
Those interactions range from direct receptor binding for leukocyte guiding or 
membrane transport to complex functions as immune regulation, fertilization, 
embryogenesis, brain development and function, neural cell growth and general 
recognition site for viral, bacterial or even parasitic protozoa pathogens.2, 6 Sialic acids 
are however not restricted to humans.7 Any higher life form like vertebrates and some 
invertebrates, even pathogens like viruses and opportunistic bacteria use sialic acids 
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extensively.8-9 The incredible amount of functions sialic acids fulfill made them 
indispensable during the one directional evolution and led to a co-evolution of sialic 
acids in pathogens.10 Regulation of this tremendous amount of functions requires 
distinguished chemical structures leading to a sialic acid family of more than 60 
different monosaccharides.11 
 
Sialic acids are a family of nine-carbon, negatively charged, acidic keto sugars that form 
the group monosaccharides with the largest and most complex structures yet 
discovered in the human body (Figure 1).12 The complexity arises from its multiple 
functional groups. The most common N-acetylneuraminic acid (Neu5Ac) carries one 
acid-, five hydroxyl- and an acetamide group where the carboxylic acid is termed C-1 
and counting reaches C-9 at the primary alcohol.5 The C-1 carboxylic acids, which are 
in majority ionized and to a small percentage bound in lactones with adjacent hydroxyl 
groups or in lactam form with the C-5 amino-group are the major cause of the negative 
charge of human cell surfaces required for cell-repulsion.13-14 The hydroxyl-groups at 
C-4 to C-9 but also the other functional groups of sialic acid contribute to the 
hydrophilicity and viscosity of sialylated molecules therefore assisting the correct 
conformation.15  All functional groups of sialic acid are frequently modified in nature 
(Figure 1).  
 
 
Figure 1. Abundant members of the sialic acid familiy, most frequent modification shown in bold. 
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Still, the precise biological function for many of these modifications remains unknown 
partially caused by challenging synthetic routes to chemically introduce site-specific 
modifications. This review therefore summarizes the recent advances in the chemical 
modifications of sialic acids in the latter area to guide chemists in the search for 
suitable synthetic routes for modifications per position. 
 
Modifications at C-1 
The negatively charged carboxylate group at the C-1 of sialic acids has been proven to 
be a critical recognition element16 for sialic acid binding proteins such as viral 
neuraminidases or host sialic acid binding immunoglobulin like lectins (Siglecs).17-19 
This ionic interaction is usually established by, under physiological pH, positively 
charged arginine residues of the sialic binding proteins and the C-1 carboxylate of sialic 
acid.19 The critical function of this arginine-carboxylic acid interaction is underlined by 
the human Siglec-12 (also named Siglec-L1 or Siglec-XII) which lost the arginine residue 
in the sialic acid binding pocket during evolution and is therefore no longer able to bind 
sialic acids.20 Several synthetic approaches have been published to replace the C-1 acid 
with other functional groups such as spirolactones, spirohydantoin, by decarboxylation 
and 1,4 or 1,7 lactones (Scheme 1).  
14 
 
Scheme 1. Modifications at C-1 including A) Spirolactone C-sialosides,21 B) Spirohydantoins,22 C) 
Decarboxylation23-24  and D) Lactonization.25-28 
 
The natural α-glycosidic linkages of sialic acid are prone to hydrolysis by 
neuraminidases and acidic conditions which complicates biological analysis.21 C-
sialosides like 5-7 were therefore chemically synthesized and used as a stable 
equivalent.21 Acetylation of sialic acid towards 1 is generally high yielding but may at 
higher temperatures lead to decarboxylation as seen for 11.23 Ester activation by 2, 4, 
6-trichlorobenzoyl chloride and nucleophilic attack produced a variety of esters 2-4.21 
Simple addition of samarium diiodide formed the corresponding spirolactones 5-7. 
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Interestingly, while all anomeric acetyl precursors were β-configured, the anomeric 
configuration of the product was found to be the α-spirolactone. This anomeric 
stereospecificity was also observed if β-anomeric thioglycosides were used, again 
yielding α-C-sialosides and therefore hinting to a common reaction intermediate. The 
configuration of the rest-group was however a racemic mixture of both 
diastereoisomers.21 Hydantoins are an important class of pharmacological molecules 
and can be easily formed from sialic acids.22 The one-pot synthesis of various 
spirohydantoins 10 highlights that care should be taken when using sialic acids in 
carbodiimide chemistry to form an amide bond.22 Carbodiimides reacted to form 
rearranged intermediates 9, which upon treatment with BF3.Et2O formed α-
spirohydantoins 10. The stereoselective formation of α-products was explained by the 
reduced sterical hindrance at the α-face. If asymmetric N-cyclohexyl-N-
arylcarbodiimide were used the aromatic aryl ended up at the top (R1) caused by 
conjugation of the  system in the intermediate.22 While the acid group was reported 
to be essential for recognition, it was recently discovered that sulfonate derivatives like 
13 were able to mimic the natural carboxylic acid and even increased the binding 
affinity.19 Therefore, sialic acid was decarboxylated under microwave radiation to 11, 
sulfonated via glycosylation with thioacetic acid to afford 12 and subsequently oxidized 
to yield 13.23-24 Interestingly, only the axial sulfonate showed good inhibition properties 
while an equatorial analogue was hardly effective, therefore demonstrating a strong 
influence of stereochemistry on neuraminidases.20 Another remarkable C-1 
modification was the reaction of unprotected sialic acid with excess of CbzCl and base. 
Instead of yielding a completely Cbz protected sialic acid, only the C-2 alcohol was 
found to be protected and the 1,7-lactone 14 was formed.25 Lactones were proposed 
to be present in sialoglycans but could not be isolated because of their instability under 
harsh treatment to retrieve sialic acids from biological samples. The lactonization is 
independent from the C-5 acetamide, allowing the same reaction for KDN 16 as well as 
C-5 glycolyl sialic acids 15.26 While initially unstable in protic solvents, this 1,7-lactone 
was shown to be stable after acetylation.26 Exposing the lactone to fluorinated 
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anhydrides did surprisingly not open the lactone but resulted in a C-5 modification.27 
Deprotection to 17 enabled new modifications like the formation of -lactone 18 which 
upon aqueous acidic conditions rearranged to sialic acid (Scheme 1).28 C-1 
modifications have been used as auxiliary during glycosylation reactions to achieve 
higher α-sectivity29 but this approach will be discussed in the next section together 
with other sialylation donors. 
Modification at C-2 
Glycosylation using sialic acids, also called sialylation, commonly links sialic acid after 
CMP activation to either galactose (C-2 or C-3) or another sialic acid (C-8 or C-9). The 
CMP-group attached to the anomeric alcohol acts in the process as leaving group. 
Other chemical modifications of the C-2 with other less common saccharide linkages 
or linking several small molecules to serve as inhibitors of Siglec-binding have been 
synthesized as well.30 One common chemical modification of sialic acid is the 
preparation of sialic acid donors, for sialylation reactions. The synthesis of α-sialosides 
is one of the most challenging reactions in carbohydrate chemistry, as it is both a 
thermodynamically and kinetically disfavored process.31 Natural sialosides are 
exclusively linked via an equatorial (α-anomer) linkage to the underlying glycan while 
the CMP of the sialic acid donor is only found to be in axial (β-anomer) position.32 
Multiple strategies to achieve α-selective sialylation and avoid elimination of the H-3 
which leads to a glycal byproduct have been developed.29, 33 In depth analysis of 
sialylation methods may be found elsewhere,34 here a brief overview of very recent 
advances in sialylation donors reflecting the different strategies is given in Table 1. 
Sialylation requires low temperatures to assure α-selectivity. Leaving groups of 
sialylation donors are therefore generally very reactive even at low temperature like 
electron-rich thiols activated with soft electrophiles or imidates which activate under 
acidic conditions. Sialyl imidates were prepared from the free C-2 alcohol via chloro-
imidates to yield 19.35-37 By the use of a nitrile-containing solvent such as acetonitrile, 
formation of the intermediate -nitrilium ion followed by SN2-like displacement lead 
to the preferred α-anomer.32, 38 Also decreasing the reaction time and addition of N-
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methyldiacetamine, capable of modifying the structure of supramolecular aggregates 
of the glycosyl donor was used to increase selectivity.39 A modern strategy shown to 
achieve good to excellent α-selectivity and avoided glycal formation was the use of 
fused oxazolidinone systems like 5-N,4-O-carbonyl 2034, 40-46 or 5-N,7-O-carbonyl-
donors 21.47-48 Yet it did require a substantial amount of additional protection and 
deprotection steps. Instead of using dipoles, coordination or ring-strain, it was also 
possible to covalently block the axial position. The sialylation donor 22 provided one 
of the rare examples of a covalent 5-N-1-C lactam intermediate to yield α-sialosides.49-
50 While the 5-ureido donor did provide decent α-selectivity without covalent 
assistance, the donor was not primarily developed to increase the α-selectivity but to 
enable easier purification of the desired product. Both stereoisomers were formed but 
caused by the stereochemistry of the C-5 nitrogen, the lactam could only be formed on 
the top side of sialic acid. This created a large difference in polarity between both 
anomers and enabled selective isolation of the lactam. After reopening of the lactam 
under basic conditions, pure α-sialosides were obtained.49-50 Due to the natural H-3 
hydrogen, auxiliaries at the C-3 positions require a substantial amount of donor-
preparation. Nevertheless, phenylselenyl and phenylthiol auxiliaries 23 were 
successfully applied for α-selective synthesis.51-52 The thiophenyl substituent was 
anticipated to avoid elimination reactions by decreasing the acidity of the axial H-3. 
After activation of the anomeric leaving group, a sulfonium ion was formed thereby 
blocking the β-side. Only α-product had been reported and the auxiliary could be 
selectively removed with Ph3SnH, AIBN.51 The C-4 aminated sialylation donor 24 was 
readily available due to the unexpected behavior of morpholines towards 
peracetylated sialic acid (this reaction is discussed in more detail in the C-4 
modification section below).  It was reasoned that the non-nucleophilic cyclic amine at 
C-4 would trap the anion after activation therefore increase in bulkiness. The sterically 
demanding activation reagent Ph2SO preferred axial (β) orientation at C-2 to avoid 
sterical hindrance. In addition, the double ion pair of positively charged amine and 
positively charged sialyl-oxysulfonium both with triflic acid counter ion, repelled each 
other and avoided proximity by adopting the axial configuration. The irreversible attack 
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by the acceptor would (assuming a pseudo SN2 mechanism) therefore come from the 
α-side.53 While being indeed highly α-selective, the C-4 auxiliary was not removable 
thereby prohibiting the synthesis of natural sialosides. In contrast, C-1 auxiliary 25 was 
readily available and easily deprotected after glycosylation by using base.54-55 The 
dimethylglycolyl amide stabilized the oxocarbenium ion after expulsion of the leaving-
group through participation of the oxygen of the amide. While the sialylation donor 
was an anomeric mixture, it was reasoned that the charged amine would rather prefer 
the axial anomeric position to benefit from the anomeric effect, thereby blocking the 
beta-side from attack by the incoming acceptor. Additionally, the intermediate was 
expected to be more reactive towards acceptor attack during axial amide participation 
as the equatorial attack would have been sterically favored.55 While in theory providing 
an easily accessible and elegant route, the stereochemical outcome was disappointing 
with modest α-selectivy.54-55 Even without participating auxiliaries, phosphite56-59 and 
isocyanate60 protected sialic acid donors have shown good to excellent 
stereoselectivity with an intermediate amount of synthetic steps towards donor 
preparation. Combinations of strategies such as phosphite donors with additional 5-
N,4-O-oxazolidinone 26 provide excellent stereoselectivity.57 Isocyanate donor 27 
provided the advantage of simple derivatization of the C-5 position after glycosylation. 
A concept that has been applied for sialic acid donors with other protecting groups 
such as N,N-diacetyl, N-TFA,61 N-Boc,62 N-Troc,50, 63-64 N-Fmoc,63-64 N-trichloroacetyl,64  
N-phthalimide65 or azide;66-69 that all showed good α-selectivity. The strategies 
discussed so far focused on the synthesis of natural α-linked sialosides. However, there 
have been donors reported to provide good β-selectivity, if an unnatural sialoside is 
desired. An efficient example was the di-bromine donor 28, readily available after 
bromination of sialic acid glycal (see same section below).70 Activation of the anomeric 
bromine leads to the asymmetrical bromonium intermediate, which blocks the α-side. 
After β-selective sialylation, the bromine auxiliary is removed again by tributyltin 
hydride.70 (Table 1) 
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Table 1. Sialic acid donors and sialylation strategy. X= activatable group 
 
Donor structure Intermediate Sialylation strategy Ref. 
  
Activation: Acid. Solvent participation 
e.g. ACN (additionally low temperature). 
35-37 
  
5-N,4-O- oxazolidinone thioglycoside  
Activation: NIS, acid or Ph2SO, Tf2O, TTBP 
or  light, cat. Ru(bpy)3(PF6)2 and Cu(OTf)2, 
oxocarbenium intermediate. 
34, 
40-46 
  
5-N,7-O- oxazolidinone thioglycoside 
Activation: NIS and acid,  standard  
oxocarbenium  intermediate. 
 
47-48 
 
 
Activation: NIS and BrAgOTf,  subsequent 
5-1. Lactam formation: DABCO, DBU, 
heat., Lactam reopening: Boc protection 
and basic conditions. 
49-50 
 
 
Activation:  AgO3SCF3, MeSBr. C-3 
episulfonium  auxiliary blocks  β-side. 
Removal: Ph3SnH, AIBN.  
51-52 
 
 
Activation:  Ph2SO, Tf2O, C-4 aminated 
sialyl-hemiketal donors,   anion sterical 
hindrance forces the activated alcohol in 
axial position.  
53 
  
Participation of C-1 amide to stabilize 
oxocarbenium formation and block β-
side. Activation with Ar2SO, Tf2O. 
54-55 
 
 
Phosphites. Activation by TMSOTf, 
standard  oxocarbenium  intermediate. 
56-59 
 
 
Isocyanate. Activation by NIS, TfOH,  
standard  oxocarbenium  intermediate. 
60 
  
For β-sialosides! Activation: AgOTf, 
Na2HPO4. Auxillary via bromonium ion 
bridge. Deprotection:  Bu3SnH. 
70 
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Many of the glycosylation reactions mentioned above (Table 1) use thiosialosides 
because of their stability during the required protection and deprotection steps until 
selective activation during glycosylation.71 Sialyl thioglycosides were prepared in good 
yield via glycosylation of the peracetylated sialic acid, which usually leads to an 
anomeric mixture.72-74 Alternatively, the anomeric center was halogenated resulting in 
α-halides like 29 that were subsequently replaced to form β-thioglycosides like 3075 
(Scheme 2). 
Scheme 2. Modifications at C-2 including A) leaving groups and thioglycosides,75 B) eliminations,76 C) 
C-sialosides,77-78 D) unsaturated C-sialosides by samarium,79 E) unsaturated C-sialosides by 
palladium.80-81 
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While thioglycosides are well established glycosylation donors, disulfides like 33 were 
less explored and expected to show beneficial properties during glycosylation. They 
were additionally used as biological mimetics and could be easily synthesized by DEAD 
assisted coupling.75 Besides being a key intermediate in several synthetic approaches 
towards C-2, -3 or -4 modifications, the sialic acid glycal (also called DANA) can act as 
a transition state analogue to inhibit sialidases. This enabled inhibition of the sialic acid 
cleaving sialidases used by several viral or bacterial pathogens.82 Elemination of the 
axial H-3 hydrogen towards the sialic acid glycal 35 could be achieved via halogenated 
intermediate 29 or directly from a peracetylated precursor by treatment with acid.76 
Acidic acetyl elimination does however contain a risk of double elimination towards 
the C-4 oxazoline discussed in a later section. Glycosylation bonds were found to be 
relatively unstable under acidic conditions and hydrolyzable by enzymes as sialidases 
mentioned before.83 There is an increasing interest in chemically synthesized C-
sialosides as stable alternative to the natural glycosylation bond for biological settings. 
Several ways have been published to establish the C-C bond: Thioaryl introduction to 
36 and 37 provided a versatile tool for samarium diiodide catalyzed α-C-C bond 
formation in 38.77-78 Even anomeric acetyls could be used for this conversion forming 
38 from peracetylated sialic acid.84 The same method was applied for sialic acid glycals 
leading to unsaturated C-sialosides 39.79 Instead of samarium, palladium ligands were 
used to form similar unsaturated C-sialosides 40.80-81 Interestingly, the regioselectivity 
of the allylic substitution depended on the catalyst used and could be steered to either 
the C-2 or C-4 position depending on the ligand and will therefore be mentioned again 
in the C-4 section.   
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Modifications at C-3 
Derivatives of the sialic acid glycal 34 are an attractive synthetic intermediate towards 
several products and also act as transition state analogues of the sialyl oxocarbenium 
ion, which is formed during neuraminidase-catalyzed cleavage of sialic acid from 
sialosides.85 Viral neuraminidases are required for the release of viral progeny from 
infected cells, therefore sialic acid derived glycals are frequently used as treatment 
against viral infections. 
  
Scheme 3. Modifications at C-3 including A) C-alkylation of sialosides,85 B) C-alkylation of sialic acid 
glycals,85 C) O-alkylation,81,86-88 D) fluorination.89-90 
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The recent discovery of an empty cavity in the pocket of influenza-type viruses near 
the C-3 position of sialic acids led to the investigation of C-3 modified sialic acids and 
sialic acid glycals with the goal of improving the currently available influenza drugs. 
Derivatives of glycal 34 are the most established way to introduce electrophiles at the 
C-3 position. Bromohydroxylation of 34 via treatment with NBS/H2O gave a mixture of 
trans-2,3-diequatorial and trans-2,3-diaxial bromohydrins 41.85 After treatment with 
allyltributylstannane using AIBN as radical initiator, the equatorial C-3 allyl derivative 
42 was obtained, which was further modified using a Grubbs’ catalyst to afford 44.85 
Treatment of bromohydrin 41 with DBU led to the formation of 2,3--epoxide 45, 
which was reacted with different alcohols in the presence of a catalytic amount of 
camphorsulfonic acid to obtain C-3 hydroxyl Neu5Ac 46.91 Alkylation of the C-3 alcohol 
followed by elimination of the anomeric hydroxyl via acetylation and halogenation led 
to several viral neuraminidase inhibitors (48) with stronger binding affinity and 
therefore potency.87-88 In addition to neuraminidases, C-3 modified sialosides have also 
been explored to increase the affinity of sialic acid or sialosides towards Siglec 
receptors.92  
Electron deficient C-3 fluorinated sialic acids such as 49 are important 
precursors for sialyltransferase inhibitors.93 Inhibition is caused by the enzymatic 
conversion of 49 into fluorinated CMP-sialic acid which acts as a competitive inhibitor 
of sialyltranferases.94 Stereoselective electrophilic fluorination of 34 was achieved by 
the use SelectfluorTM as the fluorination agent to afford mainly axial substituted 
product (3-Fax/3-Feq = 3:1).89-90 
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Modifications at C-4 
Variations at C-4 have been extensively studied, mainly because of the tolerance of 
influenza sialidases towards C-4 modifications. This is reflected by the structure of the 
commercially successful inhibitors Tamiflu (C-4 amine)95 or Relenza (C-4 guanidinyl 
group)96. Both substituents are positively charged under physiological conditions 
therefore enabling an ionic interaction with a neighboring glutamate residue to 
increase binding affinity.97 Whereas other modifications at C-5 were usually obtained 
by enzymatic synthesis, modifications at C-4 required chemical synthesis from sialic 
acid directly. This is due to the nature of enzymatic conversion from mannosamine 
analogs to sialic acid analogs where the C-4 alcohol is formed from the previous C-1 
anomeric aldehyde of mannosamine and can therefore not easily be replaced by other 
groups, as this would prevent the enzymatic aldol-condensation.98-99 
25 
 
 
Scheme 4. Modifications at C-4 including A) substitution via oxazoline,100-102 B) substitution with 
instable  oxazoline,103 C) oxidation,104-105 D) epoxidation,106 E) cyclic amines,107-108 F) O-alkylation,109-110 
G) palladium catalyzed substitution.80-81 
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A commonly reported synthetic route towards C-4 influenza inhibitors is the oxazoline 
mentioned in the previous section. Treatment of peracetylated sialic acid under acidic 
conditions either formed the glycal or under harsher conditions led to a second 
elimination towards the 4,5-oxazoline 50.79 Ring opening was performed with TMSN3 
or LiN3 towards 4-azido-glycal 51.100-101  The 4-azido glycal moiety was reacted with N-
bromosuccinimide or SelectfluorTM in H2O to obtain the 3-bromo111 or 3-fluoro89 
derivatives. The azide was transformed to the 4-isocyano glycal 52.102 45 underwent a 
four-component condensation, and the inhibitory activities against hPIV-1 sialidase of 
the products were studied.102 The N-acetyl attack on the carbocation led to the 
oxazoline and blocked the axial face of the glycal therefore leading to equatorial 
substitution. This could be prevented by either the use of non-participating groups on 
the C-5 nitrogen or using hydrolyzable groups like TFA for compound 54.103 Protonation 
and subsequent conjugated elimination of the C-4 O-acetyl led to an unstable 
fluorinated oxazoline intermediate. The intermediate was used to either introduce an 
axial hydroxyl by hydrolysis or to trap participation solvents like acetonitrile to form 
the acetamide 55.103 Another route towards C-4 modification was the selective 
oxidation of protected sialic acid112 towards C-4 ketone 56.104 Reduction led again to 
the axial hydroxide and was used via nucleophilic displacement to introduce an 
equatorial C-4 azide 59104 without previous oxazoline formation. The azide proved to 
be a versatile intermediate towards other C-4 analogues, either by using click 
chemistry113 or reduction to the corresponding amine to be reacted with acyl or 
sulfonylchlorides.114-115 Instead of ketone reduction, the ketone was also used directly 
for Wittig reactions towards 60105 and served as intermediate towards epoxide 61 that 
allowed multiple nucleophilic substitutions 62, these and other ketone based C-4 
modifications may be found elsewhere.106 On the same route towards C-4 modified 
antiviral drugs, an uncommon reaction was observed by treatment of peracetylated 
sialic acids with morpholine-like secondary amines 63.101 Apparently, the amines 
selectively attached to the C-4 position in an equatorial orientation thereby 
deprotecting the anomeric acetyl.107-108 The amine-coupling was however not 
reversible to the parent sialic acids and even stable under elimination conditions 
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towards C-4 modified glycals 64.116 The products were nevertheless effectively used as 
inhibitors against viral neuraminidases.117 
From a chemical point of view, all alcohols in sialic acid are quite different regarding 
their accessibility and nucleophilicity. The C-4 hydroxyl group is surprisingly selective 
over the C-7 alcohol under various conditions towards electrophiles. O-alkylation 
derivatives like 66 were explored against hPIV1 sialidase and the alkylation was shown 
to be very selective for the C-4 alcohol,110 even using strong conditions as 15-crown-5-
ether/NaH in DMF.109-110, 118-121 
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Modifications at C-5 
The C-5 position in sialic acid, normally substituted by an acetamide group, is an 
important position for modifications.  The biosynthetic machinery was shown to be 
promiscuous with regard to C-5 modifications and allowed the incorporation of alkyne 
or azide moieties that were used as tools for labeling and studying glycans.122 While 
not strictly controlled during incorporation, the type of the group attached at C-5 was 
demonstrated to be of highest importance during biological events as protein 
recognition.123 Substituting the acetamide group for any other group did completely 
change the biological behavior. The rarely found ketodeoxynonulosonic acid (KDN) e.g. 
is a sialic acid with C-5 hydroxyl group that shows very different binding properties.124 
Many animal species use N-glycolyl (Gc) sialic acids whereas humans lost the 
converting enzyme during evolution and only generate glycolyl sialic acid in particular 
cancers.125 The high biological impact of C-5 modifications have been demonstrated by 
adding various modifications to increase Siglec binding. Either by direct ligand coupling 
or using copper (I)-catalyzed azide–alkyne cycloaddition (CuAAC) for a diverse 
approach.126-130  
  
Scheme 5. Modifications at C-5 including A) coupling to amine,131-133 B) equatorial substituents,105, 134 
C) axial substituents.135 
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As many sialic acid functions depend on protein binding to the C-5 acetamide, there is 
a great interest in synthetic routes to easily modify and therefore enhance study or 
inhibit this binding. Modification of the C-5 position is still reported to be laborious 
because no procedure has been discovered yet for direct deacetylation of the 
acetamide. This is not only caused by a general stability of acetamide bonds but 
aggravated by the instability of unprotected sialic acids in either base or strong acid.136 
Either methyl glycosides, a glycosidic bond to another sugar or thio-compounds were 
used to prevent ring opening under basic conditions, which enabled treatment with 
base.131-132 The C-5 has also been used to link multiple sialic acids together via radical 
polymerization of C-5 acryl linkers, based on an N-acyl linkage to reflect the natural N-
acetamide, and showed hemagglutinin or neuraminidase inhibitory activities.137-138 A 
naturally occurring modification of C-5 is the replacement of the acetamide by a 
hydroxyl to form KDN. A straightforward synthesis of KDN 69 has been reported based 
on nitrosylation of the acetamide which enabled various nucleophiles to replace the 
acetamide by a fluor-, acetate- or thioacetate-group.105, 134 All previously shown 
modifications were equatorial therefore resembling the natural acetamide 
configuration. However, pseudaminic acids, bacterial members of the sialic acid family 
have an axial C-5 acetamide. The synthesis of axial substituents was performed by 
introduction of levulinoyl alcohol 68, subsequent deprotection to the hydroxyl and 
triflation to 70.135 Treatment of the triflated intermediate 70 with lithium azide was 
shown to result in axial C-5 azide 71 therefore providing a possible route to other axial 
C-5 substituents in the near future.135  
30 
 
Modifications at C-7 
Non-permanent modifications at C-7 like acetylation occur frequently and can have a 
major biological impact as demonstrated by blocking viral recognition.139 While not 
expressed in humans, legionaminic acid and pseudaminic acid are C-7 amino-acetyl 
modified sialic acids that are commonly found in bacteria. Even though interesting 
targets for antibiotics and immune adjuvants, their role in host-interactions is largely 
unknown because of their difficult and low yielding synthesis.140 Still, little is known 
about the biological impact of modifications of the C-7 hydroxyl-group. Being the least 
reactive hydroxyl-group, selective chemical reactions at the C-7 require laborious 
protection of all other alcohols. As the amount of published C-7 modifications in 
literature is rather limited, this section will also discuss synthetic routes towards the 
free C-7 alcohol. 
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Scheme 7. Modifications at C-7 including A) selective TMS deprotection,141 B) epimerization,142 C) 
azidation.143-145 
 
An example of rapid protection of all other alcohols was the partial O-acetylation via 
regioselective silyl exchange technology.141 This approach did require the carboxylic 
acid to be protected and subsequently silylated all alcohols to 72. Next, using different 
reaction times, temperature, microwave power and equivalents of acetic acid, 
different partially acetylated sialic acids were obtained. The approach was most 
beneficial for the synthesis of C-7 alcohol 73 that could be obtained in 43% yield.141 
Even though not used for further C-7 alterations, this approach can easily free the C-7 
alcohol for subsequent modifications. The synthesis towards legionamic acid required 
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epimerization of the C-7 alcohol. The oxidation towards 74142 showed the most 
commonly used protecting groups towards the sialic acid with free C-7 alcohol. 
Alternatively DMP oxidation was used as seen for 76.145 Ketones like 74 were shown to 
be valuable intermediates in many synthetic routes as  discussed in the previous C-4 
section. C-7 modifications remain difficult as demonstrated by the recent example of 
5,7-diacetylpseudaminic acid synthesis.144 Earlier attempts to synthesize pseudaminic 
acids either consisted of chemical synthesis involving multi-step processes or poor 
yielding aldol condensations.146-148 By using many of the synthetic examples listed in 
the earlier sections, 5,7-diacetylpseudaminic acid was synthesized efficiently, starting 
from Neu5Ac in 17 steps.143-144 An additional challenge in the synthesis of pseudaminic 
acid was the inversion of the C-5 acetamide. This key step required the earlier 
mentioned conversion to KDN with subsequent triflation of the C-5 and C-7 alcohols to 
77 and SN2 replacement by azides to 78. In a similar fashion, 76 was triflated and an 
azide was introduced to give 80145. Some key steps of the 76 synthesis are discussed in 
the C-9 section. 
 
  
33 
 
Modifications at C-8 
The C-8 position is the most common sialylation side of sialic acid forming polysialic 
acid via α-(2,8) linkages. Polysialic acid is abundantly present in the embryonic brain 
but hardly found in adult brains besides in the specific regions with growth ability, the 
hippocampus and olfactory bulb.149 They are found in glycoproteins of embryonic 
neutral membranes where they play a role as neutral cell adhesion molecules.32 
Modifications of C-8 which could block the α-(2,8) sialylation are synthetically possible 
but the synthesis of natural polysialic acid with typically 50-150 monosaccharides and 
sometimes even exceeding 370 monomers is beyond our chemical capabilities. 
Disialosides have already been synthesized in moderate yields and good selectivity41, 
61, 150-151 and even oligo-α-(2,8)-sialic acid synthesis was possible.41 Besides, for the 
synthesis of oligo sialic acids, the C-8 position is also used for various modifications like 
acetylation or sulfation and non-human pseudaminic acids from the previous section 
has a modified C-8 obtained via an inversion reaction.  
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Scheme 8. Modifications at C-8 including A) epimerization144, B) C-8 elimination,141-143 C) substitution 
with OMe141-143 and F152 D) direct oxidation.153 
 
Pseudaminic acid synthesis required an inversion of the C-8 alcohol. Similar to the 
inversion seen in the C-7 section, the C-8 alcohol conversion proceeded via oxidation 
and borane reduction to 81.144 To investigate the effect towards sialyltransferases and 
polysialyltransferases, several C-8 modifications have been synthesized.152 Instead of 
trusting the regioselectivity of C-8 over C-7 alcohol, a benzylidene protection was used 
to protect C-9 and C-7.152, 154 A subsequent benzyl protection of the reactive C-4 solely 
freed the C-8 alcohol 82.152 This intermediate was used for the synthesis of 8-deoxy 
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sialic acid 84 and 8-O-methyl sialic acid 86.152, 155-157 Selective benzylidene opening and 
epoxide formation provided epoxide 88, which was subsequently fluorinated to yield 
compound 89. The scope of nucleophile introduction via this route was however 
regarded as limited.152  
Very recently, a remarkable selective oxidation of the C-8 hydroxyl group has been 
reported using benzoquinone and a palladium catalyst. Sialic acid methyl ester was 
directly converted to C-8 ketone 100 in one step. Why this reaction appears to be side 
specific remains unclear.153  
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Modifications at C-9 
The C-9 position is often found to be modified in nature with direct influence on signal 
transduction. Acetylation, one of the most common modifications, was shown to 
modify the binding to several sialic acid specific lectins and impairs the binding of 
influenza A and B but creates a binding site for influenza C and different nidoviruses.158-
159 Being the chemically most accessible alcohol, multiple modifications have been 
explored. The C-9 position was the first to be investigated for its contribution in Siglec 
binding and increased Siglec binding has been reported with several modifications.129 
Earlier work has shown that the C-9 hydroxyl group was necessary for binding to CD22 
but replacing the hydroxyl with nitrogen was tolerated as well and enabled several 
Siglec-ligands via amide formation.92, 160-162 The C-9 hydroxyl group has also been 
replaced by an aldehyde163 or carboxylic acid.164  
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Scheme 9. Modifications at C-8 including A) oxidation to aldehyde,164-165 B) oxidation to acid,164 C) 
amine derivatives,92, 114, 127, 162, 166-169 D) elimination.144, 170 
 
Several sialic acids with hydrophobic modification at C-9 were used as probes for 
myelin-associated glycoprotein and as probe for sialyltransferases. An easy accessible 
route towards these modifications was based on C-9 oxidation. Selective silyl 
protection of the primary C-9 hydroxyl group followed by acetylation and silyl ether 
deprotection gave 91. The protection ensured single C-9 oxidation via Swern conditions 
to give aldehyde 92.164 The C-9 aldehyde enabled Wittig reactions shown for 
compound 94165 synthesized vial silyl protected intermediate 93. Alternatively, an 
oxidation step using TEMPO gave the carboxylic acid 95.164 The C-9 azido moiety 96 
was synthesized by selective tosylation and subsequent azidation.171 Azide 96 has been 
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a key intermediate in several C-9 modifications. It has been tested for sialidase 
inhibition172 or after reduction has been coupled to several ligands by amide 9792, 114, 
127, 166-169 or oxamide bonds.162 Iodination of the C-9 alcohol to 98 or 100 has been 
performed in the synthesis towards legionaminic or pseudaminic acid respectively. The 
C-9 iodine was subsequently eliminated via radical reaction 99170 or hydrogenation 
101.144  
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Concluding remarks and future prospects 
While all positions of sialic acids have been chemically modified, most still require 
many steps of laborious work. Generally, any chemical modification is bound to the 
different reactivity of the sialic acid alcohols (9 > 4 > 8 > 2 > 7). (Figure 2)141, 154 The C-1 
acid is easily modified by either activating the acid and subsequent nucleophilic attack 
or making use of the nucleophilicity of the carboxylic acid directly. The anomeric center 
C-2 is usually accessed by oxocarbenium formation and nucleophilic attack, which 
requires the previous conversion of the alcohol in a better leaving group like 
acetylation for good nucleophiles or e.g. thiols and imidates for weaker nucleophiles. 
Most C-3 modifications require the glycal first. The C-2 alcohol has to leave for this 
which requires a C-2 modification first. The glycal is reactive towards preferentially soft 
electrophiles while introduction of nucleophiles is more limited and requires 
introduction of a leaving group first. Introduction of a bromide enables radical coupling 
reactions at this position. Until now, no one-step procedure has been reported from 
unprotected sialic acid towards the glycal. It would be beneficial to use a direct 
elimination of the C-2 alcohol under acidic conditions to form the glycal without 
previous anomeric modifications. To our knowledge, however, no such route has been 
published yet. The C-4 alcohol comes second in reactivity after the primary alcohol. 
Electrophilic addition is therefore possible after C-9 protection. Nucleophilic 
introduction can be done either by selective oxidation or via the oxazoline 
intermediate by acidic ring opening. The C-5 amine is of course far more reactive than 
any other position towards electrophiles, but unfortunately protected by a stable 
acetyl group. Acid or basic hydrolysis can cleave the acetyl group but requires an stable 
protecting group at the anomeric center. This complicates C-5 modifications and there 
is still a lack of synthetic methods to directly deacetylate the acetamide without the 
need of additional protecting groups. The C-7 alcohol is the least reactive one but also 
not unreactive enough to protect all other alcohols in a single step while leaving it free. 
This forces the chemists to follow a laborious route of protecting all other alcohols 
before modifying a free, but still not very reactive hydroxyl. No author so far has used 
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the interesting 1,7-lactone as a protecting group for C-7 modifications. Investigation 
might be useful because it is the only procedure known to selectively protect the C-7 
alcohol in a single step from completely unprotected sialic acid. The 1,7-lactone was 
reported to be stable after acylation. To open the lactone again and to free C-7 might 
be possible with other protecting groups which are orthogonally deprotected 
compared to the lactone. Acetyls are not suitable in this case as their disarming effect 
stabilizes the lactone which requires similar deprotection conditions as the acetyls. If 
other groups would be investigated, a much shorter route towards C-7 modifications 
might be discovered. Nearly the same is true for the silyl-exchange pathway that left a 
labile TMS-protection at the C-7 and could afford the free C-7 alcohol in acceptable 
yield and effort. In a similar way, C-8 is still hard to modify because of its low reactivity 
that again requires complete protection of nearly all other alcohols. This however 
might be circumvented by the recent discovery of selective C-8 oxidation. This 
selectivity comes as a surprise and has so far not been used for further modifications 
but might provide a useful handle for the introduction of C-8 nucleophiles. The C-9 as 
a primary alcohol can be easily protected or modified making use of its nucleophilicity. 
At least in theory, because the careful reader might become suspicious because of the 
amount of different methods published to modify the C-9 position. Even though it is 
possible to modify C-9 without any further protecting groups, the majority of 
publications use not only C-1 but also C-2 protected sialic acids to avoid side reactions 
caused by the sialic acid open-conformation.  
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Figure 2. Strategy of side-specific sialic acid modifications 
After all, sialic acids are not only one of the most important building blocks of life, 
starting material for uncountable bio-active molecules and pharmacore for multiple 
drugs, but also mysterious and highly versatile molecules that tend to surprise not only 
biologists but also synthetic chemists by its behavior. We as a chemical society have 
come far in taming this molecule but still lack the synthetic skills to rebuild nature. I 
sincerely hope that this review will help other synthetic chemists to broaden our 
knowledge of sialic acid modifications and develop new applications to discover the 
mystery of sialic acids. 
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Commonly used abbreviations 
 
Ac  Acetyl 
Ac2O  Acetic anhydride  
ACN   Acetonitrile 
AIBN  Azobisisobutyronitrile 
BF3•Et2O  Boron trifluoride etherate 
Boc  Tert-butyloxycarbonyl 
bpy  Bipyridyl 
Bz  Benzoyl 
CAN  Cerum ammonium nitrate 
Cbz  Carboxybenzyl 
Cp  Cyclopentadienyl 
CSA  Camphorsulfonic acid 
DABCO 1,4-Diazabicyclo[2.2.2]octane 
DANA  Acetyl-2,3-dehydro-2-
deoxyneuraminic acid 
DBU  1,8-Diazabicyclo(5.4.0)undec-
7-ene 
DCM   Dichloromethane 
DDQ  2,3-Dichloro-5,6-dicyano-1,4-
benzochinone 
DEAD  Diethyl azodicarboxylate 
DiPEA  Diisopropylethylamine 
DMAP  Dimethylaminopyridine 
DMF  N,N-Dimethylformamide 
DMP  Dess-Martin periodinane 
EtOAc  Ethyl acetate 
Gc  Glycolyl 
HDMS  Bis(trimethylsilyl)amine 
iPr  Isopropyl 
KDN  2-Keto-3-deoxy-D-glycero-D-
galactonononic acid 
MCPBA  Meta-chloroperoxybenzoic 
acid 
MeOH   Methanol 
NBS  N-Bromosuccinimide 
NIS  N-Iodosuccinimide 
PDC  Pyridinium dichromate 
Ph  Phenyl 
PMB  4-Methoxybenzyl ether 
Pyr  Pyridine 
r.t.  Room temperature 
TBAB  Tetrabutylammoniumbromide  
TBAF  Tetrabutylammoniumfluoride 
TBS  tert-Butyldimethylsilyl 
tBu  tert-butyl 
TCBC  2,4,6-Trichlorobenzoic acid 
TEA  Triethylamine 
TEMPO  2,2,6,6-
Tetramethylpiperidinyloxyl 
Tf  Triflate 
TFA  Trifluoroacetic acid 
TFAA   Trifluoroacetic acid anhydride 
THF  Tetrahydrofuran 
TMS  Trimethylsilyl 
TMSOTf Trimethylsilyl 
trifluoromethanesulfonate 
Tol  Toluene 
TsCl  Toluenesulfonyl chloride 
TTBP  2,4,6-Tri-tert-butylpyrimidine 
TTMS  Tris(trimethylsilyl)silane 
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2 
Sialic Acid Mimetics to 
Target the Sialic Acid-Siglec 
Axis 
 
“Their specific effect on the saccharide might thus be explained by […] lock and key 
in order to be able to exercise a chemical action on each other. This concept has 
undoubtedly gained in probability and value for stereochemical research, after the 
phenomenon itself was transferred from the biological to the purely chemical field.” 
Emil Fischer (1852-1919), established carbohydrate chemistry.   
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Abstract 
Sialic acid sugars are vital regulators of the immune system through binding to 
immunosuppressive sialic acid-binding immunoglobulin-like lectin (Siglec) receptors 
on immune cells. Aberrant sialic acid–Siglec interactions are associated with an 
increasing number of pathologies including infection, autoimmunity, and cancer. 
Therefore, the sialic acid–Siglec axis is an emerging drug target in these diseases. 
Chemical modifications of the natural sialic acid ligands have led to sialic acid 
mimetics (SAMs) with improved binding affinity and selectivity towards Siglecs. 
Recent progress in glycobiotechnology allows the presentation of these SAMs on 
nanoparticles or polymers. These developments now enable the detailed study of the 
sialic acid–Siglec axis including its therapeutic potential as an immune modulator. 
 
 Heise T#, Büll C#, Adema GJ*, Boltje TJ*. Sialic Acid Mimetics to Target the Sialic 
Acid-Siglec Axis. Trends in Biochemical Sciences, 2016, 41, 519-531 
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The Sialic Acid–Siglec Axis in Health and Disease  
Following nucleic acids, lipids, and proteins, almost half of the ‘building blocks of life’ 
are glycans, sugar chains comprising various monosaccharides.1 Glycans cover the 
membrane of every living cell and display a staggering structural diversity (the 
glycome), greatly exceeding the diversity of the genome and proteome. One family of 
monosaccharides that stands out from other glycan components is the sialic acid 
family. Sialic acids literally stand out, because they are usually found at the terminal 
position of so-called sialoglycans.2-3 The sialic acid family comprises more than 50 
naturally occurring members sharing a nine-carbon backbone that can be 
enzymatically modified inside the cell. In the Golgi apparatus, a subset of the 20 
known sialyltransferases attach sialic acids to underlying monosaccharides such as 
galactose via three different types of linkage (α2,3, α2,6, and α2,8). Together, the 
diversity within the sialic acid family itself and the variable ‘linkability’ of sialic acids 
enable cells to synthesize and express a great variety of sialoglycans at the cell 
membrane, creating the sialome (Figure 1).4-5  
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Figure 1. Sialoglycan expression on the cell surface. Schematic representation of sialic acid-carrying 
glycans on the cell surface and structural representation of a sialic acid molecule. 
 
Sialic acids play important roles in many physiological processes (e.g. protein folding, 
neural development, cell–cell interactions) as well as pathological processes (e.g., 
autoimmunity, cancer).6-9 Sialic acids exert their function in biology through multiple 
mechanisms as they are directly and indirectly involved in numerous events at both 
the molecular and cellular level.2-3 Several of the biological effects of sialic acids are 
mediated via their negative charge. More specific interactions occur with sialic acid-
binding receptors such as selectins, factor H, and Siglecs. While modifications of the 
sialic acid backbone appear to play a minor role in recognition by selectins and factor 
H, Siglecs feature distinct binding preferences for the sialic acid modifications.10-11 
The sialic acid family comprises more than 50 naturally occurring, negatively charged 
carbohydrates sharing a common nine-carbon (C-1–9) neuraminic acid backbone that 
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can be modified by intracellular enzymes at several positions (Figure 1). The most 
common sialic acid variant found in humans is Neu5Ac (N-acetylneuraminic acid), a 
sialic acid carrying an acetyl group at the C-5 position. Other prominent sialic acid 
family members are Neu5,9Ac2 (N-acetyl-9- O-acetylneuraminic acid), which next to 
the acetyl group on C-5 carries a second O-acetyl group on C-9, and Neu5Gc (N-
glycolylneuraminic acid), with a glycolyl group at the C-5 position.3-4, 12 These different 
sialic acids are linked to glycans via α2,3, α2,6, or α2,8 linkages, generating a 
tremendous structural diversity of sialoglycans. The diversity of sialoglycans indicates 
an important role for these sugars in human physiology, yet many aspects of sialic 
acid biology remain elusive. Sialic acids can exert their function by interacting with 
sialic acid-binding receptors such as Siglecs. Siglecs have an extracellular N-terminal 
V-set domain that engages in extensive molecular interactions with sialic acids, 
followed by a varying number of C2-set immunoglobulin domains, a transmembrane 
domain, and a cytoplasmic C-terminus. The C-terminus of most Siglecs contains an 
ITIM that is phosphorylated on sialic acid binding and recruits SHP- 1/2 phosphatases 
that inhibit downstream activation pathways (Figure 2).13-14 Siglecs-14, -15, and -16 
are assumed to have an activating function by interacting with the adaptor protein 
DAP12.15 Siglecs show distinct binding preferences for different sialic acids and the 
type of linkage and type of underlying sugar also affect recognition of sialic acids. Via 
a conserved arginine residue in the V-set domain, Siglecs form a salt bridge with the 
carboxylate group at the C-1 position of sialic acids. Further interactions occur 
between Siglecs and the hydroxyl group (C-4) of sialic acids and conserved 
hydrophobic tryptophan or tyrosine residues of Siglecs and the N-acetyl group (C-5) 
and glycerol side chain (C-7 to C-9) of sialic acids. Responsible for the glycan-context 
specificity of Siglec binding is a highly variable loop region in the V-set domain.14-15 So 
far, little is known about the glycan-context dependency of Siglec binding to sialic 
acids. Ongoing efforts now focuses on answering crucial but challenging questions 
regarding the identity of the preferred natural sialoglycan ligands for different Siglecs. 
Siglecs are expressed predominantly by immune cells and can be divided into two 
groups: the conserved Siglecs (Siglec-1, -2, -4, and -15) and the CD33-related Siglecs 
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(Siglec-3, -5, -6, -7, -8, -9, -10, -11, -14, and -16)13. Siglec-12 lost sialic acid-binding 
capacity and is therefore not included in either of these groups. Neither are Siglec-13 
and Siglec-17 as they have been inactivated during human evolution.2, 15 Most Siglecs 
have an intracellular immunoreceptor tyrosine-based inhibition motif (ITIM) that can 
mediate inhibitory signals on binding to a sialic acid (Figure 2).2,16 
 
 
Figure 2. The sialic acid-Siglec axis. a) Sialic acid interact with a Siglec on the same cell surface in a cis 
manner resulting in ITIM phosphorylation and downstream inibitory signaling through the 
recruitment of SHP-1/2 phosphatases. b) Trans sialic acid-Siglec interactions between effector cell 
and a target cell lead to downstream inhibitory signaling. 
 
Thereby, the sialic acid–Siglec axis (the total collection of interactions between sialic 
acids and Siglec receptors leading to Siglec signaling) can modulate cellular functions. 
Although the biological functions of many Siglecs are largely unknown, Siglecs have 
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emerged as important immuno-modulatory receptors that alter immune cell function 
on binding to sialic acids. This concept is further supported by recent studies showing 
that disturbances in the sialic acid–Siglec axis contribute to autoimmunity, infection, 
inflammation, aging, and cancer.17-25 Notably, the expression and function of Siglecs is 
not limited to the immune system. For instance, Siglec-4, also called myelin-
associated glycoprotein (MAG) is expressed on cells of the central and peripheral 
nervous system and is involved in axon maintenance and function.2 The suggested 
biological functions of Siglecs are summarized in Table 1. Collectively, the increasing 
level of understanding of the role of Siglecs in health and disease together with 
recent advances in sialic acid chemistry have stimulated the development of SAMs 
with high binding affinities and their presentation as bioactive molecules to Siglecs. 
Here we discuss recently developed glycoengineering approaches that now enable 
targeted manipulation of the sialic acid–Siglec axis and their potential use in clinical 
applications.  
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Siglec Expression Suggested biological function Refs 
Siglec-1 CD169 
Sialoadhesin 
Macrophages Macrophage interaction with 
lymphocytes Internalization of sialylated 
pathogens 
2, 26 
Siglec-2 CD22 B cells Negative regulation of B cell activation 
Induces B cell tolerance 
2, 27 
Siglec-3 CD33 Myeloid cells, 
monocytes, 
microglia 
Regulates myeloid cell development and 
function Suppresses amyloid beta 
uptake by microglia in the brain 
2, 28-29 
Siglec-4 MAG Schwann cells, 
oligodendrocytes 
Maintenance of myelinated axons 
Suppresses axonal regeneration after 
injury 
2, 29 
Siglec-5 CD170 Monocytes, 
neutrophils 
Recognition and internalization of 
sialylated pathogens Inhibits immune 
cell activation 
2, 30-31 
Siglec-6 CD327 Trophoblasts, B 
cell subset 
Regulates trophoblast proliferation and 
invasiveness 
2, 32 
Siglec-7 CD328 NK cells, 
monocytes, mast 
cells, basophils 
Attenuates NK cell activation and 
function Inhibits mast cells and 
basophils 
2, 25, 33-
34 
Siglec-8 SAF2 Mast cells, 
basophils, 
eosinophils 
Induces apoptosis in eosinophils 2, 35-36 
Siglec-9 CD329 NK cells, 
monocytes, 
macrophages, 
dendritic cells, 
neutrophils 
Inhibits NK cell and neutrophil activation 
and function Immune modulation of 
myeloid cells 
2, 21, 24, 
37 
Siglec-10 SLG2 B cells, NK cells, 
monocytes, 
CD4+ T cells 
Dampens immune activation and 
overreaction Suppresses CD4+ T cells 
2, 19, 38-
39 
 
Siglec-11 Microglia, 
macrophages 
Inhibits microglial activation 2, 40 
Siglec-14 Neutrophils, 
monocytes 
Triggers proinflammatory pathway in 
monocytes Recognition of sialylated 
pathogens 
2, 30-31 
Siglec-15 CD33L3 Osteoclasts, 
macrophages 
Regulates osteoclast differentiation and 
bone resorption Immune modulation of 
macrophages 
2, 41-43 
Siglec-16 Macrophages Unknown 44 
Table 1. Human Siglec family members and suggested biological functions. 
 
 
63 
 
Emergence of SAMs for the Therapeutic Targeting of the Sialic Acid–Siglec Axis  
Sialic acid–Siglec interactions play a versatile role in human physiology as they 
mediate cell adhesion, cell signaling, or uptake of sialylated pathogens. Consequently, 
abnormal sialic acid– Siglec interactions can contribute to the onset and development 
of diseases. In addition, by expressing sialic acids on their surface, pathogens and 
cancer cells can interact with Siglecs on immune cells to escape immune recognition. 
Below we discuss pathophysiological processes involving sialic acids and Siglecs that 
provide the rationale for the development of SAMs for therapeutic targeting of the 
sialic acid–Siglec axis. As most Siglecs are expressed on immune cells, we here focus 
on immune-related disorders.  
 
Autoimmunity, inflammatory diseases, and Graft-Versus-Host Disease (GVHD)  
Consistent with the broad expression of Siglecs on cells of the immune system, faulty 
synthesis or expression of sialic acids and altered expression or mutation of Siglecs 
contributes to the development of immune abnormalities.16 For instance, loss-of-
function mutations in the human sialic acid acetylesterase (SIAE) gene, which lead to 
reduced expression of sialic acid ligands for Siglec-2 (CD22) and Siglec-10, have been 
associated with autoimmune diseases such as rheumatoid arthritis, type 1 diabetes, 
and autoimmune polyglandular syndrome.17, 35 Studies in mice and humans suggest 
that Siglec-2 and Siglec-10 (Siglec-G in mice) are immunosuppressive receptors that 
regulate B cell tolerance by counteracting B cell receptor signaling.27 Hence, reduced 
sialic acid ligand synthesis or Siglec-2 and Siglec-10/G deficiencies can result in 
uncontrolled B cell activation and systemic autoimmunity.45-46 In addition, by 
interacting with CD24, Siglec-10/G has been suggested to dampen immune activation 
in response to danger-associated molecular patterns (DAMPs) during tissue damage, 
thereby avoiding inflammation and possibly autoimmunity.19, 47 In line with these 
findings, recent evidence38 indicates that Siglec-10/G–CD24 interactions limit the 
severity of GVHD.38 Whether the observed Siglec-10/G–CD24 interactions are sialic 
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acid mediated remains to be proved. These studies suggest that SAMs with high 
binding affinities for these Siglecs could limit autoimmunity, inflammatory diseases, 
and GVHD.  
 
Pathogen and tumor immune evasion  
By expressing sialic acids on their surface, pathogens and cancer cells have been 
reported to interact with inhibitory Siglecs on immune cells in trans, thereby escaping 
immune recognition.48-49 Group B Streptococcus expresses host sialic acids that bind 
to immunosuppressive Siglecs (Siglec-5 and -9) as molecular mimicry to avoid 
immune activation.30, 37, 50 In addition to their immunomodulatory role as targets of 
pathogenic sialic acids, Siglecs can also assist in the transmission of HIV-1. Siglec-1 
expressed by dendritic cells has been shown to be an entry site for sialylated HIV-1, 
facilitating virus trans-infection.51 SAMs competing with pathogenic sialic acids for 
Siglec binding could enhance the recognition of pathogens by the immune system or 
prevent Siglec-mediated transmission of HIV-1. Tumor cells express high levels of 
sialic acids and have been reported to utilize the immuno-suppressive effect of the 
sialic acid–Siglec axis to avoid recognition and eradication by the immune system.8 
For instance, tumor cells originating from various tissues express high levels of sialic 
acid ligands for Siglec-7 and Siglec-9. Natural killer (NK) cells are effective in 
recognition and eradication of tumor cells but do express Siglec-7 and -9. As a 
consequence, the interaction of tumor sialic acids and Siglec-7 and -9 on NK cells 
strongly attenuates the NK cell ability to kill tumor cells.24 In another example, tumor 
sialoglycan interactions with Siglec-9 or Siglec-15 have been reported to render 
myeloid cells pro-tumorigenic, and non-small cell lung cancer patients carrying a 
Siglec-9 polymorphism that lowers binding to tumor sialic acids showed better initial 
tumor control.23, 41 These data suggest that tumor sialic acids attenuate immune 
responses by interacting with immunosuppressive Siglec receptors.  
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Aging and age-related disease  
Abnormalities in the sialic acid–Siglec axis have recently also been associated with 
neuro-degeneration, Alzheimer's disease, faulty bone resorption, and aging.22, 28, 42-43 
Genome-wide association studies have identified SNPs in the Siglec-3 (CD33) locus 
that protect against or correlate with a high risk for Alzheimer's.52-54 Siglec-3 is 
present on microglia – macrophage-like cells – in the brain and its expression is 
elevated in individuals carrying the high-risk Siglec-3 SNP and decreased in individuals 
with the low risk SNP. Alzheimer's disease is characterized by the deposition of 
amyloid beta protein plaques in the brain. It is hypothesized that these plaques 
interfere with neuron communication, leading to neurodegeneration. High Siglec-3 
expression was found to be sufficient to promote amyloid beta protein and plaque 
accumulation, a phenotype associated with Alzheimer's, whereas low Siglec-3 
expression was associated with low amyloid beta protein accumulation levels in the 
brain.55-56 Although the underlying mechanism is unknown, the sialic acid-binding 
capacity of Siglec-3 was shown to be essential to promote amyloid beta 
accumulation. These data imply that SAMs with high affinity for Siglec-3 could 
counteract plaque formation in the brain and Alzheimer's disease development and 
progression. In summary, sialic acid–Siglec interactions have been associated with 
various diseases ranging from autoimmunity to neurodegeneration and cancer. Still, 
further research is needed to fully elucidate their precise role in health and disease 
and guide the development of SAMs to therapeutically target aberrant sialic acid–
Siglec interactions in disease.  
 
SAMs as high-affinity ligands for Siglecs  
Aberrant sialic acid–Siglec interactions are involved in a broad spectrum of diseases; 
hence, strategies to tune the sialic acid–Siglec axis in pathophysiological processes 
could have great therapeutic potential.57-58 Twenty years ago, it was noticed that 
structural features of sialic acids are important for Siglec binding because naturally 
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occurring modifications, such as 9-O-acetylation and C-5 acetylation or glycolylation, 
showed differential binding to Siglec-2.59-60 These early findings were the starting 
point to further establish the contribution of the sialic acid substituents to Siglec 
binding using SAMs. Compared with natural sialosides, which have weak monovalent 
binding affinities for Siglecs (0.1–3 mM), SAMs can feature binding affinities in the 
nanomolar range.14, 61 Therefore, SAMs can be used to target Siglecs and to 
functionally modulate Siglec-expressing cells. The sialic acid backbone can be 
chemically modified at various positions (Figure 3). The carboxylic acid is crucial for 
Siglec binding and hence is left unmodified, but all other positions ranging from the 
aglycone (C-2) to the rest of the backbone (C-3 to C-9) can potentially be modified to 
improve Siglec binding. Early examples of SAMs to target Siglecs carried a single 
modification, but recent examples contain up to four different modifications.61 Most 
of the work on the development of SAMs has focused on Siglec-2 as target. Hence, 
we review the development of SAMs for Siglec-2 separately before discussing the 
development of SAMs for the other human Siglecs.  
 
Development of high-affinity SAMs for Siglec-2  
To the best of our knowledge, N-fluoroacetyl C-5 modification was the first SAM 
reported to increase binding affinity towards a Siglec receptor (Siglec-4). The 
screening of C-5 and C-9 modifications did not only produce the fluoroacetyl SAM but 
discovered the requirement of hydrogen donors as amines or alcohols at the C-9 
position.62 The increased binding affinity was ascribed to hydrogen bonding and 
lipophilic interactions between the SAMs and Siglec-2.63-64 Based on the notion that 
the C-9 position is flanked by a hydrophobic patch, new, unnatural Siglec-2 ligands 
carrying lipophilic groups were tried to exploit this patch to gain binding affinity and 
possibly even selectivity for Siglec-2.65-67 A small library of C-9-modified SAMs carrying 
a hydrophobic extension was synthesized and screened for binding to human Siglec-
2.66 Modification of the C-9 position with a biphenyl (BPC-Neu5Ac) showed a 244-fold 
increase in binding affinity (4 mM) as well as much improved selectivity towards 
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human Siglec-2 compared with murine Siglec-2 and Siglec-1 (Figure 3). Minor 
modifications at the C-5 position and the incorporation of a natural aglycone at C-2 
yielded a slight improvement of binding affinity (2.1 mM).68 The binding affinity 
towards Siglec-2 could be further improved by hydroxylation of the C-9 biphenyl 
substituent and conversion of the amide linkage into an amine-linked construct69. 
Moreover, by replacing the α-2,6-Gal linkage with a phenyl or biphenyl glycoside they 
developed SAMs for Siglec-2 with binding affinities in the high nanomolar range (100 
nM).70-71 At this stage it was clear that modification at various positions on the sialic 
acid backbone could improve binding affinity. Based on this, it was hypothesized that 
adding multiple modifications to the C-2, C-5, and C-9 positions of sialic acid at the 
same time should lead to optimized Siglec-2 ligands.65, 72 This approach led to a new 
SAM modified at C-2 with an o-nosyl group, at C-5 with an α2,3-dichlorobenzyl group, 
and at C-9 with a 4-(4-hydroxy)biphenyl group that showed nanomolar affinity for 
Siglec-2 (60 nM). Subsequently, a double modification of the C-4 position in 
combination with C-9 modifications was reported.73 Based on a homology model of 
Siglec-2 and other Siglecs and molecular modeling experiments, it was concluded that 
modifications at the C-4 position could lead to an increase in affinity. Modification at 
the C-4 position with an nitrophenylcarboxamido group indeed led to a 15-fold 
increase in binding affinity. Further modification of the C-9 position by a BPC group 
led to an overall 9100-fold increase in binding affinity, showing a synergistic effect of 
C-4 and C-9 modifications. Saturation transfer-difference (STD) NMR showed that C-
9- and C-4-modified SAMs are likely to bind the same pocket as natural ligands and 
that the C-9 and C-4 modifications interact with the binding pocket. Modification with 
a C-4 N-tosyl group and a C-9 BPC group showed the best binding at 150 nm. Later 
that year, a study on C-4 and C-9 modifications was reported that additionally 
changed the C-2 and C-3 positions. This led to the synthesis of SAMs containing three 
(C-2, -4, -9) or four (C-2, -3, -4, -9) modifications of the sialic acid molecule (Figure 3). 
Interestingly, the sialoside with four combined modifications showed a high binding 
affinity (6 nM) for Siglec 2, but a SAM with three modifications is so far the ligand 
with the highest binding affinity towards Siglec-2 (2 nM).61 Together, these studies 
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demonstrate that chemical modifications of the sialic acid backbone can dramatically 
increase the binding affinity to a Siglec. Compared with natural sialosides with 
affinities in the high micromolar range, SAMs with low nanomolar affinities are now 
available to target Siglec-2.  
 
 
Figure 3. Development of sialic acid mimetics as high affinity ligands for Siglec-2. Center: Structure, 
substituents and affinity of natural Siglec-2 ligands. Surrounding: Development of sialic acid mimetics 
with high affinity for Siglec-2 over time. 
 
Development of High-Affinity SAMs for the Human Siglec Family  
The development of Siglec-2 ligands with increasing potency has already allowed a 
better understanding of the role of Siglec-2 in health and disease.27 These studies 
have triggered the development of high-affinity SAMs for other members of the 
Siglec family to unravel their biological role and potential therapeutic value (vide 
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supra). In general, the same approach to developing SAMs for Siglec-2 can be applied 
to obtain high-affinity SAMs for other Siglecs. The SAMs with the highest affinity 
known to date for each of the Siglec receptors are shown in Figure 4. Although 
effective, this approach is rather slow and therefore new, high-throughput 
approaches were developed. Microarrays based on easily modifiable sialic acids were 
reported to map the effect of sialic acid modifications on a broader set of Siglecs.74 
First, sialic acids carrying a C-9 azide or alkyne or a C-5 azide or alkyne were 
enzymatically linked to a lactose scaffold in either an α2,3 linkage or an α2,6 linkage. 
The eight different constructs were then immobilized on a microarray slide and the 
azide or alkyne groups were modified by a small library of alkynes or azides, 
respectively, using copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC). Binding of 
several recombinant human Siglecs to the SAMs library was assessed. This ‘click-and-
pick’ approach identified novel SAMs with high binding to Siglec-3, -5, -7, -9, and -10. 
It is important to note that, while no IC50 values were determined, the relative affinity 
towards different Siglecs and the cross-reactivity was investigated. The comparison of 
different Siglecs indicated that the SAMs with the highest affinity are not necessarily 
the most selective. For example, the best SAM for Siglec-5 also displayed significant 
affinity for Siglec-974. At present, the affinity of SAMs for most members of the 
human Siglec family is in the (low) micromolar range and for six of the 14 Siglec 
members no SAM has yet been described (Figure 4).  
70 
 
 
Figure 4. Sialic acid mimetics with high affinity for the human Siglec family. Note: NA = not available; 
grey = for these Siglecs no sialic acid mimetic has been reported yet. 
 
Future research is needed to improve the affinities of the known SAMs and de novo 
screening exploiting combinatorial sialic acid chemistry should allow the 
identification of SAMs for Siglecs with no high-affinity ligand.  
 
Multivalent Presentation of High-Affinity SAMs to Siglecs  
Chemical modifications of the sialic acid backbone can dramatically increase binding 
affinities to Siglecs. Still, for these high-affinity ligands to trigger Siglec signaling, high-
avidity binding and clustering of the receptors is required. In nature, multiple sialic 
acids are often presented on a glycoprotein or glycolipid, enabling multivalent 
binding and clustering of Siglecs.67 At present, multivalent presentation of SAMs to 
Siglecs can be achieved via different approaches (Figure 5). SAMS can be linked to 
microarrays and interact with isolated Siglecs.74 The major advantage of the 
microarray approach is the well-defined glycan structure and a relatively easy 
readout. The spacing and representation is however artificial and binding may differ 
from a cellular situation. (Figure 5, left) Instead of using microarrays, SAM-decorated 
71 
 
nanoparticles sialosides can be crosslinked to various types of nanoparticle, such as 
liposomes, gold nano-particles, or dendrimer/poly(lactic-co-glycolic acid) (PLGA)-
based nanoparticles, allowing their multivalent presentation (Figure 5, middle). 
Recently, SAM-decorated nanoparticles for delivery of cargo to Siglec-expressing cells 
have been developed. This approach has been used to generated BPC-Neu5Ac-coated 
liposomes loaded with the cytotoxic agent doxorubicin to target and kill Siglec- 2-
expressing B cell lymphoma cells in vivo.75 Moreover, liposomes decorated with SAMs 
specific for Siglec-1 or Siglec-7 enabled targeting of antigens to antigen-presenting 
cells to activate antigen-specific T cells.76-77 Besides their function in cargo delivery, 
SAM-decorated nanoparticles can be applied to stimulate Siglec signaling.57 
Immunosuppressive signaling of B-cells was triggered by nanoparticles coated with 
SAMS specific for Siglec-2.78 The liposomes were cross-linked with antigens to target 
the B cell receptor and BPA-NeuGc or BPC-Neu5Ac to engage mouse or human Siglec-
2. B cell receptor signaling was strongly inhibited by these liposomes, leading to B cell 
apoptosis and antigen-specific tolerance induction. In a similar approach, liposomes 
decorated with 30-BPA-NeuGc that target Siglec-G on mouse B cell subsets were able 
to inhibit B cell receptor signaling and induced tolerance towards selected antigens79. 
The suppression of B cell receptor signaling was dependent on SHP-1, indicating that 
immune-inhibitory signaling of Siglec-G was directly stimulated by the 30-BPA-NeuGc 
liposomes. These so-called Siglec-engaging tolerance-inducing antigenic liposomes 
(STALs) are attractive candidates to restore B cell tolerance in autoimmune 
patients.78 In addition to liposomes, PLGA-based nanoparticles have also been 
decorated with α2,8-linked sialic acid. In this case the nanoparticles were used for 
targeting of mouse Siglec-E and have anti-inflammatory effects in mice.80 PLGA 
nanoparticle binding to Siglec-E+ macrophages and neutrophils in mice limited their 
proinflammatory cytokine production in response to lipopolysaccharide (LPS), 
avoiding severe systemic inflammation. The Siglec-E-engaging nanoparticles triggered 
immunosuppressive signaling via the recruitment of SHP-2 to the cytoplasmic tail of 
Siglec-E and resulted in enhanced production of the anti-inflammatory cytokine 
interleukin (IL)-10. Interestingly, the same nanoparticles bound Siglec-7 and Siglec-9 
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on macrophages and showed anti-inflammatory effects in a human ex vivo lung 
perfusion model. In addition to liposome- or PLGA-based nanoparticles, SAMs can be 
cross-linked to any type of nanoparticle. For instance, gold-core nanoparticles 
decorated with the sialoside GM3 were shown resemble the Siglec-1-mediated 
transmission of HIV-1.81 These early examples illustrate that different types of 
nanoparticle carrier allow multivalent presentation of high-affinity Siglec ligands to 
immune cells or other Siglec-expressing cell types. These SAM nanoparticles possess 
strong immunomodulatory properties by triggering Siglec signaling and could be of 
high value to counteract autoimmunity or inflammation. Similarly to nanoparticles, 
high-affinity Siglec ligands can be crosslinked to polymeric materials to create 
multivalency and trigger Siglec signaling (Figure 5, right). Trans interaction between 
mouse Siglec-2 and Siglec-G on B-Cells was shown by polyacrylamide conjugates with 
BPC-Neu5Gc. Engagement of sialoside polymers increased Siglec-2 phosphorylation 
and induced B cell tolerance towards a model antigen. Polyacrylamide polymers 
decorated with 60-sulfo-sialyl Lewis-X were shown to bind selectively to Siglec-8 on 
human eosinophils in trans and induced apoptosis.36 Recently, polymers carrying 
naturally occurring sialosides (α2,3- or α2,6- SiaLAcNAc, GD3, or sialyl LewisX) with a 
phospholipid tail that enabled their integration into the cell membrane were 
synthesized.33, 82 Cells loaded with specific sialoside polymers showed strongly 
enhanced binding to Siglec-7 and were largely protected against killing by Siglec-7+ 
NK cells. Further analysis showed that suppression of cytotoxic function of NK cells by 
these target cells coincided with Siglec-7 phosphorylation and subsequent SHP-1 
recruitment. In an in vitro transplantation rejection model, the sialoside 
glycopolymers were even shown to protect human stem cells from NK cell 
cytotoxicity. Together these data indicate that soluble or membrane-incorporated 
polymers can function as carriers to present SAMs to Siglecs on immune cells in cis or 
trans, thereby inducing their immunosuppressive signaling. 
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Figure 5 Multivalent presentations of sialic acid mimetics for Siglec targeting. Left: Sialylated glycans 
on array to be targeted by soluble sialic acid binding proteins Middle: Sialoside Liposomes decorated 
with sialic acid mimetics for high affinity binding to Siglecs Right: Membrane-anchored sialylated 
glycopolymers binding to siglecs on target cells. 
 
Concluding Remarks and Future Perspectives  
Recent discoveries link aberrant sialic acid–Siglec interactions to a broad spectrum of 
pathologies and thus identify the sialic acid–Siglec axis as a potential therapeutic 
target. The precise biological roles of many sialic acid–Siglec interactions, however, 
remain elusive. The development of high-affinity SAMs for individual Siglecs is crucial 
to further elucidate their biological function. SAMs for Siglec-2 are relatively 
advanced and their application on nanocarriers or glycopolymers has already been 
used to induce B cell tolerance and limit disease in animal models. Progress in sialic 
acid chemistry and high-throughput approaches for the synthesis and screening of 
chemically modified sialic acids now allows more rapid targeting of other members of 
the Siglec family. The first promising high-affinity Siglec-binding candidates have been 
defined that now require further optimization and testing for their ability to 
modulate Siglec signaling. For the future development of SAMs, their specificity for 
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and crossreactivity with other Siglec family members as well as the glycan context 
should be taken into consideration. It will be highly rewarding to further invest in 
strategies for the multivalent presentation of high-affinity ligands, to increase 
specificity but also to enhance their biological potential in vitro and in in vivo disease 
models. Collectively, these novel glycobiotechnological approaches will not only 
contribute to a better comprehension of the roles of sialic acids and their receptors in 
biology but also expose the full clinical potential of tuning the sialic acid–Siglec axis in 
disease processes. 
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Part 2 
 
Glycocalyx Engineering by 
Metabolic Incorporation 
 
 
“When I started doing chemistry, I did it the way I fished - for the excitement, the 
discovery, the adventure, for going after the most elusive catch imaginable in 
uncharted seas.” 
Karl Barry Sharpless (1941), coined the term ‘click-chemistry’ and invented the 
copper catalyzed version of the azide alkyne Huisgen cycloaddition.  
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3 
New Sialic Acid Derivative 
for Highly Efficient 
Metabolic 
Glycoengineering 
 
“I do not have more luck than you Sir, but I do try more!” 
Adolf von Baeyer (1835-1917), working on organic dyes and first to discover 
synthetic fluorescein additionally described the strain of triple bonds. 
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Abstract 
Sialoglycans play a vital role in physiology, and aberrant sialoglycan expression is 
associated with a broad spectrum of diseases. Since biosynthesis of sialoglycans is 
only partially regulated at the genetic level, chemical tools are crucial to study their 
function. This chapter describes the development of propargyloxycarbonyl sialic acid 
(Ac5NeuNPoc) as a powerful tool for sialic acid glycoengineering. Ac5NeuNPoc 
showed strongly increased labeling efficiency and exhibited less toxicity compared to 
those of widely used mannosamine analogues in vitro and was also more efficiently 
incorporated into sialoglycans in vivo. Unlike mannosamine analogues, Ac5NeuNPoc 
was exclusively utilized in the sialoglycan biosynthesis pathway, allowing a genetic 
defect in sialic acid biosynthesis to be specifically detected. Thus, Ac5NeuNPoc 
glycoengineering is a highly efficient, nontoxic, and selective approach to study and 
modulate sialoglycan interactions on living cells.  
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Introduction 
Sialic acids are a diverse family of sugars that terminate the glycan chains of cell 
surface glycolipids and glycoproteins.1 Almost every vertebrate cell can synthesize 
sialic acids via an endogenous enzymatic pathway using mannosamine sugars as the 
biosynthetic precursor. Sialic acids can also be recycled from glycan degradation in 
the lysosome or taken up from exogenous (dietary) sources.1 To date, more than 50 
derivatives of sialic acid have been identified, with the most common being N-
acetylneuraminic acid (Neu5Ac), bearing an acetyl group on the 5-amino substituent, 
and the hydroxylated N-glycolylneuraminic acid (Neu5Gc).1 Next to the diversity 
within the sialic acid family itself, sialic acids are enzymatically attached to underlying 
glycan structures (sialoglycans) via different linkages (α2,3, α2,6, α2,8), giving rise to a 
tremendously diverse collection of sialoglycan structures on the cell membrane called 
the sialome.2 The structural diversity of sialoglycans is matched by their diverse role 
in biology, and we are just beginning to understand the meaning of the sialome in 
physiology and pathology.3 Sialic acids contribute to processes ranging from 
fertilization to blood vessel formation and from pathogen recognition to cancer 
growth and progression.4-7 The biological effects of sialic acid often are mediated by 
sialic acid-recognizing receptors such as selectins or Siglecs.8 Compared to studying 
the structure and function of DNA or proteins, studying the highly complex and 
diverse structures of (sialo)glycans is more challenging because glycosylation is a 
highly dynamic, non-template-driven process and therefore inherently more variable. 
(Sialo)glycan biosynthesis heavily depends on the availability of different glycosides, 
the activity of the enzymes involved in sialoglycan biosynthesis, and the rate of 
glycosylation reactions.9 In recent years, bioorthogonal metabolic glycoengineering, 
or sialic acid glycoengineering, has emerged as a simple and powerful method to 
study sialoglycan expression.10-11 Sialic acid glycoengineering is based on the 
introduction of sialic acids or precursors carrying an unnatural functional group into 
the cellular sialylation pathway, which are than incorporated into sialoglycans to 
allow, for instance, sialoglycans to be fluorescently labeled or sialoglycan function to 
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be modulated.12-13 For sialic acid glycoengineering, unnatural sialic acid precursors 
have been developed that allow sialoglycans to be tracked or labeled. Early studies 
showed that modified derivatives of N-acetylmannosamine (ManNAc) were readily 
converted and incorporated into sialoglycans.14 Subsequently, metabolic 
incorporation of ManNAc derivatives was shown that carried a small, unique reactive 
functional group that could be chemoselectively ligated under physiological 
conditions.15 This led to the development of a number of chemical reporter groups 
such as ketones,15 azides,16 alkynes,17 and cyclopropenes18 as well as complementary 
bioorthogonal ligation chemistry.11, 13, 19-22 The two main factors that determine the 
efficiency and selectivity of sialic acid glycoengineering are the type of biosynthetic 
precursor and the type of chemical reporter group. The most commonly used 
biosynthetic precursors for sialic acid glycoengineering are mannosamine analogues. 
Mannosamine analogues are enzymatically converted into sialic acid analogues inside 
the cell and incorporated into sialoglycans. The use of mannosamine analogues, 
therefore, heavily depends on the expression and activity of enzymes like GNE (UDP-
N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase) or NANS (sialic acid 
synthase), which are involved in the conversion to sialic acids.23-24 Some 
mannosamine analogues might not be recognized by these enzymes and, 
furthermore, several mannosamine analogues have been reported to be cytotoxic.25-
26 Sialic acid glycoengineering could become more efficient using unnatural sialic 
acids that can be directly incorporated into sialoglycans without extensive enzymatic 
conversion. So far, only a few unnatural sialic acid analogues have been developed, 
and data comparing the performance of these analogues with the corresponding 
mannosamine analogues in vitro and in vivo are scarce.27-32 Secondly, the chemical 
reporter group also influences the incorporation of unnatural sialic acids into cell 
surface glycans. In a direct comparison, alkyne-tagged mannosamine (Ac4ManNAl) 
was reported to allow more potent sialic acid glycoengineering than azide-tagged 
mannosamine (Ac4ManNAz).33 Notably, cellular uptake of exogenous mannosamine 
or sialic acid is low, but uptake of unnatural glycosides can be greatly enhanced, for 
instance, by capping the polar hydroxyl groups with acetyl (Ac) groups.34 On the basis 
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of these findings, we hypothesized that a peracetylated sialic acid analogue carrying 
an alkynyl group would be the optimal combination of metabolic precursor and 
chemical reporter for sialic acid glycoengineering in terms of labeling efficiency, 
toxicity, and selectivity. Here, we report the development of a novel, peracetylated 
propargyloxycarbonyl-tagged sialic acid analogue (Ac5NeuNPoc) for efficient and 
highly specific sialic acid glycoengineering in vitro and in vivo that enabled the 
unequivocal detection of a genetic defect in sialic acid biosynthesis.  
 
Results and Discussion  
The effect of the biosynthetic precursor and the chemical reporter on sialic acid 
glycoengineering 
To explore the labeling efficiency of distinct metabolic precursor and chemical 
reporter combinations, four glycoprobes were synthesized. Two azide-carrying 
probes, N-azidoacetyl mannosamine (Ac4ManNAz)16 and N-azidoacetyl sialic acid 
(Ac5NeuNAz), and two probes carrying a propargyloxycarbonyl (Poc) group, N-Poc 
mannosamine (Ac4ManNPoc)35 and the N-Poc sialic acid (Ac5NeuNPoc), were 
prepared by chemical synthesis (Figure 1).  
 
Figure 1. Structural representation of peracetylated mannosamine and sialic acid analogues modified 
at the C-2 and C-5 nitrogen-position with azide (Az) or propargyloxycarbonyl (Poc), respectively. 
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These analogues carry a Poc or azide group on C-2 (Ac4ManNPoc and Ac4ManNAz) or 
C-5 (Ac5NeuNPoc and Ac5NeuNAz), respectively, and are peracetylated to increase 
cellular uptake. The robust chemical synthesis of Ac5NeuNPoc was readily scalable 
and allowed for the preparation of sufficient, highly pure material for in vitro and in 
vivo sialic acid glycoengineering experiments. To achieve the desired placement of 
the chemical reporter on the C-5 position, first removal of the C-5 acetamide of sialic 
acid was required. Thus, known methyl ester 1 was reacted with Boc2O and DMAP 
which reacted smoothly. We attempted to remove the N- and O-acetyl groups by 
using K2CO3 in methanol to obtain 4 after reacetylation. Unfortunately, a mixture of 
unidentified compounds was formed. Presumably the α-ketoester is not stable under 
these conditions. Hence, the anomeric center was protected as a thioglycoside and 
the aforementioned sequence of Boc-protection, deacetylation and re-O-acetylation 
smoothly afforded 5. Hydrolysis of the anomeric thioglycoside using NBS and acetone 
followed by reactylation afforded key building block 6. Boc deprotection and 
acylation led to derivatives 7 and 8. The azido acetyl derivative 9 was prepared by the 
treatment of 8 with sodium azide. The ManNPoc and ManNAz sugars were prepared 
as previously described.35,36(Figure 2)  
 
 
Figure 2. Chemical synthesis of C-5 modified sialic acids. Reagents and conditions: i) TolSH, BF3.Et2O, 
DCM. ii) Boc2O, THF, DMAP. iii) K2CO3, MeOH. iv) Ac2O, Pyr. v) NBS, Acet, H2O. vi) TFA, DCM, H2O. vii) 
ClAcCl, NaHCO3, Diox, H2O. viii) PocCl, NaHCO3, Diox, H2O. ix) NaN3, DMF.   
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After metabolic incorporation, the Poc or azide groups can be reacted selectively with 
azides or alkynes, respectively, using copper-catalyzed azide alkyne cycloaddition 
(CuAAC).16, 37 The cytotoxicity of the copper complex could be reduced by the 
addition of L-histidine, hence allowing bioorthogonal metabolic glycoengineering 
experiments to be performed on living cells.38 First, we assessed the efficiency of 
Ac4ManNPoc, Ac4ManNAz, Ac5NeuNPoc, and Ac5NeuNAz utilization by cells for the 
synthesis of cell surface glycoconjugates. Human THP-1 or Jurkat cells were incubated 
for 3 days with increasing concentrations of the sugar analogues or control 
Ac4ManNAc or Ac5NeuNAc, conjugated to azide- or alkyne-biotin using CuAAC, and 
stained with streptavidin-PE. Fluorescent intensities were quantified by flow 
cytometry. In both cell lines, there was a dose-dependent increase in labeling with a 
maximum around 100 μM (Figures 3a,b).  
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Figure 3. Incorporation of Poc sugars into cell surface glycans. a),b) Incorporation of azide- and Poc-
modified sugars into surface glycoconjugates of THP-1 a) and Jurkat b) cells. Cells cultured with 
increasing concentrations of Ac4ManNAz, Ac4ManNPoc, Ac5NeuNAz, Ac5NeuNPoc, or control 
Ac4ManNAc or Ac5NeuNAc, conjugated with alkyne- or azide-biotin, and labeled with streptavidin-
phycoerythrin for flow cytometry analysis. c),d) 7-AAD dead cell staining for THP-1 c) or Jurkat d) cells 
incubated for 3 days with the different ManNAc and NeuNAc derivates. e) Confocal images showing 
Poc-containing cell surface glycans visualized with alkyne-biotin and NeutrAvidin-Texas Red (green). 
Bright-field images show the outline of the cells, and DAPI staining shows nuclei (blue). f) Detection 
of membrane Poc glycoconjugates introduced with Ac4ManNPoc or Ac5NeuNPoc by western blot 
analysis using alkyne-biotin and NeutrAvidin-DyLight 800 conjugates. 
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Labeling with Ac5NeuNPoc, however, resulted in a significantly higher signal 
compared to Ac4ManNPoc. At 100 μM, the labeling signal with Ac5NeuNPoc was 
almost 3 times higher as compared to Ac4ManNPoc. Comparing the labeling 
intensities between Ac4ManNAz and Ac5NeuNAz confirmed that sialic acid analogues 
are incorporated more efficiently into cell surface glycans compared to the 
mannosamine analogues (Figure 3a,b). Furthermore, sialic acids with the Poc 
reporter group yielded higher labeling efficiencies compared to those with the azide 
analogue. Importantly, concentrations above 100 μM of the tested ManNAc 
analogues, but not NeuNAc analogues, decreased cell viability (Figures 3c,d). These 
findings are in line with previous work by others showing cellular toxicity of 
mannosamine analogues.25-26 Focusing on the Poc derivatives, we next confirmed 
that Ac5NeuNPoc was incorporated more efficiently into cell surface glycans than was 
Ac4ManNPoc by confocal microscopy and western blot analysis (Figures 3e,f) and in 
two additional human cell lines, HL-60 and HEK293 (Figure 4a−d).  
To show that the increased labeling holds true on the single-protein level, we 
assessed the presence of Poc groups in the N-glycans of purified transferrin isolated 
from human hepatocytes cultured with either Ac4ManNPoc or Ac5NeuNPoc. 
Transferrin has two N-glycosylation sites (Asn413, Asn611) and commonly carries two 
biantennary N-glycans terminated by sialic acids.39 Western blot analysis of whole 
human hepatocyte protein showed, again, that Ac5NeuNPoc allows significantly more 
labeling than Poc mannosamine (Figure 4e). Analysis of purified transferrin revealed 
the presence of Poc groups in the N-glycans of cells treated with Poc sialic acid but 
not with Poc mannosamine (Figure 4f). Collectively, these data demonstrate that, 
compared to mannosamine analogues, Ac5NeuNPoc is an effective and nontoxic tool 
for sialic acid glycoengineering.  
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Poc sialic acid allows efficient sialic acid glycoengineering in vivo 
Next, we tested the ability of both Poc sugars to be incorporated into surface 
sialoglycans in vivo. Mice were intraperitoneally injected with vehicle control, 
Ac4ManNPoc (700 μmol, 300 mg/kg), or an equimolar dose of Ac5NeuNPoc (700 
μmol, 400 mg/kg) for 6 consecutive days. For both Poc sugars, no signs of toxicity 
were observed neither locally at the injection site nor systemically. On day 7, single-
cell suspensions from 13 different tissues were prepared, and Poc-containing glycans 
were labeled with azide-biotin and subsequently streptavidin-PE and quantified by 
flow cytometry (Figure 4g).  
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Figure 4. Ac5NeuNPoc for efficient sialic acid glycoengineering in vitro and in vivo. Ac5NeuNPoc shows 
higher incorporation than Ac4ManNPoc in a) THP-1 b) Jurkat c) HL-60 d) HEK293. e) Western blot of 
hepatocytes treated with Ac4ManNPoc, Ac5NeuNPoc, or control Ac5NeuNAc. Poc-containing cell 
surface glycans conjugated to DyLight800 (left) and total protein (right). f) Transferrin (arrow heads) 
secreted from hepatocytes was purified from media, and Poc groups in the glycans of transferrin 
(left) and total transferrin (right) were visualized by western blot analysis. g) Mice were injected for 
six days with Ac4ManNPoc, or Ac5NeuNPoc. On day seven, single-cell suspensions were prepared 
from different tissues and Poc-containing glycans were quantified by flow cytometry. Fluorescence 
intensities were normalized to background fluorescence of the respective organs from control mice. 
Data presented as mean fluorescence values ± SEM (n = 3). 
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Except for the brain and blood cells, labeling could be detected in all organs tested. 
The labeling efficiency for most organs was significantly higher with Ac5NeuNPoc 
compared to Ac4ManNPoc. High labeling with Ac5NeuNPoc was found in particular in 
the mesenteric lymph node, lymph nodes, liver, and spleen. Altogether, these data 
indicate that, relative to Ac4ManNPoc, Ac5NeuNPoc allows more efficient sialic acid 
glycoengineering in vivo. To our knowledge, this is the first time that unnatural sialic 
acids have been used for sialic acid glycoengineering in vivo. Further research should 
explore different doses, treatment schedules, and biodistribution of Ac5NeuNPoc to 
optimize the in vivo application of this unnatural sialic acid for the study and 
manipulation of sialic acid-related processes, for instance, in cancer, infection, and 
inflammation.  
 
Different Utilization of Ac4ManNPoc and Ac5NeuNPoc for Sialoglycan Synthesis.  
To determine the reason for the improved labeling efficiency in vitro and in vivo, we 
explored the utilization of Poc sialic acid and mannosamine in different glycoside 
synthesis pathways. First, the utilization of Ac4ManNPoc and Ac5NeuNPoc in the 
sialoglycan synthesis pathway was assessed. Hereto, THP-1 cells were incubated for 3 
days in the presence of the sialyltransferase inhibitor, Ac53Fax-Neu5Ac, to block 
sialoglycan synthesis and were then cultured for another 3 days with Ac4ManNPoc or 
Ac5NeuNPoc.40-42 Blocked sialoglycan synthesis was confirmed by staining with the 
sialic acid-recognizing lectins, MALII (Figure 5a) and SNA-I (Figure 5b). Assessment of 
the Poc-carrying surface glycans by flow cytometry analysis showed that blocking 
sialoglycan synthesis almost completely prevented incorporation of Ac5NeuNPoc 
(90% reduction) (Figure 5c). These data show that the labeling that was detected is 
specifically derived from the biosynthetic incorporation of Poc sialic acids into surface 
sialoglycans. Surprisingly, incorporation of Ac4ManNPoc was only partially reduced 
(40% reduction). These findings were confirmed by western blot (Figures 5d). Our 
results suggest that Ac5NeuNPoc is used for sialoglycan synthesis only, whereas 
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Ac4ManNPoc can be utilized for the synthesis of glycosides other than sialic acids. It 
has been reported that next to sialic acid mannosamines can be converted into N-
acetylglucosamine (GlcNAc).43 Therefore, we next measured the incorporation of 
Ac4ManNPoc and Ac5NeuNPoc into cell surface glycoconjugates upon 
pharmacological inhibition of sialyltransferases with Ac53Fax-Neu5Ac and inhibition of 
the UDP-GlcNAc synthesis pathway with 4-deoxy-GlcNAc.44 Simultaneous 
interference with sialic acid and GlcNAc glycoconjugate synthesis abrogated 
metabolic labeling with either Ac4ManNPoc or Ac5NeuNPoc (Figures 5e). These 
results indicate that Ac4ManNPoc can be utilized in the sialic acid and GlcNAc 
biosynthesis pathways, as has been described by others.43 Therefore, the higher 
incorporation efficiency observed with Ac5NeuNPoc compared to that for 
Ac4ManNPoc can be ascribed to its specific utilization in the sialoglycan synthesis 
pathway. While sialic acids can be directly used for sialoglycan synthesis, the cellular 
fate of ManNAc is determined by expression levels of GNE, the key enzyme in 
ManNAc conversion to sialic acid.45 The enzymatic activity of GNE is tightly regulated 
by a negative feedback loop that is triggered by high levels of endogenous CMP-sialic 
acid.46-49 Boosting the sialic acid metabolic flux with exogenous ManNAc analogues is, 
therefore, self-limiting. In contrast, exogenous NeuNAc analogues that enter cells via 
a salvage pathway are not subjected to this feedback regulation, but they might even 
trigger feedback inhibition of GNE and inhibit synthesis of competing natural sialic 
acids from ManNAc. This difference in cellular utilization could account for the 
dramatically higher labeling efficiency of Ac5NeuNPoc compared to Ac4ManNPoc.  
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Ac5NeuNPoc as a specific Tool To Detect a Genetic Defect in the Sialic Acid Pathway.  
On the basis of our findings that Ac5NeuNPoc enables more potent and highly specific 
labeling of sialoglycans compared to Ac4ManNPoc, we exploited its use for the 
detection of genetic defects in the sialoglycan synthesis pathway. As a model system, 
we selected a CMP-sialic acid transporter (SLC35A1) knockout HAP1 cell line that fails 
to transport sialic acids from the cytoplasm to the Golgi system. Indeed, SLC35A1 
cells expressed low levels of α2,3- and α2,6-sialoglycans compared to their wild-type 
counterpart or knockout cells complemented with wild-type SLC35A1 (Figure 5f,g). In 
line with our previous findings in other cell lines, introduction of Poc-sialic acids into 
surface glycans was about 2 times more efficient using Ac5NeuNPoc compared to 
Ac4ManNPoc in wild-type HAP1 cells (Figure 5h).  
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Figure 5. Ac5NeuNPoc is specifically utilized in the sialoglycan synthesis pathway. Ac53Fax-Neu5Ac 
inhibition of sialic acid expression in THP-1 cells a) α2,3-linked sialic acids b) α2,6-linked sialic acids. c) 
Incorporation of Ac4ManNPoc or Ac5NeuNPoc in THP-1 cells with and without Ac53Fax-Neu5Ac 
inhibitor treatment. d) Western blot detection of Poc-containing surface glycoconjugates introduced 
with Ac4ManNPoc or Ac5NeuNPoc with or without sialic acid blockage. e) Incorporation of Poc sugars 
with sialoglycan Ac53Fax-Neu5Ac and/or glycosaminoglycan Ac34-deoxy-GlcNAc inhibtion. f),g) 
Expression of sialoglycoconjugates in SLC35A1 knockout HAP1 cells. Wild-type cells, SLC35A1 
knockout HAP1 cells, or knockout cells complemented with wild-type SLC35A1 (rescue) stained with 
f) MALII or g) SNA-I. h) Wild-type, SLC35A1 knockout, or wild-type-complement SLC35A1 knockout 
HAP1 cells were treated with Ac4ManNPoc or Ac5NeuNPoc and conjugated to alkynebiotin and 
streptavidin-phycoerythrin. Labeling was quantified by flow cytometry, and mean fluorescent 
intensities ± SEM of three independent experiments are presented.  
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In the SLC35A1 knockout cells, incorporation of Ac5NeuNPoc into surface sialoglycans 
was completely prevented, whereas Ac4ManNPoc treatment resulted in detectable 
levels of Poc glycoconjugates. Complementing the knockout cells with wildtype 
SLC35A1 rescued the incorporation of Poc groups into surface glycans using 
Ac5NeuNPoc. These findings indicate that mannosamine analogues are suboptimal 
for the specific detection of defects in the sialylation pathway, as ManNPoc is also 
converted into other sugar metabolic pathways. Instead, the Ac5NeuNPoc sialic acid 
derivative allows highly specific imaging of sialic acid biosynthesis and its genetic 
defects.  
 
Conclusion 
In conclusion, our data show that Ac5NeuNPoc is a powerful tool for sialic acid 
glycoengineering in vitro and in vivo. The so far unprecedented high labeling 
efficiency, high specificity, and lack of toxicity of the sialic acid analogue, 
Ac5NeuNPoc, compared to those of mannosamine analogues make this novel 
unnatural sialic acid a potent tool to functionally modulate cell surface sialoglycans.  
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Supplementary information 
General synthetic procedures: 1H and 13C NMR spectra were recorded on a Bruker Avance III 500 
MHz spectrometer. Chemical shifts are reported in parts per million (ppm) relative to 
tetramethylsilane (TMS) as the internal standard. NMR data is presented as follows: Chemical shift, 
multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet of doublet, m = 
multiplet and/or multiple resonances), integration, coupling constant in Hertz (Hz). All NMR signals 
were assigned on the basis of 1H NMR, 13C NMR, COSY and HSQC experiments. Mass spectra were 
recorded on a JEOL JMS-T100CS AccuTOF mass spectrometer. Column chromatography was 
performed on silica gel, 0.035-0.070 mm, 60 Å, ACROS organics and automatic column BÜCHI 
fraction-collector C-660, BÜCHI pump-manager C-615, Column-silicycle FLH-R10030B-ISO25 
cartridge, 4-40 g. TLC-analysis was conducted on TLC Silicagel, 60, F254, Merck, with detection by UV 
absorption (254 nm) where applicable, and by spraying with 20% sulfuric acid in methanol followed 
by charring at ~150°C or by spraying with a solution of (NH4)6Mo7O24.H2O (25 g l-1) in 10% sulfuric acid 
in ethanol followed by charring at ~150°C. Molecular sieves 3Å (AW-300) were flame activated under 
vacuum prior to use. All reactions were carried out under an argon atmosphere.  
 
 Methyl (5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-5-D-glycero-D-
galacto)onate (1). To a solution of N-acetylneuraminic acid (20 g; 64.7 mmol) in MeOH (600 mL; 0.1 
M), Dowex (10 g) was added. After stirring at r.t. for 24 h, the mixture was filtrated. The residue was 
washed with an excess of MeOH. The filtrate was concentrated in vacuo then dissolved in Pyr (250 
ml; 3.09 mol; 47.8 eq.) and Ac2O (125 mL; 1.59 mol; 24.6 eq.), stirred at r.t. for 24 h and concentrated 
in vacuo using Tol for co-evaporation. The residue was dissolved in EtOAc and washed successively 
with HCl (0.1 M) and sat. aq. NaHCO3. The organic layer was dried over MgSO4 and filtered. The 
filtrate was concentrated in vacuo affording 1 (34.5 g; 64.6 mmol; quant.) as a white foam. TLC: 
(Ace:DCM, 40:60 v/v) Rf = 0.51. 1H NMR (500 MHz, CDCl3, major anomer) δ 5.38 – 5.37 (m, 1H, H-7), 
5.26 (ddt, J = 10.1, 7.5, 4.9 Hz, 1H, H-4), 5.07 (ddd, J = 6.8, 5.1, 2.5 Hz, 1H, H-8), 4.50 (dd, J = 12.5, 2.6 
Hz, 1H, H-9a), 4.15 – 4.10 (m, 3H, H-9b; H-6; H-5), 3.80 (s, 3H, OMe), 2.55 (dd, J = 13.5, 5.0 Hz, 1H, H-
3eq), 2.15 (s, 3H, CH3OAc), 2.14 (s, 3H, CH3OAc), 2.10 – 2.09 (m, 1H, H-3ax), 2.07 (s, 3H, CH3OAc), 2.05 – 
2.03 (m, 6H, 2x CH3OAc), 1.90 (s, 3H, CH3NHAc). 13C NMR (126 MHz, CDCl3, major anomer) δ 171.15 
(CO), 170.75 (CO), 170.41 (2x CO), 170.38 (CO), 168.37 (CO), 166.46 (CO), 97.65 (C-2), 73.00 (C6), 
71.52 (C-8), 68.44 (C-4), 67.98 (C-7), 62.27 (C-9), 53.35 (OMe), 49.49 (C-5), 36.05 (C-3), 23.33 (CH3Ac), 
21.05 (CH3Ac), 20.99 (CH3Ac), 20.93 (2x CH3Ac) 20.91 (CH3Ac). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. 
for C22H31NNaO14, 556.16422; found, 556.16487. 
 
 Methyl 5-acetamido-4,7,8,9-penta-O-acetyl-2,3,5-dideoxy-2-para-
methylthiophenol-D-glycero-β-galacto-non-2-ulopyranosonate (2). Similar to the previously 
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described procedure,50 peracetylated sialic acid 1 (33.87 g; 63.5 mmol) was dissolved in DCM (400 
mL; 0.16 M). HSTol (9.26 mL; 76 mmol; 1.2 eq.) was added to form a slightly yellow solution. 
BF3•Et2O (15.7 mL; 127 mmol; 2 eq.) was added and the reaction stirred for 21 h, washed with 10% 
aqueous Na2S2O3 and sat. aqueous NaHCO3. The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. The residue was crystallized using DCM and Hept. The crystals were filtered, 
washed with Hept and collected with Acet. Evaporation of solvents in vacuo afforded 2 (35.92 g; 60.1 
mmol; 95%) as a white foam. TLC: (Acet/DCM, 30/70): Rf =0.4; 1H NMR (500 MHz, CDCl3, major 
anomer) δ 7.30 (dd, J = 8.1, 1.8 Hz, 2H, 2x CH, meta STol), 7.12 (d, J = 7.2 Hz, 2H, 2x CH, ortho STol), 
5.68 (d, J = 10.3 Hz, 1H, NH), 5.46 (t, J = 2.4 Hz, 1H, H-7), 5.37 (td, J = 11.1, 4.8 Hz, 1H, H-4), 4.95 (d, J = 
8.5 Hz, 1H, H-8), 4.61 (dd, J = 10.5, 2.5 Hz, 1H, H-6), 4.49 (dd, J = 12.3, 2.2 Hz, 1H, H-9a), 4.12 (q, J = 
10.4 Hz, 1H, H-5), 4.02 (dd, J = 12.2, 8.6 Hz, 1H, H-9b), 3.58 (s, 3H, OMe), 2.64 (dd, J = 13.8, 4.7 Hz, 1H, 
H-3eq), 2.31 (s, 3H, CH3STol), 2.11 – 2.08 (m, 4H, H-3ax; CH3Ac), 2.07 (s, 3H, CH3Ac), 2.03 (s, 3H, CH3Ac), 
1.95 (s, 3H, CH3Ac).13C NMR (126 MHz, CDCl3, major anomer) δ 171.13 (CO, Ac), 170.90 (CO, Ac), 
170.23 (CO, Ac), 170.19 (CO, Ac), 170.16 (CO, Ac), 168.21 (C-1), 140.08 (CCH3STol), 136.14 (2x CH, 
meta STol), 129.80 (2x CH, ortho STol), 125.17 (C-S, STol), 88.82 (C-2), 73.10 (C-6), 73.01 (C-8), 69.05 
(C-4), 68.78 (C-7), 62.64 (C-9), 52.51 (OMe), 49.36 (C-5), 37.33 (C-3), 23.10 (CH3Ac), 21.25 (CH3STol), 
21.04 (CH3Ac), 20.83 (CH3Ac), 20.68 (CH3Ac), 20.64 (CH3Ac). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for 
C27H35NNaO12S, 620.17776; found, 620.17694. 
 
Methyl 5-[acetyl(tert-butoxycarbonyl)amino]-4,7,8,9-penta-O-acetyl-2,3,5-
dideoxy-2-para-methylthiophenol-D-glycero-β-galacto-non-2-ulopyranosonate (3). Similar to the 
previously described procedure,51 thioglycoside 2 (30.93 g; 51.7 mmol) was dissolved in THF (500 mL; 
0.1 M). Successively, Boc2O (24.0 mL; 103 mmol; 2 eq.) and 4-dimethylaminopyridine (3.16 g; 25.9 
mmol; 0.5 eq.) were added. After stirring at 70 ˚C for 2 h, the mixture was concentrated in vacuo. The 
residue was dissolved in EtOAc and washed with sat. aq. NaHCO3. The organic layer was dried over 
MgSO4, filtered and concentrated in vacuo. Silicagel flash column chromatography (0% → 10% Acet 
in DCM) afforded 3 (31.66 g; 45.4 mmol; 88%) as a slightly yellow foam. TLC: (Acet:DCM, 5:95 v/v) Rf 
= 0.47 1H NMR (500 MHz, CDCl3, major anomer) δ 7.34 (d, J = 8.2 Hz, 2H, 2x CH, meta STol), 7.14 (d, J 
= 8.0 Hz, 3H, 2x CH, ortho STol), 5.80 (td, J = 11.0, 4.9 Hz, 1H, H-4), 5.44 (dd, J = 10.1, 2.1 Hz, 1H, H-6), 
5.35 (t, J = 2.5 Hz, 1H, H-7), 5.12 (dt, J = 8.2, 2.6 Hz, 1H, H-8), 4.85 (t, J = 10.5 Hz, 1H, H-5), 4.49 (dd, J = 
12.4, 2.3 Hz, 1H, H-9a), 4.06 (dd, J = 12.4, 8.2 Hz, 1H, H-9b), 3.58 (s, 3H, OMe), 2.74 (dd, J = 13.8, 4.9 
Hz, 1H, H-3eq), 2.36 (s, 3H, CH3NAc), 2.34 (s, 3H, CH3STol), 2.13 (dd, J = 13.8, 11.1 Hz, 1H, H-3ax), 2.07 
(s, 3H, CH3OAc), 2.06 (s, 3H, CH3OAc), 1.97 (s, 3H, CH3OAc), 1.97 (s, 3H, CH3OAc), 1.72 (s, 9H, C(CH3)3, 
Boc). 13C NMR (126 MHz, CDCl3, major anomer) δ 173.93 (CO, Ac), 170.64 (CO, Ac), 170.50 (CO, Ac), 
170.33 (CO, Ac), 169.94 (CO, Ac), 168.28 (C-1), 152.10 (CO, Boc), 140.21 (CCH3STol), 136.40 (2x CH 
meta STol), 129.95 (2x CH ortho STol), 125.76 (C-S, STol), 89.50 (C-2), 85.42 (C(CH3)3, Boc), 72.91, (C-
8), 72.29 (C-6), 68.68 (C-7), 66.54 (C-4), 62.53 (C-9), 52.98 (C-5), 52.57 (OMe), 38.88 (C-3), 28.29 
(C(CH3)3, Boc), 26.73 (CH3NHAc), 21.44 (CH3STol), 21.13 (CH3, OAc), 20.93 (CH3, OAc), 20.81 (2x CH3, 
OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C32H43NNaO14S, 720.23019; found, 720.23055. 
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Methyl 5-(tert-butoxycarbamado)-2,3,5-dideoxy-2-para-methylthiophenol-
D-glycero-β-galacto-non-2-ulopyranosonate (4). As described previously,51 Boc-protected, 
peracetylated sialic acid 3 (31.65 g; 45.4 mmol) was dissolved in MeOH (200 mL; 0.23 M) and K2CO3 
(3.13 g; 22.7 mmol; 0.5 eq.) was added. After stirring at r.t. for 24 h the reaction was quenched with 
AcOH to pH 6 and filtered. The filtrate was concentrated in vacuo. Silicagel flash column 
chromatography (0% → 10% MeOH in DCM) afforded 4 (18.39 g; 37.7 mmol; 83%). TLC: (MeOH:DCM, 
10:90 v/v) Rf = 0.56 1H NMR (500 MHz, CDCl3, major anomer) δ 7.35 (d, J = 8.1 Hz, 2H, 2x CH, meta 
STol), 7.11 (d, J = 8.0 Hz, 2H, 2x CH, ortho STol), 5.27 (d, J = 8.7 Hz, 1H, NH), 4.30 (d, J = 10.4 Hz, 1H, H-
6), 4.08 (td, J = 10.9, 4.6 Hz, 1H, H-5), 3.80 – 3.65 (m, 5H, H-9a; H-9b; H-8; H-7; H-5), 3.57 (s, 3H, OMe), 
2.71 (dd, J = 13.8, 4.7 Hz, 1H, H-3eq), 2.32 (s, 3H, CH3STol), 2.05 – 1.99 (m, 1H, H-3ax), 1.45 (s, 9H, 
C(CH3)3, Boc). 13C NMR (126 MHz, CDCl3, major anomer) δ 169.49 (C-1), 157.82 (CO, Boc), 139.98 (C-
Me STol), 135.73 (2x CH, meta STol), 129.87 (2x CH, ortho STol), 126.24 (C-S STol), 89.59 (C-2), 81.13 
(C(CH3)3, Boc) 72.85 (C-6), 70.56 (C-7), 70.23 (C-8), 68.20 (C-4), 64.55 (C-9), 54.12 (C-5), 52.78 (OMe), 
40.67 (C-3), 28.47 (C(CH3)3, Boc), 21.39 (CH3, STol). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for 
C22H33NNaO9S, 510.17737; found, 510.17732. 
 
Methyl 5-(tert-butoxycarbamado)-4,7,8,9-penta-O-acetyl-2,3,5-dideoxy-2-
para-methylthiophenol-D-glycero-β-galacto-non-2-ulopyranosonate (5). As described previously,51 
Boc-protected, non-acetylated thio-glycoside 4 (8.39 g; 17.2 mmol) was dissolved in Pyr (62 mL; 764 
mmol; 44.4 eq.). Ac2O (36 mL; 382 mmol; 22.2 eq.) was slowly added. After stirring at r.t. for 7 h, the 
mixture was concentrated in vacuo using Tol for co-evaporation. The residue was dissolved in EtOAc 
and washed successively with HCl (0.1 M) and sat. aq. NaHCO3. The organic layer was dried over 
MgSO4 and filtered and concentrated in vacuo. Silicagel flash column chromatography (0% → 50% 
EtOAc in Hept) afforded 5 (10.26 g; 15.6 mmol; 91%) as a white foam. TLC: (EtOAc:Hept, 50:50 v/v) Rf 
= 0.47 1H NMR (500 MHz, CDCl3) δ 7.32 (d, J = 7.7 Hz, 2H, 2x CH, meta STol), 7.14 (d, J = 7.7 Hz, 2H, 2x 
CH, ortho STol), 5.55 (t, J = 2.6 Hz, 1H, H-7), 5.33 (td, J = 11.1, 4.8 Hz, 1H, H-4), 5.01 (dt, J = 8.5, 2.5 Hz, 
1H, H-8), 4.55 (dd, J = 10.5, 2.6 Hz, 1H, H-6), 4.51 (dd, J = 12.2, 2.3 Hz, 1H, H-9a), 4.45 (d, J = 10.7 Hz, 
1H, NH), 4.04 (dd, J = 12.2, 8.5 Hz, 1H, H-9b), 3.79 (q, J = 10.6 Hz, 1H, H-5), 3.61 (s, 3H, OMe), 2.67 (dd, 
J = 13.8, 4.8 Hz, 1H, H-3eq), 2.34 (s, 3H, CH3STol), 2.10 (s, 3H, CH3OAc), 2.08 (s, 3H, CH3OAc), 2.05-2.03 
(m, 4H, H-3ax; CH3OAc), 1.97 (s, 3H, CH3OAc), 1.40 (s, 9H, C(CH3)3, Boc). 13C NMR (126 MHz, CDCl3) δ 
170.98 (CO, OAc), 170.61 (CO, OAc), 170.43 (CO, OAc), 169.93 (CO, OAc), 168.48 (C-1), 155.35 (CO, 
Boc), 140.22 (C-CH3STol) 136.38 (2x CH, meta STol), 129.99 (2x CH ortho STol), 125.41 (C-S, STol), 
88.87 (C-2), 80.29 (C(CH++3++)3, Boc), 73.34 (C-6), 72.90 (C-8), 69.51 (C-4), 69.12 (C-7), 62.92 (C-9), 
52.68 (OMe), 50.96 (C-5), 37.59 (C-3), 28.28 (C(CH3)3, Boc), 21.44 (CH3STol), 21.21 (CH3OAc), 20.94 
(CH3OAc), 20.83 (CH3OAc), 20.82 (CH3OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C30H41NNaO13S, 
678.21963; found, 678.21799. 
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Methyl (5-N-tert-butyloxycabonyl-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-
glycero-β-D-galacto-non-2-ulopyranoside)onate (6). Boc thio-glycoside 5 (7.6 g; 11.59 mmol; 1 eq.) 
was dissolved in a mixture of acetone (105 mL) and water (10.5 mL). NBS (10.31 g; 58 mmol; 5 eq.) 
was added and the reaction was stirred for 2 h at r.t. The reaction was quenched by adding sat. 
aqueous sodium thiosulfate (50 mL) and acetone was removed by concentrating in vacuo. The 
product was extracted with EtOAc and water, the organic layer was dried (MgSO4), filtered and 
concentrated in vacuo. The residue was dissolved in a mixture of Pyr (75 mL) and Ac2O (37 mL). The 
reaction was stirred for 16 h at r.t. and concentrated in vacuo. The residue was dissolved in EtOAc 
and the organic layer was washed with sat. aqueous NaHCO3, dried (MgSO4), filtered and 
concentrated in vacuo. The product was purified on silica column (0  50% EtOAc in Hept) yielding 6 
(5.55 g; 9.39 mmol; 81% over two steps). TLC: (EtOAc:Hept, 50:50 v/v) Rf = 0.34 1H NMR (400 MHz, 
CDCl3, Major anomer) δ 5.48 – 5.43 (m, 1H, H-7), 5.23 – 5.16 (m, 1H, H-4), 5.10 (td, J = 6.2, 2.5 Hz, 1H, 
H-8), 4.49 (dd, J = 12.4, 2.7 Hz, 1H, H-9a), 4.14 – 4.09 (m, 1H, H-9b), 4.07 – 4.01 (m, 1H, H-6), 3.87 – 
3.79 (m, 1H, H-5), 3.79 (s, 3H, OMe), 2.57 (dt, J = 13.4, 4.0 Hz, 1H, H-3eq), 2.14 (s, 3H, CH3OAc), 2.13 (s, 
3H, CH3OAc), 2.06 (s, 3H, CH3OAc), 2.04 (m, 7H, 2x CH3OAc; H-3ax), 1.40 (s, 9H, C(CH3)3 Boc). 13C NMR 
(101 MHz, CDCl3, Major anomer) δ 170.91 (CO), 170.78 (CO), 169.89 (CO), 168.39 (CO), 168.32 (CO), 
166.49 (CO), 155.20 (CO), 95.62 (C-2), 80.41 (C(CH3)3 Boc), 73.29 (C-6), 71.16 (C-8), 69.68 (C-4), 68.02 
(C-7), 62.37 (C-9), 53.31 (OMe), 50.62 (C-5), 36.13 (C-3), 28.31 (C(CH3)3 Boc), 21.03 (CH3OAc), 20.96 
(CH3OAc), 20.95 (CH3OAc), 20.94 (CH3OAc), 20.91 (CH3OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for 
C25H37NNaO15, 614.20609; found, 614.20498. 
 
Methyl (5-N-propargyloxycabonyl-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-
D-glycero-β-D-galacto-non-2-ulopyranoside)onate (7). Boc intermediate 6 (630 mg; 1.065 mmol) 
was dissolved in a mixture of DCM (7.6 mL) and TFA (3 mL). Water (0.5 mL) was added and the 
reaction was stirred for 5 h at r.t. until TLC analysis indicated the reactions was complete TLC: 
(Acet:DCM, 30:70 v:v) Rf = 0.15. The reaction was then diluted by adding water (40 mL) and extracted 
with DCM (3x20 mL). The organic layers were combined and concentrated in vacuo. The residue was 
dissolved in a mixture of dioxane (7 mL) and water (3 mL) and PocCl (0.158 mL; 1.596 mmol; 1.5 eq.) 
was added. Sodium bicarbonate (313 mg; 3.72 mmol; 3.5 eq.) was added and the reaction was stirred 
for 16 h at r.t., diluted with EtOAc and water. The organic layer was separated, dried (MgSO4), 
filtered and concentrated in vacuo. The product was purified by silica column (0%  50% EtOAc in 
heptane) yielding 7 (450 mg; 0.785 mmol; 74% over two steps). TLC: (EtOAc:Hept, 60:40 v:v) Rf= 0.55; 
1H NMR (500 MHz, CDCl3, major anomer) δ 5.44 – 5.38 (m, 1H, H-7), 5.25 (td, J = 11.0, 5.0 Hz, 1H, H-
4), 5.13 – 5.06 (m, 1H, H-8), 4.92 (d, J = 10.0 Hz, 1H, NH), 4.72 (dd, J = 15.6, 2.1 Hz, 1H, CHH Poc), 4.51 
– 4.43 (m, 2H, H-9a, CHH Poc), 4.15 – 4.08 (m, 2H, H-9b, H-6), 3.83 – 3.74 (m, 4H, OCH3H-5), 2.57 (dd, J 
= 13.4, 5.0 Hz, 1H, H-3eq), 2.45 (s, 1H, CCH Poc), 2.14 – 2.13 (m, 6H, 2x CH3Ac), 2.04 (s, 3H, CH3Ac), 
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2.04 – 2.03 (m, 4H, CH3Ac, H-3ax), 2.02 (s, 3H, CH3Ac). 13C NMR (126 MHz, CDCl3) δ 170.68 (CO), 
170.65 (CO), 170.16 (CO), 170.09 (CO), 168.28 (CO), 166.33 (C-1), 155.00 (CO, Poc), 97.37 (C-2), 77.95 
(CCH, Poc), 75.00 (CCH, Poc), 74.74 (C-6), 72.64 (C-8), 68.12 (C-4), 67.92 (C-7), 62.09 (C-9), 53.19 
(OMe), 52.95 (CH2 Poc), 51.31 (C-5), 35.98 (C-3), 20.86 (CH3OAc), 20.85 (CH3OAc), 20.79 (2x CH3OAc), 
20.74 (CH3OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C24H31NNaO15, 596.15914; found, 
596.15977. 
 
Methyl (5-N-chloroacetyl-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-β-
D-galacto-non-2-ulopyranoside)onate (8). Boc intermediate 6 (269 mg; 0.455 mmol) was dissolved 
in a mixture of DCM (3.25 mL) and TFA (1.3 mL). Water (0.2 mL) was added and the reaction was 
stirred for 5 h at r.t. TLC: (Acet:DCM, 30:70 v:v) Rf = 0.15. The reaction was then diluted by adding 
water (20 mL) and extracted thrice with DCM (3x10 mL). The organic layers were combined and 
concentrated in vacuo. The residue was solved in THF (4.5 mL; 0.1 M) and ClAcCl (54 μl; 0.681 mmol; 
1.5 eq.) was added. Sodium bicarbonate (133 mg; 1.588 mmol; 3.5 eq.) was added and the reaction 
was stirred for 16 h at r.t., diluted with EtOAc and water. The organic layer was separated, dried 
(MgSO4), filtered and concentrated in vacuo. The product was purified by silica column (0%  70% 
EtOAc in heptane) to afford 8 (136 mg; 0.239 mmol; 53% over two steps). TLC: (EtOAc:Hept, 80:20 
v:v) Rf= 0.35; 1H NMR, (500 MHz, CDCl3, major anomer) δ 6.53 (d, J = 9.9 Hz, 1H, NH), 5.41 – 5.31 (m, 
2H, H-4, H-7), 5.09 (td, J = 6.3, 2.5 Hz, 1H, H-8), 4.48 (dd, J = 12.5, 2.5 Hz, 1H, H-9a), 4.24 (dd, J = 10.7, 
2.3 Hz, 1H, H-6), 4.17 – 4.10 (m, 2H, H-5, H-9b), 3.97 (dd, J = 32.5, 15.1 Hz, 2H, CH2, ClAc), 3.80 (s, 3H, 
OMe), 2.59 (dd, J = 13.5, 5.0 Hz, 1H, H-3eq), 2.17 (s, 3H, CH3Ac), 2.14 (s, 3H, CH3Ac), 2.10 – 2.06 (m, 
4H, H-3ax, CH3Ac), 2.04 (s, 3H, CH3Ac), 2.04 (s, 3H, CH3Ac). 13C NMR (126 MHz, CDCl3) δ 170.62 (CO), 
170.58 (CO), 170.31 (CO), 170.14 (CO), 168.22 (CO), 166.58 (CO), 166.18 (CO), 97.42 (C-2), 72.37 (C-
6), 71.04 (C-8), 67.80 (C-4), 67.60 (C-7), 61.97 (C-9), 53.21 (OMe), 49.57 (C-5), 42.43 (CH2, AcCl), 35.92 
(C-3), 20.86 (CH3OAc), 20.78 (CH3OAc), 20.77 (CH3OAc), 20.74 (2x CH3OAc). HR-ESI-TOF/MS (m/z): 
[M+Na]+ calcd. for C22H30ClNNaO14, 590.12525; found, 590.12457. 
 
Methyl (5-N-azidoacetyl-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-β-D-
galacto-non-2-ulopyranoside)onate (9). ClAc intermediate 8 (100 mg; 0.176 mmol) was dissolved in 
DMF (1.7 mL; 0.1 M) and sodium azide (80 mg; 1.233 mmol; 7 eq.) was added. The reaction was 
heated to 60 °C for 3 h, diluted with water (20 mL) and extracted with EtOAc (20 mL) . The organic 
layer was separated, dried (MgSO4), filtered, and concentrated in vacuo. The residue was purified by 
silica column (0%  50% EtOAc in Hept) to afford azidoacetyl sialic acid 8 (81 mg; 0.141 mmol; 80%). 
TLC: (EtOAc:Hept, 50:50 v/v) Rf = 0.15 1H NMR (500 MHz, CDCl3) δ 6.21 (d, J = 9.9 Hz, 1H, NH), 5.37 
(dd, J = 5.8, 2.4 Hz, 1H, H-7), 5.29 (td, J = 10.4, 4.6 Hz, 1H, H-4), 5.10 (td, J = 6.0, 2.5 Hz, 1H, H-8), 4.47 
(dd, J = 12.5, 2.5 Hz, 1H, H-9a), 4.21 (dd, J = 10.7, 2.4 Hz, 1H, H-6), 4.16 – 4.08 (m, 2H, H-5; H-9b), 3.93 
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– 3.83 (m, 2H, CH2, NAz), 3.80 (s, 3H, OMe), 2.59 (dd, J = 13.5, 5.0 Hz, 1H, H-3eq), 2.17 (s, 3H, CH3OAc), 
2.14 – 2.09 (m, 4H, CH3OAc; H-3ax ), 2.07 (s, 3H, CH3OAc), 2.05-2.03 (m, 6H, CH3OAc). 13C NMR (126 
MHz, CDCl3) δ 170.82 (CO), 170.75 (CO), 170.48 (CO), 170.09 (CO), 168.34 (CO), 167.37 (CO), 166.31 
(CO), 97.67 (C-2), 72.60 (C-6), 71.00 (C-8), 68.19 (C-4), 67.69 (C-7), 62.03 (C-9), 53.38 (OMe), 52.76 
(CH2, NAz), 49.38 (C-5), 36.02 (C-3), 21.01 (CH3OAc), 20.96 (CH3OAc), 20.94 (CH3OAc), 20.91 (CH3OAc). 
HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C22H30N4NaO14, 597.16562; found, 597.16620. 
Animals. Female C57BL/6J mice were obtained from Harlan Laboratories and housed in the Central 
Animal Laboratory, Radboud University Nijmegen, The Netherlands, under specific pathogen-free 
conditions with ad libitum access to food and water. Mice were 6−8 weeks old at the beginning of 
each experiment. All experiments were authorized by the local animal ethics committee, Nijmegen, 
The Netherlands, and carried out in accordance with their guidelines.  
Reagents. Ac4ManNAz,16 Ac4ManNPoc, Ac53Fax-Neu5Ac and Ac34-deoxy-GlcNAc were synthesized as 
described before and dissolved in PBS.2-4 Azide-PEG3-biotin and alkyne-PEG4-biotin conjugates, 
sodium L-ascorbate, L-histidine, copper(II) sulfate pentahydrate, and Ponceau S solution were 
purchased from Sigma- Aldrich. Biotinylated lectins MALII (Maackia amurensis) and SNA-I (Sambucus 
nigra) and carbo-free blocking solution were purchased from Vector Laboratories, Inc.. 7-AAD 
viability dye was purchased from eBioscience, streptavidin-phycoerythrin, from BD Pharmingen, 
NeutrAvidin-Texas Red and DAPI nucleic acid stain, from Molecular Probes, Inc., Mowiol 4-88 
mounting medium, from Merck, and Neutravidin DyLight 800, from Pierce Biotechnology.  
Cell Culture. Jurkat cells (TIB-152, ATCC), THP-1 cells (TIB- 202, ATCC), and HL-60 cells (CCL-240, 
ATCC) were cultured in RRMI-1640 medium (Life Technologies) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Greiner Bio-one), 2 mM glutamine (Lonza), and 1× 
antibiotic−antimycotic solution (100 units/mL of penicillin, 100 μg/mL of streptomycin, and 0.25 
μg/mL Fungizone) (Life Technologies). HEK293 cells (CRL-1573, ATCC) were cultured in DMEM (Life 
Technologies) supplemented with 10% FBS, 2 mM Glutamine, 1% nonessential amino acids (Life 
Technologies), and 1% antibiotic−antimycotic solution. IHH cells were cultured in Williams Medium E 
(Life Technologies) supplied with 10% FBS (PAA), nonessential amino acids (NEAA) (Life 
Technologies), 100 U/mL penicillin/streptomycin (Life Technologies), 0.05 μM dexamethasone 
(Sigma), 2 mM glutamine (Life Technologies), and 20 U/mL insulin (Roche) on gelatin-coated 6-well 
plates as described.52 HAP1 cells were cultured in IMDM (Life Technologies) supplemented with 10% 
FBS, 200 μM L-glutamine (Life Technologies), and 1% antibiotic−antimycotic solution.53-54 SLC35A1 
knockout HAP1 cells were a kind gift of Thijn R. Brummelkamp, Netherlands Cancer Institute, 
Amsterdam, The Netherlands, and were complemented with full-length wild-type SLC35A1 mRNAs a 
described before.55-56 All cells were cultured in a humidified CO2 incubator at 37 °C.  
Detection of Surface Sialoglycans by Flow Cytometry. To label azide or propargyloxycarbonyl-
containing surface glycoconjugates, cells were washed in 1× PBS and incubated with 100 μL of CuAAC 
reaction buffer (1× PBS containing 250 μM CuSO4, 250 μM L-histidine, 500 μM sodium ascorbate, and 
either 100 μM azide-PEG3- biotin or 100 μM alkyne-PEG4-biotin) for 30 min at r.t..38 For detection of 
endogenous glycoconjugates, cells were incubated 1 h with the biotinylated lectins MALII (5 μg/mL), 
SNA-I (1 μg/mL), PNA (5 μg/mL), or WGA (5 μg/mL) in carbo-free blocking solution containing 1 mM 
CaCl2+ and 1 mM MgCl2+ at 4 °C. MALII was used to detect α2,3-linked sialic acids, SNA-I, for α2,6-
linked sialic acids, PNA, for terminal β-galactose, and WGA, for detection of (poly)- GlcNAc 
(chitobiose). Cells were washed in FACS buffer (1× PBS containing 1% FBS and 0.02% sodium azide), 
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and biotinylated glycoconjugates or cell-bound biotinylated lectins were conjugated for 10 min at 4 
°C with 2 μg/mL streptavidin-phycoerythrin. Additionally, cells were stained with 7-AAD viability dye. 
Fluorescence was measured using a CyAn ADP flow cytometer (BD Biosciences) and quantified 
utilizing FlowJo software (Tree Star Inc.). Untreated cells or cells stained solely with streptavidin 
served as background control. The percentage labeling or lectin binding was calculated by 
normalizing the fluorescence values to the respective control.  
Titration of Azide and Poc Sugars and Inhibition of Sialoglycan and Glycosaminoglycan Synthesis. 
To compare the incorporation efficiency of azide-/Poc-mannosamines or sialic acids into cell surface 
glycoconjugates, Jurkat or THP-1 cells were incubated for 3 days with increasing concentrations of 
Ac4ManNAz, Ac4ManNPoc, Ac5NeuNAz, or Ac5NeuNPoc and subjected to CuAAc and flow cytometry 
analysis. Ac4ManNAc and Ac5NeuNAc were used as nonlabeling controls. To determine the optimal 
incubation time for bioorthogonal metabolic glycoengineering with Ac4ManNPoc or Ac5NeuNPoc, 
Jurkat and THP-1 cells were incubated for 0−4 days with 100 μM sugar analogues, labeled, and 
analyzed by flow cytometry. Additionally, Jurkat, THP-1, HL-60, or HEK293 cells were incubated 3 
days with 100 μM Ac4ManNPoc or Ac5NeuNPoc to compare their labeling efficiencies. To inhibit 
sialoglycan or glycosaminoglycan synthesis, Jurkat or THP-1 cells were incubated with 200 μM 
Ac53Fax- Neu5Ac or 200 μM Ac34-deoxy-GlcNAc for 3 days prior to the addition of 100 μM 
Ac4ManNPoc or Ac5NeuNPoc for three more days. Efficacy of both metabolic inhibitors was 
confirmed by flow cytometry using lectin stainings with MAL-II, SNA-I, and WGA, respectively. To test 
incorporation of Ac4ManNPoc or Ac5NeuNPoc in SLC35A1 knockout HAP1 cells, cells were incubated 
3 days with 100 μM of the sugar analogues and labeled via CuAAC, and the presence of modified 
glycoconjugates as well as MALII, SNA-I, and PNA lectin binding was determined by flow cytometry.  
Confocal Microscopy. THP-1 cells were seeded on glass slides and incubated for 3 days in medium 
containing PBS and 100 μM Ac4ManNPoc or Ac5NeuNPoc. Ten hours before CuAAC, PMA (0.1 μM 
final concentration) and IL-4 (500 U/ml final concentration) were added to the medium to induce 
differentiation and adherence to the glass slides. Cells were washed with 1× PBS and incubated for 
30 min at RT in CuAAC reaction buffer. Next, cells were washed with 1× PBS, fixed for 10 min with 2% 
paraformaldehyde on ice, blocked 30 min with carbo-free blocking solution, and incubated for 20 
min at 4 °C with 5 μg/mL NeutrAvidin-Texas Red. Cell nuclei were stained by incubating the cells 10 
min with DAPI. Samples were washed and mounted with Mowiol, and images were acquired using an 
Olympus FV1000 confocal laser scanning microscope (Olympus).  
Transferrin Purification. Fully confluent 6-well plates with IHH cells were further grown in the 
presence of 200 μM Ac5NeuNAc, Ac4ManNPoc, or Ac5NeuNPoc for an additional 48 h. 1.5 mL of 
medium was collected and further used for immune affinity purification of secreted transferrin. The 
remaining cells were washed 3 to 4 times with PBS and collected by scraping, lysed, and used for 
western blot analysis as described below. Transferrin purification was done from 1.5 mL of medium 
incubated with a 40 μL of a 50% slurry of rabbit anti-human transferrin antibody (DAKO) coupled to 
NHS activated Sepharose 4 Fast Flow beads (GE Healthcare). After a 1 h incubation at RT, beads were 
washed three times with 10 mM Tris- HCl buffer, pH 7.0, and bound transferrin was eluted in 50 μL of 
100 mM glycine-HCl buffer, pH 2.7. The solution was neutralized with 1 to 2 μL of 1 M Tris-HCl buffer, 
pH 9.0, and purified transferrin was subjected to western blot analysis. Western Blot Analysis. THP-1 
cells with or without preincubation with Ac53Fax-Neu5Ac were incubated 3 days with 100 μM 
Ac4ManNPoc or Ac5NeuNPoc. Following reaction of Poc-containing cell surface glycoconjugates with 
azide-PEG3-biotin, cells were washed in 1× PBS and lysed for 1 h on ice in lysis buffer (150 mM NaCl, 
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50 mM TRIS-HCl, pH 7.5, 5 mM EDTA, 0.1% SDS, 1% Triton X-100, and 1× protease inhibitor cocktail). 
Cell lysates were resolved on 10% SDS-PAGE gels and blotted to poly(vinylidene fluoride) (PVDF) 
membranes. Membranes were blocked for 1 h at r.t. with blocking buffer (1× PBS, 2% nonfat dry 
milk, 1% BSA) and incubated with 0.1 μg/mL Neutravidin DyLight 800 in 1:4 blocking buffer for 1 h at 
RT. Following extensive washing with PBS-T (1× PBS, 0.1% Tween-20), membranes were scanned with 
an Odyssey infrared imaging system (LI-COR). To confirm loading equal amounts of protein, 
membranes were stained with Ponceau S solution according to the manufacturer’s protocol. For 
visualization of Poc groups in the glycans of whole IHH cell lysates or purified transferrin, proteins 
were resolved on 10% SDS gels, transferred to PVDF membranes, and membranes were incubated 1 
h at 37 °C with reaction buffer (1× PBS, 500 μM CuSO4, 50 μM azide-PEG3-biotin, 500 μM sodium 
ascorbate) followed by incubation with Neutravidin DyLight 800.  
In Vivo Bioorthogonal Metabolic Glycoengineering. To introduce Poc sugars into cell surface 
glycoconjugates in vivo, mice were injected intraperitoneally for six consecutive days with 
Ac4ManNPoc (700 μmol, 300 mg/kg), an equimolar dose of Ac5NeuNPoc (700 μmol, 400 mg/kg) 
(both dissolved in 60% DMSO), or vehicle control. On day 7, organs were harvested and mechanically 
dissociated using large needles followed by enzymatic digestion with 1 mg mL−1 collagenase Type III 
(Worthington Biochemical Corporation) and 30 μg/mL DNase type I (Roche) for 30 min at 37 °C. 
Single-cell suspensions were prepared using 100 μm nylon cell strainer (BD Biosciences). Cells were 
washed with 1× PBS, incubated 30 min at RT in CuAAC reaction buffer, and subsequently incubated 
for 10 min at 4 °C with 2 μg/mL with streptavidinphycoerythrin. Fluorescent signal was quantified by 
flow cytometry, and data were normalized to the background fluorescence of corresponding control 
single-cell suspensions.  
Statistical Analysis. Statistical significance between two groups was determined by an unpaired t-
test, and for multiple comparisons, one-way analysis of variance (ANOVA) followed by Bonferroni’s 
correction was performed using Prism 5.03 (GraphPad Software, Inc.). p values < 0.05 were 
considered to be significant (p < 0.05, *; p < 0.01, **; p < 0.001, ***).  
 
 
Contributions 
The synthesis and molecular design is done by Heise, T. The biological testing and statistic is done by 
Büll C1 and Beurskens DM1.  
 
1 Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 
Geert Grooteplein 28, 6525 Nijmegen GA, The Netherlands. 
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4 
Steering Siglec-Sialic Acid 
Interactions on Living Cells 
using Bioorthogonal 
Chemistry  
 
“I like to think that when Medawar and his colleagues showed that immunological 
tolerance could be produced experimentally, the new immunology was born.“ 
Frank Macfarlane Burnet (1899-1985), virologist especially interested in Sialic acid 
(not known at his time) binding proteins like hemagglutinin, thereby discovering 
neuraminidase. 
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Abstract  
Sialic acid sugars that terminate cell-surface glycans are the ligands for the sialic acid 
binding immunoglobulin-like lectin (Siglec) family, which are immunomodulatory 
receptors expressed by immune cells. Interactions between sialic acid and Siglecs 
regulate the immune system, and aberrations contribute to pathologies like 
autoimmunity and cancer. Sialic acid/Siglec interactions between living cells are 
difficult to study owing to a lack of specific tools. Here, we report a glycoengineering 
approach to remodel the sialic acids of living cells and their binding to Siglecs. Using 
bioorthogonal chemistry, a library of cells with more than sixty different sialic acid 
modifications was generated that showed dramatically increased binding toward the 
different Siglec family members. Rational design reduced cross-reactivity and led to 
the discovery of three selective Siglec-5/14 ligands. Furthermore, glycoengineered 
cells carrying sialic acid ligands for Siglec-3 dampened the activation of Siglec-3+ 
monocytic cells through the NF-kB and IRF pathways.  
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Introduction 
The immune system defends the host from pathogens and cancer yet must 
discriminate between self and non-self to avoid damage to healthy tissue. An 
important differentiator in this respect is the presence or absence of sialic acid sugars 
on the cell surface.1-2 Sialic acids are found on the terminus of cell-surface glycan 
chains and regulate the immune system by interacting with the sialic acid binding 
immunoglobulin-like lectin (Siglec) family.3-5 In humans, 14 Siglecs (Siglecs-1–11 and 
Siglecs-14–16) are expressed on immune cells. Siglecs contain an extracellular sialic 
acid binding domain and most Siglecs contain an intracellular immunoreceptor 
tyrosine based inhibitory motif (ITIM; Figure 1).6  
Figure 1. Sialic acid glycoengineering on living cells to modulate Siglec-mediated immune response. 
Scheme illustrating the use of sialic acid glycoengineering approach to generate cells that express 
chemically modified sialic acids on their surface that act as high affinity ligands for the Siglec family. 
To generate the high affinity Siglec ligand expressing cells (HASLECs), clickable sialic acids are 
introduced into the cellular sialylation pathway and incorporated into cell surface sialoglycans. (1) 
The clickable sialoglycans on the cell surface can then be reacted with clickable azides and alkynes (2) 
and their impact on binding to Siglecs can be assessed (3). The sialic acid glycoengineered cells can 
interact with Siglec expressing immune cells to modulate immune activation for instance mediated 
via Toll-like receptor stimulation (4). 
113 
 
Alternatively, Siglecs-14–16 can recruit an immunoreceptor tyrosine-based activation 
motif (ITAM). Siglecs can bind to sialic acids present on the same cell (cis binding) or 
sialic acids present on an adjacent cell (trans binding), and in general, these 
interactions dampen immune-cell activation.5-8 Aberrations in sialic acid and Siglec 
expression have been associated with autoimmunity, inflammatory diseases, 
neurodegeneration, and cancer.7, 9-15 Although the importance of the sialic acid/Siglec 
interaction in immune regulation is well documented, its role in physiological and 
pathological processes is still poorly understood.5, 7 To elucidate the function of sialic 
acid/Siglec interactions, tools are needed to specifically target Siglecs in a cellular 
context. This is difficult since sialic acids bind Siglecs in a monovalent manner with 
low affinity (0.1–3 mm).5 Chemical modification of sialic acids can augment Siglec 
binding affinity and selectivity, and such modifications can be introduced through 
copper-catalyzed azide–alkyne cycloaddition (CuAAC).16-19 However, these 
approaches are often not applicable to cell-based assays and lack multivalent 
presentation in a natural context, which is a crucial determinant in Siglec binding.20 
Recently, sialoglycan-decorated polymers have been developed that can be 
integrated into the cell surface to bind Siglec-7.21 However, the use of unnatural 
polymers does not provide a natural context and is labor-intensive. Therefore, we 
investigated the possibility of using bioorthogonal chemistry to modify sialic acids on 
living cells to enhance their binding to Siglecs whilst maintaining their natural 
multivalent presentation on the cell surface (Figure 1). To this end, alkyne- or azide-
modified sialic acids were metabolically incorporated into living cells and reacted 
with over sixty different azides/alkynes using CuAAC.22-23 The obtained library of 
glycoengineered cells was screened for binding to the human Siglec family and this 
led to the identification of modifications that dramatically increase Siglec binding 
(>100 fold). Using structure-guided design, sialic acid modifications highly selective 
for Siglec-5 and its homologue Siglec-14 were developed. Finally, functional analysis 
showed that the glycoengineered cells programmed to bind Siglec-3 are able to 
dampen the activation of Siglec-3+ immune cells.  
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Results and Discussion 
Glycoengineering was achieved by culturing Jurkat cells in the presence of 
Ac5NeuNPoc or Ac5NeuNAz, which results in the expression of alkyne and azide 
sialoglycans on the cell surface.22 Jurkat cells were used because they express α2,3- 
and α2,6-sialic acids, but do not express Siglecs thereby circumventing cis binding. To 
confirm the efficient incorporation of alkyne- and azide-modified sialic acids, the cells 
were reacted with azide- or alkyne-conjugated biotin (azide/alkyne-biotin) using 
CuAAC in the presence of histidine to minimize cytotoxicity.24 Biotin tagged surface 
glycans were detected with streptavidin conjugated phycoerythrin (streptavidin-PE) 
by flow cytometry. As expected, high fluorescence was detected for Ac5NeuNPoc and 
Ac5NeuNAz but not for the control sialic acid Ac5NeuNAc. Next, cells carrying alkyne- 
or azide-modified sialoglycans were reacted with 49 different azides (L1–L49) and 15 
different alkynes (L50–L64; Figures 2 and 3), respectively.  
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Figure 2. Clickable azides for the modification of alkyne sialic acids and yield-percentage of click 
reaction. Click reaction efficiency of L1-49 to surface alkyne or azide sialic acids were determined by 
flow cytometry using two click reactions. First with control or L1-64, second with biotin-azide or 
alkyne-biotin followed by streptavidin-PE labeling and flow cytometry analysis compared to DMSO.  
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Figure 3. Clickable alkynes for the modification of azide sialic acids and yield-percentage of click 
reaction. Click reaction efficiency of L50-64 to surface alkyne or azide sialic acids are shown (n = 3). 
Click efficiencies were determined by flow cytometry using two click reactions. First with control or 
L50-64, second with biotin-azide or alkyne-biotin followed by streptavidin-PE labeling and flow 
cytometry analysis. The reduction in streptavidin-PE labeling of cells clicked with L50-64 was used to 
calculate reaction efficiencies compared DMSO.  
 
To determine the reaction efficiency, a second reaction was performed with 
azide/alkyne-biotin to detect remaining alkynes/azides. All azides and alkynes tested 
showed reaction efficiencies of more than 78% (Figures 2, 3). L1–L64 were selected 
on the basis of known structures and in silico docking experiments (see below).25-27 To 
maximize the exploration of chemical space neighboring the sialic acid binding 
domain, aromatic, aliphatic, and charged azides or alkynes were synthesized. In 
addition, functional groups that can engage in hydrogen bonding were included 
(Figures 2,3). Having demonstrated that L1–L64 react efficiently with the clickable 
sialic acids, the binding of available recombinant human Siglecs in the form of Siglec– 
Fc chimeras (Fc = fragment crystallizable region of an anti-body) to the modified cells 
was assessed. To detect binding, the recombinant Siglec–Fc chimeras were pre-
complexed to Alex Fluor 647 (AF647)-conjugated anti-human-Fc antibodies. The 
AF647-conjugated anti-human-Fc antibodies alone showed no binding to L1–L64-
modified Jurkat cells, but significant changes in binding of the pre-complexed Siglec–
Fc chimeras to the glycoengineered cell library was observed (Figure 4, Table 1). The 
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addition of L1–64 to alkyne and azide sialic acid treated cells in the absence of CuSO4 
had no effect on Siglec binding, as expected. From the data shown in Figure 4, Table 
1, it is clear that chemical modification of the sialic acids on living cells drastically 
alters their interaction with Siglecs. Based on the binding patterns, the Siglec family 
could be roughly divided into two main groups. The first group includes Siglecs-2, -3, -
6, -8, -10, and -11, which reacted with only a few (1–6) of the sialic acid modifications 
presented by the cells. The second group, which includes Siglecs-5/-14, -7, and -9, 
reacted with many (11–49) glycoengineered cells. In contrast, no significant change in 
the binding of Siglec-4 to any of the modified cells was found. To confirm applicability 
across different cells lines, HEK293 kidney cells treated with Ac5NeuNPoc were 
reacted with a selection of azides and screened for Siglec binding. Similar results to 
those in the Jurkat cell were obtained, which confirmed that the sialic acid 
modifications specifically enhance Siglec binding. Except for Siglec-4, glycoengineered 
cells were identified for each Siglec family member tested, including the orphan 
Siglecs, Siglecs-6, -8, and -11. Some modifications showed affinity to multiple Siglecs. 
While these modifications could be useful to target different Siglecs at the same time, 
selective targeting is required to study or manipulate an individual Siglec family 
member. Siglecs-5/-14, -7, and -9 showed similar binding preferences for sialic acids 
modified with benzyl azides (Figure 4, Table 1). 
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Figure 4. Sialic acid-modified cell library for binding to human Siglec family. Jurkat cells incubated 
with control Ac5NeuNAc, Ac5NeuNPoc or Ac5NeuNAz, were reacted to nothing or L1-64, stained with 
recombinant Siglec Fc chimera pre-complexed with AF647-conjugated anti-human Fc antibodies and 
analyzed by flow cytometry (n  =4-8). Outstanding click-ligands are depicted. 
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Ligand  Sugar  Control  -2 -3 -4 -5 -6 -7 -8 -9 -10 -11 -14  >Siglecs 
-  Ac5NeuNAc  1,1 1,0 1,0 1,2 3,4 0,7 1,0 1,3 1,3 0,8 0,9 2,0   
-  Ac5NeuNPoc  1,1 1,8 1,1 1,0 6,2 1,2 1,2 1,3 1,2 0,9 1,2 1,0   
-  Ac5NeuNAz  1,3 1,3 1,2 0,6 1,0 1,1 2,2 1,1 5,4 4,0 0,9 5,2    
L1   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ac5NeuNPoc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 1.8 2.2 0.7 40.8 1.8 5.3 1.2 9.2 2.5 1.5 17.4   
L2  1.5 1.3 1.3 1.2 14.8 1.3 2.3 1.2 6.3 1.3 1.2 11.0   
L3  2.1 1.8 2.5 1.2 24.7 1.0 3.9 1.5 6.7 3.8 1.2 5.3   
L4  1.9 1.7 92.7 1.6 90.3 1.8 6.8 6.0 11.3 2.4 2.0 28.6   
L5  1.4 1.1 3.5 1.6 84.9 15.6 11.2 1.4 8.9 1.2 1.8 74.7   
L6  2.0 1.2 1.8 1.1 48.3 1.3 6.3 1.9 12.3 2.6 1.5 10.7   
L7  0.6 0.6 1.1 4.7 166.9 3.5 1.7 2.5 4.9 1.7 4.1 77.0   
L8  0.4 0.6 1.0 1.2 42.3 1.6 1.2 0.7 4.5 1.7 1.1 31.2   
L9  0.5 0.8 1.0 1.2 59.6 1.0 1.0 0.3 2.8 0.8 0.9 20.2   
L10  0.5 0.8 1.4 0.3 52.7 1.1 1.2 4.5 7.8 3.9 1.9 35.6   
L11  1.9 1.4 1.5 1.1 10.2 0.9 1.5 1.7 2.8 1.1 1.1 4.5   
L12  0.5 0.6 1.0 2.2 75.5 1.0 1.5 3.0 3.1 10.4 1.1 44.0   
L13  0.6 0.5 1.0 1.9 42.3 2.1 1.1 1.3 3.0 1.2 0.9 21.2   
L14  0.8 0.6 1.0 1.4 98.9 4.5 1.3 0.9 3.6 2.4 1.6 49.5   
L15  0.8 0.7 1.0 1.9 87.2 1.0 1.3 1.4 3.7 1.3 2.5 53.7   
L16  0.7 1.0 0.9 3.7 80.7 1.4 1.9 3.4 5.7 1.5 1.2 41.6   
L17  0.5 0.5 2.1 2.3 101.4 5.6 1.3 3.4 3.8 0.8 2.7 48.8   
L18  1.2 0.6 1.0 3.8 90.7 1.3 1.8 1.1 5.3 2.1 2.8 45.1   
L19  2.0 15.0 3.3 1.0 64.6 1.9 5.5 2.0 12.8 3.6 1.6 21.1   
L20  0.8 0.7 1.1 0.8 45.2 1.6 0.8 2.3 6.0 3.3 1.6 75.4   
L21  1.8 2.6 2.4 1.3 43.4 13.0 4.3 13.5 9.5 3.2 3.0 13.6   
L22  2.3 1.9 5.3 1.1 66.6 2.2 9.3 2.6 12.7 2.9 2.4 26.4   
L23  1.5 1.2 2.5 1.1 50.8 3.2 6.4 2.5 9.2 1.4 1.3 32.0   
L24  1.5 1.2 1.3 1.1 27.2 0.8 1.5 3.6 2.2 1.0 1.2 17.4   
L25  1.5 1.1 1.2 1.1 33.0 0.8 1.5 3.0 2.3 0.9 1.3 18.7   
L26  1.2 1.2 1.3 1.4 36.7 1.1 1.0 1.5 2.4 0.9 1.2 19.8   
L27  1.4 1.6 1.4 0.9 19.5 1.4 1.8 3.7 8.6 1.9 1.2 4.9   
L28  1.3 1.0 1.4 1.0 36.9 0.8 5.1 1.3 2.5 0.8 1.1 37.1   
L29  1.1 1.3 1.6 1.1 22.6 0.9 3.0 1.2 2.3 0.9 1.2 17.6   
L30  1.6 1.2 1.9 0.9 9.7 1.1 1.9 1.3 3.5 1.3 1.0 5.9   
L31  1.9 1.5 5.6 1.2 113.0 4.6 9.3 8.3 12.3 2.9 1.3 46.7   
L32  1.2 1.3 1.1 1.1 1.9 1.0 1.2 1.7 3.9 1.4 1.0 1.3   
L33  0.8 1.1 1.1 0.7 1.6 2.6 1.3 2.9 4.3 2.2 1.3 1.3   
L34  0.9 1.2 1.3 0.7 3.5 1.3 1.0 2.2 4.2 1.4 1.2 1.3   
L35  1.2 3.9 2.8 1.0 17.1 4.4 1.4 6.2 5.0 2.1 1.7 6.1   
L36  0.8 0.5 1.0 0.5 59.9 0.5 1.1 2.2 3.2 1.2 1.2 35.8   
L37  0.6 0.6 1.0 0.9 36.9 1.1 1.0 0.8 2.6 4.4 0.9 17.2   
L38  0.8 0.7 1.0 2.5 38.6 2.2 1.2 1.2 5.6 2.7 1.5 53.3   
L39  1.8 1.2 113.6 1.4 92.4 1.1 5.8 4.1 8.6 2.2 1.2 41.5   
L40  2.3 1.1 1.7 1.2 9.7 0.8 1.6 1.3 3.8 1.2 1.4 8.8   
L41  2.2 1.2 1.9 1.1 39.9 1.1 5.6 2.0 7.1 2.4 1.3 20.9   
L42  0.8 0.6 1.0 0.5 3.4 0.7 0.9 1.0 2.1 1.2 1.1 2.1   
L43  0.8 0.5 1.0 0.6 3.6 0.7 0.8 1.4 2.0 0.9 1.2 1.8   
L44  0.9 0.6 1.0 0.6 3.3 0.9 0.9 1.2 2.0 1.3 1.2 1.8   
L45  1.1 1.0 8.0 0.9 38.9 2.3 1.6 3.6 5.0 1.7 2.8 12.3   
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L46   
 
 
 
 
 
 
 
 
Ac5NeuNPoc 
 
1.3 0.7 1.6 0.7 2.0 1.1 1.2 2.2 2.3 1.8 1.4 1.3   
L47  1.0 0.7 2.0 0.8 53.7 1.6 1.7 1.4 2.9 0.8 2.3 8.9   
L48  0.8 0.7 1.8 0.8 18.8 1.2 1.3 2.2 3.4 1.5 1.8 8.3   
L49 
 
0.9 0.7 2.1 0.8 2.6 1.1 1.3 1.9 2.5 0.7 1.0 1.5   
L50  
Ac5NeuNAz 
1.2 1.9 1.1 0.8 1.6 1.0 1.3 1.1 1.8 1.0 1.3 1.3   
L51  1.3 1.7 1.1 0.8 1.0 1.0 1.1 1.0 2.0 0.9 1.4 1.0   
L52  1.1 1.6 1.2 0.8 1.8 1.0 1.3 0.9 2.1 1.1 1.7 1.2   
L53  1.4 1.8 1.3 0.8 1.3 1.1 1.2 0.8 1.9 1.0 1.6 0.9   
L54  1.9 9.0 2.5 1.0 31.5 1.8 4.8 8.0 5.4 1.4 8.7 12.2   
L55  0.8 0.7 2.0 0.6 2.4 1.0 0.7 0.8 1.6 2.4 0.8 1.3   
L56  0.8 0.6 2.9 0.7 3.0 1.0 0.9 1.2 2.2 2.2 1.0 1.6   
L57  1.8 1.1 46.5 1.9 155.4 4.2 3.3 3.7 4.6 1.4 9.1 54.8   
L58  0.8 0.8 7.2 0.7 25.9 1.4 1.4 1.6 3.6 1.5 1.6 7.8   
L59  1.3 0.7 2.4 0.6 6.3 1.0 1.1 1.5 1.8 0.8 0.8 1.9  Fold  
L60  1.3 0.6 1.3 0.8 22.6 1.3 1.4 1.8 3.0 1.0 1.2 6.2  Binding  
L61  0.8 0.6 0.9 0.7 4.7 0.9 0.9 1.5 1.9 1.4 1.0 2.3  >5 
L62  0.8 0.6 0.9 0.5 1.6 0.9 0.9 0.9 1.1 0.9 1.0 0.9  >10 
L63  1.2 1.8 1.1 0.7 1.0 1.2 1.2 1.2 1.6 0.9 1.4 0.8  >25 
L64  1.8 45.8 3.8 1.5 12.2 23.5 2.8 16.5 7.3 1.6 6.4 11.5  >50 
Table 1. Mean fold change binding data from the Siglec binding screen (Figure 4).  
 
To investigate the possibility of selectively targeting individual Siglecs, we modeled 
the benzyl derivatives into the crystal structure of Siglec-5.28 This revealed an aspartic 
acid residue (D130) in the F-G turn close to the sialic acid modification. Sequence 
alignment of Siglecs-7 and -9 showed that neither of them shares a negatively 
charged amino acid at this position. We reasoned that positively charged 
modifications such as L24–L26 could form a salt bridge with D130 and might allow for 
the selective binding of Siglec-5/-14, which was confirmed by docking experiments 
(Figure 5a). We therefore synthesized L24–L26, and as predicted, the presence of 
these positively charged groups on the surface of Jurkat cells enhanced binding to 
Siglec-5 and its homologue Siglec-14 but not to Siglecs-7 and -9 or any other Siglec 
family member (Figure 5b). It should however be noted that other ligands such as L6 
did perform better than L24-26 in terms of binding affinity without a positive group. 
The positive charge was generally unfavorable for binding but was tolerated better in 
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Siglec-5 compared to other Siglecs and therefore still creating high selectivity but not 
affinity. These data demonstrate that, depending on the structure of the V-set 
domain, clickable molecules can be produced that alter sialic acids selectivity for a 
particular Siglec member. Moreover, other single (C-2, C-4, C-9) or multiple 
modifications of the sialic acid backbone could further improve Siglec binding affinity 
and avidity.29-31  
  
122 
 
 
 
Figure 5. Structure-guided design to obtain selective sialic acid ligands for Siglec-5/14. a) Docking 
pose of L24-26 to the V-set domain of Siglec-5. Best scored docking poses for sialic acid conjugated 
with L24-26 (from left to right) on the Siglec-5 X-ray structure 2ZG1 are shown. The modified sialic 
acids are presented in grey sticks and hydrogen bonds are shown as yellow dotted lines. Amino acid 
residues important for sialic acid interactions are indicated. b) Binding of recombinant Siglec Fc 
chimera to Jurkat cells modified with L24-26. Data are presented as fold change Siglec binding. 
 
Having established the ability to drastically improve Siglec binding affinity and 
selectivity use bioorthogonal chemistry, we next investigated the functional 
consequences of such modifications. To this end, we investigated the effect of the 
interaction between glycoengineered Jurkat T-cells that show high binding to Siglec-
3, and Siglec-3-expressing monocytic THP1-DUAL cells. Siglec-3 is normally expressed 
on myeloid cells, monocytes, myeloid leukemia cells, and microglia cells and contains 
an intracellular ITIM.7, 16 THP1-DUAL cells express Siglec-3 but no other Siglec family 
member31 and secrete alkaline phosphatase (AP) in response to immune activation 
through the NF-kB pathway, and luciferase (Luc) in response to signaling through the 
IRF pathway.32-33 The two pathways play distinct roles in the activation of the immune 
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system and can be triggered by Tolllike receptor (TLR) ligands. Therefore, this 
reporter cell model allowed us to study the effect of sialic acid/Siglec-3 interactions 
on the activation of monocytic cells through the NF-kB and IRF pathways.33-35 From 
our glycoengineered cell library (Figure 4, Table 1), we selected three sialic acid 
modifications (L4, L39, and L57) that strongly enhance Siglec-3 binding. As a positive 
control, anti-Siglec-3 antibodies were used that have been shown to cross-link Siglec-
3, thereby inducing signaling and SHP-1/-2 recruitment to the ITIM.36 As a negative 
control, Jurkat cells modified with L40, which showed no Siglec-3 binding, and 
unconjugated Jurkat cells were used (Figure 4, Table 1). Next, the THP1-DUAL cells 
were activated by TLR ligands LPS and Pam3CSK4, resulting in high production of AP 
and Luc (Figure 6).  
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Figure 6. Glycoengineered cells dampen immune activation via Siglec-3. a,b) Effect of 
glycoengineered cells on Siglec-3+ THP1-DUAL reporter cell activation by TLR ligands. Jurkat cells 
incubated with Ac5NPoc or Ac5NeuNAz were reacted to nothing, L4, L39, L40 or L57 and co-cultured 
with Siglec-3+monocytic THP1-DUAL reporter cells. THP1-DUAL cells alone or together with anti-
Siglec-3 cross-linking antibodies were used as control. The reporter cells were treated with PBS, LPS 
or Pam3CSK4 and AP and Luc activity in the culture supernatant was determined as a measure for 
cell activation via the NF-κB or IRF pathway, respectively. Bar diagrams show mean AP reporter 
activity ± SEM (a) or mean Luc reporter activity ± SEM (b) of three independent experiments. 
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Co-culture with unmodified Jurkat cells or Jurkat cells modified with L40 had no 
significant effect on THP1-DUAL cell activation, whereas cross-linking of Siglec-3 with 
antibodies reduced AP and Luc secretion. Intriguingly, co-culture with L4, L39, or L57- 
modified Jurkat cells was as effective as antibody cross-linking of Siglec-3 in reducing 
Tolllike receptor and IRF signaling. To further show that the dampening effect of the 
glycoengineered cells was mediated by Siglec signaling, the reporter cells were pre-
treated with the SHP- 1/-2 inhibitor NSC-87877, which abrogated the inhibiting 
effects of both the anti-Siglec-3 antibodies and the L4, L39, and L57- modified Jurkat 
cells (Figure 7). 
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Figure 7. NSC-87877 inhibits immune suppression via Siglec-3. a, b) Jurkat cells incubated with 
Ac5NeuNPoc or Ac5NeuNAz were reacted to nothing, L4, L39, L40 or L57 and co-cultured with Siglec-
3+ monocytic THP1-DUAL reporter cells that were treated with the SHP-1/-2 inhibitor NSC-87877 
prior to the co-culture. THP1-DUAL cells alone or together with anti-Siglec-3 cross-linking antibodies 
were used as control. Reporter cells  were treated with PBS, LPS or Pam3CSK4. Subsequently, cell 
activation via the NF-κB or IRF pathway was determined by alkaline phosphatase a) and luciferase 
activity b) in the culture supernatant, respectively.  
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These findings suggest that glycoengineered T-cells can induce immune inhibitory 
Siglec-3 signaling that counteracts the activation of immune cells through the NF-kB 
and IRF pathways. Possibly, the glycoengineered T-cells cross-link Siglec-3, thereby 
leading to SHP-1/-2 recruitment and suppression of activation through the TLR 
pathway.  
 
Conclusion 
Altogether, the described glycoengineering approach can be used to modulate sialic 
acid/Siglec interactions on a cellular level and may hold therapeutic potential in the 
context of autoimmune diseases and allergies. In conclusion, we have developed a 
glycoengineering approach to readily modify the surface sialic acids of living cells and 
their Siglec binding. Next to being applied as a type of living glycan array, the 
glycoengineered cells can be used to study and steer sialic acid/Siglec interactions 
between living cells. The observed immune suppressive activity of the 
glycoengineered cells may be applicable to dampen the immune response in 
autoimmune diseases and allergies. Finally, the general principle of using 
bioorthogonal chemistry to edit the glycocalyx and to alter its interaction with lectins 
may be extended to other classes of sialic acid binding lectins (e.g., selectins, 
hemagglutinin) or other classes of glycan/lectin interactions (e.g., galectins).  
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Supplementary Information 
General chemical procedures: 
General synthetic procedures: 1H and 13C NMR spectra were recorded on a Bruker Avance III 400 
MHz or 500 MHz spectrometer. Chemical shifts are reported in parts per million (ppm) relative to 
tetramethylsilane (TMS) as the internal standard. NMR data is presented as follows: Chemical shift, 
multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet of doublet, m = 
multiplet and/or multiple resonances), integration, coupling constant in Hertz (Hz). All NMR signals 
were assigned on the basis of 1H NMR, 13C NMR, COSY and HSQC experiments. Mass spectra were 
recorded on a JEOL JMS-T100CS AccuTOF mass spectrometer. IR-ATR spectra were measured at 
room temperature on a Bruker TENSOR 27. Automatic column chromatography was performed on 
Biotage Isolera Spektra One, using SNAP cartridges 10-50g (Biotage, 30-100 µm, 60 Å). TLC-analysis 
was conducted on TLC Silicagel, 60, F254, Merck, with detection by UV absorption (254 nm) where 
applicable, and by spraying with 20 % sulfuric acid in methanol followed by charring at ~150 oC or by 
spraying with a solution of (NH4)6Mo7O24.H2O (25 g l-1) in 10 % sulfuric acid in methanol followed by 
charring at ~300 oC. DCM, THF, ACN and Tol were freshly distilled. Molecular sieves 3 Å (AW-300) 
were flame activated under vacuum prior to use. All reactions were carried out under an argon 
atmosphere. If commercially available, azides or alkynes were purchased from Sigma-Aldrich. 
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General method A: Azidation (L7-10, L13-20, L36-38)) 
 
The corresponding chlorinated or brominated starting material was dissolved in a 10 mL mixture of 
water:acetone (1:4 v/v). Sodium azide (1.5 eq.) and potassium iodide (0.1 eq.) were added and the 
reaction mixture was stirred at room temperature (r.t.) for 60 h. The solution was diluted with brine 
and extracted with diethyl ether (3 x 10 mL). The combined organic layers were dried (Na2SO4), 
filtered and concentrated in vacuo to afford the corresponding azide.  
 
General method B: Azidoacetic acid coupling (L41-49) 
 
The amine containing starting material was dissolved in diethyl ether (10 mL). Choroacetyl chloride 
(1.5 eq.) was added and reaction mixture was stirred at r.t. for 12 h. Compounds were extracted 
following the different extraction procedures 1-3. The organic layers separated, combined, dried 
(Na2SO4) and concentrated in vacuo to afford the corresponding intermediate I. 
I was dissolved in 10 mL mixture of water:acetone (1:4 v/v). Sodium azide (2 eq.) and potassium 
iodide (0.1 eq.) were added and the reaction mixture was stirred at r.t. for 18 h. Compounds were 
again extracted following extraction procedures D1 to D3. The organic layers were dried (Na2SO4) 
and concentrated in vacuo to afford the corresponding product (P).  
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General method C: Alkyne coupling (L55-62) 
 
The starting amine was dissolved in diethyl ether (10 mL). Propargyl chloroformate (1.5 eq.) and 
trimethylamine (2 eq.) were added and the reaction mixture was stirred at r.t. for 60 h. The reaction 
mixture was extracted following extraction procedures D1 to D3. The organic layer was dried 
(Na2SO4), filtered and concentrated in vacuo to afford the product. 
 
General method D: Extraction procedures 
D1: Intermediate I was extracted with diethyl ether (3 x 10 mL) and brine.  
D2: Intermediate I was extracted with diethyl ether (3 x 10 mL) and aqueous NaOH (5 %, 1.25 M).  
D3: Intermediate I was extracted with diethyl ether (3 x 10 mL) and aqueous HCl (1 M). 
 
 
   Azidobenzene solution, 0.5 M in tbutyl methyl ether, CAS: 622-37-7 
   Compound has been described previously.37  
  Compound has been described previously. 38 
   Compound has been described previously.39 
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  Compound has been described previously.40  
   Benzylazide solution, 0.5 M in DCM, CAS: 622-79-7 
  1-(azidomethyl)-2-methylbenzene. Compound was synthesized from 3-
methylbenzyl chloride following general method A. L7 was obtained as a colorless oil (226 mg; 1.538 
mmol; 72 %). TLC: (DCM: heptane, 20:80 v/v) Rf = 0.61; 1H NMR (500 MHz, CDCl3) δ 7.42 – 7.31 (m, 
4H, 4x CH Ar), 4.44 (s, 2H, CH2), 2.49 (s, 3H, CH3). 13C NMR (126 MHz, CDCl3) δ 136.89 (C-CH2N3), 
133.59 (C-CH3), 129.42 (CH Ar), 128.73 (CH Ar), 126.33 (CH Ar), 53.11 (CH Ar), 19.00 (CH3). IR (ATR, ν, 
cm-1): 20901 (N3). 
  1-(azidomethyl)-3-methylbenzene. Compound was synthesized from 3-
methylbenzyl chloride following general method A. L8 was obtained as a colorless oil (300 mg; 2.03 
mmol; 95 %). TLC: (DCM: heptane, 20:80 v/v) Rf = 0.66; 1H NMR (500 MHz, CDCl3) δ 7.43 (d, 1H, J = 
7.5 Hz, CH Ar), 7.33 – 7.23 (m, 3H, 3x CH Ar), 4.40 (s, 2H, CH2), 2.52 (s, 3H, CH3). 13C NMR (126 MHz, 
CDCl3) δ 138.65 (C-CH2N3), 135.53 (C-CH3), 129.18 (CH Ar), 129.08 (CH Ar), 128.84 (CH Ar), 125.42 (CH 
Ar), 54.88 (CH2), 21.42 (CH3). IR (ATR, ν, cm-1): 2093 (N3). 
  1-(azidomethyl)-4-methylbenzene. Compound was synthesized from 4-
methylbenzyl chloride following general method A. L9 was obtained as a colorless oil (283 mg; 1.92 
mmol; 90 %). TLC: (DCM: heptane, 20:80 v/v) Rf = 0.51; 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.29 (m, 
4H, 4x CH Ar), 4.38 (s, 2H, CH2), 2.50 (s, 3H, CH3). 13C NMR (126 MHz, CDCl3) δ 138.18 (C-CH2N3), 
132.54 (C-CH3), 129.63 (2x CH Ar), 128.40 (2x CH Ar), 54.67 (CH2), 21.21 (CH3). IR (ATR, ν, cm-1): 2092 
(N3). 
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  2-(azidomethyl)naphthalene. Compound was synthesized from 2-
bromomethylnaphtalene following general method A. L10 was obtained as a slightly yellow solid 
(188 mg; 1.028 mmol; 76 %). TLC: (DCM: heptane, 20:80 v/v) Rf: 0.53; 1H NMR (500 MHz, CDCl3) δ 
7.98 – 7.91 (m, 3H, 3x CH Ar), 7.84 (d, 1H, J = 1.8 Hz, CH Ar), 7.64 – 7.59 (m, 2H, CH Ar), 7.50 (dd, 1H, J 
= 8.4, 1.8 Hz, CH Ar), 4.53 (s, 2H, CH2). 13C NMR (126 MHz, CDCl3) δ 133.40 (C-CH2N3), 133.22 (C Ar), 
132.98 (C Ar), 128.87 (CH Ar), 128.10 (CH Ar), 127.91 (CH Ar), 127.28 (CH Ar), 126.60 (CH Ar), 126.48 
(CH Ar), 125.98 (CH Ar), 55.06 (CH2). IR (ATR, ν, cm-1): 2093 (N3). 
  Compound has been described previously. 41 
  1-(azidomethyl)-2-fluorobenzene. 1-(chloromethyl)-2-fluorobenzene (300 
mg; 2.075 mmol) was dissolved in a mixture water: acetone (44 mL; 1:10 v/v; 47 mM), sodium azide 
(337 mg ;5.19 mmol; 2.5 eq.) and potassium iodide (34 mg; 208 µmol; 0.1 eq.) were added and the 
reaction mixture was stirred overnight at 80 °C. The reaction mixture was diluted with brine and 
extracted with EtOAc (3 x 10 mL). The combined organic layers were dried (Na2SO4), filtered and 
concentrated in vacuo to afford L12 (0.175 g; 1.158 mmol; 55.8 %). TLC: (DCM:heptane, 20:80 v/v) Rf 
= 0.61; 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.34 (m, 2H, 2x CH Ar), 7.21 (td, 1H, J = 7.5, 1.2 Hz, CH-
CCH2N3), 7.15 (ddd, 1H, J = 9.6, 8.1, 1.2 Hz, CH Ar), 4.44 (d, 2H, J = 1.5 Hz, CH2). 13C NMR (126 MHz, 
CDCl3) δ 161.92 (C-F), 130.49 (2x CH Ar), 124.48 (CH Ar), 122.69(C-CH2N3), 115.72 (CH Ar), 48.48 
(CH2). IR (ATR, ν, cm-1): 2097 (N3).  
  4-(azidomethyl)-1,2-difluoro-benzene. Compound was synthesized from 3,4-
difluorobenzyl chloride following general method A. L13 is obtained as a colorless oil (292 mg; 1.725 
mmol; 93 %). TLC: (DCM:heptane, 20:80 v/v) Rf = 0.52; 1H NMR (500 MHz, CDCl3) δ 7.26 – 7.03 (3H, 
m, ArH), 4.33 (2H, s, CH2). 13C NMR (126 MHz, CDCl3) δ 151.26 (dd, J = 25.8, 12.7 Hz, CF), 149.28 (dd, J 
= 25.5, 12.7 Hz, CF), 132.61 (dd, J = 5.4, 3.9 Hz, C-CH2N3), 124.17 (dd, J = 6.5, 3.7 Hz, CH Ar), 117.55 (d, 
J = 17.5 Hz, CH Ar), 117.05 (d, J = 17.7 Hz, CH Ar), 53.56(CH2). IR (ATR, ν, cm-1): 2095 (N3). 
  Compound has been described previously without 13C-NMR, using a slightly 
different synthetic approach.42 1-(azidomethyl)pentafluorobenzene. Compound was synthesized 
from pentafluorobenzylbromide following general method A. Note: The product is volatile and can 
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easily be lost during lyophilization. L14 was obtained as a yellow oil (236 mg; 1.059 mmol; 92 %). TLC: 
(DCM:heptane, 20:80 v/v) Rf = 0.51; 1H NMR (500 MHz, CDCl3) δ 4.52 – 4.44 (m, 1H, CH2). 13C NMR 
(126 MHz, CDCl3) δ 147.00-125.00 (m, 5x CF), 41.63 (CH2). IR (ATR, ν, cm-1): 2101 (N3).  
  4-(azidomethyl)-2-fluoro-1-methoxybenzene. Compound was synthesized 
from 3-fluoro-4-methoxybenzyl chloride following general method A. L15 was obtained as a colorless 
oil (114 mg; 631 µmol; 37 %). TLC: (DCM:heptane, 20:80 v/v) Rf = 0.29; 1H NMR (500 MHz, CDCl3) δ 
7.1 7 – 6.85 (m, 3H, 3x CH Ar), 4.27 (s, 2H, CH2), 3.90 (d, 3H, J = 0.9 Hz, CH3). 13C NMR (126 MHz, 
CDCl3) δ 152.29 (d, J = 247.0 Hz, CF), 147.69 (d, J = 10.7 Hz, C-OCH3), 128.23 (d, J = 6.1 Hz, C-CH2N3), 
124.23 (d, J = 3.8 Hz, CH Ar), 116.06 (d, J = 18.8 Hz, CH Ar), 113.43 (d, J = 2.2 Hz, CH Ar), 56.20 (CH3), 
53.92 (d, J = 1.7 Hz, CH2). IR (ATR, ν, cm-1): 2093 (N3). 
  1-(azidomethyl)-2-methoxybenzene. Compound was synthesized from 2-
methoxybenzyl chloride following general method A. L16 was obtained as a colorless oil (258 mg; 
1.582 mmol; 82 %). TLC: (DCM: heptane, 20:80 v/v) Rf = 0.36; 1H NMR (500 MHz, CDCl3) δ 7.41 (td, 
1H, J = 7.8, 1.7 Hz, CH Ar), 7.33 (dd, 1H, J = 7.4, 1.8 Hz, CH Ar), 7.04 (td, 1H, J = 7.4, 1.1 Hz, CH Ar), 
6.99 (dd, 1H, J = 8.3, 1.0 Hz, CH Ar), 4.43 (s, 2H, CH2), 3.91 (s, 3H, CH3). 13C NMR (126 MHz, CDCl3) δ 
157.36 (C-OCH3), 129.79 (CH Ar), 129.54 (CH Ar), 123.59 (C-CH2N3), 120.28 (CH Ar), 110.25 (CH Ar), 
54.98 (CH3), 49.82 (CH2). IR (ATR, ν, cm-1): 2094 (N3). 
  1-(azidomethyl)-4-methoxybenzene. Compound was synthesized from 
paramethoxybenzyl chloride following general method A. L17 was obtained as a yellowish oil (288 
mg; 1.764 mmol; 92 %). TLC: (DCM:heptane, 20:80 v/v) Rf: 0.32; 1H NMR (500 MHz, CDCl3) δ 7.28 (d, 
2H, J = 8.7 Hz, 2x CH Ar), 6.96 (d, 2H, J = 8.7 Hz, 2x CH Ar), 4.28 (s, 2H, CH2), 3.82 (s, 3H, CH3). 13C NMR 
(126 MHz, CDCl3) δ 159.70(C-OCH3), 129.80 (CH Ar), 128.60 (CH Ar), 127.49 (C-CH2N3), 114.23 (CH Ar), 
113.93 (CH Ar), 55.20 (CH3), 54.35(CH2). IR (ATR, ν, cm-1): 2092 (N3). 
   2-(azidomethyl)-1,4-dimethoxybenzene. Compound was synthesized 
from 2,5-dimethoxybenzyl chloride following general method A. L18 was obtained as a 
brown/yellowish oil (200 mg; 1.033mmol; 64 %). TLC: (DCM:heptane, 30:70 v/v) Rf = 0.34; 1H NMR 
(500 MHz, CDCl3) δ 6.83 (d, 3H, J = 1.5 Hz, CH Ar), 4.32 (s, 2H, CH2), 3.80 (s, 3H, OCH3), 3.76 (s, 3H, 
OCH3). 13C NMR (126 MHz, CDCl3) δ 153.47 (C-OCH3), 151.67 (C-OCH3), 124.78 (C-CH2N3), 115.98 (CH 
Ar), 113.92 (CH Ar), 111.46 (CH Ar), 55.79 (CH3), 55.62 (CH3), 50.01 (CH2). IR (ATR, ν, cm-1): 2096 (N3). 
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  Compound has been described previously.43 
  1-(azidomethyl)-4-bromobenzene. Compound was synthesized from 2-
fluorobenzyl chloride following general method A. L20 was obtained as a colorless oil (0.250 g; 1.178 
mmol; 98 %). TLC: (DCM:heptane, 20:80 v/v) Rf = 0.38. 1H NMR (500 MHz, CDCl3) δ 7.57 – 7.50 (m, 
2H, 2x CH Ar), 7.24 – 7.19 (m, 2H, 2x CH Ar), 4.32 (s, 2H, CH2). 13C NMR (126 MHz, CDCl3) δ 134.43 (C-
CH2N3), 132.00 (2x CH Ar), 129.82 (2x CH Ar), 122.34 (C-Br), 54.09 (CH2). IR (ATR, ν, cm-1): 2094 (N3).  
  4-nitrobenzyl azide. To a solution of 4-nitrobenzylchloride (400 mg; 2.33 
mmol) in DMF (23 mL; 0.1 M), sodium azide (197 mg; 3.03 mmol; 1.3 eq.) was added. The reaction 
was stirred at r.t. for 24 h and concentrated in vacuo. The residue was dissolved in EtOAc and washed 
twice with sat. aq. NaHCO3 and once with brine. The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. Silicagel flash column chromatography (0 → 10 % EtOAc in heptane) afforded 
L22 (68 mg; 382 µmol; 16 %) as light yellow oil. TLC: (EtOAc:heptane, 10:90 v/v) Rf = 0.35. 1H NMR 
(400 MHz, CDCl3) δ 8.24 (d, 2H, J = 8.7 Hz, 2x CH Ar), 7.51 (d, 2H, J = 8.8 Hz, 2x CH Ar), 4.52 (s, 2H, 
CH2). 13C NMR (101 MHz, CDCl3) δ 147.78 (C-NO2), 142.83 (C-CH2N3), 128.66 (2x CH Ar), 124.07 (2x CH 
Ar), 53.77 (CH2). IR (ATR, ν, cm-1): 2096 (N3), 1516 (NO2), 1340 (NO2). 
   3-(azidomethyl)benzonitrile. 3-(bromomethyl)benzonitrile (200 mg; 1.022 
mmol) was dissolved in a mixture of THF:water (4 mL, 1:1 v/v, 0.25 M) and sodium azide (264 mg; 
4.08 mmol; 4 eq.) was added. The reaction mixture was stirred at r.t. for 64 h. The mixture was 
diluted with DCM (20 mL) and saturated, aqueous sodium hydroxyde (30 mL) was added carefully. 
The organic layer was separated, dried (MgSO4), filtered, and concentrated in vacuo. Silicagel flash 
column chromatography (0 → 50 % DCM in heptane) afforded L22 (150 mg, 0.948 mmol, 93 %). TLC: 
(DCM:heptane, 50:50 v/v) Rf = 0.37. 1H NMR (500 MHz, CDCl3) δ 7.64 – 7.56 (m, 3H, 3x CH Ar), 7.53 – 
7.49 (m, 1H, CH Ar), 4.43 (s, 2H, CH2). 13C NMR (126 MHz, CDCl3) δ 136.92 (C-CH2N3), 132.09 (CH Ar), 
131.59 (CH Ar), 131.12 (CH Ar), 129.46 (CH Ar), 118.16 (CN), 112.67 (C-CN), 53.43 (CH2). IR (ATR, ν, 
cm-1): 2099 (N3), 2232 (CN). 
   Compound has been described previously.44 
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   3-(azidomethyl)aniline. To a solution of 3-(aminomethyl)aniline (1 g; 
8.19 mmol) in MeOH (41 mL; 0.2 M), K2CO3 (2.26 g; 16.4 mmol; 2 eq.) and CuSO4 (13.1 mg; 82.0 
µmol; 0.01 eq.) were added. After one minute 1H-imidazole-1-sulfonyl azide (709 mg; 4.09 mmol; 0.5 
eq.) was added and the reaction was stirred at r.t. for 25 h. The mixture was filtered and the filtrate 
was concentrated in vacuo. Silicagel flash column chromatography (0 → 15 % EtOAc in heptane with 
1 % triethylamine) afforded L24 (87 mg; 587 µmol; 7 %) as brown oil. TLC: (EtOAc:heptane, 50:50 v/v) 
Rf = 0.57. 1H NMR (400 MHz, CD3OD) δ 7.13 – 7.08 (m, 1H, CH Ar), 6.72 – 6.68 (m, 2H, 2x CH Ar), 6.65 
(m, 1H, CH Ar), 4.63 (s, 2H, NH2), 4.20 (s, 2H, CH2). 13C NMR (126 MHz, CD3OD) δ 149.23 (C-NH2 Ar), 
137.84 (C-CH2N3), 130.58 (CH Ar), 119.19 (CH Ar), 116.51 (CH Ar), 116.36 (CH Ar), 55.81 (CH2). IR 
(ATR, ν, cm-1): 3361 (NH2), 2091 (N3). 
 3-(boc-aminomethyl)benzylazide. To a solution of a 3-(boc-
aminomethyl)benzylamine (500 mg; 2.12 mmol) in MeOH (11 mL; 0.2 M), K2CO3 (585 mg; 4.23 mmol; 
2 eq) and CuSO4 (3.4 mg; 21 µmol; 0.01 eq) were added. After one minute imidazole-1-sulfonyl azide 
(440 mg; 2.54 mmol; 1.2 eq) was added and the mixture was stirred for 4 h. The mixture was filtered 
and the filtrate was concentrated in vacuo. The residue was dissolved in EtOAc and washed with first 
aqueous HCl (0.1 M) and then saturated aqueous NaHCO3.The organic layer was dried over MgSO4, 
filtered and concentrated in vacuo. Silicagel flash column chromatography (0 → 18 % EtOAc in 
heptane) afforded precursor L25 (360 mg; 1.37 mmol; 65 %) as white crystals. TLC: (EtOAc:Heptane, 
30:70 v/v) Rf = 0.50. 1H NMR (500 MHz, CDCl3) δ 7.35 (t, J = 7.5 Hz, 1H, CH Ar), 7.28 – 7.21 (m, 3H, 3x 
CH Ar), 4.88 (s, 1H, NH), 4.34 (m, 4H, 2x CH2), 1.47 (s, 9H, 3x CH3 tBu). 13C NMR (126 MHz, CDCl3) δ 
156.03 (C=O), 139.87 (C-CH2N3), 135.92 (C-CH2NHBoc), 129.28 (CH Ar), 127.53 (CH Ar), 127.31 (CH 
Ar), 127.28 (CH Ar), 79.78 (C tBu), 54.83 (CH2-N3), 44.60 (CH2-NHBoc), 28.64 (3x CH3 tBu). IR (ATR, ν, 
cm-1): 3351 ((CONH), 2096 (N3). 
  3-(aminomethyl)benzylazide. To a solution of precursor L25 (250 mg; 953 
µmol) in dioxane (5 mL; 0.2 M), aqueous HCl (12 mL, 1.4 M) was added at r.t. over a period of 2 h. 
After 45 min the reaction was stopped and the product lyophilized under high vacuum to yield the 
product as a HCl salt of L25 (178 mg; 896 µmol; 94 %) as white crystals. TLC: (water:ACN, 30:70 v/v) Rf 
= 0.79. 1H NMR (500 MHz, CD3OD) δ 7.51 – 7.41 (m, 4H, 4x CH Ar), 4.43 (s, 2H, CH2-NH2), 4.14 (s, 2H, 
CH2-N3). 13C NMR (126 MHz, CD3OD) δ 138.40 (C-CH2NH2), 135.21 (C-CH2N3), 130.72 (CH Ar), 130.14 
(CH Ar), 129.81 (CH Ar), 129.74 (CH Ar), 55.18 (CH2-NH2), 44.19 (CH2-N3). IR (ATR, ν, cm-1): 2101 (N3). 
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 4-(boc-aminomethyl)benzylazide. To a solution of a 4-(boc-
aminomethyl)benzylamine (500 mg; 2.12 mmol) in MeOH (11 mL; 0.2 M), K2CO3 (585 mg; 4.23 mmol; 
2 eq.) and CuSO4 (3.4 mg; 21 µmol; 0.01 eq.) were added. After one minute imidazole-1-sulfonyl 
azide (440 mg; 2.54 mmol; 1.2 eq.) was added and the mixture was stirred at r.t. for 4 h. The mixture 
was then filtered, concentrated in vacuo and redissolved in EtOAc. The organic layer was washed 
with first aqueous HCl (0.1 M) and then saturated aqueous NaHCO3. The organic layer was dried over 
MgSO4, filtered and concentrated in vacuo. Silicagel flash column chromatography (0 → 20 % EtOAc 
in heptane) afforded precursor L26 (253 mg; 964 µmol; 46%) as white crystals. TLC: (EtOAc:Heptane, 
30:70 v/v) Rf = 0.51. 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.27 (m, 4H, 4x CH Ar), 4.85 (s, 1H, NH), 4.33 
(m, 4H, 2x CH2), 1.46 (s, 9H, 3x CH3 tBu). 13C NMR (126 MHz, CDCl3) δ 156.01 (C=O Boc), 139.33 (C-
CH2N3), 134.56 (C-CH2NHBoc), 128.67 (2x CH Ar), 128.06 (2x CH Ar), 54.64 (CH2-N3), 44.48 (CH2-NH2), 
28.55 (3x CH3 tBu). IR (ATR, ν, cm-1): 3357 (CONH), 2097 (N3). 
  4-(aminomethyl)benzylazide. To a solution of precursor L26 (250 mg; 953 
µmol) in dioxane (5 mL; 0.2 M), aqueous HCl (12 mL; 1.4 M) was added over a period of 2 h. After 45 
min the reaction was stopped and the product was lyophilized under high vacuum to yield the 
product as a HCl salt of L26 (126 mg; 634 µmol; 66 %). TLC: (water:ACN, 5:95 v/v) Rf = 0.79. 1H NMR 
(500 MHz, CD3OD) δ 7.52 – 7.43 (m, 4H, 4x CH Ar), 4.41 (s, 2H, CH2-NH2), 4.14 (s, 2H, CH2-N3). 13C 
NMR (126 MHz, CD3OD) δ 138.38 (C-CH2NH2), 134.41 (C-CH2N3), 130.46 (2x CH Ar), 130.20 (2x CH Ar), 
54.97 (CH2-NH2), 43.98 (CH2-N3). IR (ATR, ν, cm-1): 2121 (N3). 
  3-(azidomethyl)benzoic acid. To a solution of 3-(bromomethyl)benzoic acid 
(300 mg; 1.39 mmol) in DMF (14 mL; 0.1 M), sodium azide (109 mg; 1.67 mmol; 1.2 eq.) was added. 
The reaction was stirred overnight and concentrated in vacuo. Silicagel flash column chromatography 
(0 → 50 % EtOAc in heptane with 1 % acetic acid) afforded L27 (149 mg; 840 µmol; 60 %) as white 
crystals. TLC: (EtOAc:heptane, 50:50 v/v) Rf = 0.50. 1H NMR (400 MHz, CDCl3) δ 8.12 – 8.06 (m, 2H, 2x 
CH Ar), 7.61 – 7.57 (m, 1H, CH Ar), 7.52 (td, 1H, J = 7.6, 0.6 Hz, CH Ar), 4.44 (s, 2H, CH2). 13C NMR (101 
MHz, CDCl3) δ 171.26 (COOH), 136.24 (C-CH2N3), 133.51 (CH Ar), 130.23 (CH Ar), 130.04 (C-COOH), 
129.93 (Ar-CH), 129.29 (Ar-CH), 54.42 (CH2). IR (ATR, ν, cm-1): 2824 (COOH), 2089 (N3), 1679 (C=O), 
1284 (COOH). 
 4-(azidomethyl)benzoic acid. To a solution of 4-(aminomethyl)benzoic acid 
(500 mg; 3.31 mmol) in a mixture of MeOH and DMF (17 mL; 2:1 v/v; 0.2 M) K2CO3 (914 mg; 6.62 
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mmol; 2 eq.) and CuSO4 (5.3 mg; 33.0 µmol; 0.01 eq.) were added. After one minute imidazole-1-
sulfonyl azide (687 mg; 3.97 mmol; 1.2 eq.) was added and the reaction was stirred for 72 h. The 
mixture was filtered and concentrated in vacuo. Silicagel flash column chromatography (0 → 25 % 
EtOAc in heptane with 1 % acetic acid) afforded L28 (393 mg; 2.22 mmol; 67 %) as a white solid. TLC: 
(EtOAc:heptane, 30:70 v/v) Rf = 0.54. 1H NMR (500 MHz, CDCl3) δ 8.14 (d, J = 8.3 Hz, 2H, 2x CH Ar), 
7.44 (d, J = 8.7 Hz, 2H, 2x CH Ar), 4.45 (s, 2H, CH2). 13C NMR (126 MHz, CDCl3) δ 170.63 (COOH), 
141.53 (C-CH2N3), 130.91 (2x CH Ar), 129.19 (C-COOH), 128.17 (2x CH Ar), 54.43 (CH2). IR (ATR, ν, cm-
1): 2941 (COOH), 2099 (N3), 1708.41 (C=O), 1279 (COOH). 
 4-(azidomethyl)phenylacetic acid. To a solution of 4-(bromomethyl) 
phenylacetic acid (400 mg; 1.75 mmol) in DMF (8.7 mL; 0.2 M), sodium azide (170 mg; 2.62 mmol; 1.5 
eq.) was added. The reaction was stirred overnight and concentrated in vacuo. The residue was 
dissolved in EtOAc and washed twice with aqueous HCl (0.1 M). The organic layer was separated, 
dried over MgSO4, filtered and concentrated in vacuo. Silicagel flash column chromatography (0 → 30 
% EtOAc in heptane with 1 % Acetic acid) afforded L29 (301 mg; 1.574 mmol; 90 %) as white crystals. 
TLC: (EtOAc:heptane, 50:50 v/v) Rf = 0.44. 1H NMR (500 MHz, CDCl3) δ 9.76 (s, 1H, COOH), 7.33 – 7.23 
(m, 4H, 4x CH Ar), 4.31 (s, 2H, CH2-COOH), 3.62 (s, 2H, CH2-N3). 13C NMR (126 MHz, CDCl3) δ 176.48 
(COOH), 134.89 (C-CH2N3), 134.11 (C-CH2COOH), 130.01 (2x CH Ar), 128.49 (2x CH Ar), 54.62 (CH2N3), 
41.67 (CH2COOH). IR (ATR, ν, cm-1): 2986 (COOH), 2098 (N3), 1719 (C=O). 
  2-Azidoacetic acid, CAS: 18523-48-3 
  2-(azidomethyl)-4-methoxy-3,5-dimethylpyridine. 2-(hydroxymethyl)-4-
methoxy-3,5-dimethylpyridine (217 mg; 1.3 mmol) was dissolved in DCM (20 mL; 65 mM) and 
methanesulfonyl chloride (121 µl; 1.56 mmol; 1.2 eq.) and triethylamine (217 µl; 1.56 mmol; 1.2 eq.) 
were added. After stirring at r.t. for 5 h, additional triethylamine (217 µl; 1.56 mmol; 1.2 eq.) was 
added and the reaction was left stirring at r.t. for 16 h and quenched with MeOH (1 mL; 25 mmol). 
The reaction was diluted with water (20 mL) and EtOAc (20 mL) and extracted. The organic layer was 
washed with brine (20 mL), separated, dried (MgSO4), filtered, and concentrated in vacuo to afford 
the mesylated precursor L31. TLC (intermediate): (EtOAc:heptane, 80:20 v/v) Rf = 0.69. The 
intermediate was dissolved in DMF (13 mL; 0.1 M) and sodium azide (169 mg; 2.59 mmol; 2 eq) was 
added. The reaction was stirred for 8 h at 60°C, diluted with brine (100 mL) and EtOAc (100 mL). The 
organic layer was separated, dried (MgSO4), filtered, and concentrated in vacuo. Silicagel flash 
column chromatography (0 → 80 % EtOAc in heptane) afforded L31 (100 mg, 0.52 mmol, 40 %). TLC: 
(EtOAc: heptane, 50:50 v/v) Rf = 0.64. 1H NMR (500 MHz, CDCl3) δ 8.23 (s, 1H, CH Ar), 4.43 (s, 2H, 
CH2), 3.78 (s, 3H, OCH3), 2.27 (s, 3H, CH3-CCH), 2.26 (s, 3H, CH3). 13C NMR (126 MHz, CDCl3) δ 164.18 
(C-OCH3), 153.33 (C-CH2N3), 149.23 (CH), 126.16 (C-CH3-CCH), 125.10 (C-CH3), 59.81 (OCH3), 53.96 
138 
 
(CH2), 13.19 (CH3-CCH), 10.78 (CH3). HRMS (m/z): [M]+ calcd. for C9H13N4O1, 193.10894; found, 
193.10819. 
   Compound has been described previously.45 
   Compound has been described previously.46 
   Compound has been described previously.47 
  Compound has been described previously.48 
   2-azidoethyl phenyl sulfide. Compound was synthesized from 2-bromoethyl 
phenyl sulfide following general method A. L36 was obtained as a yellowish oil (235 mg; 1.311 mmol; 
95 %). TLC: (DCM:heptane, 20:80 v/v) Rf = 0.42; 1H NMR (500 MHz, CDCl3) δ 7.46 – 7.42 (m, 2H, 2x CH 
Ar), 7.38 – 7.33 (m, 2H, 2x CH Ar), 7.30 – 7.26 (m, 1H, CH Ar), 3.46 (t, 2H, J = 7.0 Hz, CH2N3), 3.11 (t, 
2H, J = 7.0 Hz, CH2S). 13C NMR (126 MHz, CDCl3) δ 134.66 (C-S(CH2)2N3), 130.41 (2x CH Ar), 129.23 (2x 
CH Ar), 126.97 (CH Ar), 50.32 (CH2N3), 33.58 (CH2SR) IR (ATR, ν, cm-1): 2097 (N3). 
  1-(2-azidoethyl)-3-methoxybenzene. Compound was synthesized from 3-
methoxyphenethyl bromide following general method A. L37 was obtained as a yellowish oil (202 
mg; 1.137 mmol; 82 %). TLC: (DCM: heptane, 20:80 v/v) Rf = 0.35; 1H NMR (500 MHz, CDCl3) δ 7.31 (s, 
1H, CH Ar), 6.91 – 6.83 (m, 3H, 3x CH Ar), 3.86 (s, 3H, CH3), 3.55 (t, 2H, J = 7.3 Hz, CH2-CH2N3), 2.93 (t, 
2H, J = 7.3 Hz, CH2N3). 13C NMR (126 MHz, CDCl3) δ 159.89 (C-OCH3), 139.69 (C-(CH2)2), 129.69 (CH 
Ar), 121.11 (CH Ar), 114.66 (CH Ar), 112.08 (CH Ar), 55.18 (CH3), 52.38 (CH2N3) 35.42 (CH2CH2N3). IR 
(ATR, ν, cm-1): 2094 (N3). 
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  2-(2-azidoethyl)isoindoline-1,3-dione. Compound was synthesized from 
Beta-Bromoethylphthalimide following general method A. L38 was obtained as a white solid (235 
mg; 1.085 mmol; 92 %). TLC: (DCM:heptane, 50:50 v/v ) Rf = 0.28; 1H NMR (500 MHz, CDCl3) δ 7.81 – 
7.75 (m, 2H, 2x CH Ar), 7.70 – 7.66 (m, 2H, 2x CH Ar), 4.03 (t, 2H, J = 6.7 Hz, CH2NR2), 3.56 (t, 2H, J = 
6.7 Hz, CH2N3). 13C NMR (126 MHz, CDCl3) δ 167.67 (2x C C=O), 134.18 (2x CH Ar), 131.74 (2x C Ar), 
123.36 (2x CH Ar), 39.25 (CH2NR2), 28.31 (CH2N3). IR (ATR, ν, cm-1): 2095 (N3).  
  Compound has been described previously.49 
  Compound has been described previously.50 
   Compound has been described previously. 43 
 2-azido-N-(3-(pentafluoro-l6-sulfaneyl)phenyl)acetamide. Compound was 
synthesized from 3-(pentafluorosulfanyl)aniline following general method B. L42 was extracted 
following procedure D1 and was obtained as yellow crystals (64 mg; 0.214 mmol; 63.3 %). TLC: (I): 
(DCM:heptane, 50:50 v/v) Rf = 0.27; (P): (DCM:heptane, 50:50 v/v) Rf = 0.28; 1H NMR (500 MHz, 
CDCl3) δ 8.51 (s, 1H, NH), 7.99 (t, 1H, J = 2.2 Hz, CH Ar), 7.79 – 7.74 (m, 1H, Ar), 7.60 – 7.56 (m, 1H, 
Ar), 7.47 (t, 1H, J = 8.2 Hz, H), 4.24 (s, 2H, CH2). 13C NMR (126 MHz, CDCl3) δ 172.19 (C=O), 164.72 (C-
NHR), 136.93 (C-SF5), 129.38 (CH Ar), 123.29(CH Ar), 122.73 – 122.61 (m, C-NHR), 118.02 (t, J = 4.9 
Hz, 2x CH-CSF5), 42.74 (CH2) IR (ATR, ν, cm-1): 2111 (N3). 
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  2-azido-N-(4-pentafluoro-L6-sulfaneyl)phenyl)acetamide. Compound was 
synthesized from 4-(pentafluorosulfanyl)aniline following general method B. L43 was extracted 
following procedure D1 and was obtained as yellow crystals (99 mg; 0.328 mmol; 97 %). TLC: (I): 
(DCM:heptane, 50:50 v/v) Rf = 0.23; (P): (DCM: heptane, 50:50 v/v) Rf = 0.21; 1H NMR (500 MHz, 
CDCl3) δ 8.48 (s, 1H, NH), 7.76 (d, 2H, J = 9.1 Hz, CH Ar), 7.68 (d, 2H, J = 8.8 Hz, ArH), 3.96 (s, 2H, CH2). 
13C NMR (126 MHz, CDCl3) δ 171.83 (C=O), 164.50 (C-NHR), 139.24 (C-SF5), 127.14 (t, J = 4.7 Hz, 2x 
CH-CSF5), 119.46 (2x CH-CNHR), 42.78 (CH2). IR (ATR, ν, cm-1): 2113 (N3). 
 2-azido-N-(4-bromobenzyl)acetamide. Compound was synthesized from 4-
bromophenethylamine following general method B. L44 was extracted following procedure D1 and 
was obtained as a yellow liquid (102 mg; 0.358 mmol; 99 %). TLC: (I): (DCM: heptane, 50:50 v/v) Rf = 
0.07; (P): (DCM:heptane, 50:50 v/v) Rf = 0.16; 1H NMR (500 MHz, CDCl3) δ 7.43 (d, 2H, J = 8.3 Hz, 2x 
CH Ar), 7.07 (d, 2H, J = 8.3 Hz, 2x CH Ar), 6.74 (s, 1H, NH), 4.00 (s, 2H, CH2N3), 2.80 (t, 4H, J = 7.1 Hz, 
2x CH2 RNH(CH2)2Ar. 13C NMR (126 MHz, CDCl3) δ 166.04 (C=O), 137.36 (C-(CH2)2NHR), 131.75 (2x CH 
Ar), 130.48 (2x CH Ar), 120.55 (C-Br), 42.62, (CH2N3), 40.78 (CH2NHR), 34.90 (CH2CH2NHR). IR (ATR, ν, 
cm-1): 2112 (N3).  
  2-azido-N-(benzo[d]thiazol-5-yl)acetamide. Compound was synthesized 
from 5-Amino-1,3-benzothiazole following general method B. The crude product was extracted 
following procedure D2 and was purified on silica column (0 % 40 % EtOAc in heptane) to afford 
L45 as a yellow liquid (69 mg; 0.29 mmol; 66 %). TLC: (I): (EtOAc:heptane, 40:60 v/v) Rf = 0.04; (P): 
(EtOAc:heptane, 40:60 v/v) Rf = 0.01; 1H NMR (500 MHz, CDCl3) δ 9.04 (s, 1H, SCHN), 8.37 (d, 1H, J = 
2.1 Hz, NH), 7.93 (d, 1H, J = 8.7 Hz, CH Ar), 7.70 (dt, 1H, J = 8.7, 1.9 Hz, CH Ar), 7.28 (s, 1H, CH Ar), 
4.22 (s, 2H, CH2). 13C NMR (126 MHz, CDCl3) δ 164.74 (C=O), 155.37 (CH SCHN), 153.82 (R2C-N=R), 
135.47 (C-NHR), 130.04 (R2C-SR), 122.11 (CH Ar), 118.86 (CH Ar), 114.75 (CH Ar), 153.01 (CH2). IR 
(ATR, ν, cm-1): 2107 (N3). 
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  4-((2-azidoacetamido)methyl)benzoic acid. Compound was synthesized from 
4-(aminomethyl)benzoic acid following general method B. The crude product was extracted 
following procedure D3 and L46 was obtained as yellow crystals (17 mg; 0.074 mmol; 16.8 %). TLC: 
(I): (EtOAc:heptane, 60:40 v/v) Rf = 0.11; (P): (EtOAc:heptane, 60:40 v/v) Rf = 0.19; 1H NMR (500 MHz, 
CD3OD) δ 8.00 (d, 2H, J = 8.3 Hz, 2x CHC-COOH), 7.43 – 7.40 (m, 2H, 2x CH Ar), 4.16 (s, 2H, CH2), 2.20 
(s, 2H, CH2-N3). 13C NMR (126 MHz, CD3OD) δ 169.52 (CONHR), 168.18 (COOH), 143.51 (C-NHR), 
129.62 (2x CH Ar), 129.50 (C-COOH), 127.02 (2x CH Ar), 42.66 (CH2N3), 41.75 (CH2-NR). IR (ATR, ν, cm-
1): 2113 (N3). 
  2-azido-N-(pyridin-2-ylmethyl)acetamide. Compound was synthesized from 
2-picolylamine following general method B. L47 was extracted following procedure D2 and was 
obtained as a brown solid (23 mg; 0.120 mmol; 22 %). TLC: (I): (acetone:DCM, 50:50 v/v) Rf = 0.58; 
(P): (acetone:DCM, 50:50 v/v) Rf = 0.60; 1H NMR (500 MHz, CDCl3) δ 8.57 (dd, 1H, J = 4.3, 1.8 Hz, 
CHN), 7.73 – 7.66 (m, 1H, CH, Ar), 7.30 – 7.27 (m, 1H, CH Ar), 7.24 (dd, 1H, J = 7.6, 4.9 Hz, CH, Ar), 
4.06 (s, 2H, CH2-NHR), 2.05 (s, 2H, CH2-N3). 13C NMR (126 MHz, CDCl3) δ 166.75 (C=O), 155.61 (C-
CH2NHR), 149.09 (CHN), 136.94 (CH, Ar), 122.61 (C-CH2NHR), 122.18 (CH, Ar), 60.38 (CH2N3), 44.55 
(CH2-NHR). IR (ATR, ν, cm-1): 2104 (N3). 
  2-azido-N-(pyridin-4-yl)acetamide. Compound was synthesized from 
pyridine-4-amine following general method B. L48 was extracted following procedure 2 and was 
obtained as yellow crystals (55 mg; 309 µmol; 52 %). TLC: (I): (acetone:DCM, 50:50 v/v) Rf = 0.20; (P): 
(acetone:DCM, 50:50 v/v) Rf = 0.40; 1H NMR (500 MHz, CDCl3) δ 9.89 (s, 1H, NH), 8.26 – 8.18 (m, 2H, 
2x CHN), 6.57 – 6.49 (m, 2H, 2x CH Ar), 4.32 (s, 2H, CH2). 13C NMR (126 MHz, CDCl3) δ 166.23 (C=O), 
152.92 (C-NHR), 150.70 (CHN), 149.98(CHN), 113.84 (CH-CNHR), 109.64 (CH-CNHR), 52.62 (CH2). IR 
(ATR, ν, cm-1): 2106 (N3). 
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  2-azido-N-(6-methylpyridin-2-yl)acetamide. Compound was synthesized 
from 6-methylpyridin-2amine following general method B. L49 wass extracted following procedure 
D2 and was obtained as a brown oil (51 mg; 0.266 mmol; 49 %). TLC: (I): (EtOAc:heptane, 50:50 v/v) 
Rf = 0.58; (P): (EtOAc:heptane, 50:50 v/v) Rf = 0.10; 1H NMR (500 MHz, CDCl3) δ 7.30 (dd, 1H, J = 8.2, 
7.3 Hz, CH Ar), 6.48 (d, 1H, J = 7.3 Hz, CH Ar), 6.29 (dt, 1H, J = 8.2, 0.7 Hz, CH Ar), 2.35 (s, 3H, CH3), 
2.16 (s, 2H, CH2).13C NMR (126 MHz, CDCl3) δ 210.83 (C=O), 157.93 (C-CH3), 156.59 (C-NHR), 138.16 
(CH Ar), 113.10 (CH Ar), 105.51 (CH Ar), 53.88 (CH2), 29.26 (CH3). IR (ATR, ν, cm-1): 2110 (N3). 
  Cyclopentylacetylene, CAS: 930-51-8 
  Cyclohexylacetylene, CAS: 931-48-6 
  Phenylacetylene, CAS: 536-74-3  
   4-Ethynylbiphenyl, CAS: 29079-00-3 
  3-Phenyl-1-propyne, CAS: 10147-11-2 
  prop-2-ynyl (3-(pentafluoro-sulfanyl)phenyl)carbamate. Compound was 
synthesized from 3-(pentafluorosulfanyl) aniline following general method C. L55 was extracted 
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following procedure D1 and was obtained as yellow crystals (94 mg; 312 µmol; 68.5 %). TLC: (DCM: 
heptane, 50:50 v/v) Rf = 0.53; 1H NMR (500 MHz, CDCl3) δ 7.70 (d, 1H, J = 9.2 Hz, NH), 7.53 (d, 3H, J = 
9.0 Hz, 3x CH Ar), 6.70 – 6.58 (m, 1H, CH Ar), 4.79 (d, 2H, J = 2.4 Hz, CH2), 2.59 – 2.55 (m, 1H, C≡CH). 
13C NMR (126 MHz, CDCl3) δ 154.03 (C=O), 149.06 (C-NHR), 141.94 (C-SF5), 127.42 (CH Ar), 118.08 (CH 
Ar), 113.36 (2x CH Ar), 76.04 (C≡CH), 75.41(C≡CH), 55.73 (CH2). IR (ATR, ν, cm-1): 3308 (C≡C-H), 1995 
(C≡C). 
  prop-2-ynyl (4-(pentafluoro-sulfanyl)phenyl)carbamate. Compound was 
synthesized from 4-(pentafluorosulfanyl) aniline following general method C. The crude product was 
extracted following procedure D1 and was obtained as white crystals (68 mg; 225 µmol; 49 %). TLC: 
(DCM:heptane, 50:50 v/v) Rf = 0.56; 1H NMR (500 MHz, CDCl3) δ 7.91 (s, 1H, NH), 7.13 (dd, 2H, J = 8.2, 
2.0 Hz, 2x CH-CSF5), 6.79 (dd, 2H, J = 8.0, 2.1 Hz, 2x CH-CNHR), 3.90 (s, 2H, CH2), 2.57 (d, 1H, J = 2.7 
Hz, C≡CH). 13C NMR (126 MHz, CDCl3) δ 154.03 (C=O), 146.73 (C-NHR), 129.28 (d, J = 9.7 Hz, CH-CSF5), 
117.68(CH-CSF5), 115.71 – 115.56 (m, CH-CNHR), 112.29 – 112.06 (m, CH-CNHR), 76.03 (C≡CH), 75.35 
(C≡CH), 55.72 (CH2). IR (ATR, ν, cm-1): 3309 (C≡C-H), 2134 (C≡C). 
  prop-2-ynyl benzothiazol-5-ylcarbamate. Compound was synthesized from 
5-amino-1,3-benzothiazole following general method C. Product was extracted following procedure 
D2, combined organic layers were combined, dried (Na2SO4), filtered and concentrated in vacuo. The 
product was purified on silica column (0  60 % EtOAc in heptane) to afford L57 as slightly yellow 
crystals (110 mg; 472 µmol; 70 %). TLC: (EtOAc: heptane, 60:40 v/v) Rf = 0.52; 1H NMR (500 MHz, 
CD3OD) δ 9.36 (s, 1H, NH), 9.23 (s, 1H, SCH=N), 8.32 (s, 1H, CH Ar), 7.96 (d, 1H, J = 8.7 Hz, CH Ar), 7.56 
(dd, 1H, J = 8.8, 2.1 Hz, CH Ar), 4.81 (s, 2H, CH2), 2.95 (s, 1H, C≡CH). 13C NMR (126 MHz, CD3OD) δ 
156.54 (C=O), 154.47 (SCH=N), 153.37 (C-N=CHS), 137.83 (C-SC=N), 127.75 (C-NHR), 121.78 (3x CH 
Ar), 74.74 (C≡CH), 74.72 (C≡CH), 51.93 (CH2). IR (ATR, ν, cm-1): 3286 (C≡C-H), 3252.19 (C≡C-H), 2126 
(C≡C). 
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   prop-2-ynyl (4-aminobenzyl)carbamate. Compound was synthesized from 4-
(aminomethyl)aniline following general method C. Product was extracted following procedure D2 
where EtOAc was used as organic layer. Combined organic layers were dried (Na2SO4), filtered and 
concentrated in vacuo. Product was purified on silica column (0  60 % EtOAc in heptane) to afford 
L58 was obtained as yellow crystals (16 mg; 77 µmol; 9 %). TLC: (EtOAc:heptane, 60:40 v/v) Rf = 0.63; 
1H NMR (500 MHz, CDCl3) δ 7.37 (d, 2H, J = 8.1 Hz, 2x CH-CCH2R), 7.25 – 7.22 (m, 2H, 2x CH-CNH2), 
4.79 (d, 2H, J = 2.4 Hz, CH2-C≡CH), 4.72 (d, 2H, J = 2.5 Hz, NH2), 4.34 (d, 2H, J = 6.0 Hz, CH2-NHR), 2.51 
(dt, 1H, J = 17.2, 2.5 Hz, C≡CH). 13C NMR (126 MHz, CDCl3) δ 155.49 (C=O), 136.91 (C-NH2), 133.48 (C-
CH2NHR), 128.88 (CH-CCH2NHR), 128.35 (CH-CCH2NHR), 118.99 (CH-CNH2), 113.64 (CH-CNH2), 75.07 
(C≡CH), 74.69 (C≡CH), 52.63 (CH2-C≡CH), 44.67 (CH2-NHR). IR (ATR, ν, cm-1): 3301 (C≡C-H), 2130 (C≡C). 
 4-((((prop-2-ynyloxy)carbonyl)amino)methyl)benzoic acid. Compound was 
synthesized from 4-(aminomethyl)benzoic acid following general method C. L59 was extracted 
following procedure D3 and was obtained as white crystals (44 mg; 188 µmol; 28 %). TLC: 
(EtOAc:heptane, 60:40 v/v) Rf = 0.31; 1H NMR (500 MHz, CD3OD) δ 7.98 (dd, 2H, J = 8.5, 6.8 Hz, 2x CH-
CCOOH), 7.40 (dd, 2H, J = 8.5, 2.4 Hz, 2x CH-CCH2R), 4.98 (s, 2H, CH2NHR), 4.37 (d, 2H, J = 1.8 Hz, 
CH2C≡CH), 2.89 (t, 1H, J = 2.5 Hz, C≡CH). 13C NMR (126 MHz, CD3OD) δ 168.26 (COOH), 156.75 
(CONHR), 144.45 (C-CH2NHR), 129.60 (CH-CCOOH), 129.35 (CH-CCOOH), 128.77 (C-COOH), 126.84 
(CH-CCH2), 126.75 (CH-CCH2), 75.50 (C≡CH), 74.51 (C≡CH), 51.97 (CH2-C≡CH), 43.87 (CH2-NHR). IR 
(ATR, ν, cm-1): 3285 (C≡C-H), 3251 (C≡C-H), 2127 (C≡C). 
  prop-2-ynyl (2-chlorophenethyl)carbamate. Compound was synthesized 
from 2-(2-chlorophenyl)ethanamine following general method C. L60 was extracted following 
procedure D1 and was obtained as yellow crystals (134 mg; 563 µmol; 88 %). TLC: (DCM:heptane, 
50:50 v/v) Rf = 0.32; 1H NMR (500 MHz, CDCl3) δ 7.35 (dd, 1H, J = 7.3, 1.8 Hz, CH-CCl), 7.25 – 7.15 (m, 
3H, 3x CH Ar), 4.66 (d, 2H, J = 2.5 Hz, CCH2), 3.46 (t, 2H, J = 6.7 Hz, CH2-NHR), 2.97 (t, 2H, J = 7.1 Hz, 
CH2 Ar), 2.48 (t, 1H, J = 2.5 Hz, CH Ar). 13C NMR (126 MHz, CDCl3) δ 155.47 (C=O), 136.28 (C-CH2R), 
134.13 (C-Cl), 131.02 (CH Ar), 129.64 (CH Ar), 128.08 (CH Ar), 126.97 (CH Ar), 80.24 (C≡CH), 74.63 
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(C≡CH), 52.42 (CH2-CCH), 40.71 (CH2-NHR), 33.72 (CH2 Ar). IR (ATR, ν, cm-1): 3421 (C≡C-H), 3298 (C≡C-
H), 2127 (C≡C). 
  prop-2-ynyl (4-bromophenethyl)carbamate. Compound was synthesized 
from 4-bromophenethylamine following general method C. L61 was extracted following procedure 
D1 and was obtained as white crystals (123 mg; .434 µmol; 88 %). TLC: (DCM:heptane, 50:50 v/v) Rf = 
0.35; 1H NMR (500 MHz, CDCl3) δ 7.38 (dd, 2H, J = 8.3, 1.9 Hz, 2x CH-CBr), 7.03 (dd, 2H, J = 8.4, 1.8 Hz, 
2x CH Ar), 5.32 (d, 1H, J = 7.7 Hz, NH), 4.61 (t, 2H, J = 2.1 Hz, CH2-C≡CH), 3.36 (t, 2H, J = 7.4 Hz, CH2-
NHR), 2.76 – 2.72 (m, 2H, CH2-Ar), 2.47 (q, 1H, J = 2.3 Hz, C≡CH). 13C NMR (126 MHz, CDCl3) δ 155.58 
(C=O), 137.61 (C-CH2R), 131.60 (CH Ar), 131.46 (CH Ar), 130.50 (2x CH Ar), 120.29 (C-Br), 80.60 
(C≡CH), 74.67 (C≡CH), 52.40 (CH2-C≡CH), 41.92 (CH2-NHR), 35.31 (CH2 Ar). IR (ATR, ν, cm-1): 3316 
(C≡C-H), 3284 (C≡C-H), 2132 (C≡C). 
  4-(((prop-2-ynyloxy)carbonyl)amino)nicotinic acid. Compound was 
synthesized from 4-aminonicotinic acid following general method C. Reaction was directly 
concentrated in vacuo to afford L62 as a colorless oil (12 mg; 54 µmol; 7 %). TLC: (EtOAc:heptane, 
60:40 v/v) Rf = 0.61; 1H NMR (500 MHz, CDCl3) δ 7.00 (d, 1H, J = 0.7 Hz, NH), 4.88 (d, 1H, J = 2.5 Hz, 
CH-N), 4.79 (d, 1H, J = 2.5 Hz, CH Ar), 4.30 (d, 1H, J = 2.4 Hz, CH-CCOOH), 2.67 (t, 2H, J = 2.5 Hz, CH2), 
2.56 (t, 1H, J = 2.5 Hz, C≡CH). 13C NMR (126 MHz, CDCl3) δ 154.01 (COOH), 150.43 ((C=O)NHR), 125.51 
(3x CH Ar), 77.64 (C≡CH), 75.99 (C≡CH), 55.71 (CH2). IR (ATR, ν, cm-1): 3298 (C≡C-H), 2134 (C≡C). 
   Compound has been described previously. 51 
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General biological procedures 
Ac5NeuNAc, Ac5NeuNPoc and Ac5NeuNAz were prepared as previously described by us.16 Azide-PEG3-
biotin and alkyne-PEG4-biotin, sodium L-ascorbate, L-histidine and copper(II) sulfatepentahydrate, 
lipopolysaccharide (LPS) and mouse anti-human Siglec-2- phycoerythrin (PE) antibody(MEM-01) were 
purchased from Sigma-Aldrich (St. Louis, MO). Recombinant human Siglec Fcchimeras, mouse anti-
human Siglec-6-PE antibody (767329), mouse-anti Siglec-8-APC antibody (837535) and PE-conjugated 
mouse anti-human Siglec-9 antibody (191240) were purchased from R&D Systems (Minneapolis, MN) 
and Alexa Fluor 647-conjugated goat anti-human IgG (H+L) secondary antibody and Hank's balanced 
salt solution (HBSS) from Life Technologies (Burlington, Ontario, Canada). Biotin-MALII, Biotin-SNA-I, 
Biotin-PNA and carbo-free blocking solution were purchased from Vector Laboratories, Inc. 
(Burlingame, CA). 7-AAD viability dye was purchased from eBioscience (San Diego, CA) and 
streptavidin-PE from BD Pharmingen (Franklin Lakes, NJ). Mouse anti-human Siglec-3-PE antibody 
(WM53), mouse anti-human Siglec-5/14-PE antibody (1A5), mouse anti-human Siglec-7-PE antibody 
(6-434), mouse anti-human Siglec-10-PE antibody (5G6) and PEconjugated mouse IgG isotype 
antibodies were purchased from Biolegend (San Diego, CA). Pam3CSK4, blasticidin, zeocin and 
alkaline phosphatase detection medium (QUANTI-Blue) was obtained from Invivogen (San Diego, CA). 
Rabbit anti-human Siglec-3 polyclonal antibody was purchased from Proteintech (Chicago, IL), goat 
anti-rabbit IgG antibody from Jackson ImmunoResearch (Baltimore, PA). SHP-1/-2 phosphatase 
inhibitor NSC-87877 (CAS 56932-43-5) was obtained from Merck Millipore (Billerica, MA). 
Cell culture 
Jurkat cells (TIB-152, ATCC) and THP1-DUAL cells (Invivogen) were cultured in RRMI 1640 medium 
(Life Technologies) supplemented with 10 % heat-inactivated fetal bovine serum (FBS) (Greiner 
Bioone, Frickenhausen, Germany), 2 mM glutamine (Lonza, Walkersville, MD) and 
antibioticantimycotic solution (100 units/mL of penicillin, 100 μg/mL of streptomycin, and 0.25 
μg/mL Fungizone) (Life Technologies). To maintain selection pressure in the THP1-DUAL reporter 
cells, medium was supplemented with zeocin (100 μg/mL) and blasticidin (10 μg/mL). HEK293 cells 
(CRL-1573, ATCC) were cultured in DMEM (Life Technologies) supplemented with 10% FBS, 2 mM 
glutamine, 1 % non-essential amino acids (Life Technologies) and 1% antibiotic-antimycotic solution. 
All cells were cultured in a humidified CO2 incubator at 37 °C. 
 
On-cell synthesis of sialic acid-based Siglec ligands 
Cells were incubated for 3 days with PBS, 150 μM Ac5NeuNAc, 150 μM Ac5NeuNPoc or 200 μM 
Ac5NeuNAz to achieve equal incorporation efficiencies and washed with PBS prior to the click 
reaction. To react surface alkyne or azide sialic acids with biotin-azide, biotin-alkyne or L1-64, 
respectively, cells were incubated for 20 minutes at 37 °C with click buffer (PBS, 250 μM CuSO4, 200 
μM L-histidine, 500 μM sodium ascorbate) containing 100 μM of an azide or alkyne. Cells incubated 
with click buffer without any reactive molecule were used as control. Click reaction efficiencyTo 
determine the efficiency of the click reaction between alkyne and azide surface sialic acids and L1-64 
Jurkat cells were incubated for three days with 150 μM Ac5NeuNPoc or 200 μM Ac5NeuNAz 
andreacted for 20 minutes at 37 °C to L1-49 and, respectively. Cells incubated with click buffer 
without azides or alkynes were used as control. After the first click reaction, cells were clicked a 
second time for 20 minutes at 37 °C with azide- or alkyne-biotin and incubated with Streptavidin-PE. 
148 
 
Streptavidin-PE signal was measured with flow cytometry. Using the MFI of control cells that were 
not conjugated with an azide or alkyne in the first click reaction as maximum labeling, the percentage 
labeling of cells reacted to L1-49 and L50-64 during the first click reaction was calculated. Lectin and 
antibody staining and flow cytometry To detect expression of Siglec ligands on the cell surface, cells 
were washed with HBSS and incubated for 45 minutes at 4 °C with 0.4 μg/ml recombinant human 
Siglec Fc chimeras, preconjugated with Alexa Fluor 647 goat anti-human IgG antibodies in HBSS. Cells 
were washed with PBS containing 1% bovine serum albumin (BSA) and resuspended for flow 
cytometry analysis. To detect α2,3-linked sialic acids, α2,6-linked sialic acids or non-sialylated β-
galactose cells were incubated for 45 minutes at 4 °C with biotinylated MALII, SNA-I or PNA, washed 
and incubated 10 minutes at 4°C with streptavidin-PE. Cells were washed and resuspended in PBA 
(PBS, 1% bovine serum albumin, 0.02% sodium azide) prior to flow cytometry analysis. To detect 
expression of Siglecs, cells were incubated for 20 minutes 4°C with isotype control antibodies or 
fluorescent antihuman Siglec antibodies, washed and resuspended in PBA. Lectin or antibody binding 
was quantified using a CyAn ADP flow cytometer (BD Biosciences, San Jose, CA). Data were analyzed 
with FlowJo software (Tree Star Inc., Ashland, OR) to obtain the mean fluorescence intensity (MFI). 
Fold change Siglec binding was calculated by normalizing the MFI to control cells treated with control 
click buffer. 
Sequence alignment and Siglec-5/-14 docking model 
Sequence alignment of Siglec-5 (UniProt O15389), -7 (UniProt Q9Y286) and -9 (UniProt Q9Y336) was 
performed using Clustal Omega on the EMBL-EBI webserver and Jalview software.36 For the docking, 
the X-ray structure of Siglec-5 was obtained from the Protein Data Bank (PDB) (entry: 2ZG1) and L24-
26 were built using Molecular Operating Environment (MOE) 2015.10 ed. 1010 from Chemical 
Computing Group Inc. (Montreal, QC, Canada). Docking of L24-26 was performed using MOE. The 
Siglec-5 structure was prepared for docking by protonation at pH = 7.2. All dockings were performed 
using the MMFF94x force field and the induced fit protocol, implemented in the MOE 2013.08 
docking tool. Full flexibility was allowed for the side chain atoms in pocket residues. The binding 
pocket for sialic acid is very solvent exposed, therefore the docking was guided by a pharmacophore 
model (Figure S9) to ensure similar placement of the sugar moiety as observed in the X-ray structure 
of Siglec-5 with sialic acid (6'-sialyllactose). Poses were scored using the London dG and GBVI/WSA 
dG methodology, which both estimate the free energy of binding of the ligand from a given pose 
after placement or refinement respectively. In both the placement and the refinement step, the best 
scoring poses (at most 50) were retained as output in a MOE database for each compound and 
visually inspected. 
Toll-like receptor stimulation reporter cell assay 
To study the effects of glycoengineered Jurkat cells modified with sialic acid modifications that 
enhance binding to Siglec-3, these cells were co-cultured with Siglec-3+ THP1-DUAL reporter cells. 
The monocytic THP1-DUAL reporter cells secrete alkaline phosphatase upon activation of the NF-κB 
pathway and luciferase upon IRF induction.[20] These pathways can be stimulated by TLR ligands. 
Jurkat cells with high Siglec-3 binding were generated by incubating them for 3 days with PBS, 150 
μM Ac5NeuNPoc or 200 μM Ac5NeuNAz followed by the reacted with L4, L39, or L57 as described 
above. Non-reacted, Jurkat cells incubated with PBS, Ac5NeuNPoc or Ac5NeuNAz and Jurkat cells 
incubated with Ac5NeuNPoc and reacted to L40 were used as negative control. 3x 105 modified 
Jurkat cells were co-cultured for 4 h with105 THP1-DUAL reporter cells and medium, 10 ng/ml LPS or 
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50 ng /ml Pam3CSK was added to the co-culture. After 24 h of stimulation, alkaline phosphatase 
activity and luciferase activity in the medium was determined using a QUANTI-Blue colorimetric 
enzyme or a QUANTI-Luc assay following the manufacturer’s protocol (Invivogen). Briefly, to detect 
alkaline phosphatase activity 20 μl culture supernatants were incubated with 180 μl QUANTI-Blue 
detection reagent for 30 minutes at 37 °C and analyzed with a spectrophotometer at 620 nm. To 
measure luciferase activity, 10 μl supernatant was incubated for 4 seconds with 50 μl QUANTI-Luc 
solution and analyzed using a Victor luminometer (Perkin Elmer, Waltham, MA) with a 0.1 seconds 
reading time. To trigger Siglec-3 signaling as a positive control, 10 μg/ml isotype antibody or anti-
Siglec-3 antibody was added to the co-culture for 20 minutes followed by the addition of 20 μg/ml 
corresponding cross-linking antibody. Cross-linking of Siglec-3 has been shown to result in signaling, 
ITIM phosphorylation and SHP-1 recruitment.21 To inhibit SHP-1/-2 phosphatase activity, THP1-DUAL 
cells were incubated with or without 50 μM SHP-1/-2 inhibitor NSC-87877 for 3 h prior to the co-
culture. 
Statistical analysis 
Statistical significance was calculated using Prism 5.03 (GraphPad Software, Inc., La Jolla, CA). For 
comparisons between groups one-way ANOVA with Bonferroni post-hoc test was used. P-values 
<0.05 were considered significant (p<0.05 *, p<0.01 **, p<0.001 ***). 
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5 
 Synthesis and Evaluation of 
Sialic Acid Derivatives for 
Metabolic 
Glycoengineering 
 
“Sialic acids are not only the most interesting molecules in the world, but also the 
most important.” 
Eric Sixmister (-), discovered the wide role of sialic acid metabolism in bacteria and 
concentrated his work on poly-sialic acid.  
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Abstract 
Sialic acids are a large family of saccharides abundantly capping the non-reducing 
terminus of the glycocalyx reaching into the extracellular space.1 This unique location 
enables sialic acids to play a leading role in interactions with cells, pathogens, toxins 
and other biomolecules. A powerful tool to study sialic acids in their natural 
environment is MOE (Metabolic Oligosaccharide Engineering). MOE frequently uses 
sialic acid derivatives carrying a chemical reported either at C-5 or C-9.2 To explore the 
potential of other positions and functional groups we developed simple synthetic 
routes for azide modifications at C-2,-3,-4,-5,-7 and C-9 positions and the alkynes at C-
4,-5 and C-9 positions that could be used for bioorthogonal labeling reactions. All 
derivatives expect the C-2 azide were tolerated for MOE in THP-1 cells albeit with 
markedly different incorporation efficiency. 
 
 Heise T, Gerrits L, Rossing E, Büll C, Adema G.J, Boltje TJ*. Synthesis and 
Evaluation of Sialic Acid Derivatives for Metabolic Glycoengineering, 
Manuscript in preparation. 
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Introduction 
Sialic acid saccharides are abundantly capping the non-reducing terminus of cell 
surface glycoconjugates.1 With several millions of molecules per µm2 on an exposed 
position of every human cell, sialic acids play a major role in cell-communication, are 
responsible for physical cellular properties like the surface charge and increase the life-
time of secreted biomolecules.3-6 Sialic acids can be recognized by Siglec receptors 
expressed on immune cells and are important for the regulation of the immune 
system.7 We have previously shown that sialic acids on living cells can be modified 
using bioorthogonal chemistry to alter their binding to Siglec receptors (Chapter 4).8 
To this end, the C-5 position of sialic acid was modified with a propargyloxycarbonyl 
(Poc) or azidoacetyl (Az) group. Earlier studies have shown that modifications on other 
positions of sialic acid were also able to increase Siglec binding (Chapter 2).9 Hence, we 
became interested in the possibility to modify sialic acids at positions other than C-5 
to introduce a chemical reporter for bioorthogonal chemistry.   
To design new reagents for metabolic sialic acid glycoengineering, an in-depth 
understanding of the sialic acid metabolism is needed (Figure 1). Sialic acid is 
biosynthesized from UPD N-acetyl glucosamine in three steps. Next, sialic acid diffuses 
to the nucleus via the NPC (nuclear pore complex) which is not restrictive for small 
molecules and hence even tolerates sialic acid analogs with large modifications.10 CMP 
activation is carried out by the enzyme CMAS in the nucleus followed by transport of 
CMP-sialic acid to the Golgi via SLC35A1.11   
This pathway can be used to incorporate unnatural sialic analogues utilizing either 
precursors of sialic acids such as N-acetyl mannosamine or sialic acid itself.12 
Peracetylation of derivatives is used to increase the lipophilicity and thereby uptake by 
passive diffusion across the membrane and can be reversed again by cytosolic or 
lysosomal esterases.13-14 As we have shown earlier (Chapter 3), N-acetyl mannosamine 
analogues are much less efficient precursors for sialic acid glycoengineering since they 
are toxic at high concentration and more enzymatic steps are required to yield sialic 
acid. Furthermore, N-acetyl mannosamine analogs are not always specific for the sialic 
acid pathway. CMP-sialic acid on the other hand inhibits GNE via a feedback 
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mechanism thereby limiting N-acetyl mannosamine conversion and increasing the 
incorporation of modified sialic acids.15-16 In addition, not all positions in sialic acid can 
be labeled using mannosamines. For example, the O-6 position in N-acetyl 
mannosamine is phosphorylated during biosynthesis and can therefore not be 
modified. Furthermore, the C1-C-3 positions of sialic acid cannot be modified as they 
originate from pyruvate. Finally, the C-4 position is a reactive center in the aldol 
reaction carried out by NANS and cannot be modified as well.  
 
  
Figure 1. Human metabolic pathway of Sialic acid. Uptake of acetyl and methyl ester protected sialic 
acid analogs e.g. for metabolic labeling in red. 
 
Bioorthogonal on-cell chemistry has been reported with a variety of chemical groups, 
an overview can be found elsewhere.2 Azide groups are small, inert and can be used 
for strain-promoted as well as copper-catalyzed alkyne-azide cycloadditions and 
158 
 
nucleophilic amine coupling after Staudinger reduction. This renders azides an ideal 
modification to visualize on-cell modifications while enabling multiple chemical on-cell 
reactions to uncover the consequences of large libraries of chemical groups. From a 
chemical point of view, azide-modified sialic acids are also versatile as they can be 
diversely modified after reduction towards an reactive amine. Herein we report the 
synthesis and biological evaluation of sialic acid derivatives carrying an azide at the C-
2,-3,-4,-5,-7 and-9 position. In addition, based on recent findings that C-5 alkyne 
carbamate sialic acid showed higher incorporation than C-5 azido acetamide, we used 
the C-4, -5 and C-9 positions to investigate the reproducibility of this effect on other 
positions.17  
 
Results and Discussion 
 
Chemical synthesis 
Synthesis of C-2 modifications 
Site-specific azidation requires suitably protected sialic acid starting materials which 
were prepared from known sialic acid methylester 1 for all synthetic routes. Treatment 
of 1 with an excess of acetic anhydride in pyridine afforded peracetylated sialic acid 2. 
Bromination of the anomeric center with HBr in acetic acid and subsequent halide 
replacement by sodium azide yielded the C-2 azide 3 (Scheme 1).  
 
 
Scheme 1. C-2 azidation via anomeric halide displacement. i) Dowex H+, MeOH, 80 °C µW, 60 min; ii) 
Ac2O, Pyr, r.t., 16 h, 85% (2 steps). iii) AcOH, HBr, Ac2O, r.t., 16 h; iv) NaN3, TBAB, r.t., 4 h, 79%.  
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Synthesis of C-3 modifications 
Treatment of peracetylated sialic acid 2 with TMSOTf resulted in the formation of glycal 
4 due to H-3 elimination (Scheme 2). Subsequent azidonitration afforded the C-3 azide 
as described previously.18 Finally, acetylation yielded compound 5. Based on earlier 
research it was known that the equatorial proton of the C-3 position could not be 
exchanged as this would block activation by the CMAS.11, 19 While our synthesis led to 
both the equatorial and axial azide, the isomers were separated and only the axial azide 
was used for our studies. 
 
 
Scheme 2. C-3 azidation via radical double bond-azidation. i) TMSOTf, 0 °C, 4 h, 61%. ii) Ce (NO3)6(NH4)2, 
NaN3, ACN, 0 ˚C, 1 h; iii) AcOH, H2O, 50 ˚C, 16 h; iv) Ac2O, pyr, r.t., 16 h, 50% (3 steps). 
 
Synthesis of C-4 modifications 
Prolonged treatment of 2 under acidic conditions led to the formation of oxazoline 6a 
(Scheme 3). Azide introduction via acidic ring opening led to the previously described 
azido-glycal 6.20 In our hands, even harsh acidic treatment of 6 did not result in 
protonation of the double bond whereas halonium ions smoothly afforded 7a. Several 
attempts to eliminate the bromine via a radical reaction were not successful leading to 
either decomposition or no reaction at all. Even slightly basic conditions led to 
undesired epoxide formation (hydrolyzed on silica column). Instead, hydrogenation 
finally formed the C-4 amine. Azido-transfer and subsequent acetylation was 
eventually successful to synthesize C-4 azide 7. In a similar approach, acylation of the 
free amine led to the C-4 Poc sialic acid 8. 
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Scheme 3. C-4 azidation via oxazoline opening. i) TMSOTf, 50 °C, 3 h, 75%.21 ii) TMSN3, tBuOH, 100 °C, 
16 h, 80%.22  iii) NBS, ACN, H2O, 50 ˚C, 16 h; iv) Pd/C, tBuOH, H2O, r.t., 16 h; iv) TEA, r.t., 7: Imidazole-
1-sulfonyl-N3, CuSO4, MeOH, 3 h; 8: PocCl, DCM, 8 h, v) Ac2O, pyr, r.t., 16 h, 7: 42% 8: 24%; (four steps 
each).  
 
Synthesis of C-5 modifications 
The previously known Boc-Sialic acid precursor 1317 (Chapter 3) can, after acidic 
deprotection, be converted into many different C-5 modifications. Direct azide transfer 
leads to 14, acylation forms azidoacetyl 15, azido carbamate 16 or alkynes with 
different linkage types like Poc 17, acetamide 18 and urea 19 (Scheme 4).  
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Scheme 4. C-5 azidation via C-5 deacetylation and azide transfer or amine coupling. i) HSTol, BF3ּ Et2O, 
DCM, 21 h, 95%.23 ii) Boc2O, DMAP, THF, 70 °C, 1 h, 88%.24 iii) K2CO3, MeOH, 72 h, 83%.24 iv) Ac2O, Pyr, 
r.t., 7 h, 91%. v) NBS, AcOH, Ac2O, ACN, DCM, r.t., 1.5 h, 77% vi) TFA, DCM, r.t., 16 h; vi) 14: Imidazole-
1-sulfonyl-N3, CuSO4, TEA, DMF, r.t., 3 h, 82%; 15: AzOSu, TEA, DCM, r.t., 16 h, 81%; 16: AzeocOSu, TEA, 
DCM, r.t., 16 h, 63%; 17: PocCl, TEA, DCM, 74%; 18: 4-pentynoic acid, DIC, DMAP, 68%; 19: N-propargyl-
4-nitrophenyl carbamate, TEA, DCM, 48%; (two steps each).  
 
Synthesis of C-7 modifications 
Labeling of the C-7 position of sialic acid has been achieved using a C-4 modified N-
acetyl mannosamine precursor.25-26 For the aforementioned reasons, however, we set 
out to prepare the sialic acid derivative chemically. The C-7 alcohol of sialic acid is the 
least reactive one.27 In theory, it could remain free while acetylating all other alcohols 
under kinetic conditions. As expected, however, this approach gave the C-7 alcohol as 
major product but in an inseparable mixture of other partially acetylated sialic acids. 
Blocking the C-9 and C-8 with an isopropylidene group however helped to reduce the 
amount of products and yielded the desired di-acetylated product in on average 50% 
after selective acetylation (~25% was mono-acetylated of C-4 and ~25% tri-acetylated). 
The problem, however, was that the product remained inseparable from the 
byproducts by standard column chromatography. Direct triflation and azidation of the 
162 
 
mixture did lead to some product formation but was very low yielding. Instead, we 
decided to protect the C-2 alcohol which has an only slightly lower reactivity compared 
to the C-7 alcohol and was therefore expected to cause problems. This led to the new 
strategy depicted in Scheme 5. Given their difference in reactivity, selective acetylation 
of the C-4 over the C-7 alcohol towards 22 did not even require cooling. The 
subsequent triflation of the free C-7 alcohol proceeded smooth and did not show any 
byproduct formation on TLC. After column chromatography, the isolated yield was 
18%, which might be due to decomposition on the silica gel. Subsequent azidation did 
proceed nearly quantitatively. To improve the yield of the triflation, we left out column 
chromatography, which increased the crude yield to approximately 80% for triflation. 
Leaving out column purification seemed reasonable pure on NMRR, it did however 
reduce the yield of the subsequent azidation to only 60%. C-7 azide 23 might be an 
interesting sialylation donor, but for cellular application, the protecting groups had to 
be exchanged to acetyls to assure intracellular deprotection by esterases. C-7 azide 23 
was therefore deprotected in three steps to yield the final C-7 metabolic reagent 25. 
 
Scheme 5. C-7 azidation via triflation and azidation. i) K2CO3, MeOH, r.t., 16 h, 90%. ii) 2,2-
Dimethoxypropane, Dowex H+, acet, 1 h, 120 °C µW, 82%. iii) Ac2O, Pyr, r.t., 90 min, 92%. iv) Tf2O, Pyr, 
DCM, -78 °C, 15 min; v) NaN3, DMF, r.t., 2 h, 36% (two steps). 
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Synthesis of C-8 modifications 
The synthesis of C-8 modifications of sialic acid are not directly possible via the typical 
enzymatic approach from a mannosamine precursor as the C-8 alcohol of sialic acid is 
the former ring oxygen of mannosamine.28 We envisioned a simple four step procedure 
to solely free the C-8 alcohol starting from methyl ester 1 by protecting the C-9 and C-
8 with isopropylidene first, then completely acetylating the sialic acid and deprotecting 
the isopropylidene again. Final selective acetylation of the primary C-9 alcohol over the 
C-8 one could free the C-8 alcohol solely in a rapid synthetic procedure with only one 
column purification (Scheme 6). The first steps worked well, using a microwave 
procedure to speed up isopropylidene protection, to afford 26 followed by direct 
acetylation to yield 27. Isopropylidene deprotection and selective acetylation yielded 
free C-8 alcohol 29. To our surprise, the subsequent modification of the C-8 alcohol 
turned out to be challenging. Probably a combination of steric hindrance, an 
unfavorable dipole interaction and of course the disarming effect of the acetyls 
rendered the C-8 alcohol rather unreactive and even applying heat and a vast excess 
of triflic anhydride was not successful in triflating the C-8 alcohol. Further heating led 
to decomposition. Tosylation and mesylation were both successful even though the 
unreactive alcohol required heating instead of the usual cooling. To our 
disappointment, all approaches to replace the tosylated alcohol with an azide were 
unsuccessful. Neither Mitsunobo conditions, TMS-azide with TBAF to create a more 
reactive azide anion, nor different solvents (water, acetone, dimethylformamide, 
dimethyl sulfoxide) nor heating to reflux yielded the C-8 azide (Scheme 6). We 
concluded, that our approach would not lead to the C-8 azide, but the quick and 
relatively easy synthesis of a free C-8 alcohol 29 could still be of general interest for the 
chemical community e.g. as C-8 glycosylation acceptor or as scaffold for other C-8 
modifications. It should be mentioned, that it was possible to synthesize compound 29 
even faster using no work-up but extractions after acetylation and one final column. 
Additionally, the acetylation steps could be carried out faster in microwave (70 °C, 120 
min) using imidazole instead of pyridine as previously described.29 While the reduction 
of the total time of synthesis to one working day might sound beneficial, we do not 
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recommend this method as in our hands it caused the yield to drop dramatically so 
that we did not further optimize this approach.  
 
  
Scheme 6. Synthesis of free C-8 alcohol. i) 2,2-Dimethoxypropane, Dowex H+, acet, 30 min, 120 °C µW, 
90%. ii) Ac2O, Pyr, 16 h, 95%. iii) AcOH, H2O, 2 h, 82%. iv) Ac2O, Pyr, 16 h, 53%. 
 
To circumvent the problem of an unreactive leaving group and steric hindrance of 
neighboring groups, we envisioned synthesizing the C8,7-epoxide inspired by earlier 
research.30 Generally, the alcohols at C-8 and -7 are the least reactive ones and 
regioselective acetylation of C-9, -4 and -2 can be performed. However, the difference 
in reactivity between C-2 and C-8 is not high enough for exclusive selectivity and 
therefore yielded about 50% of the desired product and about 25% of C-4 and C-9 
acetylated and 25% of C-4, C-9 and C-8 acetylated byproduct. Both byproducts 
required laborious purification, which resulted in low yields. Starting again from a C-2 
thiol-protected sialic acid 20 instead circumvented this problem. The higher reactivity 
of C-9 and C-4 compared to C-8 and C-7 enabled regioselective acetylation to 30 in high 
yields. However, instead of forming an epoxide, the C-5 acetamide participated in the 
reaction and formed the oxazoline structure 31 (Scheme 7).  
 
Scheme 7. Oxazoline byproduct. i) Ac2O, DMAP, Pyr, r.t., 16 h, 66%. ii) TsCl, Pyr, 80 °C, 2 h, 43%. 
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To block participation of C-5, we started again with Boc-protected compound 11. 
Regioselective acetylation to 32 went smoothly but neither tosylation nor triflation 
worked for 33. We reasoned that the Boc-group might sterically hinder the reaction 
and therefore we chose for the smaller mesyl chloride. Mesylation towards compound 
33 was successful and treatment with base partly gave the epoxide but did not go 
further than 50% conversion based on MS analysis. We did not perform a workup 
because of the anticipated epoxide instability. While nucleophilic solvents like 
methanol resulted in epoxide opening and methanol addition at r.t. in minutes, 
addition of sodium azide did not form any azidation product. Addition of DMF to 
promote azidation resulted in minor quantities of C-8 azide but the conversion 
remained low (Scheme 8). We therefore decided to abandon the C-8 azide and focus 
on other positions.  
  
Scheme 8. C-8 azidation via epoxide opening. i) Ac2O, Pyr, r.t., 3 h, 61%. ii) MsCl, DCM, r.t., 18 h, 83%. 
iii) BuLi, THF, 0 °C, 6 h. 
 
Synthesis of C-9 modifications 
Synthesis of C-9 azido sialic acid from the corresponding tosylate is a well-established 
process.9, 31-37 However, methyl ester deprotection is frequently observed during 
azidation of tosylated sialic acid 34. Therefore, we acetylated 34 first, to enable easier 
purification and stabilize the methyl ester. We were surprised to find, that acetylated 
tosyl-sialic acid 35 was remarkably resistant towards azidation. Heating in DMSO, 
however, eventually afforded C-9 azide 36. This surprising resistance against azidation 
after acetylation might hint to a different mechanism than the simple SN2 azide 
replacement. Many articles describe not purifying the tosylated intermediate and it 
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might therefore be, that partially a 9,8-epoxide intermediate is formed. This 
couldhappen during the reaction but even more likely when concentrating the 
tosylation reaction in the presence of base (often without quenching at elevated 
temperature). This is in line with previous research describing the epoxide formation 
under basic conditions.38 Azide reduction enabled acylation with azides to azidoacetyl 
azide 38 and azido ethyl carbamate 39. In addition, propargyl carbamate 40 and amide 
41 were synthesized in a similar manner.  (Scheme 9). 
 
 
Scheme 9. C-9 azidation via tosylation and amine coupling.  i) TsCl, 0 °C-r.t., 16 h, 80%. ii) Ac2O, Pyr, 
r.t., 16 h, 46%. . iii) NaN3, TsCl, Pyr, DMSO, r.t., 3 h, 59%. iv) SnCl2, HCl, MeOH, r.t., 16 h; v) DCM, TEA,  
HCl, MeOH, r.t., 36 h, 38: AzOSu, 31%; 39: AzeocOSu, 24%; 40: PocCl, 42%; 41: pentynoic-OSu, 18%; 
(two steps each). 
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Biological evaluation 
Efficiency of metabolic incorporation 
We set out to explore which sialic acid analogs would still be recognized by the 
biosynthetic machinery (Figure 1). Generally, the sialic acid analogs were applied to 
the cell at different concentrations for three days and incorporation was measured by 
copper-catalyzed azide alkyne cycloaddition to azide or alkyne biotin and subsequent 
staining with streptavidin-PE. The procedures for metabolic incorporation and analysis 
have been published previously, containing and more detailed descriptions (Chapter 
3).17  
First, the azides directly attached to the carbon skeleton at C-2,-3,-4,-5,-7 and C-9 were 
investigated. To our surprise, all but the C-2 azide showed incorporation (Figure 2). 
While it was expected that C-2 modifications could not be incorporated, the 
biosynthetic sialic acid machinery was surprisingly tolerant towards analogs at all other 
positions. While the amount of labeling showed differences depending on the position, 
none of the alcohol seemed to be indispensable for incorporation. The acetamide at 
the C-5 position of sialic acid has been described as very important for sialic acid 
recognition.39-41 Despite of this fact, the C-5 azide was still accepted as a substrate.   
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Figure 2. Metabolic incorporation of azides directly bound to the sialic acid backbone. Compound 
numbers are given in bold black. 
 
While all azides were incorporated, the incorporation differs with the C-4 azide 7 
showed the lowest labeling. This might either hint towards an important hydrogen 
bonding-event of the C-4 alcohol or could be due to space restrictions. At low 
concentration, the C-7 azide performed best, which vice versa might indicate a higher 
tolerance towards C-7 modifications and less important binding-events of the C-7 
alcohol. This is especially interesting as C-7 modifications have hardly been used for 
metabolic engineering. In addition, even the C-3 azide derivative was incorporated. The 
previously reported Poc-sialic acid (Chapter 3) was shown to be better incorporated 
than the corresponding azidoacetamide. We therefore synthesized a Poc-modified 
sialic acid 8 for the C-4 position because this position had shown the least effective 
labeling. The Poc modification is bulkier and longer than the C-4 azide but does enable 
hydrogen bonding via the carbamate functionality. This could indicate wether space 
restrictions or binding events might be the reason for the lower incorporation. We 
tested the C-4 Poc sialic acid 8 and were surprized by the high incorporation (Figure 3). 
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The data suggest a strong molecular interaction of Poc carbamate in the binding 
pockets of the biosynthetic enzymes that cannot be achieved by azides.  
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Figure 3. Azide and Poc C-4 modification in direct comparison. Compound numbers are given in bold 
black. 
 
For the C-5 position, it was already known that changing the natural acetamide could 
affect incorporation efficiency. Earlier research had shown that azidoacetamide 15 
analogs are inferior to Poc carbamate 17.17 We set out to investigate the nature of this 
interaction. Either it could be size dependent, an alkyne could be intrinsically better 
accepted than an azide, or the linkage type-carbamate versus -acetamide could be 
beneficial. Therefore, we compared azide 14, azidoacetyl 15 and azido carbamate 16. 
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Figure 4. Metabolic incorporation of C-5 azides. Compound numbers are given in bold black. 
 
As expected, the more natural acetamide linkage of azidoacetyl 15 was preferred over 
the direct C-azide 14 directly linked to the carbon skeleton. Interestingly, the azide 
carbamate 16 worked clearly better than the acetamide, which indicated that 
carbamates might be preferred over the natural acetamide (Figure 4). It should be 
noted, that MFI values approaching 6000 probably reach the upper detection limit and 
might not reflect the incorporation anymore. To further expand this screen, we 
evaluated alkynes as well and tested an acetamide alkyne (Al) 18, an urea 19, and the 
Poc-carbamate linker 17, all with the same number of atoms and therefore a 
comparable length.  As expected, the direct linked azide 14 performed worst. Similar 
to the azide order, the acetamide alkyne 18 was incorporated less than carbamate Poc 
17. The carbamates Poc 17 and Azeoc (azidoethanyloxycarbonyl) 16 both performed 
very well, closely followed by the urea 19 (Figure 5). There is no clear trend in length 
as the azidoacetyl is shorter than the acetamide alkyne, but does perform slightly 
better and all alkynes share the same length. There is, however, a clear trend towards 
additional hetero atoms. Urea and carbamates are better incorporated into the 
glycocalyx.  
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Figure 5. Metabolic incorporation of all C-5 modifications. Compound numbers are given in bold black. 
 
To investigate whether this was a general trend for all positions or whether this effect 
is site-specific, we applied different C-9 modifications for metabolic labeling including 
the directly linked azide 36, the azido acetamide 38 an azido carbamate 39 and alkynes 
linked via acetamide 41 or carbamate linkage 40. However, the same trend could not 
be reproduced. While little differences were seen, azides performed equally well and 
the C-9 Poc 40 was even inferior at low concentrations. Only the C-9 acetamide alkyne 
41 surprised with high toxicity, even after repeating the synthesis. Data of all other C-
9 modifications combined, suggest that the type of linkage at this position does not 
seem to have a big influence. This was however, surprising as the C-9 alcohol was 
expected to perform important hydrogen-bonding interactions. The overall lower 
incorporation of C-9 modifications compared to C-4 or C-5 might indicate that there is 
indeed an important interaction. The beneficial effect of acetamide or carbamate on 
hydrogen bonding might be cancelled by their bulkiness. Alternatively, the sterically 
demanding groups shield the hydrogen from participating in a hydrogen bonding. 
While the precise nature of the different incorporation efficiencies remain unclear, the 
examples demonstrate that the C-9 position is tolerant for modifications (Figure 6). 
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Figure 6. Metabolic incorporation of C-9 modifications. Compound numbers are given in bold black. 
 
Conclusion 
In conclusion, 16 different azide- or alkyne- bearing sialic acid analogs have been 
synthesized with highly reliable synthetic routes and were applied for metabolic 
engineering on THP-1 cells. All but the C-2 azide 3 were tolerated by the synthetic 
machinery and incorporated into the glycocalyx. Significant differences in 
incorporation efficiency based on the azide position, but also on the linkage type were 
observed. In general, carbamates and a urea linkage were superior to directly linked 
azides at the C-4 and -5 positions. Especially the C-4 modifications, that have not been 
reported earlier, showed much better incorporation with carbamate alkyne 8 than 
directly linked azide 7, probably because of hydrogen bonding interactions of the C-4 
alcohol. The difference was observed earlier even though to a lesser extent for the C-
5 position where carbamates 16 and 17 but also urea 19 were superior to acetamides 
15 and 18 and far superior to carbon-linked azide 14. This might hint to a general trend, 
but was not reflected by modifications at the C-9 position where labeling was generally 
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not as high and azide 36 did perform about equally well as azidoacetamide 38 or 
carbamates 40 and 39. We were satisfied with the labeling of the C-7 azide 25 as it had 
only be described once and was also synthesized by enzymatic conversion and not 
chemically.42 To our knowledge, this was moreover the first time that C-3 azide 5 has 
been used for metabolic engineering. Our synthetic method allows easy additional 
modifications and addition of a carbamate (e.g. the Poc group) which could be 
especially interesting as it might either lead to a better incorporation of C-3 and C-7 
modifications, comparable with C-5 or C-4 modifications, or give more insight into the 
pocket restrictions. We hope that these new metabolic glycoengineering reagents will 
expand the toolbox of sialic acid scientists and will be applied in the near future in 
binding studies to give more insight in the nature of site specific modifications in the 
sialome. 
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Supplementary information 
 
General synthetic methods: 1H and 13C NMR spectra were recorded on a Varian Iinova 400 MHz or 
Bruker Avance III 500 MHz spectrometer. Chemical shifts are reported in parts per million (ppm) 
relative to tetramethylsilane (TMS) as the internal standard. NMR data is presented as follows: 
Chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet of 
doublet, dt = doublet of triplet, m = multiplet and/or multiple resonances), integration, coupling 
constant in Hertz (Hz). All NMR signals were assigned on the basis of 1H, 13C, 19F NMR, COSY and HSQC 
experiments. Mass spectra were recorded on a JEOL JMS-T100CS AccuTOF mass spectrometer. 
Automatic column chromatography was performed on Biotage Isolera Spektra One, using SNAP 
cartridges 10-50g filled with normal silica (Biotage, 30-100 μm, 60 Å) or water resistant iatro beads. 
Microwave reactions were performed on a Biotage Initiator 4.1.3. TLC analysis was conducted on TLC 
Silica gel, 60, F254, Merck, with detection by UV absorption (254 nm) where applicable, and by spraying 
with 20% sulfuric acid in methanol followed by charring at ~150 °C or by spraying with a solution of 
(NH4)6Mo7O24.H2O (25 g l-1) in 10% sulfuric acid in methanol followed by charring at ~300°C. DCM, ACN 
and Tol were freshly distilled. All reactions were carried out under an argon atmosphere. 
 
 
Commonly used abbreviations 
Ac  Acetyl 
Ac2O  Acetic anhydride  
Acet  Acetone 
ACN   Acetonitrile 
aq.  Aqueous 
Azeoc  2-azidoethanyloxycarbonyl 
AzOSu   Azidoacetic acid -
hydroxysuccinimide ester 
BF3•Et2O  Boron trifluoride etherate 
Boc  Tert-butyloxycarbonyl 
CD3OD  Deuterated methanol 
CDCl3  Deuterated chloroform 
D2O  Deuterium oxide 
DCM   Dichloromethane 
DMAP  Dimethylaminopyridine 
DMF  N,N-Dimethylformamide 
DMSO  Dimethylsulfoxide 
EtOAc  Ethyl acetate 
IP  Isopropylidene 
MeOH   Methanol 
MsCl  Methanesulfonyl chloride 
NBS  N-Bromosuccinimide 
OSu   Hydroxysuccinimide 
Poc  Propargylcarboxycarbonyl 
Pyr  Pyridine 
r.t.  Room temperature 
sat.  Saturated 
STol  Para-thiocresol 
Su  Succinimide 
TBAB  Tetrabutylammoniumbromide  
TEA  Triethylamine 
TFA  Trifluoroacetic acid 
TFAA   Trifluoroacetic acid anhydride 
THF  Tetrahydrofuran 
TMSOTf Trimethylsilyl 
trifluoromethanesulfonate 
Tol  Toluene 
TsCl  Toluenesulfonyl chloride 
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 Methyl (5-acetamido- -3,5-dideoxy-5-D-glycero-D-galacto)onate (1). Dowex H+ 
resin was washed with MeOH three times before adding 0.2 g resin to a solution of N-acetylneuraminic 
acid (1 g; 3.24 mmol) in MeOH (20 mL; 0.16 M). After stirring at 80 °C for 1 h under microwave 
radiation, the colorless mixture was filtered. The filtrate was concentrated in vacuo affording 1 (1.05 
g; 3.24 mmol; quant.) as a white foam. TLC: (H2O:ACN, 20:80 v/v) Rf = 0.39. 1H NMR (500 MHz, CD3OD) 
δ 4.07 – 3.98 (m, 2H, H-4; H-6), 3.85 – 3.79 (m, 2H, H-5; H-9a), 3.78 (s, 3H, OCH3), 3.70 (ddd, J = 8.8, 5.7, 
2.8 Hz, 1H, H-8), 3.62 (dd, J = 11.3, 5.7 Hz, 1H, H-9b), 3.48 (dd, J = 9.2, 1.1 Hz, 1H, H-7), 2.22 (dd, J = 
12.9, 4.9 Hz, 1H, H-3eq), 2.02 (s, 3H, CH3, Ac), 1.89 (dd, J = 12.8, 11.5 Hz, 1H, H-3ax). 13C NMR (126 MHz, 
CD3OD) δ 175.10 (C-1), 171.78 (CO, Ac), 96.65 (C-2), 72.06 (C-6), 71.62 (C-8), 70.16 (C-7), 67.83 (C-4), 
64.82 (C-9), 54.29 (C-5), 53.71 (OCH3), 40.68 (C-3), 22.68 (CH3, Ac). HR-ESI-TOF/MS (m/z): [M+Na]+ 
calcd. for C12H21NNaO9, 346.11140; found, 346.11286. 
 
Methyl (5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-5-D-glycero-D-
galacto)onate (2). To a solution of sialic acid methylester 1 (20.9 g; 64.6 mmol) in Pyr (250 mL; 3.09 
mol; 47.8 eq.), Ac2O (125 mL; 1.59 mol; 24.6 eq.) was slowly added. After stirring at r.t. for 24 h, the 
mixture was concentrated in vacuo with Tol co-evaporation. The residue was dissolved in EtOAc and 
washed successively with HCl (0.1 M) and sat. aq. NaHCO3. The organic layer was dried over MgSO4 
and filtered. The filtrate was concentrated in vacuo affording 2 (34.5 g; 64.6 mmol; quant.) as white 
foam. TLC: (Acet:DCM, 40:60 v/v) Rf = 0.51. 1H NMR (500 MHz, CDCl3, major anomer) δ 5.38 – 5.37 (m, 
1H, H-7), 5.26 (ddt, J = 10.1, 7.5, 4.9 Hz, 1H, H-4), 5.07 (ddd, J = 6.8, 5.1, 2.5 Hz, 1H, H-8), 4.50 (dd, J = 
12.5, 2.6 Hz, 1H, H-9a), 4.15 – 4.10 (m, 3H, H-9b; H-6; H-5), 3.80 (s, 3H, OCH3), 2.55 (dd, J = 13.5, 5.0 Hz, 
1H, H-3eq), 2.15 (s, 3H, CH3, OAc), 2.14 (s, 3H, CH3, OAc), 2.10 – 2.09 (m, 1H, H-3ax), 2.07 (s, 3H, CH3, 
OAc), 2.05 – 2.03 (m, 6H, 2x CH3, OAc), 1.90 (s, 3H, CH3, NHAc). 13C NMR (126 MHz, CDCl3, major 
anomer) δ 171.15 (CO, Ac), 170.75 (CO, Ac), 170.41 (2x CO, Ac), 170.38 (CO, Ac), 168.37 (C-1), 166.46 
(CO, Ac), 97.65 (C-2), 73.00 (C-6), 71.52 (C-8), 68.44 (C-4), 67.98 (C-7), 62.27 (C-9), 53.35 (OCH3), 49.49 
(C-5), 36.05 (C-3), 23.33 (CH3, Ac), 21.05 (CH3, Ac), 20.99 (CH3, Ac), 20.93 (2x CH3, Ac) 20.91 (CH3, Ac). 
HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C22H31NNaO14, 556.16422; found, 556.16487. 
 
 Methyl (5-acetamido-7,8,9-tri-O-acetyl-4-azido-2-chloro-3,4,5-trideoxy-β-D-
glycerol-D-galacto-2-nonulopyranosid)onate (3). Peracetylated sialic acid (300 mg; 0.562 mmol) was 
solved in AcOH (1.61 mL; 28.1 mmol; 50 eq.) and Ac2O (27 µl; 0.28 mmol; 0.5 eq.). A solution of 33% 
HBr in AcOH (0.555 mL; 3.37 mmol; 6eq.) was added dropwize and the reaction was stirred 16 h at r.t., 
extracted using EtOAc and ice-cold, aq.NaHCO3. The organic layer was collected and NaN3 (366 mg; 
5.63 mmol; 10 eq.) and TBAB (91 mg; 0.281 mmol; 0.5 eq.) were added. The reaction was stirred at r.t. 
for 4 h, washed with aqueous NaHCO3, dried with Na2SO4, filtered and concentrated in vacuo to yield 
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3 (229 mg; 0.443 mmol; 79%) TLC: (Acet:DCM, 40:60 v/v) Rf = 0.60.  1H NMR (500 MHz, CDCl3) δ 5.34 – 
5.32 (m, 2H, H-7, H-8), 5.04 (ddd, J = 11.7, 10.2, 4.8 Hz, 1H, H-4), 4.40 – 4.33 (m, 1H, H-9a), 4.17 – 4.10 
(m, 1H, H-9b), 4.05 (q, J = 10.2 Hz, 1H, H-5), 3.91 – 3.89 (m, 1H, H-6), 3.88 (s, 3H, OCH3), 2.56 (dd, J = 
13.1, 4.8 Hz, 1H, H-3eq), 2.14 (s, 3H, CH3, OAc), 2.11 (s, 3H, CH3, OAc), 2.03 (s, 3H, CH3, OAc), 2.03 (s, 3H, 
CH3, OAc), 1.87 (s, 3H, CH3, OAc), 1.83 (dd, J = 13.1, 11.8 Hz, 1H, H-3ax).13C NMR (126 MHz, CDCl3) δ 
170.80 (CO), 170.60 (CO), 170.28 (CO), 170.04 (CO), 167.11 (C-1), 89.00 (C-2), 73.95 (C-6), 69.53 (C-7), 
68.76 (C-4), 67.47 (C-8), 62.13 (C-9), 53.47 (OCH3), 49.28 (C-5), 36.54 (C-3), 23.15 (CH3, OAc), 21.01 
(CH3, OAc), 20.80 (CH3, OAc), 20.73 (CH3, OAc), 20.71 (CH3, OAc). IR (ATR, ν, cm-1): 2120.60 (N3). HR-
ESI-TOF/MS (m/z): [M+Na]+ calcd. for C20H28N4NaO12, 539.16014; found, 539.16057.  
 
Methyl (5-acetamido-4,7,8,9-tetra-O-acetyl-3-dehydro-2,3,5-trideoxy-5-β-D-
glycero-D-galacto)onate (4). Peracetylated sialic acid 2 (1.02 g, 1.912 mmol) was dissolved in ACN (4 
mL; 0.478 M) and cooled to 0 °C. TMSOTf (1.03 mL; 5.736 mmol; 3 eq.) was added dropwise to the 
solution which turned slightly yellow. After 4 h, the reaction was diluted with an excess EtOAc and 
washed three times with sat. aqueous NaHCO3 (30 mL). The organic layer was concentrated in vacuo 
and the product was purified on silica gel flash column chromatography (0  30% Acet in DCM), and 
a white solid was obtained (0.552 g, 1.166 mmol, 61% yield as a white foam). TLC: (Acet:DCM, 30:70 
v/v) Rf = 0.50. 1H NMR (400 MHz, CDCl3) δ 6.05 (d, J = 8.9 Hz, 1H, NH), 5.99 (d, J = 3.1 Hz, 1H, H-3), 5.54 
– 5.48 (m, 2H, H-4; H-7), 5.35 (ddd, J = 7.5, 4.4, 3.1 Hz, 1H, H-8), 4.65 (dd, J = 12.3, 3.1 Hz, 1H, H-9a), 
4.40 (dd, J = 7.8, 5.1 Hz, 2H, H-6; H-5), 4.20 (dd, J = 12.3, 7.3 Hz, 1H, H-9b), 3.81 (s, 3H, OCH3), 2.13 (s, 
3H, CH3, Ac), 2.08 (s, 3H, CH3, Ac), 2.07 (s, 3H, CH3, Ac), 2.06 (s, 3H, CH3, Ac), 1.93 (s, 3H, CH3, Ac). 13C 
NMR (101 MHz, CDCl3) δ 170.82 (CO, Ac), 170.61 (CO, Ac), 170.19 (CO, Ac), 170.17 (CO, Ac), 161.63 (C-
1), 145.06 (C-2), 107.98 (C-3), 76.64 (C-6), 70.85 (C-8), 68.03 (C-7), 67.64 (C-4), 61.97 (C-9), 52.57 
(OCH3), 46.46 (C-5), 23.09 (CH3, Ac), 20.85 (CH3, Ac), 20.76 (CH3, Ac), 20.72 (CH3, Ac), 20.70 (CH3, Ac). 
HRMS (m/z): [M+Na]+ calcd for C20H27NO12, 496.1431; found, 496.1430. 
 
 Methyl (5-acetamido-2,4, 7,8,9-penta-O-acetyl-3-azido -3,5-dideoxy-β-D-
glycerol-D-galacto-2-nonulopyranosid)onate (5). Sialic acid glycal 4 (0.557 g, 1.177 mmol) and NaN3 
(0.122 g, 1.882 mmol; 1.6 eq.) were solved in ACN (12 mL) with mole sieves under continous argon 
flow. The mixture was cooled to 0 °C and (NH4)2Ce(NO3)6 (1.490 g, 3.290 mmol; 2.8 eq.) was added. 
After stirring vigorously for 1 h, the reaction was concentrated in vacuo, extracted with DCM and 
aqueous NaHCO3, dried with MgSO4, filtered, and concentrated in vacuo. The crude solid was 
redissolved in a mixture of AcOH (7 mL) and H20 (5 mL) and stirred at 50 °C for 16 h, and concentrated 
in vacuo. The crude product was directly used for acetylation and solved in a mixture of Pyr (8 mL) and 
Ac2O (4 mL) and stirred at r.t. for 16 h, concentrated in vacuo, redissolved in EtOAc and washed with 
1M HCl and sat. aqueous NaHCO3, dried with MgSO4, filtered, concentrated aqueous NaHCO3 in vacuo 
and subsequently purified by column chromatography (0  20% Acet/DCM), and 5 (0.337 g, 0.588 
mmol, 50% yield mixture of isomers) was obtained. TLC: (Acet:Tol, 20:80 v/v) Rf = 0.40. 1H NMR (500 
MHz, CDCl3, axial-N3 isomer) δ 5.63 (dd, J = 10.7, 3.7 Hz, 1H, H-4), 5.37 (d, J = 9.3 Hz, 1H, NH), 5.33 (dd, 
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J = 4.8, 2.1 Hz, 1H, H-7), 5.07 (ddd, J = 6.7, 4.9, 2.5 Hz, 1H, H-8), 4.57 (dd, J = 12.4, 2.5 Hz, 1H, H-9a), 
4.25 – 4.21 (m, 2H, H-3eq; H-5), 4.17 (dd, J = 12.1, 6.3 Hz, 1H, H-9b), 4.16 – 4.13 (m, 1H, H-6), 3.86 (s, 
3H, OCH3), 2.18 (s, 3H, CH3, Ac), 2.18 (s, 3H, CH3, Ac), 2.13 (s, 3H, CH3, Ac), 2.04 (s, 3H, CH3, Ac), 2.03 (s, 
3H, CH3, Ac), 1.92 (s, 3H, CH3, Ac). 13C NMR (126 MHz, CDCl3) δ 170.64 (CO), 170.55 (CO), 170.40 (CO), 
170.37 (CO), 170.23 (CO), 167.18 (CO), 165.71 (C-1), 96.10 (C-2), 72.10 (C-6), 71.51 (C-8), 69.94 (C-4), 
67.99 (C-7), 62.31 (C-3), 62.07 (C-9), 53.58 (OCH3), 45.74 (C-5), 23.30 (CH3, Ac), 20.91 (CH3, Ac), 20.86 
(CH3, Ac), 20.77 (CH3, Ac), 20.55 (CH3, Ac), 20.53 (CH3, Ac). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for 
C22H30N4NaO14, 597.16562; found, 597.16615. 
 
 Methyl (5-acetamido-7,8,9-tri-O-acetyl-4-azido-3-dehydro-2,3,4,5-trideoxy-5-
β-D-glycero-D-galacto)onate (6). Oxazoline sialic acid was synthesized as described previously21 (650 
mg; 1.574 mmol) was solved in tBuOH (7.15 mL; 0.22 M) and TMS-N3 (310 µl; 2.359 mmol; 1.5 eq) was 
added. The reaction was stirred at 100 °C for 16 h, then cooled to r.t. before quenching with an excess 
of 0.1 M HCl aq. (100 mL), then extracted with EtOAc, washed with aqueous NaHCO3, dried with Na2SO4 
and filtered. The filtrate was concentrated in vacuo. Silica gel flash column chromatography (0 → 40% 
Acet in DCM) afforded azidoglycal 6 (577 mg; 1.26 mmol; 80%)22 as a white foam.  TLC: (Acet:DCM, 
25:75 v/v) Rf = 0.46. 1H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 9.3 Hz, 1H, NH), 5.95 (d, J = 2.5 Hz, 1H, H-
3), 5.49 (dd, J = 5.2, 2.1 Hz, 1H, H-7), 5.30 (ddd, J = 7.7, 5.2, 2.7 Hz, 1H, H-8), 4.65 (dd, J = 12.4, 2.4 Hz, 
1H, H-9a), 4.41 (dd, J = 10.3, 1.9 Hz, 1H, H-6), 4.29 (dd, J = 9.2, 2.4 Hz, 1H, H-4), 4.20 – 4.10 (m, 2H, H-
5, H-9b), 3.80 (s, 3H, OCH3), 2.12 (s, 3H, CH3, Ac), 2.05 (s, 3H, CH3, Ac), 2.04 (s, 3H, CH3, Ac), 1.99 (s, 3H, 
CH3, Ac). 13C NMR (126 MHz, CDCl3) δ 170.90 (CO), 170.52 (CO), 169.73 (CO), 169.72 (CO), 161.22 (CO), 
144.88 (C-2), 107.59 (C-3), 76.09 (C-6), 70.52 (C-8), 67.27 (C-7), 61.81 (C-9), 58.36 (C-4), 52.29 (OCH3), 
47.01 (C-5), 22.87 (CH3, Ac) 20.48 (CH3, Ac), 20.46 (CH3, Ac), 20.44 (CH3, Ac). HR-ESI-TOF/MS (m/z): 
[M+Na]+ calcd. for C18H24N4NaO10, 479.13901; found, 479.13853.  
 
 Methyl (5-acetamido-2, 7,8,9-tetra-O-acetyl-4-azido -3,4,5-trideoxy-β-D-
glycerol-D-galacto-2-nonulopyranosid)onate (7). Azido glycal sialic 6 (400 mg; 0.876 mmol) was solved 
in a 19:1 mixture of ACN: H2O (16.65 mL: 0.876; 0.05 M) and NBS (187 mg; 1.052 mmol; 1.2 eq.) was 
added and the reaction was stirred at 50 °C for 16 h. Note: As there is hardly difference in Rf, the 
reaction can either be followed by mass-spectroscopy or by monitoring the dissapearing UV-activity of 
the glycal at 240 nm. The mixture was concentrated in vacuo and directly without additional 
purification.  Note: While the halide intermediate is stable on column chromatography, the use of base 
should be avoided because the 2,3-epoxide is formed imeadiately. The crude mixture was redissolved 
in a mixture of 3:1 tBuOH: H2O (13.15 mL: 4.38 mL; 0.05 M) under argon atmosphere. Pd/C (100 mg; 
10% w/w) was added and the atmosphere was exchanged to hydrogen-gas and stirred at r.t. for 16 h. 
The atmosphere was carefully exchanged to argon and the mixture was filtered through an celite 
equipped filter and rinsed several times with additional tBuOH before concentrating in vacuo. The C-4 
amine intermediate was dissolved in MeOH (17.53 mL; 0.05 M) Imidazole-1-sulfonyl azide (379 mg; 
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2.191 mmol; 2.5 eq) and CuSO4 pentahydrade (10.94 mg; 0.044 mmol; 0.05 eq.) were added. The 
mixture was stirred vigorously and TEA (0.244 mL; 1.753 mmol; 2 eq.) was added. The reaction was 
stirred at r.t for 3 h, concentrated in vacuo, extracted with EtOAc and aqueous NaHCO3, the organic 
layer was filtered, concentrated and purified on silica column (0 → 30% Acet in DCM). TLC: (Acet:DCM, 
20:80 v/v) Rf = 0.22. Product was redissolved in a 2:1 mixture pyr: Ac2O (20 mL:10ml) and stirred at r.t. 
for 16 h, concentrated in vacuo, redissolved in EtOAc and washed with 1M HCl and aqueous NaHCO3, 
dried with MgSO4, filtered and again purified by column chromatomatography (0% → 20% Acet in 
DCM) to yield C-4 azide 7 (190 mg; 0.368 mmol; 42%) as white foam. TLC: (Acet:DCM, 20:80 v/v) Rf = 
0.30. 1H NMR (500 MHz, CDCl3) δ 5.92 (d, J = 8.6 Hz, 1H, NH), 5.34 (dd, J = 5.8, 2.1 Hz, 1H, H-7), 5.09 
(td, J = 6.1, 2.5 Hz, 1H, H-8), 4.45 (dd, J = 12.5, 2.5 Hz, 1H, H-9a), 4.36 (dd, J = 10.5, 2.0 Hz, 1H, H-6), 4.34 
– 4.25 (m, 1H, H-4), 4.16 (dd, J = 12.5, 6.2 Hz, 1H, H-9b), 3.78 (s, 3H, OCH3), 3.44 (q, J = 9.5 Hz, 1H, H-5), 
2.53 (dd, J = 13.7, 4.8 Hz, 1H, H-3eq), 2.15 (s, 3H, CH3, Ac), 2.14 (s, 3H, CH3, Ac), 2.05 (s, 3H, CH3, Ac), 
2.02 (s, 3H, CH3, Ac), 2.00 (s, 3H, CH3, Ac), 1.84 (dd, J = 13.8, 12.0 Hz, 1H, H-3ax).13C NMR (126 MHz, 
CDCl3) δ 170.91 (CO), 170.77 (CO), 170.57 (CO), 170.09 (CO), 168.22 (CO), 166.47 (CO), 96.83 (C-2), 
71.08 (C-6), 70.83 (C-8), 68.13 (C-7), 62.01 (C-9), 56.14 (C-4), 53.19 (OCH3), 51.53 (C-5), 36.25 (C-3), 
23.39 (CH3, Ac), 20.84 (CH3, Ac), 20.81 (CH3, Ac), 20.72 (CH3, Ac), 20.66 (CH3, Ac). HR-ESI-TOF/MS (m/z): 
[M+Na]+ calcd. for C18H24N4NaO10, 539.16014; found, 539.16057.  
 
 Methyl (5-N-acetyl-4-N-propargylaminocarbonyl-2,7,8,9-tetra-O-acetyl-3,4,5-
trideoxy-D-glycero-β-D-galacto-non-2-ulopyranoside)onate (8). Azido glycal sialic 6 (400 mg, 0.876 
mmol) was solved in a 19:1 mixture of ACN: H2O (16.65 mL: 0.876, 0.05 M) and NBS (187 mg, 1.052 
mmol, 1.2 eq.) was added and the reaction was stirred at 50°C for 16 h. The crude mixture was 
redissolved in a mixture of 3:1 tBuOH: H2O (13.15 mL: 4.38 mL; 0.05 M) under argon atmosphere. Pd/C 
(100 mg, 10% w/w) was added and the atmosphere was exchanged to hydrogen-gas and stirred at r.t. 
for 16 h. The atmosphere was carefully exchanged to argon and the mixture was filtered through an 
celite equipped filter and rinsed several times with additional tBuOH before concentrating in vacuo. 
The C-4 amine intermediate was dissolved in DCM (5.8 mL), PocCl (80 µL, 0.876, 1 eq.) and TEA (122 
µL, 0.876, 1 eq.) were added. The reaction was stirred at r.t. for 8 h and concentrated in vacuo, 
extracted with EtOAc and aq. NaHCO3, the organic layer was filtered, concentrated and purified on 
silica column (0 → 30% Acet in DCM). TLC: (Acet:DCM, 20:80 v/v) Rf = 0.16. Product was redissolved in 
a 2:1 mixture pyr: Ac2O (20 mL:10ml) and stirred at r.t. for 16 h, concentrated in vacuo, redissolved in 
EtOAc and washed with 1M aq. HCl and aq. NaHCO3, dried with MgSO4, filtered and again purified by 
column chromatomatography (0 → 20% Acet in DCM) to yield C-4 Poc 8 (120 mg; 0.201 mmol; 24% 
four steps) as white foam. TLC: (Acet:DCM, 20:80 v/v) Rf = 0.20. 1H NMR (500 MHz CDCl3) δ 5.64 (d, J = 
8.6 Hz, 1H, NHAc), 5.41 (dd, J = 5.0, 2.3 Hz, 1H, H-7), 5.36 (d, J = 8.2 Hz, 1H, NHPoc), 5.08 (ddd, J = 6.7, 
5.1, 2.6 Hz, 1H, H-8), 4.64 (qd, J = 15.6, 2.5 Hz, 2H, CH2, Poc), 4.50 (dd, J = 12.5, 2.6 Hz, 1H, H-9a), 4.16 
– 4.06 (m, 2H, H-9b; H-6), 4.06 – 4.00 (m, 2H, H-4: H-5), 3.78 (s, 3H, CH3, OCH3), 2.56 (dd, J = 13.6, 3.5 
Hz, 1H, H-3eq), 2.48 (t, J = 2.5 Hz, 1H, CH, Poc), 2.15 (s, 3H, CH3, Ac), 2.13 (s, 3H, CH3, Ac), 2.06 (s, 3H, 
CH3, Ac), 2.04 (s, 3H, CH3, Ac), 1.94 – 1.92 (m, 4H, H-3ax; CH3, Ac). 13C NMR (126 MHz, CDCl3) δ 171.37 
(CO, Ac), 170.61 (CO, Ac), 170.19 (CO, Ac), 170.04 (CO, Ac), 168.29 (CO, Ac), 166.46 (C-1), 155.89 (CO, 
NPoc), 97.26 (C-2), 73.33 (C-6), 71.31 (C-8), 67.98 (C-7), 62.11 (C-9), 53.16 (OCH3), 52.75 (CH2, Poc), 
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49.37 (C-5), 49.14 (C-4), 36.72 (C-9), 23.18 (CH3, Ac), 20.91 (CH3, Ac), 20.79 (CH3, Ac), 20.77 (CH3, Ac), 
20.74 (CH3, Ac). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C24H32N2O14Na, 595.17512; found, 
595.17588.  
 
Methyl (5-acetamido-4,7,8,9-tetra-O-acetyl-2-p-toluylthio-3,5-dideoxy-5-β-
D-glycero-D-galacto)onate (9). As described previously,23 2 (33.87 g; 63.5 mmol) was dissolved in DCM 
(400 mL; 0.16 M). HSTol  (9.26 mL; 76 mmol; 1.2 eq.) was added to form a slightly yellow solution. To 
initiate the reaction, BF3ּ Et2O (15.7 mL; 127 mmol; 2 eq.) was added and stirred for 21 h. The DCM 
mixture was successively washed with 10% Na2S2O3 and sat. aq. NaHCO3. The organic layer was dried 
over MgSO4, filtered and concentrated in vacuo. The residue was crystallized using DCM and hept. The 
crystals were filtered, washed with hept and collected with Acet Evaporation of solvents in vacuo 
afforded 9 (35.92 g; 60.1 mmol; 95%) as a white foam. TLC: (Acet:DCM, 30:70 v/v) Rf = 0.40. 1H NMR 
(500 MHz, CDCl3, major anomer) δ 7.30 (dd, J = 8.1, 1.8 Hz, 2H, 2x CH, meta STol), 7.12 (d, J = 7.2 Hz, 
2H, 2x CH, ortho STol), 5.68 (d, J = 10.3 Hz, 1H, NH), 5.46 (t, J = 2.4 Hz, 1H, H-7), 5.37 (td, J = 11.1, 4.8 
Hz, 1H, H-4), 4.95 (d, J = 8.5 Hz, 1H, H-8), 4.61 (dd, J = 10.5, 2.5 Hz, 1H, H-6), 4.49 (dd, J = 12.3, 2.2 Hz, 
1H, H-9a), 4.12 (q, J = 10.4 Hz, 1H, H-5), 4.02 (dd, J = 12.2, 8.6 Hz, 1H, H-9b), 3.58 (s, 3H, OCH3), 2.64 (dd, 
J = 13.8, 4.7 Hz, 1H, H-3eq), 2.31 (s, 3H, CH3, STol), 2.11 – 2.08 (m, 4H, H-3ax; CH3, Ac), 2.07 (s, 3H, CH3, 
Ac), 2.03 (s, 3H, CH3, Ac), 1.95 (s, 3H, CH3, Ac).13C NMR (126 MHz, CDCl3, major anomer) δ 171.13 (CO, 
Ac), 170.90 (CO, Ac), 170.23 (CO, Ac), 170.19 (CO, Ac), 170.16 (CO, Ac), 168.21 (C-1), 140.08 (CCH3, 
STol), 136.14 (2x CH, meta STol), 129.80 (2x CH, ortho STol), 125.17 (C-S, STol), 88.82 (C-2), 73.10 (C-
6), 73.01 (C-8), 69.05 (C-4), 68.78 (C-7), 62.64 (C-9), 52.51 (OCH3), 49.36 (C-5), 37.33 (C-3), 23.10 (CH3, 
Ac), 21.25 (CH3, STol), 21.04 (CH3, Ac), 20.83 (CH3, Ac), 20.68 (CH3, Ac), 20.64 (CH3, Ac). HR-ESI-TOF/MS 
(m/z): [M+Na]+ calcd. for C27H35NNaO12S, 620.17776; found, 620.17694.  
 
Methyl (5-acetamido-5-N-tert-butyloxycarbonyl-4,7,8,9-tetra-O-acetyl-2-p-
toluylthio-3,5-dideoxy-5-β-D-glycero-D-galacto)onate (10). As described previously,24 9 (30.93 g; 51.7 
mmol) was dissolved in THF (500 mL; 0.1 M). Successively, Boc2O (24.0 mL; 103 mmol; 2 eq.) and 4-
dimethylaminopyridine (3.16 g; 25.9 mmol; 0.5 eq.) were added. After stirring at 70 ˚C for 1 h, the 
mixture was concentrated in vacuo. The residue was dissolved in EtOAc and washed with sat. aq. 
NaHCO3. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Silica gel flash 
column chromatography (0 → 10% Acet in DCM) afforded 10 (31.66 g; 45.4 mmol; 88%) as a slightly 
yellow foam. TLC: (Acet:DCM, 5:95 v/v) Rf = 0.47 1H NMR (500 MHz, CDCl3, major anomer) δ 7.34 (d, J 
= 8.2 Hz, 2H, 2x CH, STol, meta), 7.14 (d, J = 8.0 Hz, 3H, 2x CH, STol, ortho), 5.80 (td, J = 11.0, 4.9 Hz, 
1H, H-4), 5.44 (dd, J = 10.1, 2.1 Hz, 1H, H-6), 5.35 (t, J = 2.5 Hz, 1H, H-7), 5.12 (dt, J = 8.2, 2.6 Hz, 1H, H-
8), 4.85 (t, J = 10.5 Hz, 1H, H-5), 4.49 (dd, J = 12.4, 2.3 Hz, 1H, H-9a), 4.06 (dd, J = 12.4, 8.2 Hz, 1H, H-9b), 
3.58 (s, 3H, OCH3), 2.74 (dd, J = 13.8, 4.9 Hz, 1H, H-3eq), 2.36 (s, 3H, CH3, NAc), 2.34 (s, 3H, CH3, STol), 
2.13 (dd, J = 13.8, 11.1 Hz, 1H, CH3, OAc), 2.07 (s, 3H, CH3, OAc), 2.06 (s, 3H, CH3, OAc), 1.97 (s, 3H, CH3, 
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OAc), 1.97 (s, 3H, CH3, OAc), 1.72 (s, 9H, C(CH3)3, Boc). 13C NMR (126 MHz, CDCl3, major anomer) δ 
173.93 (CO), 170.64 (CO), 170.50 (CO), 170.33 (CO), 169.94 (CO), 168.28 (C-1), 152.10 (CONH), 140.21 
(C-CH3, STol), 136.40 (2x CH, STol, meta), 129.95 (2x CH, STol, ortho), 125.76 (C-S, STol), 89.50 (C-2), 
85.42 (C(CH3)3, Boc), 72.91, (C-8), 72.29 (C-6), 68.68 (C-7), 66.54 (C-4), 62.53 (C-9), 52.98 (C-5), 52.57 
(OCH3), 38.88 (C-3), 28.29 (C(CH3)3, Boc), 26.73 (CH3, NAc), 21.44 (CH3, STol), 21.13 (CH3, OAc), 20.93 
(CH3, OAc), 20.81 (2x CH3, OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C32H43NNaO14S, 720.23019; 
found, 720.23055.  
 
Methyl (5-N-tert-butyloxycarbonyl-2-p-toluylthio-3,5-dideoxy-5-β-D-glycero-
D-galacto)onate (11). As described previously,24 10 (31.65 g; 45.4 mmol) was dissolved in MeOH (200 
mL; 0.23 M) and K2CO3 (3.13 g; 22.7 mmol; 0.5 eq.) were added. After stirring at r.t. for 72 h the reaction 
was quenched with AcOH to pH 6 and filtered. The filtrate was concentrated in vacuo. Silica gel flash 
column chromatography (0 → 10% MeOH in DCM) afforded 11 (18.39 g; 37.7 mmol; 83%). TLC: 
(MeOH:DCM, 10:90 v/v) Rf = 0.56 1H NMR (500 MHz, CDCl3, major anomer) δ 7.35 (d, J = 8.1 Hz, 2H, 2x 
CH, STol meta), 7.11 (d, J = 8.0 Hz, 2H, 2x CH, STol ortho), 5.27 (d, J = 8.7 Hz, 1H, NH), 4.30 (d, J = 10.4 
Hz, 1H, H-6), 4.08 (td, J = 10.9, 4.6 Hz, 1H, H-5), 3.80 – 3.65 (m, 5H, H-9a; H-9b; H-8; H-7; H-5), 3.57 (s, 
3H, OCH3), 2.71 (dd, J = 13.8, 4.7 Hz, 1H, H-3eq), 2.32 (s, 3H, CH3, STol), 2.05 – 1.99 (m, 1H, H-3ax), 1.45 
(s, 9H, C(CH3)3, Boc). 13C NMR (126 MHz, CDCl3, major anomer) δ 169.49 (C-1), 157.82 (CONH), 139.98 
(CCH3, STol), 135.73 (2x CH, STol meta), 129.87 (2x CH, STol ortho), 126.24 (CS, STol), 89.59 (C-2), 81.13 
(C(CH3)3, Boc), 72.85 (C-6), 70.56 (C-7), 70.23 (C-8), 68.20 (C-4), 64.55 (C-9), 54.12 (C-5), 52.78 (OCH3), 
40.67 (C-3), 28.47 (C(CH3)3, Boc), 21.39 (CH3, STol). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for 
C22H33NNaO9S, 510.17737; found,  
 
Methyl (5-N-tert-butyloxycarbonyl-4,7,8,9-tetra-O-acetyl-2-p-toluylthio-3,5-
dideoxy-D-glycero-β-D-galacto-non-2-ulopyranoside)onate (12). As described previously,24 11 (8.39 
g; 17.2 mmol) was dissolved in Pyr (62 mL; 764 mmol; 44.4 eq.). Ac2O (36 mL; 382 mmol; 22.2 eq.) was 
slowly added. After stirring at r.t. for 7 h, the mixture was concentrated in vacuo using Tol for co-
evaporation. The residue was dissolved in EtOAc and washed successively with HCl (0.1 M) and sat. aq. 
NaHCO3. The organic layer was dried over MgSO4 and filtered and concentrated in vacuo. Silica gel 
flash column chromatography (0 → 50% EtOAc in hept) afforded 12 (10.26 g; 15.6 mmol; 91%) as a 
white foam. TLC: (EtOAc:Heptane, 50:50 v/v) Rf = 0.47 1H NMR (500 MHz, CDCl3) δ 7.32 (d, J = 7.7 Hz, 
2H, 2x CH, STol, meta), 7.14 (d, J = 7.7 Hz, 2H, 2x CH, STol, ortho), 5.55 (t, J = 2.6 Hz, 1H, H-7), 5.33 (td, 
J = 11.1, 4.8 Hz, 1H, H-4), 5.01 (dt, J = 8.5, 2.5 Hz, 1H, H-8), 4.55 (dd, J = 10.5, 2.6 Hz, 1H, H-6), 4.51 (dd, 
J = 12.2, 2.3 Hz, 1H, H-9a), 4.45 (d, J = 10.7 Hz, 1H, NH), 4.04 (dd, J = 12.2, 8.5 Hz, 1H, H-9b), 3.79 (q, J = 
10.6 Hz, 1H, H-5), 3.61 (s, 3H, OCH3), 2.67 (dd, J = 13.8, 4.8 Hz, 1H, H-3eq), 2.34 (s, 3H, CH3, STol), 2.10 
(s, 3H, CH3, OAc), 2.08 (s, 3H, CH3, OAc), 2.04 (s, 4H, H-3ax; CH3, OAc), 1.97 (s, 3H, CH3, OAc), 1.40 (s, 9H, 
C(CH3)3, Boc). 13C NMR (126 MHz, CDCl3) δ 170.98 (CO), 170.61 (CO), 170.43 (CO), 169.93 (CO), 168.48 
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(C-1), 155.35 (CO, Boc), 140.22 (CCH3, STol) 136.38 (2x CH, STol meta), 129.99 (2x CH, STol ortho), 
125.41 (CS, STol), 88.87 (C-2), 80.29 (C(CH3)3, Boc), 73.34 (C-6), 72.90 (C-8), 69.51 (C-4), 69.12 (C-7), 
62.92 (C-9), 52.68 (OCH3), 50.96 (C-5), 37.59 (C-3), 28.28 (C(CH3)3, Boc), 21.44 (CH3, STol), 21.21 (CH3, 
OAc), 20.94 (CH3, OAc), 20.83 (CH3, OAc), 20.82 (CH3, OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for 
C30H41NNaO13S, 678.21963; found, 678.21799.  
 
Methyl (5-N-tert-butyloxycarbonyl-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-
glycero-β-D-galacto-non-2-ulopyranoside)onate (13). 12 (5.00 g; 7.63 mmol) was dissolved in a 1:3:6 
mixture of AcOH/ACN/DCM (10.5 mL: 31.5 mL: 63 mL; 0.05 M). Subsequently, Ac2O (3.60 mL; 38.1 
mmol; 5 eq.) and NBS (1.493 g; 8.39 mmol; 1.1 eq.) were added, yielding an orange mixture. After 
stirring at r.t. for 1.5 h, the mixture was concentrated in vacuo at r.t.. The residue was dissolved in DCM 
and washed successively with sat. aq. Na2S2O3 and sat. aq. NaHCO3. The H2O layers were extracted with 
DCM. The organic layers were combined and dried over MgSO4, filtered and concentrated in vacuo 
yielding a yellow foam. Silica gel flash column chromatography (0 → 40 % EtOAc in hept) afforded 13 
(3.460 g; 5.85 mmol; 77 %) as white foam. TLC:(EtOAc:Heptane, 50:50 v/v) Rf = 0.34 1H NMR (400 MHz, 
CDCl3, major anomer) δ 5.48 – 5.43 (m, 1H, H-7), 5.23 – 5.16 (m, 1H, H-4), 5.10 (td, J = 6.2, 2.5 Hz, 1H, 
H-8), 4.49 (dd, J = 12.4, 2.7 Hz, 1H, H-9a), 4.14 – 4.09 (m, 1H, H-9b), 4.07 – 4.01 (m, 1H, H-6), 3.87 – 3.79 
(m, 1H, H-5), 3.79 (s, 3H, OCH3), 2.57 (dt, J = 13.4, 4.0 Hz, 1H, H-3eq), 2.14 (s, 3H, CH3, OAc), 2.13 (s, 3H, 
CH3, OAc), 2.06 (s, 3H, CH3, OAc), 2.04 (m, 7H, 2x CH3, OAc; H-3ax), 1.40 (s, 9H, C(CH3)3, Boc). 13C NMR 
(101 MHz, CDCl3, Major anomer) δ 170.91 (CO), 170.78 (CO), 169.89 (CO), 168.39 (CO), 168.32 (CO), 
166.49 (CO), 155.20 (CO), 95.62 (C-2), 80.41 (C(CH3)3, Boc), 73.29 (C-6), 71.16 (C-8), 69.68 (C-4), 68.02 
(C-7), 62.37 (C-9), 53.31 (OCH3), 50.62 (C-5), 36.13 (C-3), 28.31 (C(CH3)3, Boc), 21.03 (CH3, OAc), 20.96 
(CH3, OAc), 20.95 (CH3, OAc), 20.94 (CH3, OAc), 20.91 (CH3, OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. 
for C25H37NNaO15, 614.20609; found, 614.20498.  
 
 Methyl (5-azido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-β-D-galacto-
non-2-ulopyranoside)onate (14). Boc-Sialic acid  13 (100 mg, 169 µmol) in DCM (1.6 mL, 0.1 M) was 
cooled to 0°C and TFA (1.6 mL) and H2O (0.1 mL) were subsequently added. The reaction mixture was 
allowed to warm up to r.t. and stirred for 4 h, in vacuo and co-evaporated with Tol. The residue was 
redissolved in DMF (10 mL 16.9 mM) and 1H-imidazole-1-sulfonyl azide (36 mg; 0.211 mmol; 1.2 eq), 
TEA (47 µl; 338 mmol; 2 eq.) and CuSO4 pentahydrate (4 mg; 0.018 mmol; 0.1 eq.) were added and the 
reaction was stirred at r.t. for 16 h, diluted with EtOAc and washed with 1M aqueous HCl and aqueous 
NaHCO3. The organic phase was separated concentrated in vacuo and purified using column 
chromatography (0  50% EtOAC in hept), yielding C-5 azide 14 (74 mg, 0.144 mmol, 82%). TLC: 
(EtOAc/Hept, 50/50): Rf = 0.4; 1H NMR (500 MHz, CDCl3) δ 5.53 (dd, J = 7.0, 0.8 Hz, 1H, H-7), 5.22 (ddt, 
J = 12.3, 7.2, 3.7 Hz, 2H, H-4; H-8), 4.43 (dd, J = 12.7, 2.0 Hz, 1H, H-9a), 4.20 (dd, J = 12.6, 5.1 Hz, 1H, H-
9b), 3.79 (s, 3H, OCH3), 3.77 (s, 1H, H-6), 3.38 (t, J = 10.1 Hz, 1H, H-5), 2.68 (dd, J = 13.5, 5.1 Hz, 1H, H-
3eq), 2.21 (s, 3H, CH3, Ac), 2.15 (s, 3H, CH3, Ac), 2.13 (s, 3H, CH3, Ac), 2.08 (s, 3H, CH3, Ac), 2.07 (s, 3H, 
CH3, Ac), 1.92 (dd, J = 13.1, 11.7 Hz, 1H, H-3ax). 13C NMR (126 MHz, CDCl3) δ 170.65 (CO), 169.90 (CO), 
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169.68 (CO), 169.54 (CO), 168.16 (CO), 166.19 (C-1), 97.02 (C-2), 71.53 (C-6), 70.24 (C-4), 69.88 (C-8), 
68.24 (C-7), 61.79 (C-9), 59.75 (C-5), 53.18 (OCH3), 35.36 (C-3), 20.86 (CH3, Ac), 20.80 (CH3, Ac), 20.76 
(CH3, Ac), 20.71 (CH3, Ac), 20.69 (CH3, Ac). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C20H27N3NaO13, 
540.14416; found, 540.14313.  
 
 Methyl (5-N-azidoacetyl-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-β-D-
galacto-non-2-ulopyranoside)onate (15). A solution of 13 (100 mg, 169  µmol) in DCM (1.6 mL, 0.1 M) 
was cooled to 0 °C and TFA (1.6 mL) and H2O (0.1 mL) were subsequently added. The reaction mixture 
was allowed to slowly warm up to r.t. and stirred for 4 h. The reaction mixture was then concentrated 
in vacuo and co-evaporated with Tol. The residue was dissolved in DCM and washed with H2O and 
brine. The combined aqueous layers were extracted with DCM. The combined organic layers were 
concentrated in vacuo. The residue was dissolved in DCM (2 mL, 0.08 M) and cooled to 0 °C. AzOSu (84 
mg; 422 µmol; 2.5 eq.) and TEA (59 µl; 422 µmol; 2.5 eq.) were added and the reaction was allowed to 
slowly warm up to r.t. and stirred 16 h. The reaction mixture was diluted with DCM and subsequently 
washed with 1M aq. HCl sat. aqueous NaHCO3 and brine. The organic layer was dried over anhydrous 
Na2SO4, filtered and concentrated in vacuo. Silica gel flash column chromatography (0 → 60% EtOAc in 
hept) afforded 15 (78 mg; 137 µmol; 81%). TLC: (EtOAc:hept, 50:50 v/v) Rf = 0.15 1H NMR (500 MHz, 
CDCl3) δ 6.21 (d, J = 9.9 Hz, 1H, NH), 5.37 (dd, J = 5.8, 2.4 Hz, 1H, H-7), 5.29 (td, J = 10.4, 4.6 Hz, 1H, H-
4), 5.10 (td, J = 6.0, 2.5 Hz, 1H, H-8), 4.47 (dd, J = 12.5, 2.5 Hz, 1H, H-9a), 4.21 (dd, J = 10.7, 2.4 Hz, 1H, 
H-6), 4.16 – 4.08 (m, 2H, H-5; H-9b), 3.88 (ABq, J = 16.6, 13.9 Hz, 2H, CH2, NAz), 3.80 (s, 3H, OCH3), 2.59 
(dd, J = 13.5, 5.0 Hz, 1H, H-3eq), 2.17 (s, 3H, CH3, OAc), 2.14 – 2.09 (m, 4H, CH3, OAc; H-3ax), 2.07 (s, 3H, 
CH3, OAc), 2.04 (s, 3H, CH3, OAc), 2.03 (s, 3H, CH3, OAc). 13C NMR (126 MHz, CDCl3) δ 170.82 (CO), 
170.75 (CO), 170.48 (CO), 170.09 (CO), 168.34 (CO), 167.37 (CO), 166.31 (CO), 97.67 (C-2), 72.60 (C-6), 
71.00 (C-8), 68.19 (C-4), 67.69 (C-7), 62.03 (C-9), 53.38 (OCH3), 52.76 (CH2, NAz), 49.38 (C-5), 36.02 (C-
3), 21.01 (CH3, OAc), 20.96 (CH3, OAc), 20.94 (CH3, OAc), 20.91 (CH3, OAc). HR-ESI-TOF/MS (m/z): 
[M+Na]+ calcd. for C22H30N4NaO14, 597.16562; found, 597.16620.  
 
 Methyl (5-N-2-azidoethoxycarbonyl-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-
glycero-β-D-galacto-non-2-ulopyranoside)onate (16). To a solution of Boc sialic acid 12 (50 mg; 0.084 
mmol) in DCM (2 mL; 0.042 M ) at 0 °C, TFA (2 mL; 26 mmol; 612 eq.) and H2O (0.1 mL) were added. 
The mixture was stirred for 4 h at r.t.. The mixture then was diluted with DCM and washed with 1% 
aqueous NaOH, sat. aq. NaHCO3 and brine. The organic layer was then concentrated in vacuo and again 
dissolved in DCM (2 mL; 0.042 M ). AzeocOSu (39 mg, 0.17 mmol, 2 eq.) and TEA (24 μl, 0.17 mmol, 2 
eq.) were added and the mixture was stirred 16 h. The mixture was then diluted in DCM, washed with 
1M HCl, sat. aq. NaHCO3 and brine and purified on silica column chromatography (20-80% EtOAc in 
hept) to afford azide 16 (32 mg, 0.053 mmol, 63%, major anomer) TLC (EtOAc:hept, 50:50 v/v) Rf = 0.30  
1H NMR (500 MHz, CDCl3) (major anomer) δ 5.45 (dd, J = 7.7, 2.3 Hz, 1H, H-7), 5.20 (ddd, J = 7.7, 5.2, 
2.7 Hz, 1H, H-8), 5.02 (ddd, J = 11.7, 10.2, 4.8 Hz, 1H, H-4), 4.69 (dd, J = 10.8, 2.3 Hz, 1H, H-6), 4.34 (dd, 
J = 12.5, 2.7 Hz, 1H, H-9a), 4.29 (ddd, J = 11.8, 5.3, 3.5 Hz, 1H, N3CH2CHHO, azidoethoxycarbonyl), 4.13 
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(dddd, J = 9.9, 7.1, 5.3, 2.5 Hz, 1H, N3CH2CHHO, azidoethoxycarbonyl), 4.06 (dd, J = 12.5, 5.2 Hz, 1H, H-
9b), 3.86 – 3.74 (m, 4H, H-5; OCH3), 3.54 (ddd, J = 13.5, 8.1, 3.5 Hz, 1H, N3CHHCH2O, 
azidoethoxycarbonyl), 3.34 (ddd, J = 13.6, 5.3, 3.3 Hz, 1H, N3CHHCH2O, azidoethoxycarbonyl), 2.61 (dd, 
J = 13.0, 4.8 Hz, 1H, H-3eq), 2.17 – 2.11 (m, 4H, H-3ax; CH3, Ac), 2.10 (CH3, Ac), 2.10 (CH3, Ac), 2.06 – 2.03 
(2x CH3, Ac). 13C NMR (126 MHz, CDCl3) δ 170.80 (CO), 170.42 (CO), 169.97 (CO), 169.74 (CO), 168.40 
(CO), 168.13 (CO), 155.34 (CO NH), 95.39 (C-2), 73.70 (C-6), 69.41 (C-8), 68.29 (C-4), 67.37 (C-7), 64.14 
(N3CH2CH2O, azidoethoxycarbonyl), 61.94 (C-9), 52.91 (OCH3), 51.06 (C-5), 50.01 (N3CH2CH2O, 
azidoethoxycarbonyl), 37.02 (C-3), 20.86(CH3, Ac), 20.80(2x CH3, Ac), 20.78 (CH3, Ac), 20.75 (CH3, Ac). 
HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C23H32N4NaO15, 627.17618; found, 627.17524 IR  (ATR, ν, cm-
1): 2105.45 (N3). 
 
Synthesis is described in Chapter 3. 
 
 Methyl (5-N-4-pentynoyl-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-β-
D-galacto-non-2-ulopyranoside)onate (18). To a solution of Boc-sialic acid 12 (50 mg, 0.084 mmol, 1 
eq.) in DCM (2 mL) at 0 °C, TFA (2 mL) and H2O (0.1 mL) were added. The mixture was stirred for 4 h at 
r.t.. The mixture then was diluted with DCM (25 mL) and washed with 1% aq. NaOH (25 mL), saturated 
aq. NaHCO3 and brine. The organic layer was then concentrated in vacuo and dissolved in dry THF (0.4 
mL). To a solution of 4-pentynoic acid (17 mg, 0.17 mmol, 2 eq.) in dry THF (0.4 mL), DIC (26 μl, 0.17 
mmol, 2 eq.) was added. This mixture was then added dropwise to the dissolved sugar after which 
DMAP (1 mg, 8.4 μmol, 0.1 eq.) was added. The reaction was left to stir for 4 h after which the mixture 
was diluted with DCM, washed with 1M aq. HCl, saturated aq. NaHCO3 and brine and purified over 
silica (20 → 50% EtOAc in Hept) to afford the product 18 (33 mg, 0.057 mmol, 68%) TLC: (EtOAc:Hept 
50:50, v/v) Rf = 0.18. 1H NMR (500 MHz, CDCl3) δ 5.52 (dd, J = 7.8, 2.0 Hz, 1H, NH), 5.39 (dd, J = 7.3, 2.5 
Hz, 1H, H-7), 5.19 (ddt, J = 7.2, 5.5, 3.3 Hz, 1H, H-8), 5.02 (ddd, J = 11.7, 10.2, 4.8 Hz, 1H, H-4), 4.71 (dd, 
J = 10.7, 2.3 Hz, 1H, H-6), 4.34 (dd, J = 12.5, 2.6 Hz, 1H, H-9a), 4.22 – 4.10 (m, 1H, H-5) 4.06 (dd, J = 12.5, 
5.5 Hz, 1H, H-9b), 3.76 (m, 3H,  OCH3), 2.66 – 2.40 (m, 3H, H-3eq, CCHHCH2, pentynoyl, CCHHCH2, 
pentynoyl), 2.38 – 2.24 (m, 2H, CH2CHHCON, pentynoyl, CH2CHHCON), 2.20 – 1.92 (m, 16H, H-3ax, 5x 
CH3, Ac) 13C NMR (126 MHz, CDCl3) δ 171.16 (CO), 170.73 (CO), 170.71 (CO), 170.02 (CO), 169.83 (CO), 
168.54 (CO), 168.21 (CO), 95.41 (C-2), 73.78 (C-6), 69.77 (C-8), 69.50 (HCC, pentynoyl), 68.38 (C-4), 
67.37 (C-7), 62.08 (C-9), 52.91 (OCH3), 48.91 (C-5), 36.92 (C-3), 35.41 (CCH2CH2CON, pentynoyl), 20.96 
(5x CH3, Ac), 14.61 (CCH2CH2CON, pentynoyl). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C25H33N1NaO14, 
594.17987; found, 594.17772. 
 
Methyl (5-N-propargylaminocarbonyl-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-
D-glycero-β-D-galacto-non-2-ulopyranoside)onate (19). To a solution of Boc-sialic acid 12 (50 mg, 
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0.084 mmol) in DCM (2 mL) at 0°C, TFA (2 mL) and H2O (0.1 mL) were added. The mixture was stirred 
for 4 h at r.t.. The mixture then was diluted with DCM and washed with 1% aq. NaOH, saturated aq. 
NaHCO3 and brine. The organic layer was then concentrated in vacuo and diluted in DCM (2 mL). N-
propargyl-4-nitrophenyl carbamate (37 mg, 0.17 mmol, 2 eq.) synthesized as previously described43 
and TEA (24 μl, 0.17 mmol, 2 eq.) were added and the mixture was stirred for 16 h. The mixture was 
then diluted in DCM, washed with 1M aq. HCl, saturated aq. NaHCO3 and brine and purified over silica 
(20 → 50% EtOAc in Hept) to afford the product 19 (23.3 mg, 0.041 mmol, 48%) TLC: (EtOAc:Hept 
50:50, v/v) Rf = 0.15. 1H NMR (500 MHz, CDCl3) (major anomer) δ 5.45 (dd, J = 4.8, 2.3 Hz, 1H, H-7), 
5.24 (ddd, J = 11.5, 10.2, 5.0 Hz, 1H, H-4), 5.08 (ddd, J = 7.2, 4.8, 2.6 Hz, 1H, H-8), 4.72 (dd, J = 6.5, 4.7 
Hz, 1H, H-9a), 4.53 (dd, J = 12.4, 2.6 Hz, 1H, H-6), 4.43 – 4.35 (m, 1H, H-9b), 4.19 – 3.93 (m, 2H, H-5, 
CHH, poc), 3.80 (s, 3H, OCH3), 3.78 – 3.74 (m, 1H, CHH, poc) 2.54 (dd, J = 13.4, 5.0 Hz, 1H, H-3eq), 2.23 
(t, 2.5 Hz, HCC–, poc), 2.20 – 2.14 (m, 6H, (CH3)2, Ac), 2.14 – 2.01 (m, 13H, H-3ax, (CH3)4, Ac). 13C NMR 
(126 MHz, CDCl3) δ 171.32 (CO), 170.64 (CO), 170.43 (CO), 170.42 (CO), 168.34 (CO), 166.46 (CO), 
156.39 (CO, carbamate), 97.50 (C-2), 73.33 (HCC–, poc), 71.63 (C-8), 71.35 (HCC–, poc), 68.74 (C-4), 
68.08 (C-7), 62.26 (C-9), 53.18 (OCH3), 50.61 (C-5), 36.10 (C-3), 30.21 (CH2-poc), 20.96 ((CH3)6, Ac). HR-
ESI-TOF/MS (m/z): [M+Na]+ calcd. for C24H32N2NaO14, 595.17512; found, 595.17331. 
 
 Methyl (5-acetamido-2-p-toluylthio-3,5-dideoxy-5-D-glycero-D-galacto)onate 
(20). Peracetylated thioglycoside 9 (0.697 g, 1.166 mmol) was dissolved in MeOH (11.66 mL, 288.0 
mmol, 0.1 M). K2CO3 (0.161 g, 1.166 mmol, 1.00 eq.) was added. The reaction was stirred at r.t. for 16 
h, subsequently  filtered, and AcOH was added until the pH reached 6, concentrated in vacuo and 
purified on silica column (0 → 20% MeOH in DCM) to afford 20 (0.451 g, 1.049 mmol, 90%) as a white 
foam. TLC: (Acet:DCM 40:60, v/v) Rf = 0.39. 1H NMR (500 MHz, CD3OD) δ 7.36 (d, J = 8.1 Hz, 2H, 2x CH, 
STol ortho), 7.07 (d, J = 7.9 Hz, 2H, 2x CH, STol meta), 4.40 (dd, J = 10.5, 1.1 Hz, 1H, H-6), 4.00 (ddd, J = 
11.6, 9.9, 4.7 Hz, 1H, H-4), 3.79 (t, J = 10.2 Hz, 1H, H-5), 3.72 (dd, J = 11.0, 3.0 Hz, 1H, H-9a), 3.68 (ddd, 
J = 8.6, 5.1, 3.0 Hz, 1H, H-8), 3.59 – 3.54 (m, 1H, H-9b), 3.46 (dd, J = 9.0, 1.1 Hz, 1H, H-7), 3.43 (s, 3H, 
CH3, OCH3), 2.57 (dd, J = 13.6, 4.6 Hz, 1H, H-3eq), 2.23 (s, 3H, CH3, STol), 1.93 (s, 3H, CH3, AcNH), 1.85 
(dd, J = 13.6, 11.7 Hz, 1H, H-3ax). 13C NMR (126 MHz, MeOD) δ 173.29 (CO, AcNH), 169.53 (C-1), 139.64 
(CCH3, STol), 135.97 (2x CH, STol meta), 129.26 (2x CH, STol ortho), 126.41 (SC(CH)4CCH3, STol), 90.03 
(C-2), 72.00 (C-6), 69.91 (C-8), 69.27 (C-7), 66.71 (C-4), 63.71 (C-9), 52.67 (C-5), 51.61 (OCH3), 40.70 (C-
3), 21.46 (CH3, AcNH), 19.90 (CH3, STol). HR-ESI- TOF/MS (m/z): [M+Na] + calcd. for C19H27NNaO8S, 
452.13551; found, 452.13560. 
 
 Methyl (4-methylphenyl 5-acetamido-8,9-O-isopropylidene-3,5-dideoxy-2-thio-
D-glycero-D-galacto-non-2-ulopyranoside)onate  (21). Sialic acid 20 (0.70 g, 1.63 mmol) was dissolved 
in acet (20 mL, 0.08 M). Dowex H+(0.25 g) and 2,2-dimethoxypropane (0.85 g, 8.15 mmol, 5 eq.) were 
added. The reaction mixture was heated in a sealed vial under microwave radiation for 60 min at 120 
°C, subsequently filtered, concentrated in vacuo and purified on silica column (0 → 20% MeOH in DCM) 
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to afford IP-thioglycoside 21 (0.624 g, 1.329 mmol, 82%) as white foam. TLC: (MeOH:DCM 10:90, v/v) 
Rf = 0.41. 1H NMR (500 MHz, CDCl3) δ 7.42 (d, J = 8.1 Hz, 2H, 2x CH, STol ortho), 7.13 (d, J = 7.7 Hz, 2H, 
2x CH, STol meta), 5.98 (d, J = 8.0 Hz, 1H, NH), 4.19 (q, J = 6.7 Hz, 1H, H-8), 4.07 (dd, J = 8.4, 6.3 Hz, 1H, 
H-9a), 3.95 (dd, J = 8.4, 6.7 Hz, 1H, H-9b), 3.83 (td, J = 10.2, 7.9 Hz, 1H, H-5), 3.68 – 3.62 (m, 1H, H-4), 
3.52 (s, 3H, CH3, OCH3), 3.47 (d, J = 8.6 Hz, 1H, H-7), 3.26 (dd, J = 10.4, 1.3 Hz, 1H, H-6), 2.88 (dd, J = 
12.9, 4.8 Hz, 1H, H-3eq), 2.34 (s, 3H, CH3, STol), 2.01 (s, 3H, CH3, AcNH), 1.84 (dd, J = 12.9, 11.2 Hz, 1H, 
H-3ax), 1.35 (s, 3H, CH3, IP), 1.24 (s, 3H, CH3, IP). 13C NMR (126 MHz, CDCl3) δ 173.14 (CO, AcNH),  169.37 
(C-1), 140.29 (CCH3, STol), 136.74 (2x CH, STol meta), 129.45 (2x CH, STol ortho), 125.46 (SC(CH)4CCH3, 
STol), 108.64 (C(CH3)2, IP), 87.22 (C-2), 76.48 (C-6), 74.90 (C-8), 70.34 (C-7), 68.63 (C-4), 67.28 (C-9), 
52.83 (C-5), 52.27 (OCH3), 40.84 (C-3), 26.78 (CH3, IP), 25.31 (CH3, IP), 23.19 (CH3, AcNH), 21.30 (CH3, 
STol). HR-ESI- TOF/MS (m/z): [M+Na] + calcd. for C22H31NNaO8S, 492.16681; found, 492.16578. 
 
 Methyl (p-methylphenyl 5-acetamido-4-O-Acetyl-8,9-O-isopropylidene-3,5-
dideoxy-2-thio-D-glycero-D-galacto-non-2-ulopyranoside)onate (22). Compound 21 (0.833 g, 1.77 
mmol) was dissolved in Pyr (35.5 mL, 441 mmol 0.05 M). Ac2O (0.235 g, 2.306 mmol, 1.3 eq) was added. 
The reaction mixture was stirred for 90 min, concentrated in vacuo and purified on silica column (0% 
→ 20% acet in DCM) to afford mono-acetylated 22 (0.837 g, 1.64 mmol, 92%) as white foam. TLC: 
(Acet:DCM 20:80, v/v) Rf = 0.65. 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 8.1 Hz, 2H, 2x CH, STol ortho), 
7.15 (d, J = 7.6 Hz, 2H, 2x CH, STol meta), 5.96 (d, J = 7.9 Hz, 1H, NH), 4.98 (ddd, J = 11.6, 10.5, 5.0 Hz, 
1H, H-4), 4.25 (dt, J = 7.5, 6.4 Hz, 1H, H-8), 4.11 (dd, J = 8.4, 6.3 Hz, 1H, H-9a), 3.98 (dd, J = 8.5, 6.5 Hz, 
1H, H-9b), 3.91 (td, J = 10.5, 7.9 Hz, 1H, H-5), 3.55 (s, 3H, CH3, OCH3), 3.42 (d, J = 4.7 Hz, 1H, H-7), 3.24 
(dd, J = 10.5, 1.3 Hz, 1H, H-6), 2.78 (dd, J = 12.8, 5.0 Hz, 1H, H-3eq), 2.35 (s, 3H, CH3, STol), 2.07 (s, 3H, 
CH3, Ac C-4), 2.03 – 1.98 (m, 1H, H-3ax), 1.96 (s, 3H, CH3, AcNH), 1.35 (s, 3H, CH3, IP), 1.25 (s, 3H, CH3, 
IP). 13C NMR (126 MHz, CDCl3) δ 172.49 (CO, AcNH),  172.32 (CO, Ac C-4), 168.95 (C-1), 140.28 (CCH3, 
STol), 136.79 (2x CH, STol meta), 129.45 (2x CH, STol ortho), 125.39 (SC(CH)4CCH3, STol), 108.61 
(C(CH3)2, IP), 87.04 (C-2), 76.83 (C-6), 74.58 (C-8), 70.05 (C-7), 68.58 (C-4), 67.39 (C-9), 52.31 (OCH3), 
51.83 (C-5), 37.44 (C-3), 26.80 (CH3, IP), 25.30 (CH3, IP), 23.07 (CH3, AcNH), 21.31 (CH3, STol), 21.04 
(CH3, Ac C-4). HR-ESI- TOF/MS (m/z): [M+Na] + calcd. for C24H33NNaO9S, 534.17737; found, 534.17693. 
 
 Methyl (p-methylphenyl 5-acetamido-4-O-Acetyl-2-azido-8,9-O-isopropylidene-
3,5-dideoxy-2-thio-D-glycero-D-galacto-non-2-ulopyranoside)onate (23). Sialic acid 22 (0.050 g, 
0.098 mmol) was dissolved in anhydrous DCM (0.767 mL, 11.92 mmol, 0.14 M). Tf2O (0.030 mL, 0.176 
mmol, 1.8 eq.) and Pyr (0.031 mL, 0.391 mmol, 3 eq.) were added. The reaction mixture was stirred 
under N2 atmosphere at -78 °C for 15 min, before being allowed to warm to 0 °C and stir for additional 
2 h. Subsequently, the mixture was diluted with DCM and extracted with ice cold 1M HCl aq. The 
combined organic layers were collected, dried with Na2SO3 and concentrated in vacuo at r.t. to afford 
the triflated intermediate as a slightly yellow foam which was, used without further purification TLC: 
(Acet:DCM 20:80, v/v) Rf = 0.68. HR-ESI- TOF/MS (m/z): [M+Na] + calcd. for C25H32F3NNaO11S2, 
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666.12666; found, 666.12863. The intermediate was dissolved in anhydrous DMF (1.75 mL, 0.05 M). 
Molsieves and NaN3 (0.111 g, 1.71 mmol, 20 eq.) were added and the reaction was stirred under N2 
atmosphere at r.t. for 2 h, diluted with EtOAc and washed with brine and H2O. The combined organic 
layers were dried with Na2SO3 and purified on silica column (0 → 20% acet in DCM) to afford C-7 azide 
23 (0.019 g, 0.035 mmol, 36% (two steps) as a white foam. TLC: (Acet:DCM 15:85, v/v) Rf = 0.53. 1H 
NMR (500 MHz, CDCl3) δ 7.28 (d, J = 8.3 Hz, 2H, 2x CH, STol ortho), 7.14 (d, J = 7.9 Hz, 2H, 2x CH, STol 
meta), 5.98 (d, J = 8.2 Hz, 1H, NH), 5.32 (ddd, J = 11.5, 9.5, 4.8 Hz, 1H, H-4), 4.15 – 4.07 (m, 2H, H-5; H-
8), 3.92 (dd, J = 8.5, 6.4 Hz, 1H, H-9a), 3.88 (dt, J = 8.2, 6.0 Hz, 1H, H-7), 3.74 (dd, J = 8.6, 6.1 Hz, 1H, H-
9b), 3.64 (dd, J = 8.0, 6.7 Hz, 1H, H-6), 3.62 (s, 3H, CH3, OCH3), 2.65 (dd, J = 13.8, 4.9 Hz, 1H, H-3eq), 2.34 
(s, 3H, CH3, STol), 2.12 – 2.07 (m, 1H, H-3ax), 2.06 (s, 3H, CH3, Ac C-4), 2.05 (s, 3H, CH3, AcNH), 1.42 (s, 
3H, CH3, IP), 1.31 (s, 3H, CH3, IP). 13C NMR (126 MHz, CDCl3) δ 171.08 (CO, Ac C-4), 170.85 (CO, AcNH), 
168.16 (C-1), 140.35 (CCH3, STol), 135.86 (2x CH, STol meta), 129.81 (2x CH, STol ortho), 125.12 
(SC(CH)4CCH, STol), 108.62 (C(CH3)2, IP), 88.45 (C-2), 76.97 (C-7), 72.84 (C-8), 68.41 (C-4), 67.64 (C-9), 
66.37 (C-6), 54.12 (C-5), 52.57 (OCH3), 37.71 (C-3), 26.22 (CH3, IP), 25.09 (CH3, IP), 23.26 (CH3, NHAc), 
21.28 (CH3, Ac STol), 20.91 (CH3, Ac C-4). HR-ESI- TOF/MS (m/z): [M+Na] + calcd. for C24H32N4NaO8S, 
559.18385; found, 559.18311. 
 
 Methyl (p-methylphenyl 5-acetamido-4-O-Acetyl-2-azido-8,9-3,5-dideoxy-2-
thio-D-glycero-D-galacto-non-2-ulopyranoside)onate (24). C-7 azide 23 (0.038 g, 0.071 mmol) was 
dissolved in a AcOH:H2O mixture (60:40 v/v, 1.416 mL, 0.05M) and stirred at 60 °C for 2 h. The reaction 
mixture was concentrated in vacuo and purified on silica column (0 → 40% acet in DCM) to afford 24 
(0.015 g, 0.031 mmol, 43.2%) as white foam. TLC: (Acet:DCM 30:70, v/v) Rf  = 0.20. 1H NMR (500 MHz, 
CDCl3) δ 7.36 (d, J = 8.1 Hz, 2H, 2x CH, STol ortho), 7.13 (d, J = 8.4 Hz, 2H, 2x CH, STol meta), 6.23 (d, J 
= 8.8 Hz, 1H, NH), 5.36 (ddd, J = 11.8, 10.2, 4.8 Hz, 1H, H-4), 4.60 (dd, J = 10.8, 1.5 Hz, 1H, H-6), 4.37 
(td, J = 6.4, 1.5 Hz, 1H, H-8), 4.02 (td, J = 10.5, 8.8 Hz, 1H, H-5), 3.81 (dd, J = 11.1, 6.0 Hz, 1H, H-9a), 3.63 
(dd, J = 11.1, 6.8 Hz, 1H, H-9b), 3.58 (t, J = 1.5 Hz, 1H, H-7), 3.54 (s, 3H, CH3, OCH3), 2.71 (dd, J = 13.8, 
4.7 Hz, 1H, H-3eq), 2.32 (s, 3H, CH3, STol), 2.12 (dd, J = 13.8, 11.7 Hz, 1H, H-3ax), 2.07 (s, 3H, CH3, Ac C-
4), 1.99 (s, 3H, CH3, NHAc). 13C NMR (126 MHz, CDCl3) δ 171.55 (CO, AcNH), 171.38 (CO, Ac C-4), 168.19 
(C-1), 140.35 (CCH3, STol), 135.63 (2x CH, STol meta), 130.00 (2x CH, STol ortho), 124.74 (SC(CH)4CCH3, 
STol), 88.93 (C-2), 77.42 (C-6), 70.86 (C-8), 68.18 (C-4), 63.42 (C-9), 59.65 (C-7), 52.97 (OCH3), 51.99 (C-
5), 37.98 (C-3), 23.23 (CH3, AcNH), 21.29 (CH3, STol), 20.92 (CH3, Ac C-4). HR-ESI- TOF/MS (m/z): [M+Na] 
+ calcd. for C21H28N4NaO8S, 519.15255; found, 519.15187. 
 
 Methyl (5-acetamido-2,4,8,9-tetra-O-acetyl-2-azido-3,5-dideoxy-5-D-glycero-D-
galacto)onate (25). Compound 24 (0.015 g, 0.031 mmol) was dissolved in a Acet:H2O mixture (95:5 
v/v, 0.612 mL, 0.05 M). NBS (0.014 g, 0.077 mmol, 2.5 eq.) was added at 0 °C. The reaction mixture 
was stirred for 1 h and concentrated in vacuo. TLC: (Acet:DCM 60:40, v/v) Rf = 0.36. The crude 
intermediate was redissolved in Pyr ( 0.198 mL, 2.50 mmol, 0.15 M) and Ac2O (0.116 mL, 1.23 mmol, 
40 eq.) was added. The reaction mixture was stirred at r.t. for 2.5 h, concentrated in vacuo and purified 
on silica column (0 → 50% acet in DCM) to afford 25 (0.015 g, 0.029 mmol, 93% (two steps) as a 
187 
 
colourless solid. TLC: (Acet:DCM 50:50, v/v) Rf = 0.83. 1H NMR (500 MHz, CDCl3) δ 5.77 (ddd, J = 6.6, 
4.7, 2.6 Hz, 1H, H-8), 5.66 (d, J = 8.6 Hz, 1H, NH), 5.25 (ddd, J = 11.7, 10.1, 5.0 Hz, 1H, H-4), 4.35 (dd, J 
= 11.6, 6.6 Hz, 1H, H-9a), 4.27 (td, J = 10.4, 8.6 Hz, 1H, H-5), 4.19 (dd, J = 11.6, 4.7 Hz, 1H, H-9b), 4.00 
(dd, J = 10.6, 3.5 Hz, 1H, H-6), 3.76 (s, 3H, CH3, OCH3), 3.33 (dd, J = 3.5, 2.6 Hz, 1H, H-7), 2.49 (dd, J = 
13.4, 4.9 Hz, 1H, H-3eq), 2.15 (s, 3H, CH3, Ac C-2), 2.10 (s, 3H, CH3, Ac C-8), 2.09 (d, J = 1.7 Hz, 1H, H-3ax), 
2.07 (s, 3H, CH3, Ac C-4), 2.07 (s, 3H, CH3, Ac C-9), 1.95 (s, 3H, CH3, AcNH). 13C NMR (126 MHz, CDCl3) δ 
171.63 (CO, Ac C-4), 170.63 (CO, AcNH), 170.61 (CO, Ac C-9), 169.94 (CO, Ac C-8), 168.04 (CO, Ac C-2), 
166.05 (C-1), 96.97 (C-2), 76.11 (C-6), 69.08 (C-8), 67.78 (C-4), 63.69 (C-9), 59.27 (C-7), 53.08 (OCH3), 
51.68 (C-5), 35.58 (C-3), 23.15 (CH3, NHAc), 20.93 (CH3, Ac C-9), 20.81 (CH3, Ac C-4), 20.79 (CH3, Ac C-
8), 20.70 (CH3, Ac C-2). IR (ATR, ν, cm-1): 2109.08 (N3). HR-ESI- TOF/MS (m/z): [M+Na] + calcd. for 
C20H28N4NaO12, 539.16014; found, 539.15989. 
 
 Methyl 5-acetamido-3,5-dideoxy-8,9-O-isopropylidene-D-glycero-D-galacto-2-
nonulopyranosonate (26). Methylester 1  (0.10 g, 0.31 mmol) was dissolved in Acet (5.16 mL, 70.3 
mmol, 0.06 M). Dowex H+(0.05 g) and 2,2-dimethoxypropane (0.13 g, 1.24 mmol, 4 eq.) were added. 
The reaction mixture was heated in a sealed vial under microwave radiation for 30 min at 120 °C, 
subsequently filtered, concentrated in vacuo and purified on silica column (0 → 20% MeOH in DCM) 
to afford 26 (0.10 g, 0.28 mmol, 90%) as a white foam. TLC: (MeOH:DCM 20:80, v/v) Rf = 0.74. 1H NMR 
(500 MHz, CD3OD) δ 4.17 (ddd, J = 7.3, 6.2, 5.3 Hz, 1H, H-8), 4.10 – 3.99 (m, 3H, H-9a; H-4; H-9b), 3.91 
(dt, J = 10.5, 1.3 Hz, 1H, H-6), 3.85 (d, J = 10.1 Hz, 1H, H-5), 3.80 (s, 3H, CH3, OCH3), 3.56 (dd, J = 7.3, 1.4 
Hz, 1H, H-7), 2.04 (d, J = 0.9 Hz, 3H, CH3, Ac), 1.39 (s, 3H, CH3, IP), 1.34 (s, 3H, CH3, IP). 13C NMR (126 
MHz, CD3OD) δ 173.48 (C-1), 170.39 (CO, Ac), 108.73 (C(CH3)2, IP), 95.20 (C-2), 75.22 (C-8), 71.23 (C-6), 
69.58 (C-7), 66.36 (C-4), 66.34 (C-9), 52.82 (C-5), 51.82 (OCH3), 39.45 (C-3), 25.79 (CH3, IP), 24.36 (CH3, 
IP), 21.36 (CH3, Ac). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C15H25NNaO9, 386.14270; found, 
386.14221.  
 Methyl 5-Acetamido-2,4,7-tri-O-acetyl-3,5-dideoxy-8,9-O-isopropylidene-D-
glycero-D-galactononulopyranosonate  (27). IP-sialic acid 26 (0.412 g, 1.134 mmol) was dissolved in 
Pyr (10.00 mL, 124.0 mmol, 0.11 M) and Ac2O (5 mL, 53.89 mmol, 47.5 eq.). The reaction mixture was 
stirred at r.t. for 16 h and subsequently concentrated in vacuo and purified on silica column (0 → 30 % 
Acet in DCM) to afford 25 (0.527 g, 1.077 mmol, 95%) as a yellow foam. TLC: (Acet:DCM 30:70, v/v) Rf 
= 0.41. 1H NMR (500 MHz, CDCl3) δ 5.69 (d, J = 9.6 Hz, 1H, NH), 5.28-5.25 (m, 1H, H-7), 5.24 (dd, J = 5.5, 
2.2 Hz, 1H, H-4), 4.14 – 4.05 (m, 2H, H-5; H-8), 4.00 (dd, J = 10.7, 2.1 Hz, 1H, H-6), 3.97 (dd, J = 8.9, 6.3 
Hz, 1H, H-9a), 3.86 (dd, J = 8.9, 6.8 Hz, 1H, H-9b), 3.75 (s, 3H, OCH3), 2.44 (dd, J = 13.3, 5.2 Hz, 1H, H-
3eq), 2.09 (s, 3H, CH3, Ac), 2.08 (s, 3H, CH3, Ac), 1.99 (s, 3H, CH3, Ac), 1.91 (dd, J = 13.4, 11.4 Hz, 1H, H-
3ax), 1.86 (s, 3H, CH3, Ac), 1.28 (s, 3H, CH3, IP), 1.25 (s, 3H, CH3, IP). 13C NMR (126 MHz, CDCl3) δ 170.86 
(CO, Ac), 170.49 (CO, Ac), 170.42 (CO, Ac), 167.97 (CO, Ac), 166.94 (CO, Ac), 108.53 (C(CH3)2, IP), 96.64 
(C-2), 74.65 (C-8), 72.36 (C-6), 68.89 (C-4), 68.47(C-7), 65.85 (C-9), 53.04 (OCH3), 49.11 (C-5), 36.60 (C-
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3), 26.46 (CH3, IP), 25.22 (CH3, IP), 23.06 (CH3, Ac), 20.95 (CH3, Ac), 20.83 (CH3, Ac), 20.54 (CH3, Ac). HR-
ESI-TOF/MS (m/z): [M+Na]+ calcd. for C21H31NNaO12, 512.17439; found, 512.17412.  
 
 Methyl (5-acetamido-2,4,7-tri-O-acetyl-3,5-dideoxy-5-D-glycero-D-
galacto)onate (28). Acetylated IP sialic acid 27 (1.393 g, 2.850 mmol) was dissolved in a AcOH/H2O 
mixture (60:40 v/v, 57 mL, 0.05M) and stirred at 60 °C for 2 h. The reaction mixture was concentrated 
in vacuo and purified on silica column (0 → 50% Acet in DCM) to afford 28 (1.050 g, 2.336 mmol, 82%) 
as white foam. TLC: (Acet:DCM 50:50, v/v) Rf = 0.21. 1H NMR (500 MHz, CDCl3) δ 6.07 (d, J = 9.6 Hz, 1H, 
NH), 5.26 (ddd, J = 11.4, 10.1, 5.1 Hz, 1H, H-4), 4.98 (dd, J = 9.0, 2.1 Hz, 1H, H-7), 4.29 (q, J = 10.1 Hz, 
1H, H-5), 4.24 (d, J = 2.1 Hz, 1H, H-6), 3.88 (dt, J = 8.8, 2.6 Hz, 1H, H-8), 3.79 (s, 3H, OCH3), 3.65 (dd, J = 
12.4, 2.9 Hz, 1H, H-9a), 3.44 (dd, J = 12.4, 3.6 Hz, 1H, H-9b), 2.48 (d, J = 8.1 Hz, 1H, H-3eq), 2.14 (s, 3H, 
CH3, Ac), 2.13 (s, 3H, CH3, Ac), 2.02 (s, 3H, CH3, Ac), 1.98 – 1.95 (m, 1H, H-3ax), 1.88 (s, 3H, CH3, Ac). 13C 
NMR (126 MHz, CDCl3) δ 172.15 (CO, Ac), 171.04 (CO, Ac), 170.57 (CO, Ac), 169.78 (CO, Ac), 167.02 (C-
1), 97.19 (C-2), 72.08 (C-6), 68.98 (C-8), 68.84 (C-7), 68.79 (C-4), 62.64 (C-9), 53.28 (OCH3), 48.74 (C-5), 
36.71 (C-3), 23.00 (CH3, Ac), 21.08 (CH3, Ac), 20.90 (CH3 Ac), 20.78 (CH3, Ac). HR-ESI-TOF/MS (m/z): 
[M+Na]+ calcd. for C18H27NNaO12, 472.14309; found, 472.14299. 
 
 Methyl (5-acetamido-2,4,7,9-tetra-O-acetyl-3,5-dideoxy-5-D-glycero-D-
galacto)onate (29). Compound 28 (0.257 g, 0.572 mmol) was dissolved in Pyr (11.44 mL, 141 mmol, 
0.05 M). Ac2O (0.088 g, 0.858 mmol, 1.5 eq.) was added. The reaction mixture was stirred for 16 h, 
concentrated in vacuo and purified on silica column (0 → 50% Acet in DCM) to afford 29 (0.150 g, 0.305 
mmol, 53%) as a white foam. TLC: (Acet:DCM 50:50, v/v) Rf = 0.62. 1H NMR (500 MHz, CDCl3) δ 5.60 (d, 
J = 9.1 Hz, 1H, NH), 5.27 (ddd, J = 11.4, 9.8, 5.1 Hz, 1H, H-4), 5.11 (dd, J = 8.6, 2.2 Hz, 1H, H-7), 4.25 – 
4.17 (m, 2H, H-5; H-6), 4.08 (q, J = 2.7, 2.0 Hz, 1H, H-8), 4.05 – 3.98 (m, 2H, H-9a, H-9b), 3.80 (s, 3H, CH3, 
OCH3), 2.46 (dd, J = 13.2, 5.1 Hz, 1H, H-3eq), 2.14 (s, 3H, CH3, Ac), 2.11 (s, 3H, CH3, Ac), 2.06 (s, 3H, CH3, 
Ac), 2.02 (s, 3H, CH3, Ac), 1.96 (dd, J = 13.2, 11.4 Hz, 1H, H-3ax), 1.88 (s, 3H, CH3, Ac). 13C NMR (126 MHz, 
CDCl3) δ 171.19 (CO, Ac), 170.97 (CO, Ac), 170.55 (CO, Ac), 170.39 (CO, Ac), 169.99 (CO, Ac), 166.75 (C-
1), 97.4 (C-2), 71.98 (C-6), 68.67 (C-4), 68.44 (C-7), 67.91 (C-8), 65.24 (C-9), 53.34 (OCH3), 48.75 (C-5), 
36.69 (C-3), 23.11 (CH3, Ac), 20.96 (CH3, Ac), 20.88 (CH3, Ac), 20.86 (2x CH3, Ac). HR-ESI-TOF/MS (m/z): 
[M+Na]+ calcd. for C20H29NNaO12, 514.15366 ; found, 514.15324. 
 
 Methyl (5-acetamido-4,9-di-O-acetyl-2-p-toluylthio-3,5-dideoxy-5-β-D-
glycero-D-galacto)onate (30). Thioglycoside 20 (0.091 g, 0.213 mmol) was dissolved in Pyr (2.13 mL, 
26.6 mmol 0.1 M). Ac2O (0.054 g, 0.532 mmol, 2.5 eq.) and DMAP (0.002 g, 0.021 mmol, 0.1 eq.) were 
added. The reaction mixture was stirred at r.t. for 16 h, concentrated in vacuo and purified on silica 
column (0 → 40% Acet in DCM) to afford 30 (0.072 g, 0.140 mmol, 66%) as white foam. TLC: (Acet:DCM 
40:60, v/v) Rf = 0.42. 1H NMR (500 MHz, CDCl3) δ 7.38 (d, J = 8.2 Hz, 2H, 2x CH, STol meta), 7.11 (d, J = 
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7.7 Hz, 2H, 2x CH, STol ortho), 6.24 (d, J = 8.3 Hz, 1H, NH), 5.47 (ddd, J = 11.7, 10.4, 4.8 Hz, 1H, H-4), 
4.41 (dd, J = 11.7, 2.6 Hz, 1H, H-9a), 4.34 (dd, J = 10.5, 1.5 Hz, 1H, H-6), 4.22 (dd, J = 11.7, 6.5 Hz, 1H, H-
9b), 4.07 – 4.01 (m, 1H, H-5), 3.98 (ddd, J = 8.8, 6.1, 2.9 Hz, 1H, H-8), 3.54 (s, 3H, CH3, OCH3), 3.53 (s, 
1H, H-7), 2.66 (dd, J = 13.8, 4.8 Hz, 1H, H-3eq), 2.33 (s, 3H, CH3, STol), 2.15 – 2.12 (m, 1H, H-3ax), 2.09 (s, 
3H, CH3, Ac C-9), 2.08 (s, 3H, CH3, Ac C-4), 2.02 (s, 3H, CH3, AcNH). 13C NMR (126 MHz, CDCl3) δ 172.67 
(CO, AcNH), 171.91 (CO, Ac C-4), 171.66 (CO, Ac C-9), 168.30 (C-1), 139.99 (CCH3, STol), 135.83 (2x CH, 
STol ortho), 129.74 (2x CH, STol meta), 125.83 (SC(CH)4CCH3, STol), 89.02 (C-2), 73.04 (C-6), 69.14 (C-
7), 68.92 (C-8), 68.57 (C-4), 66.98 (C-9), 52.57 (OCH3), 51.77 (C-5), 37.65 (C-3), 23.08 (CH3, AcNH), 21.29 
(CH3, STol), 21.02 (CH3, Ac C-4), 20.96 (CH3, Ac C-9). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for 
C23H31NNaO10S, 536.15664; found, 536.15622. 
 
  Methyl ([5,2]-oxazoline-4,9-di-O-acetyl-8-O-tosyl-2-p-toluylthio-3,5-dideoxy-
5-β-D-glycero-D-galacto)onate (31). Di-alcohol 30 (0.036 g, 0.07 mmol) was dissolved in Pyr (0.455 mL, 
5.62 mmol, 0.16 M). Molsieves and TsCl (0.107 g, 0.562 mmol, 8 eq.) were added and the reaction 
mixture was stirred at 80°C under N2 flow for 2 h. The reaction mixture was concentrated in vacuo, 
diluted with EtOAc and washed with 1M HCl aq. The combined organic layers were dried with Na2CO3 
and purified on silica column (0 → 20 % acet in DCM) to afford 31 (0.020 g, 0.030 mmol, 43%) as a light 
yellow foam. TLC: (Acet:DCM 20:80, v/v) Rf = 0.71. 1H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 8.4 Hz, 2H, 
, 2x CH, Ts ortho), 7.31 (d, J = 7.9 Hz, 2H, 2x CH, Ts meta), 7.25 (d, J = 8.9 Hz, 2H, 2x CH, STol meta), 7.12 
(d, J = 7.8 Hz, 2H, 2x CH, STol ortho), 5.12 (ddd, J = 7.1, 4.2, 2.9 Hz, 1H, H-8), 5.03 (td, J = 10.8, 4.8 Hz, 
1H, H-4), 4.61 – 4.54 (m, 2H, H-7; H-8), 4.27 – 4.19 (m, 2H, H-9a; H-9b), 3.60 (s, 3H, OCH3), 3.46 (td, J = 
10.3, 1.9 Hz, 1H, H-5), 2.78 (dd, J = 13.9, 4.8 Hz, 1H, H-3eq), 2.43 (s, 3H, CH3, Ts), 2.33 (s, 3H, CH3, STol), 
2.13 (s, 3H, CH3, Ac C-4), 2.05 – 1.98 (m, 1H, H-3ax), 1.89 (s, 3H, CH3, Ac C-9), 1.84 (d, J = 1.7 Hz, 3H, CH3, 
NAc). 13C NMR (126 MHz, CDCl3) δ 170.38 (CO, Ac C-4), 170.36 (CO, Ac C-9), 168.04 (C-1), 156.76 (CO, 
NAc), 144.90 (CSO3, Ts), 139.85 (CCH3, STol), 135.54 (2x CH, STol meta), 133.67 (CCH3, Ts), 129.81 (2x 
CH, Ts ortho), 129.75 (2x CH, Ts meta), 128.05 (2x CH, STol ortho), 125.90 (SC(CH)4CCH3, STol), 89.43 
(C-2), 79.53 (C-8), 71.54 (C-7), 70.06 (C-4), 66.25 (C-6), 62.68 (C-9), 53.79 (C-5), 52.50 (OCH3), 37.63 (C-
3), 21.65 (CH3, Ts), 21.34 (CH3, STol), 21.30 (CH3, Ac), 20.89 (CH3, Ac), 20.56 (CH3, Ac). HR-ESI-TOF/MS 
(m/z): [M+Na]+ calcd. for C30H36NO11S2, 650.17298; found, 650.17174. 
 
 Methyl (5-N-tert-butyloxycarbonyl-4,9-di-O-acetyl-2-p-toluylthio-3,5-dideoxy-
5-β-D-glycero-D-galacto)onate (32). Boc thioglycoside 11 (0.500 g, 1.026 mmol) was dissolved in Pyr 
(20.51 mL, 254 mmol, 0.05 M) and Ac2O (0.209 g, 2.051 mmol, 2 eq.) was added. The reaction mixture 
was stirred for 3 h, concentrated in vacuo and purified on silica column (0 → 30% acet in DCM) to 
afford 32 (0.360 g, 0.630 mmol, 61%) as white foam. TLC: (Acet:DCM 30:70, v/v) Rf = 0.82. 1H NMR 
(500 MHz, CDl3) δ 7.39 (dd, J = 8.1, 1.8 Hz, 2H, 2x CH, STol ortho), 7.10 (dd, J = 8.1, 2.2 Hz, 2H, 2x CH, 
STol meta), 5.47 – 5.39 (m, 2H, NH ; H-4), 4.44 – 4.39 (m, 2H, H-6 ; H-9a), 4.28 (ddd, J = 11.7, 5.7, 1.6 
Hz, 1H, H-9b), 4.01 (ddd, J = 8.6, 5.8, 2.5 Hz, 1H, H-8), 3.86 (d, J = 9.7 Hz, 1H, H-5), 3.72 (d, J = 8.6 Hz, 
1H, H-7), 3.52 (s, 3H, CH3, OCH3), 2.69 (dd, J = 13.8, 4.7 Hz, 1H, H-3eq.), 2.32 (s, 3H, CH3, STol), 2.12 (d, J 
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= 12.0 Hz, 1H, H-3ax), 2.08 (s, 3H, CH3, Ac C-4), 2.07 (s, 3H, CH3, Ac C-9), 1.44 (s, 9H, C(CH3)3, Boc). 13C 
NMR (126 MHz, CDCl3) δ 171.49 (CO, Ac C-4), 171.06 (CO, Ac C-9), 168.42 (C-1), 157.20 (CO, Boc), 
139.72 (CCH3, STol), 135.88 (2x CH, STol meta), 129.60 (2x CH, STol ortho), 126.00 (SC(CH)4CCH3, STol), 
89.02 (C-2), 80.63 (C(CH3)3, Boc), 73.12 (C-6), 68.87 (C-7), 68.64 (C-8), 68.57 (C-4), 66.79 (C-9), 52.42 
(OCH3), 51.60 (C-5), 37.68 (C-3), 28.20 (C(CH3)3, Boc), 21.22 (CH3, STol), 20.90 (CH3, Ac C-4), 20.81 (CH3, 
Ac C-9). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C26H37NNaO11S, 594.19850; found, 594.19703. 
 
 Methyl (5-N-tert-butyloxycarbonyl-4,9-di-O-acetyl-8-O-mesyl-2-p-toluylthio-
3,5-dideoxy-5-β-D-glycero-D-galacto)onate (33). Compound 32 (0.150 g, 0.262 mmol) was dissolved 
in DCM (5.25 mL, 82.0 mmol, 0.05 M). Molesieves, MsCl (0.030 mL, 0.394 mmol, 1.5 eq.) and TEA (0.110 
mL, 0.787 mmol, 3 eq.) were added. The reaction mixture was stirred under N2 atmosphere at r.t. for 
18 h, subsequently, quenched with MeOH, concentrated in vacuo and purified on silica column (0% → 
30% Acet in DCM) to afford 33 (0.141 g, 0.218 mmol, 83%) as a light yellow foam TLC: (Acet:DCM 30:70, 
v/v) Rf = 0.80. 1H NMR (500 MHz, CDCl3) δ 7.32 (d, J = 8.1 Hz, 2H, 2x CH, STol ortho), 7.16 (d, J = 7.8 Hz, 
2H, 2x CH, STol meta), 5.46 (ddd, J = 11.5, 10.5, 4.8 Hz, 1H, H-4), 4.99 (d, J = 8.4 Hz, 1H, NH), 4.65 (dt, J 
= 8.0, 2.3 Hz, 1H, H-8), 4.59 (dd, J = 12.7, 2.1 Hz, 1H, H-9a), 4.31 (dd, J = 12.7, 7.9 Hz, 1H, H-9b), 4.17 (dd, 
J = 10.3, 1.7 Hz, 1H, H-6), 4.10 (d, J = 2.9 Hz, 1H, H-7), 3.73 (td, J = 10.4, 8.4 Hz, 1H, H-5), 3.63 (s, 3H, 
CH3, OCH3), 3.08 (s, 3H, CH3, Ms), 2.62 (dd, J = 13.9, 4.8 Hz, 1H, H-3eq), 2.34 (s, 3H, CH3, STol), 2.09 (s, 
3H, CH3, Ac C-4), 2.07 (d, J = 4.3 Hz, 1H, H-3ax), 1.99 (s, 3H, CH3, Ac C-9), 1.44 (s, 9H, C(CH3)3, Boc). 13C 
NMR (126 MHz, CDCl3) δ 171.27 (CO, Ac C-4), 169.78 (CO, Ac C-9), 168.58 (C-1), 157.48 (CO, AcNH), 
140.10 (CCH3, STol), 136.24 (2x CH, STol meta), 129.93 (2x CH, STol ortho), 125.28 (SC(CH)4CCH3, STol), 
88.20 (C-2), 81.61 (C(CH3)3, Boc), 81.28 (C-8), 74.85 (C-6), 70.14 (C-7), 67.86 (C-4), 63.25 (C-9), 52.66 
(OCH3), 51.97 (C-5), 38.60 (CH3, Ms), 37.06 (C-3), 28.17 (C(CH3)3, Boc), 21.35 (CH3, STol), 20.95 (CH3, Ac 
C-4), 20.72 (CH3, Ac C-9). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C27H39NNaO13S2, 672.17605; found, 
672.17501. 
 
 Methyl 5-acetamido-9-O-tosyl-3,5-dideoxy-D-glycero-D-galacto-non-2-
ulopyranosonate (34). Sialic acid methyl ester 1 (1 g, 3.1 mmol) was solved in Pyr (1 mL; 3.1 M) and 
cooled to 0°C before adding TsCl (0.7 g, 3.72 mmol, 1.2 eq.) portionwize. The reaction stirred at 0°C 
and allowed to slowly warm up to r.t. for 16 h, before concentrating in vacuo. The product was purified 
by iatro-bead column chromatography column (0% → 20% H2O in ACN) to yield tosylated sialic acid 34 
(1.183 g, 2.48 mmol , 80%). TLC: (H2O:ACN 20:80, v/v) Rf =0.60. 1H NMR (500 MHz, CDCl3) δ 7.80 (d, J = 
8.3 Hz, 2H, 2x CH, Ts ortho), 7.45 (d, J = 8.1 Hz, 1H, 2x CH, Ts meta), 4.31 (dd, J = 10.0, 2.2 Hz, 1H, H-9a), 
4.09 (dd, J = 10.0, 6.1 Hz, 1H, H-9b), 4.08 – 4.03 (m, 1H, H-4), 3.97 (dd, J = 10.5, 1.2 Hz, 1H, H-6), 3.89 
(ddd, J = 8.5, 6.0, 2.1 Hz, 1H, H-8), 3.81 – 3.76 (m, 1H, H-5), 3.78 (s, 3H, OCH3), 3.47 (dd, J = 9.1, 1.2 Hz, 
1H, H-7), 2.46 (s, 3H, CH3, Ts), 2.24 (dd, J = 12.9, 4.9 Hz, 1H, H-3eq), 2.04 (s, 3H, CH3, NHAc), 1.90 (dd, J 
= 12.7, 11.6 Hz, 1H, H-3ax). 13C NMR (126 MHz, MeOD) δ 173.84 (CO), 170.30 (C-1), 145.08 (CS, Ts), 
132.75 (CCH3,Ts), 129.71 (2x CH, Ts meta), 127.71 (2x CH, Ts ortho), 95.25 (C-2), 72.44 (C-9), 70.44 (C-
6), 68.59 (C-7), 67.92 (C-8), 66.34 (C-4), 52.90 (C-5), 51.95 (OCH3), 39.34 (C-3), 21.41 (CH3, Ac), 20.30 
(CH3, Ts). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C19H27N1NaO11S1, 500.12025; found, 500.12135.  
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Methyl (5-acetamido-2,4,7,8-tetra-O-acetyl-9-O-tosyl-3,5-dideoxy-5-D-glycero-
D-galacto)onate (35). Tosylated sialic acid 34 (0.25 g, 0.52 mmol) was dissolved in Pyr (2.54 mL, 31.4 
mmol, 0.21 M). Ac2O (1.60 g, 15.7 mmol, 30 eq.) was added. The reaction mixture was stirred at r.t. for 
18 h, subsequently concentrated in vacuo, diluted with EtOAc, washed with 1 M HCl aq. and sat. aq. 
NaHCO3. The combined organic layers were dried with MgSO4 and purified on silica column (0 → 40% 
acet in DCM) to obtain 35 as a light yellow foam (0.16 g, 0.24 mmol, 46%). TLC: (Acet:DCM 40:60, v/v) 
Rf =0.75. 1H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 6.5 Hz, 2H, 2x CH, Ts ortho), 7.32 (d, J = 7.8 Hz, 2H, 2x 
CH, Ts meta) 5.47 (d, J = 9.4 Hz, 1H, NH), 5.38 (dd, J = 4.6, 2.1 Hz, 1H, H-7), 5.24 (ddd, J = 11.6, 9.9, 5.0 
Hz, 1H, H-4), 5.01 (ddd, J = 6.4, 3.3, 1.8 Hz, 1H, H-8), 4.52 (dd, J = 11.2, 2.8 Hz, 1H, H-9a), 4.12 – 4.08 (m, 
2H, H-5; H-6), 4.07 – 4.03 (m, 1H, H-9b), 3.75 (s, 3H, OCH3), 2.52 (ddd, J = 13.4, 5.0, 2.8 Hz, 1H, H-3eq), 
2.43 (s, 3H, CH3, Ts), 2.13 (s, 3H, CH3, Ac), 2.08 (s, 3H, CH3, Ac), 2.05 (dd, J = 3.0, 1.8 Hz, 1H, H-3ax), 2.01 
(s, 3H, CH3, Ac), 1.98 (s, 3H, CH3, Ac), 1.87 (s, 3H, CH3, Ac). 13C NMR (126 MHz, CDCl3) δ 170.89 (CO, Ac), 
170.36 (CO, Ac), 170.21 (CO, Ac), 170.02 (CO, Ac), 168.21 (CO, Ac), 166.25 (C-1), 144.73 (C-SO3, Ts), 
132.99 (CCH3, Ts), 129.78 2x CH, Ts meta), 127.95 (2x CH, Ts ortho), 97.33 (C-2), 72.73 (C-6), 70.88 (C-
8), 68.18 (C-4), 67.66 (C-7), 67.43 (C-9), 53.16 (OCH3), 49.23 (C5), 35.94 (C-3), 23.17 (CH3, Ac), 21.64 
(CH3, Ts), 20.83 (CH3, Ac), 20.76 (CH3, Ac), 20.72 (CH3, Ac), 20.70 (CH3, Ac). HR-ESI-TOF/MS (m/z): 
[M+Na]+ calcd. for C27H35NNaO15S, 668.16251; found, 668.16329. 
 
 Methyl (5-acetamido-2,4,7,8-tetra-O-acetyl-9-azido-3,5-dideoxy-5-D-glycero-D-
galacto)onate (36). Tosylated peracetylated sialic acid 35 (0.60 g, 0.93 mmol) was dissolved in 
anhydrous DMSO (11.5 mL, 0.08 M). Molesieves, NaN3 (1.21 g, 18.6 mmol, 20 eq.), TsCl (0.35 g, 1.86 
mmol, 2 eq.) and Pyr (0.29 g, 3.72 mmol, 4 eq.) were added and the reaction mixture was stirred at 50 
°C under N2 flow for 60 h. The reaction mixture was filtered, diluted in EtOAc and washed with H2O  
and brine. The combined organic layers were dried with MgSO4 and purified on silica column (0 → 30% 
Acet in Et2O) to afford 36 (0.28 g, 0.55 mol, 59%) as yellow oil. TLC: (Acet:Et2O 30:70, v/v) Rf = 0.51; 1H 
NMR (500 MHz, CDCl3) δ5.50 (d, J = 10.0 Hz, 1H, NH),  5.38 (td, J = 4.1, 3.5, 2.0 Hz, 1H, H-7), 5.24 (ddd, 
J = 11.5, 10.2, 5.0 Hz, 1H, H-4), 4.90 (dt, J = 7.7, 3.1 Hz, 1H, H-8), 4.15 (q, J = 10.2 Hz, 1H, H-5), 4.07 (dd, 
J = 10.6, 2.3 Hz, 1H, H-6), 3.85 – 3.81 (m, 1H, H-9a), 3.80 (s, 3H, OCH3), 3.37 (dd, J = 13.6, 7.7 Hz, 1H, H-
9b), 2.52 (ddd, J = 13.5, 9.1, 4.9 Hz, 1H, H-3eq), 2.17-2.15 (m, 6H, 2x CH3, Ac), 2.09 (s, 3H, CH3, Ac), 2.06 
(d, J = 0.9 Hz, 1H, H-3ax), 2.03 (s, 3H, CH3, Ac), 1.91 (s, 3H, CH3, NHAc). 13C NMR (126 MHz, CDCl3) δ 
171.03 (CO, Ac C-7) 171.00 (CO, Ac C-4), 170.72 (CO, Ac C-8), 170.33 (CO, NHAc), 168.32 (CO, Ac C-2), 
166.32 (C-1), 97.13 (C-2), 73.54 (C-8), 73.15 (C-6), 68.26 (C-7), 68.14 (C-4), 53.25 (OCH3), 50.12 (C-9), 
49.29 (C-5), 36.13 (C-3), 23.03 (CH3, NHAc), 20.90 (CH3, Ac C-8), 20.79 (CH3, Ac C-4), 20.74 (CH3, Ac C-
7), 20.70 (CH3, Ac C-2). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C20H28N4NaO12, 539.16014; found, 
539.15938. IR (ATR, ν, cm-1): 2104.84 (N3). 
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 Methyl (5-acetamido-2,4,7,8-tetra-O-acetyl-9-amino-3,5-dideoxy-5-D-glycero-
D-galacto)onate (37). C-9 azide 36 (0.39 mg, 0.76 mmol) was dissolved in MeOH (4.2 mL, 0.18 M) 
before adding a solution of SnCl2 (0.72 g, 3.81 mmol, 5 eq.) in MeOH (2.1 mL, 0.35 M) and 12 M HCl 
(95 µl, 1.14 mmol, 1.5 eq). The reaction mixture was stirred at r.t. for 24 h, filtered and concentrated 
in vacuo to obtain free amine intermediate 37 (0.374 g, 0.76 mmol) as a yellow foam. The intermediate 
was directly used for further reactions without previous purification due to possibility of acetyl 
migration. TLC: (Acet:DCM:TEA 39:60:1, v/v) Rf = 0.33; HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for 
C20H30N2NaO12, 491.18770; found, 491.18636. 
 
 Methyl (5-acetamido-2,4,7,8-tetra-O-acetyl-9-N-azidoacetyl-3,5-dideoxy-5-
D-glycero-D-galacto)onate (38). C-9 amine 37 (0.094 g, 0.19 mmol) was dissolved in DCM (3.81 mL, 
0.05 M) and ACN (1.9 mL, 0.1 M). AzOSu (0.19 g, 0.95 mmol, 5 eq.) and TEA (0.08 g, 0.76 mmol, 4 eq.) 
were added and the reaction mixture was stirred for 36 h, concentrated in vacuo and purified on silica 
column (0 → 40% acet in DCM) to obtain 38 (0.03 g, 0.06 mmol, 31%) as a white foam. TLC: (Acet:DCM 
40:60, v/v) Rf = 0.49; 1H NMR (500 MHz, CDCl3) δ 5.68 (d, J = 9.8 Hz, 1H, NH C-5), 5.27 (dd, J = 5.7, 4.5 
Hz, H-4), 5.24 (dd, J = 5.4, 2.2 Hz, 1H, H-7), 4.85 (dt, J = 5.4, 4.1 Hz, 1H, H-8) 4.20 – 4.16 (m, 1H, H-5), 
4.11 (dd, J = 10.7, 2.2 Hz, 1H, H-6), 3.98 – 3.90 (m, 3H, CH2N3; H-9a), 3.80 (s, 3H, OCH3), 3.25 (ddd, J = 
14.9, 5.8, 4.2 Hz, 1H, H-9b), 2.52 (dd, J = 13.3, 5.0 Hz, 1H, H-3eq), 2.19 (s, 3H, CH3, Ac C-7), 2.16 (s, 3H, 
CH3, Ac C-2), 2.04 (s, 3H, CH3, Ac C-4), 2.03 (s, 1H, H-3ax), 2.02 (s, 3H, CH3, Ac C-8), 1.92 (s, 3H, CH3, 
NHAc). 13C NMR (126 MHz, CDCl3) δ 171.26 (CO, Ac C-7), 171.13 (CO, Ac C-4), 170.91 (CO, NHAc), 170.52 
(CO, Ac C-8), 168.58 (CO, Ac C-2), 167.74 (COCH2N3), 166.59 (C-1), 97.07 (C-2), 72.55 (C-6), 72.06 (C-8), 
68.19 (C-7), 53.35 (OCH3), 52.54 (CH2N3), 49.20 (C-5), 38.63 (C-9), 36.21 (C-3), 23.04 (CH3, NHAc), 20.92 
(CH3, Ac C-7), 20.89 (CH3, Ac C-4), 20.85 (CH3, Ac C-8), 20.70 (CH3, Ac C-2). HR-ESI-TOF/MS (m/z): 
[M+Na]+ calcd. for C22H31N5NaO13, 596.18160; found, 596.18055. IR (ATR, ν, cm-1): 2109.84 (N3). 
 
 Methyl (5-acetamido-2,4,7,8-tetra-O-acetyl-9-N-azidoethoxycarbonyl -3,5-
dideoxy-5-D-glycero-D-galacto)onate (39). Amine intermediate 37 (0.094 g, 0.19 mmol) was dissolved 
in DCM (3.81 mL, 0.05 M) and ACN (1.9 mL, 0.1 M). AzeocOsu (0.17 g, 0.76 mmol, 4 eq.) and TEA (0.08 
g, 0.76 mmol, 4 eq.) were added and the reaction mixture was stirred for 36 h at r.t., concentrated in 
vacuo and purified on silica column (0 → 40% Acet in DCM) to obtain 39 (0.03 g, 0.05 mmol, 24%) as a 
white foam. TLC: (Acet:DCM 40:60, v/v) Rf = 0.56; 1H NMR (500 MHz, CDCl3) δ 5.55 (d, J = 9.9 Hz, 1H, 
NHAc), 5.47 (d, J = 6.6 Hz, 1H, NHCOO(CH2)2N3), 5.27 – 5.21 (m, 1H, H-4; H-7), 4.85 (dt, J = 7.0, 3.7 Hz, 
1H, H-8), 4.32 – 4.26 (m, 1H, CHH-CH2N3), 4.23 – 4.13 (m, 2H, CHHCH2N3, H-5), 4.07 (dd, J = 10.7, 2.1 
Hz, 1H, H-6), 3.86 (ddd, J = 15.2, 7.6, 3.4 Hz, 1H, H-9a), 3.79 (s, 3H, OCH3), 3.44 (q, J = 3.8, 3.2 Hz, 2H, 
CH2N3), 3.07 (ddd, J = 15.3, 5.5, 4.0 Hz, 1H, H-9b), 2.53 (dd, J = 13.4, 5.0 Hz, 1H, H-3eq), 2.17 (s, 3H, CH3, 
Ac C-7), 2.14 (s, 3H, CH3, Ac C-2), 2.08 – 2.06 (m, 1H, H-3ax), 2.04 (s, 3H, CH3, Ac C-4), 2.02 (s, 3H, CH3, 
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Ac C-8), 1.92 (s, 3H, CH3 , NHAc). 13C NMR (126 MHz, CDCl3) δ 171.67 (CO, Ac C-7), 171.15 (CO, Ac C-4), 
170.82 (CO, NHAc), 170.06 (CO, Ac C-8), 168.35 (CO, Ac C-2), 166.41 (C-1), 156.23 (COO(CH2)2N3), 97.36 
(C-2), 72.34 (C-6), 71.47 (C-8), 68.34 (C-4), 67.71 (C-7), 63.56 (CH2CH2N3), 53.28 (OCH3), 50.32 
(CH2CH2N3), 49.22 (C-5), 39.79 (C-9), 36.06 (C-3), 23.08 (CH3, NHAc), 20.92 (CH3, Ac C-8), 20.89 (CH3, Ac 
C-4), 20.86 (CH3, Ac C-2), 20.73 (CH3, Ac C-7). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C23H33N5NaO14, 
626.19217; found, 626.19094. IR (ATR, ν, cm-1): 2107.55 (N3). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. 
for C23H33N5NaO14, 626.19217; found, 626.19094.  
 
 
Methyl (5-N-acetyl-9-N-methylpent-4-ynamide-2,4,7,8-tetra-O-acetyl-3,5,9-trideoxy-D-glycero-β-D-
galacto-non-2-ulopyranoside)onate (40). Amine intermediate 37 (0.094 g, 0.19 mmol) was dissolved 
in DCM (3.81 mL, 0.05 M) and ACN (1.9 mL, 0.1 M). Poc-Cl (0.09 g, 0.76 mmol, 4 eq.) and TEA (0.08 g, 
0.76 mmol, 4 eq) were added and the reaction mixture was stirred for 36 h at r.t., concentrated in 
vacuo and purified on silica column (0 → 40% Acet in DCM) to obtain 40 (0.05 g, 0.08 mmol, 42%) as a 
white foam. TLC: (Acet:DCM 40:60, v/v) Rf = 0.48; 1H NMR (500 MHz, CDCl3) δ 6.49 (t, J = 6.2 Hz, 1H, 
NH  C-9), 5.73 (d, J = 9.2 Hz, 1H, NH C-5), 5.26 (ddd, J = 11.4, 9.8, 5.0 Hz, 1H, H-7), 5.21 (dd, J = 4.8, 2.0 
Hz, 1H, H-4), 4.81 (q, J = 4.6 Hz, 1H, H-8), 4.18 (d, J = 10.0 Hz, 1H, H-5), 4.13 (dd, J = 10.7, 2.3 Hz, 1H, H-
6), 3.85 – 3.81 (m, 1H, H-9a), 3.80 (s, 3H, OCH3), 3.26 (ddd, J = 14.8, 6.2, 4.3 Hz, 1H, H-9b) 2.54 – 2.49 
(m, 3H, H-3eq; CH2CCH), 2.43 (ddd, J = 10.1, 6.4, 2.8 Hz, 2H, CH2CH2CCH), 2.16 (d, J = 1.7 Hz, 6H, 2x CH3 
Ac C-2; Ac C-7), 2.03 (s, 3H, CH3 Ac C-4), 2.01 (s, 3H, CH3 NHAc), 2.00 – 1.97 (m, 2H, H-3ax; C≡CH), 1.91 
(s, 3H, CH3 Ac C-8). 13C NMR (126 MHz, CDCl3) δ 171.80 (CO(CH2)2CCH), 171.10 (CO, Ac C-7), 171.05 
(CO, Ac C-4), 170.82 (CO, NHAc), 170.71 (CO, Ac C-8), 168.67 (CO, Ac C-2), 166.70 (C-1), 97.03 (C-2), 
83.09 (C≡CH), 72.72 (C-6), 72.59 (C-8), 69.11 (C≡CH), 68.55 (C-7), 68.25 (C-4), 53.34 (OCH3), 49.20 (C-
5), 38.64 (C-9), 36.25 (C-3), 35.14 (CH2CH2CCH), 23.07 (CH3 Ac C-8), 20.95 (CH3 NHAc), 20.90 (CH3 Ac C-
4), 20.86 (CH3 Ac C-2), 20.70 (CH3 Ac C-7), 14.86 (CH2CCH). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for 
C25H34N2NaO13, 593.19586; found, 593.19583. IR (ATR, ν, cm-1): 3275.82 (C≡C-H). 
 
  Methyl (5-N-acetyl-9-N-propargylaminocarbonyl-2,4,7,8-tetra-O-acetyl-
3,5,9-trideoxy-D-glycero-β-D-galacto-non-2-ulopyranoside)onate (41). Amine intermediate 37 (0.09 
g, 0.19 mmol) was dissolved in DCM (3.81 mL, 0.05 M) and ACN (1.9 mL, 0.1 M). Pentynoic acid-OSu 
(0.19 g, 0.95 mmol, 5 eq.) and TEA (0.08 g, 0.76 mmol, 4 eq.) were added and the reaction mixture was 
stirred at r.t. for 36 h, concentrated in vacuo and purified on silica column (0 → 40% Acet in DCM) to 
afford 41 (0.02 g, 0.04 mmol, 18%) as a white foam. TLC: (Acet:DCM 40:60, v/v) Rf = 0.60; 1H NMR (500 
MHz, CDCl3) δ 5.45 (t, J = 6.7 Hz, 1H, NHPoc), 5.39 (d, J = 9.7 Hz, 1H, NHAc), 5.26 – 5.19 (m, 2H, H-4; H-
7), 4.85 (dt, J = 6.9, 3.8 Hz, 1H, H-8), 4.65 (dd, J = 10.1, 2.5 Hz, 2H, CH2, Poc), 4.19 (q, J = 10.3 Hz, 1H, H-
5), 4.05 (dd, J = 10.7, 2.3 Hz, 1H, H-6), 3.84 (ddd, J = 14.8, 7.4, 3.6 Hz, 1H, H-9a), 3.79 (s, 3H, OCH3), 3.08 
(ddd, J = 15.1, 5.5, 3.9 Hz, 1H, H-9b), 2.53 (dd, J = 13.4, 5.0 Hz, 1H, H-3eq), 2.46 (t, J = 2.4 Hz, 1H, 
C≡CHPoc), 2.16 (s, 3H, CH3 Ac C-7), 2.13 (s, 3H, CH3 Ac C-2), 2.06 (d, J = 2.7 Hz, 1H, H-3ax), 2.03 (d, J = 
0.9 Hz, 3H, CH3 Ac C-4), 2.01 (s, 3H, CH3 Ac C-8), 1.90 (s, 3H, CH3 NHAc). 13C NMR (126 MHz, CDCl3) δ 
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171.21 (CO, Ac C-7), 171.07 (CO, Ac C-4), 170.29 (CO, NHAc), 169.85 (CO, Ac C-8), 168.26 (CO, Ac C-2), 
166.38 (C-1), 155.73 (CO, Poc), 97.41 (C-2), 74.48 (C≡CH, Poc), 72.58 (C-6), 71.30 (C-8), 68.30 (C-4), 
67.88 (C-7), 53.31 (OMe), 52.45 (CH2C≡CHPoc), 49.28 (C-5), 39.98 (C-9), 36.06 (C-3), 23.20 (CH3 NHAc) 
, 20.93 (CH3 Ac C-7), 20.88 (CH3 Ac C-4), 20.85 (CH3 Ac C-8), 20.73 (CH3 Ac C-2). HR-ESI-TOF/MS (m/z): 
[M+Na]+ calcd. for C24H32N2NaO14, 595.17512; found, 595.17490. IR (ATR, ν, cm-1): 3276.86 (C≡C-H).  
 
 
Contributions 
Synthesis and molecular design done by Heise T and his students: Gerrits L1 and Rossing E1. The 
biological testing was performed by Büll C2. 
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6 
Metabolic Oligosaccharide 
Engineering with Alkyne 
Sialic Acids Confers 
Neuraminidase Resistance 
and Inhibits Influenza 
Reproduction  
 
“I have been trying to point out that in our lives chance may have an astonishing 
influence and, if I may offer advice to the young laboratory worker, it would be this - 
never to neglect an extraordinary appearance or happening.” 
Alexander Fleming (1881-1955), most famous for his work on penicillin which 
established the era of antibiotics.  
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Abstract 
Metabolic incorporation of azide- or alkyne-modified sialic acids into the cellular 
glycosylation pathway enables the study of sialoglycan expression, localization, and 
trafficking via bioorthogonal chemistry. Herein, we report that such modifications of the 
sialic acid sugar can have a profound influence on their hydrolysis by neuraminidases 
(sialidase). Azidoacetyl (Az)-modified sialic acids were prone to neuraminidase cleavage, 
whereas propargyloxycarbonyl (Poc)-modified sialic acids were largely resistant to 
cleavage. Because the influenza virus infection cycle depends on the hydrolysis of host-
cell-surface sialic acids, influenza cell-to-cell transmission was strongly reduced in Poc 
sialic acid glycoengineered host cells. The use of Poc sialic acids may disturb biological 
processes involving neuraminidase cleavage but also provides perspective for use in 
applications in which sialic acid hydrolysis is not desired, such as antibody modification, 
viral infection, and expanding the circulation time of therapeutic proteins. 
 
 Heise T#, Büll C#, Beurskens DM, Rossing E, de Jonge MI, Adema GJ, Boltje TJ*, 
Langereis JD*. Metabolic Oligosaccharide Engineering with Alkyne Sialic Acids 
Confers Neuraminidase Resistance and Inhibits Influenza Reproduction. 
Bioconjugate chemistry, 2017, 28, 1811-1815 
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Introduction 
Sialic acids (also known as neuraminic acids) are nine carbon sugars abundantly expressed 
at the termini of cell surface glycoconjugates.1 Sialylated glycans are recognized by 
endogenous and exogenous receptors and play an important role in physiology and 
pathology, respectively.2 An important tool for the study of the function and localization 
of glycans in living cells and organisms is metabolic oligosaccharide engineering (MOE).3 
In this process, monosaccharides carrying an unnatural modification are supplied to cells 
and incorporated into glycans at the cell surface. In a second step, the unnatural 
modification, also called a chemical reporter, can be visualized using bioorthogonal 
reactions with, for instance, fluorescent molecules.4 This powerful technique can be used 
to study and to manipulate glycans at the cell surface in various cells and living organisms. 
Studying biological processes without disturbing them is a major challenge, and hence, 
the chemical reporter carried by the monosaccharides must preferably be small and 
biologically inert. This approach is based on earlier work showing that small modifications 
on the N-acyl chain of N-acetylmannosamines were well-tolerated by the glycosylation 
machinery and ultimately expressed at the cell surface in the form of modified sialic 
acids.5 However, these modifications were intended to actively perturb biological 
processes involving sialic acids, such as pathogenic infection, immune-cell dampening, 
and neurite outgrowth.6-7 The acyl chain of sialic acid is also a site of natural modifications, 
which has probably arisen to avoid pathogen recognition.8 Chemical modifications at this 
site may therefore affect the biological function of sialic acids. Here, we report that 
azidoacetyl (Az) sialic acids are sensitive to bacterial and viral neuraminidases (also called 
sialidases), whereas propargyloxycarbonyl (Poc) sialic acids are resistant. Subsequently, 
incorporation of a propargyloxycarbonyl (Ac5SiaNPoc) into host cells, but not an 
azidoacetyl (Ac5SiaNAz), markedly reduced neuraminidase dependent influenza cell-to-
cell transmission.  
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Results and discussion.  
We have previously shown that sialic acids modified at the C-5 position with Ac5SiaNAz or 
Ac5SiaNPoc are utilized by the cellular sialylation pathway with high selectivity resulting 
in their incorporation into cell surface sialoglycans (Figure 1).9-10  
  
Figure 1. Schematic presentation of metabolic labeling with Ac5SiaNAz or Ac5SiaNPoc and the resistance 
of Ac5SiaNPoc against influenza neuraminidase.  
 
Both sialic acid analogues are well-tolerated by the cellular sialylation pathway, and these 
small modifications to the C-5 position are generally thought to be nonintrusive. There is 
evidence, however, that the modification of sialic acids at the C-5 position affects their 
recognition and cleavage by bacterial neuraminidases.11 Therefore, we assessed whether 
cell surface Az and Poc sialic acids can be cleaved by bacterial neuraminidase. Human 
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monocytic THP-1 cells were cultured for 3 days with Ac5SiaNAz or Ac5SiaNPoc and reacted 
to biotin−alkyne or biotin−azide, respectively, using copper-catalyzed alkyne azide 
cycloaddition (CuAAc).12-14 The biotin-tagged surface sialoglycans were visualized with 
fluorescent streptavidin. Confocal images show the dense expression of Az and Poc sialic 
acids at the cell surface of THP-1 cells (Figure 2a).   
 
Figure 2. Metabolic labeling of THP-1 cells. a) The cells were incubated for 3 days with PBS, 100 μM 
Ac5SiaNAz, or 100 μM Ac5SiaNPoc and reacted to biotin−alkyne or biotin−azide, respectively, using CuAAC. 
Biotin-containing sialoglycans were stained with PE−streptavidin and visualized by confocal microscopy. 
b) Fluorescence was quantified by flow cytometry, and the mean fluorescence intensity ± SEM is shown 
(n = 3).  
 
Quantification of the fluorescence with flow cytometry showed that both sialic acid 
analogues were incorporated into surface glycans with high efficiency. Ac5SiaNAz (MFI 
7979) showed slightly lower incorporation compared to Ac5SiaNPoc (MFI 9345) (Figure 
2b). The difference in labeling intensity between Ac5SiaNAz and Ac5SiaNPoc is linked to 
their different incorporation efficiency and not the labeling step, because the CuAAc 
reaction is faster for Ac5SiaNAz compared to Ac5SiaNPoc.15 Next, it was determined 
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whether surface SiaNAz and SiaNPoc containing glycans can be cleaved by bacterial 
neuraminidase (Figure 3). 
 
Figure 3. Enzymatic removal of Az and Poc sialic acids from the cell surface of THP-1 cells. Cells incubated 
for 3 days with PBS, 100 μM Ac5SiaNAz, or 100 μM Ac5SiaNPoc were treated for 1 h with 250mU/ mL 
Clostridium perf ringens neuraminidase. Az and Poc sialoglycans were reacted to fluorescent biotin using 
CuAAC a), α2,3-sialoglycans were detected with MALII lectin b), α2,6-sialoglycans were detected with 
SNA-I lectin c), and terminal β-galactose was detected with PNA lectin d). Bar diagrams show mean 
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fluorescence intensity or mean lectin binding normalized to control ± SEM of three independent 
experiments. MALII: Maackia amurensis lectin; PE: Phycoerythrin, PNA: Peanut agglutinin lectin; SEM: 
standard error of the mean; SNA-I: Sambucus nigra lectin.  
 
 
THP-1 cells cultured for 3 days with Ac5SiaNAz and Ac5SiaNPoc were treated with 
Clostridium perfringens neuraminidase and then reacted with biotin−alkyne and 
biotin−azide, respectively, followed by staining with streptavidin−phycoerythrin (PE).16 
Flow cytometry analysis revealed that SiaNAz was cleaved from the cells (>64% removal), 
whereas SiaNPoc could not be removed from the cell surface (<8% removal) (Figure 3a). 
To evaluate the cleavage selectivity with respect to the linkage type (α-2,3 or α-2,6), the 
cells were analyzed Maackia amurensis lectin (MALII, binding to α-2,3-sialoglycans), 
Sambucus nigra lectin (SNA-I, binding to α-2,6-sialoglycans), and peanut agglutinin lectin 
(PNA, binding to terminal β-galactose). Cells incubated with Ac5SiaNAz showed also a 
strong reduction in sialic acid expression following treatment with neuraminidase (MALII, 
↓93%; SNA-I, ↓72%). In contrast, the sialylation of THP-1 cells cultured with Ac5SiaNPoc 
was barely altered following neuraminidase treatment (MALII, ↓18%; SNA-I, ↓13%). The 
low sensitivity of Poc sialic acids toward neuraminidase activity was also confirmed by the 
minor change in PNA binding. Similar findings were obtained when THP-1 cells were 
treated with neuraminidase derived from Vibrio cholerae or Arthrobacter ureafaciens 
(Figure 4).  
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Figure 4. Removal of Az and Poc sialic acids from the cell surface by bacterial sialidases. THP-1 cells 
incubated for 3 days with PBS, 100 μM Ac5SiaNAz or 100 μM Ac5SiaNPoc were treated for 1 hour with 250 
mU/ml neuraminidase from V.cholera or A.ureafaciens. Az and Poc sialoglycans were reacted to 
fluorescent biotin using CuAAC (a) and α-2,3-sialoglycans were detected with MALII lectin (b) and α-2,6-
sialoglycans with SNA-I lectin (c), respectively. Bar diagrams show mean fluorescence intensity or mean 
lectin binding normalized to control ± SEM.  
 
Together, these data show that sialic acids modified with an Az group at the C-5 position 
are substrates for neuraminidases, whereas Poc-modified sialic acids are not. Whether 
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this effect is due to inhibited recognition or hydrolysis of sialic acids by neuraminidases 
remains to be investigated. Several pathogens make use of neuraminidases to infect host 
cells or release host cell sialic acids for their own metabolism.17-18 In particular, influenza 
virus makes use of the host cell sialic acids to enter and leave the cell. Influenza virus has 
two major glycoproteins on the outside of the viral particle, hemagglutinin (HA) and 
neuraminidase (NA).19 Hemagglutinin is a lectin that mediates binding to sialic acids on 
host cells, whereas neuraminidase is involved in the release of progeny virus from 
infected cells by cleaving the sialic acid that binds the mature viral particle to the cell 
surface. Neuraminidase inhibitors including Oseltamivir (Tamiflu) and Zanamivir (Relenza) 
block neuraminidase enzyme activity and prevent influenza virus reproduction.20-22 
Therefore, we assessed whether neuraminidase resistant Poc sialic acid alters influenza 
reproduction in an A549 cell infection model. In this model, a GFP-reporter influenza virus 
strain A/PR8-GFP/8/34 was used that expresses GFP in infected cells.23 A549 cells were 
cultured for 3 days with Ac5SiaNAz or Ac5SiaNPoc, and incorporation of Az and Poc sialic 
acids as well as cleavage resistance of Poc sialic acid was confirmed (Figure 5).  
  
207 
 
 
Figure 5 Poc sialic acids are sialidase resistant in A549 cells. A549 cells incubated for 3 days with PBS, 100 
µM Ac5SiaNAz or 100 µM Ac5SiaNPoc were treated for 1 hour with 250 mU/ml neuraminidase from C. 
perfringens. Az and Poc sialoglycans were reacted to fluorescent biotin using CuAAC (a), α-2,3-sialoglycans 
were detected with MALII lectin (b) and α-2,6-sialoglycans with SNA-I lectin (c). Bar diagrams show mean 
fluorescence intensity or mean lectin binding normalized to control ± SEM (n = 3). 
 
Next, confluent A549 cells were infected with different dilutions of influenza virus strain 
A/PR8-GFP/8/34 (IVA) for 1 h and the percentage of GFP-positive A549 cells was 
determined by flow cytometry 6 and 24 h post-infection, representing the initial infection 
and the infection of viral progeny, respectively. The initial infection after 6 h did not show 
a significant difference in the percentage of GFP-positive A549 cells between cells 
cultured with Ac5SiaNAz, Ac5SiaNPoc, or a solvent control (333 × dilution Figure 7a; 1000 
× dilution, Figure 6). 
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Figure 6. Effect of Az and Poc sialic acid on influenza reproduction (1000 x dilution). A549 cells cultured 
with either Ac5SiaNAz or Ac5SiaNPoc were treated with influenza virus strain A/PR8-GFP/8/34 and the GFP 
expression was measured as readout for successful viral infection after 6 hours (a) and reinfection after 
24 hours (b). 
 
In contrast, after 24 h, the cells incubated with Ac5SiaNPoc showed a significant reduction 
in GFP-positive A549 cells compared with solvent control or cells incubated with 
Ac5SiaNAz, indicating that Ac5SiaNPoc, which is resistant to bacterial neuraminidase 
activity, has a profound effect on virus reproduction (333 × dilution, Figure 7a; 1000 × 
dilution, Figure 6).  
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Figure 7. Effect of Az and Poc sialic acid on influenza reproduction (333 × dilution). A549 cells cultured 
with either Ac5SiaNAz or Ac5SiaNPoc were treated with influenza virus strain A/PR8-GFP/8/34, and the 
GFP expression was measured as a readout for successful viral infection after 6 h and reinfection after 24 
h (a). Az and Poc sialoglycans were detected 24 h post-infection by reaction with fluorescent biotin using 
the CuAAC (b). Bar diagrams show mean fluorescence intensity ± SEM (n = 4). 
 
Earlier research has shown that modifications of the N-acyl chain could inhibit influenza 
infections and led to the hypothesis that longer site chains would sterically hinder binding 
of hemagglutinin.24 Our experimental data with Ac5SiaNAz or Ac5SiaNPoc after 24 h are 
indeed in line with earlier observations that sialic acid C-5 modifications can lead to viral 
resistance. However, the initial infection after 6 h shows no resistance, therefore 
suggesting a different mechanism. In contrast to the current hypothesis, we found that 
initial infection (and, therefore, hemagglutinin recognition) is not significantly hindered 
by longer C-5 modifications such as Az or Poc. Instead, the gain in resistance in the case 
of Ac5SiaNPoc is probably caused by neuraminidase resistance, thereby inhibiting the 
release of the viral progeny. This was further confirmed by labeling the Ac5SiaNAz- and 
Ac5SiaNPoc- treated cells after 24 h of IVA infection (Figure 7b). The Ac5SiaNAz-treated 
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cells showed a significant reduction in labeling signal, indicating the release of SiaNAz 
after infection. In contrast, Ac5SiaNPoc treated cells showed very similar labeling levels 
24 h post infection compared to an untreated control. This clearly indicates that SiaNPoc 
is stable under IVA infection and resists neuraminidase cleavage.  
 
Conclusions 
In conclusion, we demonstrate that metabolic engineering with Poc-modified sialic acids 
confers resistance toward neuraminidases. Consequently, the incorporation of Poc sialic 
acids into host cells reduced neuraminidase-dependent influenza cell-to-cell 
transmission. Furthermore, these findings indicate that, depending on the chemical 
reporter used, metabolic oligosaccharide engineering may not be biologically inert. The 
neuraminidase resistance conferred by Poc sialic acids may disturb biological processes 
involving neuraminidase cleavage but could be applied in situations in which sialic acid 
hydrolysis is not desired, such as therapeutic protein modification, viral infection, etc.  
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Supplementary information 
The synthesis of all compounds is described in Chapter 3 & 5. The labeling method is described in Chapter 
3. 
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Part 3 
 
Glycosyl-transferase 
Inhibitors for Glycocalyx 
Engineering  
 
 
“Will fluorine ever have practical applications? 
It is very difficult to answer this question. I may, however, say in all sincerity that I 
gave this subject little thought when I undertook my researches, and I believe that 
all the chemists whose attempts preceded mine gave it no more consideration. 
A scientific research is a search after truth, and it is only after discovery that the 
question of applicability can be usefully considered.” 
Henri Moissan (1852-1907), first to chemically isolate the element fluorine.  
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7 
Potent Metabolic 
Sialyltransferase Inhibitors 
based on C-5 Carbamate 
Modified Sialic Acid 
Derivatives 
“The problem of chemotherapy […] could be solved neither by the experimental 
medical research worker nor by the chemist alone, but only by the two together 
working in very close cooperation over many years.” 
Gerhard Domagk (1895-1964), famous for the discovery of the first drug effective 
against bacterial infections but focused on cancer therapy later. 
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Abstract: Several million sialic acids decorate every human cell to protect host cells 
against attacks of the immune system by attenuating the immune response. While 
being an essential regulation mechanism under physiological conditions, 
overexpression of sialic acids is a common strategy to evade the immune system 
associated with diseases such as infections and cancer. Efficient therapeutics are 
needed to counter sialylation and therefore increase immune system targeting. 
Fluorinated sialic acids have been reported to inhibit sialylation but suffer from low 
potency and are ineffective in the most resistant types of cancer. To overcome this 
problem, a library of fluorinated sialic acids has been synthesized. Here we report C-5 
carbamate inhibitors with low micromolar inhibitory effect exceeding the potency of 
every sialylation inhibitor yet published. The inhibitors effectively countered sialylation 
in the most resistant cancer cell lines and were used in a therapeutic setting to slow 
down cancer-growth in vivo.  
 Heise T, Pijnenborg JFA, Büll C, Kers-Rebel ED, Balneger N, Elferink H, Adema GJ, 
Boltje TJ*. Potent Metabolic Sialyltransferase Inhibitors Based on C-5 Modified 
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Introduction 
Sialic acids are abundantly expressed at the termini of cell surface glycans and on 
secreted glycoproteins,1 thereby masking underlying galactose residues that cause 
immune responses2 and engaging with a variety of endogenous immunoregulatory 
receptors such as Siglecs3,4 and Selectins.5 Combined, these functions attenuate the 
immune system therefore creating an important threshold for inflammation to prevent 
autoimmune reactions.6 However, overexpression of sialic acids as seen in cancer cells 
has been linked to immune evasion,7 improved extravasation, metastasis and 
resistance to chemo- and radiotherapy.8 Strategies are needed to efficiently counter 
cancer cell sialylation in therapeutic settings. Sialidases, the natural enzymes to cleave 
sialic acids, are not suitable as their effect is short-lived since it does not block 
biosynthesis and is moreover often contaminated and immunogenic.9 Instead, a 
chemical inhibition that blocks de novo synthesis is needed. Previously published 
fluorinated sialic acid Ac5SiaNAc-3Fax (short SiaFAc 1)10 was a promising first step 
towards chemical sialic acid inhibition, but fails to counter the most aggressive tumors 
due to its low efficiency. Despite its low efficiency, SiaFAc does target the de novo 
biosynthesis of sialic acid and was considered a promising lead-structure towards the 
design of more efficient inhibitors. Human N-acetylneuraminic acid (NeuNAc) is 
biosynthesized from phosphorylated N-acetylmannosamine (ManNAc-6-P) which is 
synthesized by the bifunctional UDP-N-acetylglucosamine 2-epimerase/N-
acetylmannosamine-kinase (GNE). GNE is the key regulator for the cellular sialic acid 
concentration as it is inhibited by CMP-activated sialic acid. CMP-activation of sialic 
acid is the last step before incorporation in glycans by sialyl transferases (STs) and is 
necessary for ST recognition. The importance of this feedback inhibition was 
demonstrated by a point mutation of GNE thereby blocking any feedback inhibition. 
This led to a highly increased synthesis of sialic acid and enabled gram-scale 
production.11 Fluorinated sialic acid stabilizes the CMP and prevents coupling to 
glycans thereby not only inhibiting STs competitively but also leading to an 
accumulation of fluorinated CMP sialic acid that triggers the feedback inhibition.12,13 
Instead of using a sialic acid analogue, a recent approach has effectively demonstrated 
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sialylation inhibition (IC50 8.5 µM) by blocking GNE phosphorylation with mannosamine 
analogues.14 It should however be noted, that several studies raised concerns about 
toxicity and specificity of mannosamine analogues.15 Instead, non-toxic, specific and 
highly effective chemical reagents are needed to inhibit sialylation in therapeutic 
settings. Here we report on a library of effective C-5 carbamate modified sialic acid 
inhibitors. Different sialic acid positions and linkage types were synthesized and 
evaluated based on an in vitro model (Figure 1). 
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Figure 1. Cell-permeable fluorinated sialic acid as inhibitor of sialylation. a) Proposed mechanism of 
action of fluorine sialic acids. Acetylated fluorinated sialic acid diffuses over the cell membrane before 
deacetylation by cellular esterases. The fluorinated sialic acid is then CMP-activated in the nucleus and 
transported into the Golgi system where it inhibits sialyltransferase function and the incorporation of 
sialic acids into glycans. b) Chemical structure of the SiaF backbone and added acetamide and 
carbamate groups. 
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With SiaFAc as lead compound we set out to improve the inhibitory potency of SiaFAc 
by introducing modifications on the sialic acid scaffold. With fluoride occupying the C-
3 position and C-1 or C-2 being essential for sialic acid recognition and CMP activation, 
respectively, the C-4-9 positions were considered for further modification. For 
synthetic ease, C-7 and C-8 were excluded and C-4, C-5 and C-9 were chosen for 
derivatization.  
 
C-3 electrophilic fluorination required a glycal precursor, therefore, C-4 and C-9 azide 
glycals were synthesized based on previous synthetic approaches. The C-5 glycal was 
prepared from thioglycoside 23,16 reacted with bromine to afford a mixture of the 
corresponding glycosyl bromide and glycal 24. Reaction of the mixture under basic 
conditions then afforded glycal 24 in a good overall yield (78%) (Scheme 1). 
 
Electrophilic fluorination of glycals 19, 22 and 24 using Selectfluor in a mixture of water 
and DMF and subsequent acetylation afforded axial-fluorides 20, 22 and 12 as the 
major products.17 In a first trial, the inhibitors were tested, but the inhibition properties 
of 20 and 22 did not exceed those of published inhibitor 1 (Figure S1). While C-4 azide 
22 performed in a comparable way, the C-9 azide 20 did not show any significant 
inhibition. The C-5 modified inhibitor 12 did however show improved inhibition 
properties (Figure 2). It was therefore decided to abandon C-4 and C-9 modifications 
and concentrate on C-5 analogues  as inhibitors. 
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Scheme 1. Synthesis of modified fluorinated sialic acid analogues. i) TMSOTf, ACN, 0 °C, 3 h, 52%;  ii) 
selectfluor, H2O, DMF, 50-60 °C, 3-16 h;  iii) Ac2O, Pyr, 16 h, 23: 35%; 25: 58%; 12: 68% (2 steps). iv) 
Br2, DCM, r.t., 2.5 h; v) TEA, DCM, r.t., 16 h, 78% (2 steps); vi) TFA, DCM, H2O, r.t., 2 h; vii) activated 
acyl substituents (A), TEA, DCM, r.t.; 2: Side product of the reaction (vii) 90%; 3: A = chloroacetyl 
chloride, 16 h, 60%; 4: A = acetoxyacetyl chloride , 16 h, 43%; 5: A = Azidoacetic acid NHS ester, 23 h, 
16%; 6: A = 4-Pentynoic acid NHS ester, 16 h, 7%; 7: A = N-propargyloxycarbonyl-succinimide, 15 h, 
40%; 8: A = Allyl chloroformate, 21.5 h, 16%; 9: A = methyl chloroformate, 16 h, 33%; 10: A = ethyl 
chloroformate, 16 h, 16%; 11: A = isobutyl chloroformate, 16 h, 33%; 13: A = benzyl chloroformate, 
21.5 h, 6%; 15: A = n-nutyl chloroformate, 16 h, 32%;  16: A = 2-methoxymethyl chloroformate, 16 h, 
90%;   17: A = 2,2,2 trichloroethoxycarbonyl chloroformate, 16 h, 17%; 18: A = 2-fluoroethyl 
chloroformate, 16 h, 60%; vii) 14: benzyl azide, TBTA, CuI, Cu, DMF, H2O, tBuOH, r.t., 16 h, 46%. 
 
Boc inhibitor 12 was modified in a two-step sequence of Boc deprotection followed by 
acylation of the amine. We reported an analogous method to prepare non-fluorinated 
C-5 modified sialic acid derivatives in good yield.16 In case of 12, however, the yields of 
this two-step sequence were on average considerably lower. Presumably, the presence 
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of the C-3 axial fluoride renders the C-5 amine much less reactive giving rise to various 
side reactions.15 Nevertheless, including precursor 12, 17 new inhibitor derivatives (2-
18, Scheme 1, structures shown in Figure 1) were prepared by direct amine acylation, 
carrying a variety of acyl groups with a range of yields (6-90%). Derivatives 5, 6 and 7 
contain an alkyne or azide group which is amenable for modification using the copper-
catalyzed azide alkyne cycloaddition (CuAAC) reaction. To explore whether 
modifications introduced by CuAAC are tolerated by the sialic acid biosynthesis 
derivative 14 was prepared using 7, benzyl azide and CuI/TBTA. 
 
All inhibitors were tested in direct comparison to the previously published SiaFAc 118 
and DMSO as 100% control. B16-F10 cells were treated for three days with 0.1-204.8 
µM acetamide 1-6 or carbamate fluorinated sialic acids 7-14 or DMSO and exposed to 
biotinylated lectins MALII that recognize α-2,3-linked (Figure 2a,b) or SNA-I that α-2,6-
linked sialic acids (Figure 2c,d) and subsequently fluorescently labeled with and 
Streptavidin-PE. Binding of the lectins was determined by flow cytometry and data of 
three independent experiments were presented as mean percentage lectin binding ± 
SEM normalized to control cells. Inhibitors with an acetamide linkage (Figure 2a, c) 
were significantly inferior to inhibitors with a carbamate linkage (Figure 2b, d) for 
reduction of α-2,3-linked as well as α-2,6-linked sialic acids.  
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Figure 2. Acetamide and carbamate fluorinated sialic acids inhibit sialylation in B16-F10 cells. a-d) B16-
F10 cells were treated for three days with 0.1-204.8 µM acetamide or carbamate fluorine sialic acids 
or DMSO control and stained with the biotinylated lectins MALII or SNA-I that recognize α-2,3-linked 
or α-2,6-linked sialic acids, respectively, and streptavidin-PE. Binding of the lectins was determined by 
flow cytometry and data of three independent experiments are presented as mean percentage lectin 
binding ± SEM normalized to control cells. Graphs show MALII and SNA-I binding to cells treated with 
acetamide fluorinated sialic acids (a, c) and carbamate fluorinated sialic acids (b, d). 
 
In terms of EC50 values, the acetamides 2, 5 and 6 had comparable values to the 
previously published 1 for α-2,6- (Table 1) and α-2,3- linked sialic acids (Table 2). Only 
a Gc group was found to significantly outcompete the human acetyl group in the B16-
F10 and THP-1 cell line. This could hint to a higher affinity of sialyl transferases or CMAS 
towards glycolyl sialic acid compared to acetyl sialic acid in these cell lines. This is in 
line with the high incorporation of Gc Sialic acids in animal cells when both acetyl and 
glycolyl are available.19 Why acetamide 2 was specifically effective in THP-1 cells but 
not in any other cell-line remains unclear. Chloro acetamide 3 could not accurately be 
measured because it was found to be cytotoxic.  
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Group SiaFR B16-F10 rIP THP-1 HEK293 HeLa 9464D EL4 
Amides Ac (1) 26.79 ± 
5.72 
 8.50 ± 
1.54 
45.22 ± 
8.30 
52.95 ± 
3.61 
> 102.4 > 102.4 
TFA (2) 14.32 ± 
0.77 
2 3.30 ± 
1.26 
42.75 ± 
2.38 
25.54 ± 
2.61 
46.53 ± 
4.41 
> 102.4 
ClAc 
(3) 
17.98 ± 
2.12 
1 ND ND ND ND ND 
Gc (4) 4.98 ± 
0.33 
5 4.24 ± 
2.00 
53.60 ± 
5.25 
16.61 ± 
3.91 
> 102.4 > 102.4 
Az (5) 19.94 ± 
2.08 
1 10.93 ± 
1.98 
45.55 ± 
5.14 
80.61 ± 
3.26 
> 102.4 > 102.4 
Pen (6) 40.56 ± 
5.67 
1 10.39 ± 
2.14 
26.24 ± 
2.37 
62.31 ± 
3.91 
> 102.4 > 102.4 
Carbamates Poc (7) 0.72 ± 
0.20 
37 0.42 ± 
0.90 
1.19 ± 
1.47 
1.65 ± 
2.27 
10.70 ± 
2.85 
51.00 ± 
8.62 
All (8) 1.39 ± 
0.21 
19 0.41 ± 
0.73 
1.83 ± 
1.19 
1.77 ± 
1.78 
6.91 ± 
3.56 
39.92 ± 
4.95 
Me (9) 04.89 ± 
0.25 
5 1.98 ± 
0.91 
3.31 ± 
1.24 
06.33 ± 
3.26 
18.31 ± 
2.67 
59.18 ± 
4.17 
Et (10) 1.78 ± 
0.16 
15 0.45 ± 
0.74 
2.02 ± 
2.72 
2.02 ± 
1.52 
8.91 ± 
2.38 
42.03 ± 
11.04 
iBu 
(11) 
3.33 ± 
0.12 
8 0.50 ± 
1.34 
11.42 ± 
4.73 
5.15 ± 
2.40 
24.45 ± 
2.95 
51.82 ± 
18.70 
Boc 
(12) 
3.48 ± 
0.56 
8 1.28 ± 
1.36 
10.44 ± 
4.76 
12.83 ± 
1.61 
36.48 ± 
3.81 
54.58 ± 
3.22 
Cbz 
(13) 
14.46 ± 
3.51 
2  EC50 < 5 
µM 
PBn 
(14) 
ND  EC50 < 20 
µM 
nBu 
(15) 
7.45 ± 
0.92 
4 EC50 < 50 
µM 
Mox 
(16) 
25.49 ± 
2.53 
1 
Tro 
(17) 
3.83 ± 
1.06 
7 
FEt 
(18) 
1.25 ± 
1.07 
21 
Table 1. EC50 values in µM for inhibition of α-2,3-linked sialic acid. Cell lines were cultured for three 
days with 0-204.8 µM amide or carbamate fluorinated sialic acids or DMSO vehicle control. The cells 
were stained with biotinylated MALII lectin that recognizes α-2,3-linked sialic acids and streptavidin-
PE. Lectin binding was determined by flow cytometry and is presented as mean percentage lectin 
binding ± SEM normalized to the control (n = 3). The relative inhibitory potency (rIP) was calculated for 
the B16-F10 cell line by dividing the EC50 of SiaFAc (1) by the EC50 of the compound of interest.  
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This is probably due to the chloride as good leaving group, which is expected to be 
prone to attack by cellular nucleophiles. The carbamates 7-12 (Figure 2) were better 
inhibitors than the corresponding acetamides at all concentrations tested. The 
inhibition even exceeded the Gc inhibitor 4 which was the best of the acetamide 
inhibitors. Carbamates 14 did however not and carbamate 13 did hardly show 
inhibitory properties. We assume that this is due to the bulkiness of the Cbz 13 and the 
benzyl-substituted triazole 14, indicating an upper limit for available space in the 
sialyltransferase pocket or that they are not tolerated by CMAS. Both compounds were 
not used for further studies. In direct comparison, the carbamate Poc inhibitor 7 had 
37 times the potency of former Ac inhibitor 1 for α-2,3-linkages in B16 cells, thereby 
reaching high nanomolar effective concentrations. This is remarkable as the 
structurally very similar inhibitor 6 was significantly inferior compared to the original 
Ac 1. Strikingly, the only difference between 6 and 7 is the substitution of the first CH2 
for 6 by an oxygen for 7 leading to an increase in potency by a factor of 56 due to the 
oxygen alone. Based on their structural similarity, this is strong evidence for a binding 
interaction of the additional oxygen, e.g. a hydrogen bridge which cannot be formed 
by CH2. As additional confirmation, the carbamate inhibitors 15-18 were synthesized 
and performed comparably to  7 in the inhibition assay (Tables 1,2 and Figure S4).  
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Group SiaFR B16-F10 rIP THP-1 HEK293 HeLa 9464D EL4 
Amides Ac (1) 32.80 ± 
3.08 
 10.87 ± 
2.47 
36.69 ± 
3.59 
34.50 ± 
2.18 
> 102.4 > 102.4 
TFA (2) 33.33 ± 
2.63 
1 7.19 ± 
3.60 
41.36 ± 
10.44 
33.38 ± 
4.38 
> 102.4 > 102.4 
ClAc 
(3) 
ND  ND ND ND ND ND 
Gc (4) 11.78 ± 
2.27 
3 5.94 ± 
2.18 
54.06 ± 
15.34 
12.50 ± 
2.52 
> 102.4 > 102.4 
Az (5) 32.82 ± 
3.55 
1 13.23 ± 
3.02 
47.21 ± 
2.89 
42.19 ± 
8.42 
> 102.4 > 102.4 
Pen (6) 52.49 ± 
4.31 
1 12.58 ± 
3.51 
44.71 ± 
4.33 
51.23 ± 
6.06 
> 102.4 > 102.4 
Carbamates Poc (7) 2.59 ± 
0.07 
13 0.44 ± 
1.59 
5.42 ± 
1.40 
1.37 ± 
0.81 
40.19 ± 
6.56 
51.65 ± 
2.62 
All (8) 2.87 ± 
0.80 
11 0.38 ± 
1.67 
1.68 ± 
3.20 
2.04 ± 
1.40 
9.64 ± 
3.93 
50.9 ± 
6.44 
Me (9) 7.54 ± 
1.34 
4 2.65 ± 
1.60 
4.77 ± 
2.80 
05.23 ± 
1.88 
29.60 ± 
4.67 
52.68 ± 
5.45 
Et (10) 3.87 ± 
1.14 
8 0.37 ± 
1.76 
1.57 ± 
4.23 
1.67 ± 
1.31 
28.13 ± 
5.51 
50.58 ± 
8.84 
iBu 
(11) 
15.07 ± 
3.70 
2 0.62 ± 
1.77 
9.61 ± 
4.83 
4.32 ± 
1.82 
36.15 ± 
6.40 
51.07 ± 
8.97 
Boc 
(12) 
8.21 ± 
0.67 
4 1.72 ± 
2.30 
28.03 ± 
2.57 
20.55 ± 
1.95 
> 102.4 50.31 ± 
3.99 
Cbz 
(13) 
ND   EC50 <5 
µM 
PBn 
(14) 
ND  EC50 <20 
µM 
nBu 
(15) 
7.91 ± 
1.95 
4 EC50 <50 
µM 
Mox 
(16) 
32.38 ± 
1.38 
1 
Tro 
(17) 
7.85 ± 
2.07 
4 
FEt 
(18) 
2.05 ± 
1.29 
16 
Table 2: EC50 values in µM for inhibition of α-2,6-linked sialic acid. B16-F10 cells were treated with 
0.1-205.8 µM, and THP-1, HEK293, HeLa, 9464D and EL4 cells with 0.1-102.4 µM amide or carbamate 
fluorinated sialic acids or DMSO vehicle control. After three days the cells were stained with 
biotinylated lectins that recognize α-2,6-linked (SNA-I) sialic acids, and streptavidin-PE. Binding of the 
lectins was determined by flow cytometry, as mean percentage lectin binding ± SEM normalized to 
the control (n = 3). The relative inhibitory potency (rIP) was calculated for the B16-F10 cell line by 
dividing the EC50 of SiaFAc (1) by the EC50 of the compound of interest. 
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None of the inhibitors discussed above (1-3, 5-12) did show any negative effect on 
metabolic-activity or viability of the cells (Figure S2). Also the specificity of the sialic 
acid inhibitors was tested by treatment of B16-F12 cells for three days with 102.4 µM 
fluorinated sialic acids or DMSO control and monitoring the total cell surface 
glycosylation by MALII (a), PNA (b), AAL (c), LCA (d), PHA-L (e), GSL-I (f), WGA (g), SJA 
(h) and PSA (i) (Figure S3). Fluorinated sialic acids were highly specific towards the sialic 
acid pathway with no unexpected changes for non-sialic acid binding events.  
 
In a therapeutic setting, the number of injections and the time span of the desialylation 
effect might have a profound effect on cancer clearance. We therefore investigated 
the time of sialylation recovery by incubating B16-F10 cells for three days with 51.2 µM 
acetamide or carbamate fluorine sialic acids, which is about twice of the IC50 
concentration of the previously published Ac inhibitor 1, or DMSO as control. The 
inhibitors where subsequently removed by exchanging the medium and carefully 
washing the cells before reseeding. A subpopulation of the cells were removed daily 
for six days and screened for sialic acids by MALII or SNA-I lectins followed by staining 
and flow cytometry. The recovery to a level of 50% sialylation compared with the 
control cells was slower for carbamate inhibitors (Figure 3b,d) and took approximately 
5 days whereas all acetamide inhibitors reached 50% sialylation after 1 or 2 days 
(Figure 3a,c). In a similar experiment, recovery was tested with lower inhibitor 
concentration in which again carbamate inhibitors appeared to be superior compared 
to acetamide inhibitors (Figure S5). 
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Figure 3. Recovery of sialylation after acetamide and carbamate fluorine sialic acid treatment. a-d) 
B16-F10 cells were incubated for three days with 51.2 µM acetamide or carbamate fluorinated sialic 
acids or DMSO control. Fluorinated sialic acids were removed from the culture and the cells were 
reseeded. During a period of six days, sialylation was assessed daily with flow cytometry by MALII or 
SNA-I lectins. Graphs show recovery of α-2,3-sialylation (a, b) or α-2,6-sialylation (c, d) in time 
presented as mean percentage lectin binding ± SEM normalized to control (n = 3). 
 
We next assessed the new inhibitors in highly resistant cell-lines that were not affected 
by the previously published Ac inhibitor 1. Neuroblastoma cell line 9464D and murine 
T-cell lymphoma cell line EL4 were treated for three days with DMSO control or 102.4 
µM acetamide and carbamate fluorinated sialic acids and again bound with MALII or 
SNA-I lectin and subsequently labeled with streptavidin-PE before analyzing by flow 
cytometry. Even with the unusually high concentration of roughly four times its IC50 
concentration for THP-1 cells, the standard Ac inhibitor 1 failed to show any significant 
reduction of sialylation (Figure 4).  
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Figure 4. Carbamate fluorinated sialic acids inhibit sialylation in 9464D and EL4 cells. a-d) 9464D cells 
or EL4 cells were treated for three days with DMSO control or 102.4 µM acetamide and carbamate 
fluorine sialic acids. Cells were stained with MALII or SNA-I lectin and streptavidin-PE and lectin binding 
was determined by flow cytometry. Bar diagrams show mean binding percentages ± SEM of MALII and 
SNA-I to 9464D cells (a, b) and EL4 cells (c, d) of three independent experiments. 
 
All acetamide inhibitors showed either little or none inhibition in 9464D (Figure 4 a,b) 
or EL4 (Figure 4 c,d) cells. The carbamate inhibitors however did show a significant 
effect in both cell-types. Interestingly, the α-2,3-linked sialic acids in EL4 cells were 
reduced to less than 20% for most carbamates (Figure 4c) whereas the α-2,6-linked 
sialic acids were only reduced to approximately 40%  (Figure 4d) which might indicate 
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a higher affinity towards either α-2,3-sialyl transferases of EL4 cells. This difference is 
however not visible in 9464D cells (Figure 4 a,b).  
 
In conclusion, we have developed a selection of non-toxic, fluorinated sialic acid based 
carbamate inhibitors SiaF-carbamate which show EC50 values in the low micromolar 
range in multiple cell-lines. Application to cancer-cell types 9464D and EL4 which were 
found to be resistant against SiaFAc inhibition, showed that both cell lines were 
affected by the new inhibitors while the previously published ones failed to show any 
effect. Furthermore, we discovered a high linkage dependence indicating an 
interesting selectivity of STs towards carbamates over acetamides. This preference 
should be considered by designing new sialylation inhibitors as well as metabolic 
labeling reagents, which uses the same enzymatic machinery.  
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Supporting information 
 
Figure S1. Sialic acid inhibition with C-4N3SiaF 25 (a-c) and C-9N3SiaF 23 (d-f) compared to SiaF. 
Measured by MALII, SNA-I (sialylation decrease) and PNA (exposed galactose increase).  
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Figure S2. Effect of fluorinated sialic acids on cell metabolic activity/viability. a-b) B16-F10 cells were 
cultured for three days with increasing concentrations of fluorine sialic acids or DMSO and subjected 
to an MTT assay. Representative graphs show absorbance at 595 nm for cells treated with acetamide 
(a) or carbamate (b) fluorinated sialic acids. 
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Figure S3. Effect of fluorinated sialic acids on total cell surface glycosylation. a-i) B16-F10 cells treated 
for three days with 102.4 µM fluorine sialic acids or DMSO control were stained with a panel of 
biotinylated lectins and streptavidin-PE. Lectin binding was determined in two independent 
experiments by flow cytometry and is presented as mean fluorescence intensity (MFI) ± SEM. Bar 
diagrams show binding of MALII (a), PNA (b), AAL (c), LCA (d), PHA-L (e), GSL-I (f), WGA (g), SJA (h) and 
PSA (i). 
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Figure S4 Effect of additional fluorinated sialic acids on B16-F10 sialylation. a) Structures of acetamide 
and carbamate modifications made to the SiaF backbone. b, c) B16-F10 cells were cultured for three 
days in the presence of 0-102.4 µM fluorinated sialic acids and stained with MALII and SNA-I. Graphs 
show mean percentage binding ± SEM normalized to control cells of MALII (b) and SNA-I (c). 
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Figure S5 Recovery of sialylation after treatment with 25.6 µM fluorinated sialic acids. a-d) B16-F10 
cells were treated with 25.6 µM fluorinated sialic acids, thoroughly washed and recovery of sialylation 
was followed in time by flow cytometry using MALII and SNA-I staining. Data of three independent 
experiments are presented as mean percentage lectin binding ± SEM normalized to control and show 
MALII and SNA-I binding after treatment with acetamide (a, c) and carbamate (b, d) fluorine sialic acids. 
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Supplementary information 
General synthetic procedures1H and 13C NMR spectra were recorded on a Varian Iinova 400 MHz or 
Bruker Avance III 500 MHz spectrometer. Chemical shifts are reported in parts per million (ppm) 
relative to TMS as the internal standard. NMR data is presented as follows: Chemical shift, multiplicity 
(s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet of doublet, dt = doublet of triplet, 
m = multiplet and/or multiple resonances), integration, coupling constant in Hertz (Hz). All NMR signals 
were assigned on the basis of 1H, 13C, 19F NMR, COSY and HSQC experiments. Mass spectra were 
recorded on a JEOL JMS-T100CS AccuTOF mass spectrometer. Automatic column chromatography was 
performed on Biotage Isolera Spektra One, using SNAP cartridges 10-50g filled with normal silica 
(Biotage, 30-100 μm, 60 Å) or water resistant iatro beads. Microwave reactions were performed on a 
Biotage Initiator 4.1.3. TLC analysis was conducted on TLC Silica gel, 60, F254, Merck, with detection 
by UV absorption (254 nm) where applicable, and by spraying with 20% sulfuric acid in methanol 
followed by charring at ~150 °C or by spraying with a solution of (NH-4)6Mo7O24.H2O (25 gl-1) in 10% 
sulfuric acid in methanol followed by charring at ~300 °C. DCM, ACN and Tol were freshly distilled. All 
reactions were carried out under an argon atmosphere. 
 
Commonly used abbreviations 
Ac2O  Acetic anhydride  
Acet  Acetone 
ACN   Acetonitrile 
AcOH  Acetic acid 
Alloc  Allyloxycarbonyl 
Az  Azidoacetic acid  
BF3•Et2O  Boron trifluoride etherate 
Boc2O  Di-tert-butyl dicarbonate 
Br2  Bromine 
Cbz  Carboxybenzyl 
CD3OD  Deuterated methanol 
CDCl3  Deuterated chloroform 
D2O  Deuterium oxide 
DCM   Dichlormethane 
DMAP  Dimethylaminopyridine 
DMF  N,N-Dimethylformamide 
EtOAc  Ethyl acetate 
Hept  Heptane 
iBu  Iso-butyl 
CH3,   Methyl 
n-Bu  Butyl 
Poc  Propargylcarboxycarbonyl 
Pyr  Pyridine 
ROSu  Hydroxysuccinimide ester 
SAda  Adamantyl-thiol 
STol  4-methylthiophenol 
TBTA  Tris(benzyltriazolyl 
methyl)amine 
tBu  Tert-butyl 
TEA  Triethylamine 
TFA  Trifluoroacetic acid 
TFAA   Trifluoroacetic acid anhydride 
TfOH  Trifluormethanesulfonic acid 
TMS  Trimethylsilyl 
TMSOTf Trimethylsilyl 
trifluormethanesulfonate 
Tol  Toluene 
Troc  2,2,2 trichloroethoxycarbonyl
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 Methyl 5-(acetamido)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-fluoro-D-glycero-
β-galacto-non-2-ulopyranosonate (1). Synthesis was performed as described previously the data is 
identical to the data previously reported.10 TLC: (Acet:DCM, 30:70 v/v) Rf = 0.40. HRMS (m/z): [M+Na]+ 
calcd for C-20H28FNO13, 532.1443; found, 532.1442. The crude fluorinated alcohol was dissolved in Pyr 
(14.5 mL) and Ac2O (7.3 mL), stirred for 16 hours at r.t. and was evaporated in vacuo. The resulting 
solid dissolved in EtOAc and sat. aq. NaHCO3. The organic phase was separated and the solvent 
evaporated in vacuo and purified on silica flash-column chromatography (0  30% ACE in DCM) 
affording 1 (1.46 g, 2.54 mmol, 80% yield two steps) as a slightly yellow foam. TLC: (Acet:DCM, 30:70 
v/v) Rf = 0.55. 1H-NMR (500 MHz, CD3OD, major anomer) δ 5.58 (d, J = 8.9 Hz, 1H, NH), 5.46 (dd, J = 
27.9, 10.7 Hz, 1H, H-4), 5.29 (dd, J = 5.0, 1.8 Hz, 1H, H-7), 5.05 (ddd, J = 6.7, 5.2, 2.5 Hz, 1H, H-8), 4.87 
(dd, J = 49.1, 2.5 Hz, 1H, H-3), 4.51 (dd, J = 12.5, 2.5 Hz, 1H, H-9a), 4.21 – 4.10 (m, 3H, H-9b; H-5; H-6), 
3.77 (s, 3H, OCH3), 2.12 – 2.09 (m, 6H, 2x CH3,OAc), 2.04 (s, 3H, CH3,OAc), 1.98 (s, 3H, CH3,OAc), 1.97 
(s, 3H, CH3,OAc), 1.85 (s, 3H, CH3,NHAc).; 13C-NMR (126 MHz, CD3OD) δ 170.58 (CO, Ac), 170.56 (CO, 
Ac), 170.50 (CO, Ac), 170.34 (CO, Ac), 167.11 (C-1), 95.16 (d, J = 28.8 Hz, C-2), 86.95 (d, J = 185.3 Hz, C-
3), 71.91 (C-6), 71.37 (C-8), 68.40 (d, J = 17.2 Hz, C-4), 67.93 (C-7), 62.09 (C-9), 53.49 (OCH3), 45.53 (C-
5), 29.27 (CH3,Ac), 20.88 (CH3,Ac), 20.79 (CH3,Ac) , 20.74 (CH3,Ac), 20.65 (CH3,Ac), 20.51 (CH3,Ac); HRMS 
(m/z): [M+Na]+ calcd for C22H30FNO14, 574.1548; found, 574.1548. 
 
Methyl 5-(trifluoroacetamido)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-fluoro-D-
glycero-β-galacto-non-2-ulopyranosonate (2). TFA-protected Sialic acid 2 was a common side product 
after TFA deprotection. Further investigation discovered that TFA, if not removed carefully, forms a 
mixed anhydride with chloroformates resulting in a sometimes quantitative coupling of TFA to the 
relatively unreactive amine. Later deprotection reactions were therefore done with TfOH which avoided 
this problem. Boc inhibitor 12 (50 mg; 82 µmol) was dissolved in a 1:2 mixture of TFA and DCM (1.6 
mL; 0.05 M). The mixture was stirred for 2 h at r.t. (TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.09). The mixture 
was then concentrated in vacuo. The residue was dissolved in DCM (0.83 mL; 0.1 M) and additional 
TFA (188 µl,  2.5 mmol, 30 eq) and TEA (690 µl; 4.95 mmol; 60 eq.) were added.  Isobutyl chloroformate 
(also possible with other chloroformates) (76 µl; 589 µmol; 20 eq.) was added and the reaction was 
stirred for 16 h. The mixture was diluted with DCM and washed successively with 0.1M HCl and sat. 
NaHCO3. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Silica gel flash 
column chromatography (0 → 50% EtOAc in Hept) afforded 2 (44 mg; 74 µmol; 90%) as a white solid. 
TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.50 1H NMR (500 MHz, CDCl3) δ 7.02 (d, J = 9.1 Hz, 1H, NH), 5.61 
(ddd, J = 27.4, 11.0, 2.5 Hz, 1H, H-4), 5.29 (dd, J = 5.3, 2.0 Hz, 1H, H-7), 5.13 (ddd, J = 6.1, 5.2, 2.4 Hz, 
1H, H-8), 4.97 (dd, J = 48.9, 2.5 Hz, 1H, H-3), 4.57 (dd, J = 12.5, 2.5 Hz, 1H, H-9a), 4.38 (ddd, J = 10.7, 2.0, 
0.8 Hz, 1H, H-6), 4.26 – 4.17 (m, 2H, H-5; H-9b), 3.85 (s, 3H, OCH3), 2.19 (s, 3H, CH3,OAc), 2.18 (s, 3H, 
CH3,OAc), 2.11 (s, 3H, CH3,OAc), 2.05 (s, 3H, CH3,OAc), 2.04 (s, 3H, CH3,OAc). 13C NMR (126 MHz, CDCl3) 
δ 171.70 (CO, Ac), 170.78 (CO, Ac), 170.76 (CO, Ac), 170.51 (CO, Ac), 167.22 (C-1), 164.94 (CO, Ac), 
157.68 (q, J = 37.8 Hz, CO, TFA), 115.50 (q, J = 288.4 Hz, CF3), 95.16 (d, J = 29.0 Hz, C-2), 86.90 (d, J = 
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186.1 Hz, C-3), 71.27 (C-8), 71.00 (C-6), 68.00 (d, J = 16.9 Hz, C-4), 67.91 (C-7), 62.06 (C-9), 53.75 (OCH3), 
46.43 (d, J = 2.4 Hz, C-5), 20.99 (CH3,OAc), 20.82 (CH3,OAc), 20.80 (CH3,OAc), 20.60 (CH3,OAc), 20.56 
(CH3,OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C22H27F4NNaO14, 628.12654; found, 628.12591.
  
 
 Methyl 5-(chloroacetamido)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-fluoro-
D-glycero-β-galacto-non-2-ulopyranosonate (3). Boc inhibitor 12 (200 mg; 329 µmol) was dissolved in 
a 1:1:2 mixture of DCM, H2O and TFA (3.3 mL; 0.1 M). The mixture was stirred for 2 h at r.t. (TLC: 
(EtOAc:Hept, 60:40 v/v) Rf = 0.09). The mixture was then diluted with H2O and concentrated in vacuo. 
The residue was dissolved in DCM (3.3 mL; 0.1 M) and successively ClAcCl (39 µL; 492 µmol; 1.5 eq.) 
and TEA (273 µL; 1.97 mmol; 6 eq.) were added. After stirring at r.t. 16 h the mixture was concentrated 
in vacuo. The residue was dissolved in EtOAc and washed with sat. aq. NaHCO3. The organic layer was 
dried over MgSO4, filtered and concentrated in vacuo. Silica gel flash column chromatography (0 → 
50% EtOAc in Hept) afforded 3 (116 mg; 198 µmol; 60 %) as a white solid. TLC: (EtOAc:Hept, 80:20 v/v) 
Rf = 0.48) 1H NMR (500 MHz, CDCl3) δ 6.63 (d, J = 8.6 Hz, 1H, NH), 5.58 (ddd, J = 27.5, 10.6, 2.5 Hz, 1H, 
H-4), 5.34 (dd, J = 5.2, 1.8 Hz, 1H, H-7), 5.12 (ddd, J = 6.4, 5.1, 2.4 Hz, 1H, H-8), 4.95 (dd, J = 49.0, 2.5 
Hz, 1H, H-3), 4.59 (dd, J = 12.5, 2.5 Hz, 1H, H-9a), 4.33 – 4.23 (m, 2H, H-6; H-5), 4.21 (dd, J = 12.5, 6.5 
Hz, 1H, H-9b), 4.02 – 3.93 (m, 2H, CH2, ClAc), 3.85 (s, 3H, OCH3), 2.19 (s, 3H, CH3,OAc), 2.16 (s, 3H, 
CH3,OAc), 2.12 (s, 3H, CH3,OAc), 2.06 (s, 3H, CH3,OAc), 2.04 (s, 3H, CH3,OAc). 13C NMR (126 MHz, CDCl3) 
δ 170.77 (CO, Ac), 170.66 (CO, Ac), 170.61 (CO, Ac), 170.47 (CO, Ac), 167.23 (C-1), 166.73 (CO, Ac), 
165.08 (CO, ClAc), 95.28 (d, J = 29.0 Hz, C-2). 87.01 (d, J = 185.7 Hz, C-3), 71.79 (C-6), 71.50 (C-8), 68.14 
(d, J = 17.2 Hz, C-4), 67.88 (C-7), 62.15 (C-9), 53.68 (OCH3), 45.91 (d, J = 2.6 Hz, C-5), 42.56 (CH2, ClAc), 
21.03 (CH3,Ac), 20.91 (CH3,Ac), 20.86 (CH3,Ac), 20.76 (CH3,Ac), 20.66 (CH3,Ac). HR-ESI-TOF/MS (m/z): 
[M+Na]+ calcd. for C22H29ClFNNaO14, 608.11583; found, 608.11438.  
 
 Methyl 5-(acetoxyamido)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-fluoro-D-
glycero-β-galacto-non-2-ulopyranosonate (4). Boc inhibitor 12 (40 mg; 66 µmol) was dissolved in a 
1:1:2 mixture of DCM, H2O and TFA (0.7 mL; 0.1 M). The mixture was stirred for 2 h at r.t. (TLC: 
(EtOAc:Hept, 60:40 v/v) Rf = 0.09). The mixture was then diluted with H2O and concentrated in vacuo. 
The residue was dissolved in DCM (0.7 mL; 0.1 M) and successively acetoxyacetyl chloride (11 µl; 97 
µmol; 1.5 eq.) and TEA (45 µl; 324 µmol; 5 eq.) were added. After stirring at r.t. 16 h the mixture was 
diluted with DCM and washed successively with 0.1M HCl and sat. NaHCO3. The organic layer was dried 
over MgSO4, filtered and concentrated in vacuo. Silica gel flash column chromatography (0% → 60% 
EtOAc in Hept) afforded (17 mg; 28 µmol; 43%) as a white solid. TLC: (EtOAc:Hept, 80:20 v/v) Rf = 0.19. 
1H NMR (500 MHz, CDCl3) δ 6.18 (d, J = 9.0 Hz, 1H, NH), 5.64 (ddd, J = 27.9, 11.0, 2.5 Hz, 1H, H-4), 5.28 
(dd, J = 5.3, 2.0 Hz, 1H, H-7), 5.13 (ddd, J = 6.3, 5.2, 2.4 Hz, 1H, H-8), 4.95 (dd, J = 49.1, 2.5 Hz, 1H, H-3), 
4.61 (d, J = 15.3 Hz, 1H, CHH Glc ), 4.56 (dd, J = 12.5, 2.4 Hz, 1H, H-9a), 4.32 (d, J = 15.3 Hz, 1H, CHH Gc), 
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4.30 – 4.26 (m, 1H, H-6), 4.22 – 4.15 (m, 2H, H-9b; H-5), 3.84 (s, 3H, OCH3), 2.20 (s, 3H, CH3,OAc), 2.19 
(s, 3H, CH3,OAc), 2.17 (s, 3H, CH3,OAc), 2.11 (s, 3H, CH3,OAc), 2.05 (s, 3H, CH3,OAc), 2.05 (s, 3H, 
CH3,OAc). 13C NMR (126 MHz, CDCl3) δ 171.05 (CO, Ac), 170.88 (CO, Ac), 170.83 (CO, Ac), 170.53 (CO, 
Ac), 169.98 (CO, Ac), 168.03 (CO, Ac), 167.35 (CO, C-1), 165.23 (CO, NHGc), 95.38 (d, J = 29.0 Hz, C-2), 
87.28 (d, J = 185.5 Hz, C-3), 71.91 (C-6), 71.41 (C-8), 68.27 (C-7), 67.98 (d, J = 17.1 Hz, C-4), 63.01 (CH2, 
Gc), 62.20 (C-9), 53.76 (OCH3), 45.88 (d, J = 2.6 Hz, C-5), 21.11 (CH3,OAc), 21.07 (CH3,OAc), 20.95 
(CH3,OAc), 20.85 (2x CH3,OAc), 20.80 (CH3,OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for 
C24H32FNNaO16, 632.16028; found, 632.15804. 
 
 Methyl 5-(azidoacetamido)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-fluoro-D-
glycero-β-galacto-non-2-ulopyranosonate (5). Boc inhibitor 12 (20 mg; 33 µmol) was dissolved in a 
1:1:2 mixture of respectively DCM, H2O and TFA (0.65 mL; 0.05 M). The mixture was stirred for 2 h at 
r.t. (TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.09). The mixture was then diluted with water and concentrated 
in vacuo. The residue was dissolved in DCM (0.33 mL; 0.1 M) and successively AzOSu (42 mg; 167 µmol; 
5 eq.), Pyr (27 µl; 334 µmol; 10 eq.) and DMAP (2 mg, 17 µmol; 0.5 eq.) were added. After stirring at 
r.t. for 23 h the mixture was diluted with DCM and washed successively with 0.1 M HCl and sat. 
NaHCO3. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Silica gel flash 
column chromatography (0 → 50% EtOAc in Hept) afforded 5 (3.1 mg; 5.2 µmol; 16%). TLC: 
(EtOAc:Hept, 60:40 v/v) Rf = 0.20. 1H NMR (500 MHz, CDCl3) δ 6.31 (d, J = 8.6 Hz, 1H, NH), 5.54 (ddd, J 
= 27.5, 10.6, 2.5 Hz, 1H, H-4), 5.34 (dd, J = 5.3, 1.8 Hz, 1H, H-7), 5.13 (td, J = 5.7, 2.4 Hz, 1H, H-8), 4.95 
(dd, J = 49.0, 2.5 Hz, 1H, H-3), 4.55 (dd, J = 12.5, 2.4 Hz, 1H, H-9a), 4.30 – 4.22 (m, 2H, H-5; H-6), 4.19 
(dd, J = 12.6, 6.3 Hz, 1H, H-9b), 3.94 – 3.83 (m, 5H, CH2 NAz; OCH3), 2.20 (s, 3H, CH3,OAc), 2.16 (s, 3H, 
CH3,OAc), 2.11 (s, 3H, CH3,OAc), 2.05 (s, 3H, CH3,OAc), 2.04 (s, 3H, CH3,OAc). 13C NMR (126 MHz, CDCl3) 
δ 170.94 (CO, Ac), 170.84 (CO, Ac), 170.66 (CO, Ac), 170.47 (CO, Ac), 167.52 (CO, Ac), 167.31 (C-1), 
165.20 (CO, Az), 95.64 (d, J = 185.7 Hz, C-2), 87.16 (d, J = 185.7 Hz, C-3), 71.95 (C-6), 71.43 (C-8), 68.49 
(d, J = 17.2 Hz, C-4), 68.02 (C-7), 62.16 (C-9), 53.82 (OCH3), 52.89 (CH2, Az), 49.50 (C-5), 21.13 (CH3,OAc), 
21.06 (CH3,OAc), 21.00 (CH3,OAc), 20.91 (CH3,OAc), 20.81 (CH3,OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ 
calcd. for C22H29FN4NaO14, 615.15620; found, 615.15758.  
 
 Methyl 5-(4-pentynacetamido)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-
fluoro-D-glycero-β-galacto-non-2-ulopyranosonate (6). Boc inhibitor 12 (50 mg; 82 µmol) was 
dissolved in a 1:1:2 mixture of TFA, H2O and DCM (1.6 mL; 0.05 M) respectively. The mixture was stirred 
for 2 h at r.t. (TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.09). The mixture was then diluted with water and 
concentrated in vacuo. The residue was dissolved in DCM (0.83 mL; 0.1 M) and successively 4-
Pentynoic acid-OSu (226 mg; 1.158 mmol; 14 eq.) and TEA (69 µl; 495 µmol; 6 eq.) were added. After 
stirring at r.t. 16 h the mixture was diluted with DCM and washed successively with 0.1M HCl and sat. 
aq. NaHCO3. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Silica gel flash 
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column chromatography (0 → 55% EtOAc in Hept) afforded 6 (3.3 mg; 5.60 µmol; 7%) as a white solid. 
TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.09. 1H NMR (500 MHz, CDCl3) δ 5.60 (ddd, J = 27.9, 11.0, 2.6 Hz, 1H, 
H-4), 5.54 (d, J = 9.0 Hz, 1H, NH), 5.37 (dd, J = 5.5, 2.0 Hz, 1H, H-7), 5.15 (ddd, J = 6.3, 5.4, 2.5 Hz, 1H, 
H-8), 4.95 (dd, J = 49.1, 2.5 Hz, 1H, H-3), 4.53 (dd, J = 12.5, 2.4 Hz, 1H, H-9a), 4.30 – 4.26 (m, 1H, H-6), 
4.21 (dd, J = 12.5, 6.3 Hz, 1H, H-9b), 4.13 (q, J = 10.3 Hz, 1H, H-5), 3.84 (s, 3H, OCH3), 2.56 – 2.44 (m, 2H, 
CH2C≡CH), 2.40 – 2.27 (m, 2H, CH2-CONH), 2.19 (s, 3H, CH3,OAc), 2.16 (s, 3H, CH3,OAc), 2.11 (s, 3H, 
CH3,OAc), 2.04 (s, 3H, CH3,OAc), 2.04 (s, 3H, CH3,OAc), 2.02 (t, J = 2.6 Hz, 1H, HC≡C). 13C NMR (126 MHz, 
CDCl3) δ 171.38 (CO, Ac), 170.85 (CO, Ac), 170.69 (CO, AC), 170.53 (CO, Ac), 170.31 (CO, Ac), 167.28 (C-
1), 165.21 (CONH), 95.29 (d, J = 29.0 Hz, C-2), 87.12 (d, J = 185.1 Hz, C-3), 82.88 (HC≡C), 71.75 (C-6), 
71.21 (C-8), 69.79 (HC≡C), 68.33 – 68.14 (m, C-4; C-7), 62.22 (C-9), 53.65 (OCH3), 46.01 (C-5), 35.67 
(CH2CONH), 21.02 (CH3,OAc), 20.98 (CH3,OAc), 20.93 (CH3,OAc), 20.92 (CH3,OAc), 20.74 (CH3,OAc), 
14.80 (CH2C≡CH). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C25H32FNNaO14, 612.17045; found, 
612.16924.  
 
 Methyl 5-(propargylcarbamado)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-
fluoro-D-glycero-β-galacto-non-2-ulopyranosonate (7). Boc inhibitor 12 (50 mg; 82 µmol) was 
dissolved in a 1:1:2 mixture of respectively DCM, H2O and TFA (1.6 mL; 0.05 M). The mixture was stirred 
for 2 h at r.t. (TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.09). The mixture was then diluted with H2O and 
concentrated in vacuo. The residue was dissolved in DCM (0.83 mL; 0.1 M) and successively PocOSu 
(98 mg; 497 µmol; 6 eq.) and TEA (35 µl; 248 µmol; 3 eq.) were added. After stirring at r.t. for 15 h the 
mixture was diluted with DCM and washed successively with 0.1 M HCl and sat. aq. NaHCO3. The 
organic layer was dried over MgSO4, filtered and concentrated in vacuo. Silica gel flash column 
chromatography (0 → 60% EtOAc in Hept) afforded 7 (20 mg; 83 µmol; 40%) as a white solid. TLC: 
(EtOAc:Hept, 60:40 v/v) Rf = 0.36. 1H NMR (500 MHz, CDCl3) δ 5.53 (dd, J = 26.9, 10.8 Hz, 1H, H-4), 5.39 
– 5.36 (m, 1H, H-7), 5.18 (td, J = 5.9, 2.5 Hz, 1H, H-8), 4.95 (dd, J = 49.1, 2.5 Hz, 1H, H-3), 4.87 (d, J = 9.5 
Hz, 1H, NH), 4.73 (ddd, J = 15.5, 5.4, 2.5 Hz, 1H, CHH, Poc), 4.57 – 4.49 (m, 2H, CHH, Poc; H-9a), 4.23 – 
4.17 (m, 2H, H-9b; H-6), 3.95 – 3.86 (m, 1H, H-5), 3.84 (s, 3H, OCH3), 2.47 (t, J = 2.4 Hz, 1H, C≡CH, Poc), 
2.18 (s, 3H, CH3,OAc), 2.17 (s, 3H, CH3,OAc), 2.13 (s, 3H, CH3,OAc), 2.05 (s, 3H, CH3,OAc), 2.04 (s, 3H, 
CH3,OAc). 13C NMR (126 MHz, CDCl3) δ 170.75 (CO, Ac), 170.69 (CO, Ac), 170.46 (CO, Ac), 170.24 (CO, 
Ac), 167.27 (C-1), 165.17 (CO, Ac), 154.75 (CO, Poc), 95.20 (d, J = 28.8 Hz, C-2), 87.18 (d, J = 185.1 Hz, 
C-3), 77.95 (C≡CH, Poc), 75.00 (C≡CH, Poc), 71.89 (C-6), 71.00 (C-8), 68.32 – 67.98 (m, C-4; C-7), 62.20 
(C-9), 53.66 (OCH3), 53.16 (CH2, Poc), 47.37 (C-5), 21.00 (CH3,OAc), 20.94 (CH3,OAc), 20.92 (CH3,OAc), 
20.82 (CH3,OAc), 20.72 (CH3,OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C24H30FNNaO15, 
614.14972; found, 614.15007. 
 
 5-(alloxycarbamado)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-fluoro-D-
glycero-β-galacto-non-2-ulopyranosonate (8). Boc inhibitor 12 (50 mg; 82 µmol) was dissolved in a 
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1:1:2 mixture of respectively TFA, H2O and DCM (1.6 mL; 0.05 M). The mixture was stirred for 2 h at 
r.t. (TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.09). The mixture was then diluted with water and concentrated 
in vacuo. The residue was dissolved in DCM (0.83 mL; 0.1 M) and Alloc-Cl (11 µl; 99 µmol; 1.2 eq.) and 
TEA (69 µl; 495 µmol; 6 eq.) were added. After stirring at r.t. for 1 hr additional Alloc-Cl (18 µl; 165 
µmol; 2 eq.) was added. The reaction was stirred for 15 h after which the reaction was still not finished, 
so additional Alloc-Cl (90 µl; 844 µmol; 10.2 eq.) and TEA (35 µl; 252 µmol; 3 eq.) were added. After 
stirring at r.t. for 5.5 h the mixture was diluted with DCM and washed successively with 0.1M HCl and 
sat. NaHCO3. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Silica gel 
flash column chromatography (0 → 50% EtOAc in Hept) afforded 8 (7.7 mg; 13 µmol; 16%) as a white 
solid. TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.32. 1H NMR (500 MHz, CDCl3) δ 5.89 (tdd, J = 16.1, 8.3, 3.3 Hz, 
1H, CHH=CH, Alloc), 5.54 (dd, J = 27.7, 10.9 Hz, 1H, H-4), 5.39 (dd, J = 5.5, 2.0 Hz, 1H, H-7), 5.28 (dd, J = 
16.1, 2.4 Hz, 1H, CHH=CH, Alloc), 5.21 (d, J = 11.2 Hz, 1H, CHH=CH, Alloc), 5.18 (td, J = 6.0, 2.5 Hz, 1H, 
H-8), 4.95 (dd, J = 49.1, 2.5 Hz, 1H, H-3), 4.79 (d, J = 9.3 Hz, 1H, NH), 4.60 – 4.45 (m, 3H, H-9a; OCH2 
Alloc), 4.24 – 4.17 (m, 2H, H-6; H-9b), 3.94 – 3.87 (m, 1H, H-5), 3.84 (s, 3H, OCH3), 2.18 (s, 3H, CH3,OAc), 
2.17 (s, 3H, CH3,OAc), 2.11 (s, 3H, CH3,OAc), 2.05 (s, 3H, CH3,OAc), 2.04 (s, 3H, CH3,OAc). 13C NMR (126 
MHz, CDCl3) δ 170.75 (CO, Ac), 170.66 (CO, Ac), 170.45 (CO, Ac), 170.27 (CO, Ac), 167.30 (C-1), 165.22 
(CO, Ac), 155.41 (CO, Alloc), 132.65 (CH2=CH, Alloc), 117.84 (CH2=CH, Alloc), 95.21 (d, J = 28.8 Hz, C-2), 
87.20 (d, J = 184.9 Hz, C-3), 71.98 (C-6), 71.07 (C-8), 68.17 – 67.92 (C-4; C-7), 66.09 (OCH2, Alloc), 62.24 
(C-9), 53.64 (OCH3), 47.22 (C-5), 20.99 (CH3,OAc), 20.93 (CH3,OAc), 20.91 (CH3,OAc), 20.80 (CH3,OAc), 
20.71 (CH3,OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C24H32FNNaO15, 616.16537; found, 
616.16544. 
 
 Methyl 5-(methylcarbamado)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-fluoro-D-
glycero-β-galacto-non-2-ulopyranosonate (9). Boc inhibitor 12 (50 mg; 82 µmol) was dissolved in a 
1:1:3 mixture of respectively TFA, water and DCM (1.6 mL; 0.05 M). The mixture was stirred for 2 h at 
r.t. (TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.09). The mixture was then diluted with H2O and concentrated 
in vacuo. The residue was dissolved in DCM (0.8 mL; 0.1 M) and Me-chloroformate (183 µl; 1.649 mmol; 
20 eq.) and TEA (229 µl; 1.649 mmol; 20 eq.) were added. The reaction was stirred at r.t. 16 h after 
which the mixture was diluted with DCM and washed successively with 0.1M HCl and sat. NaHCO3. The 
organic layer was dried over MgSO4, filtered and concentrated in vacuo. Silica gel flash column 
chromatography (0 → 50% EtOAc in Hept) afforded 9 (16 mg; 27 µmol; 33%). TLC: (EtOAc:Hept:MeOH, 
45:45:10 v/v) Rf = 0.27. 1H NMR (400 MHz, CDCl3) δ 5.59 – 5.47 (m, 1H, H-4), 5.41 – 5.38 (m, 1H, H-7), 
5.17 (ddd, J = 6.3, 5.3, 2.5 Hz, 1H, H-8), 4.95 (dd, J = 49.1, 2.6 Hz, 1H, H-3), 4.77 (d, J = 9.2 Hz, 1H, NH), 
4.54 (dd, J = 12.5, 2.6 Hz, 1H, H-9a), 4.25 – 4.17 (m, 2H, H-9b; H-6), 3.88 – 3.85 (m, 1H, H-5), 3.84 (s, 3H, 
CH3O-C-1), 3.64 (s, 3H, CH3O-CONH), 2.18 (s, 3H, CH3,OAc), 2.17 (s, 3H, CH3,OAc), 2.12 (s, 3H, CH3,OAc), 
2.05 (s, 3H, CH3,OAc), 2.04 (s, 3H, CH3,OAc). 13C NMR (101 MHz, CDCl3) δ 170.73 (2x CO, Ac), 170.45 
(CO, Ac), 170.30 (CO, Ac), 167.30 (C-1), 165.21 (CO, Ac), 156.17 (NHCO), 95.20 (d, J = 28.7 Hz, C-2), 
87.18 (d, J = 184.8 Hz, C-3), 72.04 (C-6), 71.20 (C-8), 68.42 – 68.16 (m, C-4; C-7), 62.26 (C-9), 53.62 
(CH3O-C-1), 52.76 (CH3O-CONH), 47.26 (C-5), 20.99 (CH3,OAc), 20.91 (CH3,OAc), 20.90 (CH3,OAc), 20.78 
(CH3,OAc), 20.68 (CH3,OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C22H30FNNaO15, 590.14972; 
found, 590.14874.  
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 Methyl 5-(ethylcarbamado)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-fluoro-D-
glycero-β-galacto-non-2-ulopyranosonate (10). Boc inhibitor 12 (50 mg; 82 µmol) was dissolved in a 
1:1:3 mixture of respectively TFA, water and DCM (1.6 mL; 0.05 M). The mixture was stirred for 2 h at 
r.t. (TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.09). The mixture was then diluted with water and concentrated 
in vacuo. The residue was dissolved in DCM (0.8 mL; 0.1 M) and Et-chloroformate (197 µl; 1.649 mmol; 
20 eq.) and TEA (229 µl; 1.649 mmol; 20 eq.) were added. The reaction was stirred at r.t. 16 h after 
which the mixture was diluted with DCM and washed successively with 0.1M HCl and sat. NaHCO3. The 
organic layer was dried over MgSO4, filtered and concentrated in vacuo. Silica gel flash column 
chromatography (0 → 50% EtOAc in Hept) afforded 10 (8 mg; 13 µmol; 16%). TLC: (EtOAc:Hept:MeOH, 
45:45:10 v/v) Rf = 0.28. 1H NMR (400 MHz, CDCl3) δ 5.58 – 5.46 (m, 1H, H-4), 5.40 (dt, J = 5.0, 2.4 Hz, 
1H, H-7), 5.18 (td, J = 5.8, 2.7 Hz, 1H, H-8), 4.95 (dd, J = 49.2, 2.5 Hz, 1H, H-3), 4.65 (d, J = 9.3 Hz, 1H, 
NH), 4.57 – 4.51 (m, 1H, H-9a), 4.24 – 4.16 (m, 2H, H-9b; H-6), 4.11 – 4.03 (m, 2H, CH2, Et), 3.90 (d, J = 
10.3 Hz, 1H, H-5), 3.84 (s, 3H, OCH3), 2.18 (s, 3H, CH3,OAc), 2.17 (s, 3H, CH3,OAc), 2.12 (s, 3H, CH3,OAc), 
2.05 (s, 3H, CH3,OAc), 2.04 (s, 3H, CH3,OAc), 1.25 – 1.20 (m, 3H, CH3,Et). 13C NMR (101 MHz, CDCl3) δ 
170.73 (CO, Ac), 170.66 (CO, Ac), 170.42 (CO, Ac), 170.29 (CO, Ac), 167.27 (C-1), 165.42 (CO, Ac), 155.74 
(CONH), 95.24 (d, J = 28.6 Hz, C-2), 87.23 (d, J = 184.8 Hz, C-3), 72.15 (C-6), 71.16 (C-8), 68.20 (C-4), 
67.89 (C-7), 62.27 (C-9), 61.63 (CH2, Et), 53.62 (OCH3), 47.13 (C-5), 20.99 (CH3,OAc), 20.93 (CH3,OAc), 
20.91 (CH3,OAc), 20.78 (CH3,OAc), 20.71 (CH3,OAc), 14.62 (CH3,Et). HR-ESI-TOF/MS (m/z): [M+Na]+ 
calcd. for C23H32FNNaO15, 604.16537; found, 604.16438.  
 
 Methyl 5-(isobutylcarbamado)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-
fluoro-D-glycero-β-galacto-non-2-ulopyranosonate (11). Boc inhibitor 12 (18 mg; 30 µmol) was 
dissolved in a 1:1:3 mixture of respectively TFA, H2O and DCM (0.6 mL; 0.05 M). The mixture was stirred 
for 2 h at r.t. (TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.09). The mixture was then diluted with H2O and 
concentrated in vacuo. The mixture was redissolved in Tol and concentrated in vacuo three times. The 
residue was then dissolved in DCM (0.3 mL; 0.1 M) and iBu chloroformate (76 µl; 589 µmol; 20 eq.) and 
TEA (82 µl; 589 µmol; 20 eq.) were added. The reaction was stirred at r.t. 16 h after which the mixture 
was diluted with DCM and washed successively with 0.1M HCl and sat. NaHCO3. The organic layer was 
dried over MgSO4, filtered and concentrated in vacuo. Silica gel flash column chromatography (0 → 
50% EtOAc in Hept) afforded 11 (6 mg; 9.8 µmol; 33%). TLC: (EtOAc:Hept:MeOH, 45:45:10 v/v) Rf = 
0.40. 1H NMR (400 MHz, CDCl3) δ 5.64 – 5.49 (m, 1H, H-4), 5.42 – 5.37 (m, 1H, H-7), 5.18 (td, J = 6.0, 
2.5 Hz, 1H, H-8), 4.95 (dd, J = 49.2, 2.5 Hz, 1H, H-3), 4.73 (d, J = 9.1 Hz, 1H, NH), 4.53 (dd, J = 12.5, 2.5 
Hz, 1H, H-9a), 4.25 – 4.17 (m, 2H, H-9b; H-6), 3.92 – 3.75 (m, 6H, H-5; OCH3; CH2, iBu), 2.18 (s, 3H, 
CH3,OAc), 2.17 (s, 3H, CH3,OAc), 2.11 (s, 3H, CH3,OAc), 2.04 (s, 3H, CH3,OAc), 2.04 (s, 3H, CH3,OAc), 1.95 
– 1.84 (m, 1H, CH, iBu), 0.90 (d, J = 6.8 Hz, 6H, 2x CH3,iBu). 13C NMR (101 MHz, CDCl3) δ 170.72 (CO, Ac), 
170.39 (CO, Ac), 170.21 (CO, Ac), 170.00 (CO, Ac), 167.28 (C-1), 165.24 (CO, Ac), 155.87 (CONH), 95.25 
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(d, J = 29.0 Hz, C-2), 87.24 (d, J = 184.8 Hz, C-3), 72.00 (C-6), 71.56 (CH2, iBu), 71.06 (C-8), 68.16 – 68.01 
(m, C-7; C-4), 62.21 (C-9), 53.62 (OCH3), 47.18 (C-5), 28.05 (CH2, iBu), 20.98 (CH3,OAc), 20.92 (CH3,OAc), 
20.89 (CH3,OAc), 20.75 (CH3,OAc), 20.70 (CH3,OAc), 19.02 (2x CH3,iBu) HR-ESI-TOF/MS (m/z): [M+Na]+ 
calcd. for C25H36FNNaO15, 632.19667; found, 632.19698. 
 
  Methyl 5-(tert-butoxycarbamado)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-
fluoro-D-glycero-β-galacto-non-2-ulopyranosonate (12).  To a solution of 21 (789 mg; 1.39 mmol) in 
Pyr (12 mL; 148 mmol; 107 eq.), Ac2O (6 mL; 63.6 mmol; 45.7 eq.) was slowly added. After stirring at 
r.t. for 24 h, the mixture was concentrated in vacuo using Tol for co-evaporation. The residue was 
dissolved in EtOAc and washed successively with HCl (0.1M) and sat. aq. NaHCO3. The organic layer 
was dried over MgSO4, filtered and concentrated in vacuo. Silica gel flash column chromatography (0 
→ 50% EtOAc in Hept) afforded 12 (717 mg; 1.176 mmol; 95%) as a white foam. TLC: (EtOAc:Hept, 
50:50 v/v) Rf = 0.42 1H NMR (500 MHz, CDCl3) δ 5.46 – 5.34 (m, 2H, H-7; H-4), 5.18 – 5.11 (m, 1H, H-8), 
4.92 (dd, J = 49.1, 2.5 Hz, 1H, H-3), 4.60 – 4.54 (m, 1H, H-9a), 4.48 (d, J = 9.5 Hz, 1H, NH), 4.19 (dd, J = 
12.4, 6.6 Hz, 1H, H-9b), 4.12 – 3.97 (m, 2H, H-6; H-5), 3.84 (s, 3H, OCH3), 2.17 (s, 3H, CH3,OAc), 2.16 (s, 
3H, CH3,OAc), 2.12 (s, 3H, CH3,OAc), 2.05 (s, 3H, CH3,OAc), 2.04 (s, 3H, CH3,OAc), 1.40 (s, 9H, tBu, Boc). 
13C NMR (126 MHz, CDCl3) δ 170.73 (CO, Ac), 170.48 (CO, Ac), 170.36 (CO, Ac), 170.25 (CO, Ac), 167.24 
(CO, Ac), 165.28 (C-1), 154.88 (CO, Boc), 95.33 (d, J = 29.0 Hz, C-2), 87.21 (d, J = 185.1 Hz, C-3), 80.51 
(C(CH3)3, Boc), 72.67 (C-6), 71.39 (C-8), 68.97 (d, J = 17.2 Hz, C-4), 68.09 (C-7), 62.32 (C-9), 53.60 (OCH3), 
46.32 (C-5), 28.27 (tBu, Boc), 21.00 (CH3,OAc), 20.90 (CH3,OAc), 20.86 (CH3,OAc), 20.82 (CH3,OAc), 
20.74 (CH3,OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C25H36FNNaO15, 632.19667; found, 
632.19540. 
 
 Methyl 5-(benzylcarbamado)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-
fluoro-D-glycero-β-galacto-non-2-ulopyranosonate (13). Boc inhibitor 12 (50 mg; 82 µmol) was 
dissolved in a 1:1:2 mixture of respectively TFA, H2O and DCM (1.6 mL; 0.05 M). The mixture was stirred 
for 2 h at r.t. (TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.09). The mixture was then diluted with H2O and 
concentrated in vacuo. The residue was dissolved in DCM (0.83 mL; 0.1 M) and Cbz-Cl (14 µl; 99 µmol; 
1.2 eq.) and TEA (69 µl; 495 µmol; 6 eq.) were added. After stirring at r.t. for 1 hr additional Cbz-Cl (24 
µl; 165 µmol; 2 eq.) was added. The reaction was stirred for 15 h after which the reaction was still not 
finished, so additional Cbz-Cl (125 µl; 874 µmol; 10.5 eq.) and TEA (35 µl; 252 µmol; 3 eq.) were added. 
After stirring at r.t. for 5.5 h the mixture was diluted with DCM and washed successively with 0.1M HCl 
and sat. NaHCO3. The organic layer was dried over MgSO4, filtered and concentrated in vacuo. Silica 
gel flash column chromatography (0 → 50% EtOAc in Hept) afforded 13 (3.3 mg; 5.1 µmol; 6%) as a 
white solid. TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.43. 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.30 (m, 5H, 5x 
CH, Cbz), 5.52 (dd, J = 27.7, 11.0 Hz, 1H, H-4), 5.41 (dd, J = 5.8, 2.0 Hz, 1H, H-7), 5.18 (td, J = 5.9, 2.6 Hz, 
1H, H-8), 5.15 (d, J = 12.4 Hz, 1H, CHH, Cbz), 5.02 – 4.88 (m, 2H, CHH, Cbz; H-3), 4.78 (d, J = 9.5 Hz, 1H, 
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NH), 4.56 – 4.49 (m, 1H, H-9a), 4.24 – 4.17 (m, 2H, H-9b; H-6), 3.91 (q, J = 10.5 Hz, 1H, H-5), 3.83 (s, 3H, 
OCH3), 2.16 (s, 3H, CH3,OAc), 2.17 (s, 3H, CH3,OAc), 2.03 (s, 3H, CH3,OAc), 2.02 (s, 3H, CH3,OAc), 1.97 
(s, 3H, CH3,OAc). 13C NMR (126 MHz, CDCl3) δ 170.74 (CO, Ac), 170.64 (CO, Ac), 170.43 (CO, Ac), 170.20 
(CO, Ac), 167.26 (C-1), 165.21 (CO, Ac), 155.54 (CO, Cbz), 136.39 (C, Cbz), 128.68 (2x CH, ortho Cbz), 
128.36 (CH, para Cbz), 128.15 (2x CH, meta Cbz), 95.22 (d, J = 29.0 Hz, C-2), 87.21 (d, J = 184.9 Hz, C-
3), 71.99 (C-6), 70.98 (C-8), 68.11 – 67.91 (m, C-4; C-7), 67.18 (CH2, Cbz), 62.21 (C-9), 53.64 (OCH3), 
47.27 (C-5), 20.97 (CH3,OAc), 20.94 (CH3,OAc), 20.92 (CH3,OAc), 20.72 (CH3,OAc), 20.62 (CH3,OAc). HR-
ESI-TOF/MS (m/z): [M+Na]+ calcd. for C28H34FNNaO15, 666.18102; found, 666.18010. 
 
Methyl 5-[(1-benzyl-1H-1,2,3-triazol-4-yl)methylcarbamado]-
2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-fluoro-D-glycero-β-galacto-non-2-ulopyranosonate (14). To 
a mixture of 7 (10 mg; 17 µmol) in a 1:9 mixture of H2O and tBuOH (0.19 mL; 0.09 M), Bn-N3 (4.5 mg; 
34 µmol; 2 eq.) was added.  A premixture of TBTA (29 mg), DMF (750 µL) and CuI (5.1 mg) was agitated 
until a homogenous solution was obtained. The TBTA mixture (95 µl) was added to the H2O/tBuOH 
mixture and 10 mg of copper flakes were added. The reaction was stirred at r.t. 16 h, filtered and 
concentrated in vacuo. Silica gel flash column chromatography (0 → 80% EtOAc in Hept) afforded 14 
(5.7 mg; 17 µmol; 46%) as a white solid. TLC: (EtOAc:Hept, 80:20 v/v) Rf = 0.37. 1H NMR (500 MHz, 
CDCl3) δ 7.64 (s, 1H, CH, triazole), 7.37 (d, J = 2.2 Hz, 2H, 2x CH, ortho Bn), 7.32 – 7.29 (m, 2H, 2x CH, 
meta Bn), 6.91 (dd, J = 10.3, 6.8 Hz, 1H, CH, para Bn), 5.58 – 5.41 (m, 2H, CH2, Bn), 5.34 – 5.28 (m, 1H, 
H-7), 5.23 – 5.05 (m, 2H, CH2, Poc), 5.00 (d, J = 8.9 Hz, 1H, NH), 4.93 (dd, J = 49.1, 2.5 Hz, 1H, H-3), 4.50 
(dd, J = 12.6, 2.6 Hz, 1H, H-9a), 4.20 – 4.14 (m, 2H, H-9b; H-6), 3.92 (q, J = 10.4 Hz, 1H, H-5), 3.83 (s, 3H, 
OCH3), 2.16 (s, 3H, CH3,OAc), 2.14 (s, 3H, CH3,OAc), 2.02 (s, 3H, CH3,OAc), 2.02 (s, 3H, CH3,OAc), 1.97 
(s, 3H, CH3,OAc). 13C NMR (126 MHz, CDCl3) δ 170.88 (CO, Ac), 170.72 (CO, Ac), 170.52 (CO, Ac), 170.34 
(CO, Ac), 167.39 (C-1), 165.27 (CO, Ac), 155.63 (CO, Poc), 134.64 (C, Bn), 129.38 (2x CH, meta Bn), 
129.09 (CH, para Bn), 128.44 (2x CH, ortho Bn), 125.00 (CH, triazole), 95.25 (d, J = 28.9 Hz, C-2), 87.21 
(d, J = 185.0 Hz, C-3), 72.15 (C-6), 71.15 (C-8), 68.47 (d, J = 17.0 Hz, C-4), 68.30 (C-7), 62.30 (C-9), 58.65 
(CH2, Poc), 54.52 (CH2, Bn), 53.74 (OCH3), 47.22 (C-5), 21.07 (CH3,OAc), 21.05 (CH3,OAc), 21.01 
(CH3,OAc), 20.78 (CH3,OAc), 20.74 (CH3,OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for 
C31H37FN4NaO15, 747.21371; found, 747.21371.  
 
 Methyl 5-(butylcarbamado)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-fluoro-
D-glycero-β-galacto-non-2-ulopyranosonate (15). Boc inhibitor 12 (25 mg; 41 µmol) was dissolved in 
DCM (1 mL; 0.041 M) and TfOH (14 µl; 164 µm; 4 eq.)) was added and stirred for 5 min at r.t. (TLC: 
(EtOAc:Hept, 60:40 v/v) Rf = 0.09) then n-Bu chloroformate (27 µl; 205 µm; 5 eq.) and TEA (57 µl; 410 
µm; 10 eq.) were added. The reaction was left stirring for 16 h at r.t., diluted with an excess of DCM 
washed successively with 0.1M HCl and sat. NaHCO3. The organic layer was dried over MgSO4, filtered 
and concentrated in vacuo. Silica gel flash column chromatography (0 → 50% EtOAc in Hept) afforded 
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15 (8 mg; 41 µmol; 32%) as a white solid. TLC: (EtOAc) Rf = 0.90. 1H NMR (500 MHz, CDCl3) δ 5.54 (dd, 
J = 27.9, 11.3 Hz, 1H, H-4), 5.39 (d, J = 5.9 Hz, 1H, H-7), 5.18 (td, J = 6.0, 2.5 Hz, 1H, H-8), 4.95 (dd, J = 
49.2, 2.5 Hz, 1H, H-3), 4.73 – 4.66 (m, 1H, NH), 4.53 (dd, J = 12.4, 2.6 Hz, 1H, H-9a), 4.24 – 4.17 (m, 2H, 
H-9b; H-6), 4.08 – 3.96 (m, 2H, (CO)CH2, n-Bu), 3.93 – 3.84 (m, 1H, H-5), 3.84 (s, 3H, OCH3), 2.18 (s, 3H, 
CH3,OAc), 2.17 (s, 3H, CH3,OAc), 2.11 (s, 3H, CH3, OAc), 2.05 (s, 3H, CH3,OAc), 2.04 (s, 3H, CH3,OAc), 
1.61 – 1.54 (m, 2H, CH2CH2CH2, n- Bu), 1.39 – 1.32 (m, 2H, CH2CH3, n-Bu), 0.93 (t, J = 7.4 Hz, 3H, CH2CH3, 
n-Bu). 13C NMR (126 MHz, CDCl3) δ 170.59 (CO, Ac), 170.45 (CO, Ac), 170.25 (CO, Ac), 170.09 (CO, Ac), 
167.14 (C-1), 165.10 (CO, Ac), 155.70 (CONH), 95.09 (d, J = 28.8 Hz, C-2), 87.08 (d, J = 184.7 Hz, C-
3),71.92 (C-6), 70.96 (C-8), 69.30 (d, J = 13.5 Hz, C-4), 68.00 (C-7), 65.31 (C(O)CH2, n-Bu), 62.09 (C-9), 
53.48 (OCH3), 46.99 (C-5), 30.85 (CH2CH2CH2, n-Bu), 20.84 (CH3,OAc), 20.78 (CH3,OAc), 20.75 (CH3,OAc), 
20.62 (CH3,OAc), 20.56 (CH3,OAc), 18.93 (CH2CH3, n-Bu), 13.68 (CH2CH3, n-Bu). 19F NMR (470 MHz, 
CDCl3) δ -209.10 (dd, J = 49.1, 27.9 Hz). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C25H36FN4NaO15, 
632.19667; found, 632.19640.   
 
 Methyl 5-(2-methoxy-ethylcarbamado)-2,4,7,8,9-penta-O-acetyl-3,5-
dideoxy-3-fluoro-D-glycero-β-galacto-non-2-ulopyranosonate (16). Boc inhibitor 12 (40 mg; 66 µmol) 
was dissolved in DCM (1 mL; 0.066 M) and TfOH (23 µl; 262 µm; 4 eq.)) was added and stirred for 5 
min at r.t. (TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.09) then 2-methoxyethyl chloroformate (38 µl; 328 µm; 
5 eq.) and TEA (91 µl; 656 µm; 10 eq.) were added. The reaction was left stirring for 16 h at r.t., diluted 
with an excess of DCM washed successively with 0.1M HCl and sat. NaHCO3. The organic layer was 
dried over MgSO4, filtered and concentrated in vacuo. Silica gel flash column chromatography (0 → 
50% EtOAc in Hept) afforded 16 (36 mg; 66 µmol; 90%) as a white solid. TLC: (EtOAc) Rf = 0.80.1H NMR 
(500 MHz, CDCl3) δ 5.51 (ddd, J = 27.9, 11.1, 3.1 Hz, 1H, H-4), 5.39 (dd, J = 5.7, 1.9 Hz, 1H, H-7), 5.21 – 
5.14 (m, 1H, H-8), 4.95 (dd, J = 49.1, 2.5 Hz, 1H, H3), 4.86 (d, J = 9.1 Hz, 1H, NH), 4.52 (dd, J = 12.5, 2.6 
Hz, 1H, H-9a), 4.23 – 4.15 (m, 4H, H-9b, H-6, CH2CH2C(O)), 3.92 – 3.86 (m, 1H, H-5), 3.83 (s, 3H, 
COOCH3), 3.55 (ddd, J = 6.6, 5.2, 2.7 Hz, 2H, CH3OCH2CH2), 3.37 (s, 3H, OCH3), 2.17 (s, 3H, CH3, OAc), 
2.15 (s, 3H, CH3, OAc), 2.11 (s, 3H, CH3, OAc), 2.04 (s, 3H, CH3, OAc), 2.03 (s, 3H, CH3, OAc). 13C NMR 
(126 MHz, CDCl3) δ 170.61 (CO), 170.44 (CO), 170.26 (CO), 170.04 (CO), 167.17 (CO), 165.07 (CO), 
155.43 (CONH), 95.05 (d, J = 28.9 Hz, C-2), 87.01 (d, J = 184.8 Hz, C-3), 71.82 (C-6), 70.66 (C-8), 70.61 
CH2CH2C(O), 68.16 (d, J = 17.1 Hz, C-4), 67.98 (C-7), 64.46 (CH3OCH2CH2), 62.06 (C-9), 58.87 (OCH3), 
53.47 (COOCH3), 46.99 (C-5), 20.83 (CH3, OAc), 20.78 (CH3, OAc), 20.76 (CH3, OAc), 20.63 (CH3, OAc), 
20.56 (CH3, OAc). 19F NMR (470 MHz, CDCl3) δ -209.21 (dd, J = 49.2, 27.9 Hz). HR-ESI-TOF/MS (m/z): 
[M+Na]+ calcd. for C24H34FNNaO16, 634.17593; found, 634.17656.   
 
 Methyl 5-(2,2,2-trichloroethylcarbamado)-2,4,7,8,9-penta-O-acetyl-3,5-
dideoxy-3-fluoro-D-glycero-β-galacto-non-2-ulopyranosonate (17). Boc inhibitor 12 (27 mg; 44 µmol) 
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was dissolved in DCM (1 mL; 0.044 M) and TfOH (16 µl; 262 µm; 4 eq.)) was added and stirred for 5 
min at r.t. (TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.09) TrocCl (31 µl; 221 µm; 5 eq.) and TEA (62 µl; 443 µm; 
10 eq.) were added. The reaction was left stirring for 16 h at r.t., diluted with an excess of DCM washed 
successively with 0.1M HCl and sat. NaHCO3. The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. Silica gel flash column chromatography (0 → 50% EtOAc in Hept) afforded 17 
(5.2 mg; 66 µmol; 17%) as a white solid. TLC: (EtOAc) Rf = 0.85. 1H NMR (500 MHz, CDCl3) δ 5.67 (ddd,  
J = 27.9, 11.1, 2.5 Hz, 1H, H-4), 5.37 (dd, J = 6.3, 1.7 Hz, 1H, H-7), 5.26 – 5.16 (m, 2H, NH, H-8), 4.97 (dd, 
J = 49.1, 2.5 Hz, 1H, H3), 4.91 (d, 1H, CHH Troc), 4.53 (d, J = 12.1 Hz, 1H, CHH Troc), 4.49 (dd, J = 12.6, 
2.5 Hz, 1H, H-9a), 4.29 (d, J = 10.4 Hz, 1H, H-6), 4.23 (dd, J = 12.6, 5.6 Hz, 1H, H-9b), 3.84 (s, 3H, OCH3), 
3.83 – 3.78 (m, 1H, H-5), 2.18 – 2.17 (m, 6H, 2x CH3, OAc), 2.17 (s, 3H, CH3, OAc), 2.04 (s, 3H, CH3, OAc), 
2.04 (s, 3H, CH3, OAc). 13C NMR (126 MHz, CDCl3) δ 170.75 (CO), 170.56 (CO), 170.12 (CO), 169.87(CO), 
167.04 (CO), 164.93 (CO), 153.75 (CONH), 95.05 (d, J = 28.9 Hz, C-2), 86.97 (d, J = 184.9 Hz, C-3), 95.11 
(CCl3 Troc), 74.33 (CH2 Troc), 70.99 (C-6), 70.50 (C-8), 67.85 (C-7), 67.62 (d, J = 17.5 Hz, C-4), 61.84 (C-
9), 53.50 (OCH3), 47.43 (C-5), 30.93 (CH3, OAc), 20.79 (CH3, OAc), 20.73 (CH3, OAc), 20.65 (CH3, OAc), 
20.52 (CH3, OAc). 19F NMR (470 MHz, CDCl3) δ -209.54 (dd, J = 49.1, 27.7 Hz). HR-ESI-TOF/MS (m/z): 
[M+Na]+ calcd. for C23H29Cl3FNNaO15, 706.04845; found, 706.04999.  
 
 Methyl 5-(2-fluoroethylcarbamado)-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-
fluoro-D-glycero-β-galacto-non-2-ulopyranosonate (18). Boc inhibitor 12 (27 mg; 44 µmol) was 
dissolved in DCM (1 mL; 0.044 M) and TfOH (16 µl; 262 µm; 4 eq.)) was added and stirred for 5 min at 
r.t. (TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.09) 2-fluoroethyl chloroformate (21 µl; 221 µm; 5 eq.) and TEA 
(62 µl; 443 µm; 10 eq.) were added. The reaction was left stirring for 16 h at r.t., diluted with an excess 
of DCM washed successively with 0.1M HCl and sat. NaHCO3. The organic layer was dried over MgSO4, 
filtered and concentrated in vacuo. Silica gel flash column chromatography (0 → 50% EtOAc in Hept) 
afforded 18 (16 mg; 66 µmol; 60%) as a white solid. TLC: (EtOAc) Rf = 0.85. 1H NMR (500 MHz, CDCl3) δ 
5.51 (ddd, J = 27.9, 11.0, 2.5 Hz, 1H, H-4), 5.40 (dd, J = 5.4, 2.0 Hz, 1H, H-7), 5.17 (td, J = 5.9, 2.5 Hz, 1H, 
H-8), 4.95 (dd, J = 49.1, 2.5 Hz, 1H, H3), 4.94 (d, J = 9.4 Hz, 1H, NH), 4.67 – 4.46 (m, 3H, FCH2CH2, H-9a), 
4.41 – 4.24 (m, 2H FCH2CH2), 4.25 – 4.16 (m, 2H, H-9b, H-6), 4.00 – 3.89 (m, 1H, H-5), 3.84 (s, 3H, OCH3), 
2.18 (s, 3H, CH3, OAc), 2.16 (s, 3H, CH3, OAc), 2.12 (s, 3H, CH3, OAc), 2.05 (s, 3H, CH3, OAc), 2.04 (s, 3H, 
CH3, OAc). 13C NMR (126 MHz, CDCl3) δ 170.63 (CO), 170.48 (CO), 170.37 (CO), 170.12 (CO), 167.13 
(CO), 165.04 (CO), 155.24 (CONH), 95.07 (d, J = 28.7 Hz, C-2), 87.03 (d, J = 185.2 Hz, C-3), 81.60 (d, J = 
170.2 Hz, FCH2CH2), 71.91 (C-6), 71.00 (C-8), 68.21 (d, J = 17.3 Hz, C-4), 67.96 (C-7) 64.29 (d, J = 19.9 
Hz, FCH2CH2), 62.02 (C-9), 53.50 (OCH3), 47.05 (C-5), 20.83 (CH3, OAc), 20.77 (CH3, OAc), 20.75 (CH3, 
OAc), 20.57 (CH3, OAc), 20.54 (CH3, OAc). 19F NMR (470 MHz, CDCl3) δ -209.07 (dd, J = 49.1, 27.9 Hz). 
HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C23H31F2NNaO15, 622.15594; found, 622.15531.  
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 Methyl 5-(Acetamido]-9-azido-4,7,8-tri-O-acetyl-2,6-anhydro-3,5,9-dideoxy-D-
glycero-D-galacto-non-2-enonate (19). Data corresponds with compound previously published.20 
Peracetylated C-9 azide sialic acid (300 mg, 0.632 mmol) was dissolved in ACN (2 mL) and cooled to 
0°C. TMSOTf (4.22 mL; 1.896 mmol; 3 eq.) was added dropwise to the solution. After 4 h, the reaction 
was diluted with an excess EtOAc and washed three times with sat. aqueous NaHCO3. The organic layer 
was concentrated in vacuo and the product was purified on silica gel flash column chromatography (0 
 30% Acet in DCM), and 19 was was obtained as a white solid (150 mg, 0.329 mmol, 52%). TLC: 
(Acet:DCM, 30:70 v/v) Rf = 0.60.  1H NMR (500 MHz, CDCl3) δ 5.98 (d, J = 2.9 Hz, 1H, H-3), 5.86 (d, J = 
8.9 Hz, 1H, NH), 5.57 – 5.54 (m, 1H, H-6), 5.51 (dd, J = 3.7, 2.8 Hz, 1H, H-7), 5.21 (ddd, J = 8.0, 3.7, 2.9 
Hz, 1H, H-8), 4.44 – 4.36 (m, 2H, H-4;H-5), 3.92 (dd, J = 13.5, 2.9 Hz, 1H, H-9a), 3.83 (s, 3H, CH3, OCH3), 
3.50 (dd, J = 13.5, 8.0 Hz, 1H, H-9b), 2.16 (s, 3H, CH3, Ac), 2.11 (s, 3H, CH3, Ac), 2.09 (s, 3H, CH3, Ac), 1.93 
(s, 3H, CH3, Ac). 13C NMR (126 MHz, CDCl3) δ 170.94 (CO, Ac), 170.51 (CO, Ac), 170.31 (CO, Ac), 170.26 
(CO, Ac), 161.55 (C-1), 108.35 (C-3), 77.05 (C-5), 68.43 (C-8), 67.98 (C-6), 58.52 (C-7), 52.63 (OCH3), 
50.10 (C-9), 46.48 (C-4), 23.16 (CH3, Ac), 20.88 (CH3, Ac), 20.87 (CH3, Ac), 20.75 (CH3, Ac). ESI-HRMS 
calculated for C18H24N4Na O10, 479.13901; found 479.13802.  ESI-HRMS calculated for C18H24N4 NaO10 
479.13901; found 479.13802. 
 
 Methyl 5-(acetamido)-9-azido-2,4,7,8-tetra-O-acetyl-3,5,9-trideoxy-3-fluoro-D-
glycero-β-galacto-non-2-ulopyranosonate (20).  Sialic acid glycal 19 (145 mg, 0.317 mmol) was solved 
in DMF (2.38 mL) and H2O (0.79 mL; 0.1 M). Selectfluor (0.337 g, 0.951 mmol; 3 eq.) was added and 
the reaction was heated to 60°C for 16 h, then concentrated in vacuo. The compound was redissolved 
in EtOAc washed with sat. aq. NaHCO3, dried with MgSO4, filtered, concentrated in vacuo. And 
subsequently solved in Ac2O (5 mL) and Pyr (10 mL) and stirred at r.t. for 18 h before concentrating in 
vacuo.  The residue was redissolved in EtOAc washed with 1 M HCl aq. then sat. aq. NaHCO3, dried with 
MgSO4 and purified by column chromatomatography (0 → 20% Acet in DCM) to yield 20 (59 mg; 0.111 
mmol; 35%) as white foam. TLC: (Acet:DCM, 20:80 v/v) Rf = 0.35.  1H NMR (500 MHz, CDCl3) δ 5.49 
(ddd, J = 27.8, 11.0, 2.5 Hz, 1H, H-4), 5.43 – 5.37 (m, 2H, H-7, NH), 4.99 – 4.95 (m, 1H, H-8), 4.95 (dd, J 
= 49.0, 2.5 Hz, 1H, H-3), 4.29 (q, J = 10.4 Hz, 1H, H-6), 4.20 (dd, J = 10.6, 1.6 Hz, 1H, H-5), 3.91 (dd, J = 
13.6, 2.6 Hz, 1H, H-9a), 3.88 (s, 3H, CH3, OCH3), 3.45 (dd, J = 13.6, 7.7 Hz, 1H, H-9b), 2.22 (s, 3H, CH3, Ac), 
2.21 (s, 3H, CH3, Ac), 2.14 (s, 3H, CH3, Ac), 2.11 (s, 3H, CH3, Ac), 1.94 (s, 3H, CH3, Ac). 13C NMR (126 MHz, 
CDCl3) δ 170.71 (CO, Ac), 170.63 (CO, Ac), 170.62 (CO, Ac), 170.61 (CO, Ac), 170.25 (CO, Ac), 167.27 (C-
1),  95.18 (d, J = 28.9 Hz, C-2), 86.93 (d, J = 185.7 Hz, C-3), 73.48 (C-5), 72.61, 68.42 (d, J = 17.1 Hz, C-4), 
53.60 (OCH3), 50.15 (C-9), 23.27 (CH3, Ac), 20.92 (CH3, Ac), 20.81 (CH3, Ac), 20.67 (CH3, Ac), 20.57 (CH3, 
Ac). 19F NMR (471 MHz, CDCl3) δ -208.71. ESI-HRMS calculated for C10H25N5O12Na, 557.15072; found 
557.15051.  
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 Methyl 5-(Acetamido]-4-azido-7,8,9-tri-O-acetyl-2,6-anhydro-3,4,5-dideoxy-D-
glycero-D-galacto-non-2-enonate (21). Oxazoline sialic acid was synthesized as described previously21 
(650 mg; 1.574 mmol) was solved in tBuOH (7.15 mL; 0.22 M) and TMS-N3 (310 µl; 2.359 mmol; 1.5 eq) 
was added. The reaction was stirred at 100°C for 16 h, then cooled to r.t. before quenching with an 
excess of 0.1 M HCl aq. (100 mL), then extracted with EtOAc, washed with aqueous NaHCO3, dried with 
Na2SO4 and filtered. The filtrate was concentrated in vacuo. Silica gel flash column chromatography (0 
→ 40% Acet in DCM) afforded azidoglycal 21 (577 mg; 1.26 mmol; 80%)22 as a white foam.  TLC: 
(Acet:DCM, 25:75 v/v) Rf = 0.46. 1H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 9.3 Hz, 1H, NH), 5.95 (d, J = 2.5 
Hz, 1H, H-3), 5.49 (dd, J = 5.2, 2.1 Hz, 1H, H-7), 5.30 (ddd, J = 7.7, 5.2, 2.7 Hz, 1H, H-8), 4.65 (dd, J = 12.4, 
2.4 Hz, 1H, H-9a), 4.41 (dd, J = 10.3, 1.9 Hz, 1H, H-6), 4.29 (dd, J = 9.2, 2.4 Hz, 1H, H-4), 4.20 – 4.10 (m, 
2H, H-5, H-9b), 3.80 (s, 3H, OCH3), 2.12 (s, 3H, CH3, Ac), 2.05 (s, 3H, CH3, Ac), 2.04 (s, 3H, CH3, Ac), 1.99 
(s, 3H, CH3, Ac). 13C NMR (126 MHz, CDCl3) δ 170.90 (CO), 170.52 (CO), 169.73 (CO), 169.72 (CO), 161.22 
(CO), 144.88 (C-2), 107.59 (C-3), 76.09 (C-6), 70.52 (C-8), 67.27 (C-7), 61.81 (C-9), 58.36 (C-4), 52.29 
(OCH3), 47.01 (C-5), 22.87 (CH3, Ac) 20.48 (CH3, Ac), 20.46 (CH3, Ac), 20.44 (CH3, Ac). HR-ESI-TOF/MS 
(m/z): [M+Na]+ calcd. for C18H24N4NaO10, 479.13901; found, 479.13853.  
 
 Methyl 5-(acetamido)-4-azido-2,7,8,9-tetra-O-acetyl-3,4,5-trideoxy-3-fluoro-D-
glycero-β-galacto-non-2-ulopyranosonate (22). Sialic acid glycal 21 (500 mg, 1.096 mmol) was solved 
in DMF (8.22 mL) and H2O (2.74 mL; 0.1 M). Selectfluor (0.337 g, 0.951 mmol; 3 eq.) was added and 
the reaction was heated to 60°C for 16 h, then concentrated in vacuo. The compound was redissolved 
in EtOAc washed with sat. aq. NaHCO3, dried with MgSO4, filtered, concentrated in vacuo. And 
subsequently solved in Ac2O (5 mL) and Pyr (10 mL) and stirred at r.t. for 18 h before concentrating in 
vacuo.  The residue was redissolved in EtOAc washed with 1 M HCl aq. then sat. aq. NaHCO3, dried with 
MgSO4 and purified by column chromatomatography (0 → 20% Acet in DCM) to yield 22 (340 mg; 0.636 
mmol; 58%) as white foam. TLC: (Acet:DCM, 25:75 v/v) Rf = 0.40. 1H NMR (500 MHz, CDCl3) δ 6.02 (d, 
J = 7.7 Hz, 1H, NH), 5.30 (dd, J = 6.4, 1.7 Hz, 1H, H-7), 5.18 (td, J = 6.0, 2.4 Hz, 1H, H-8), 4.92 (dd, J = 
48.3, 2.4 Hz, 1H, H-3), 4.79 – 4.60 (m, 1H, H-4), 4.51 – 4.42 (m, 2H, H-9a; H-6), 4.22 (dd, J = 12.6, 5.8 Hz, 
1H, H-9b), 3.82 (s, 3H, CH3, OCH3), 3.50 (bs, 1H, H-5), 2.15 (s, 3H, CH3, Ac), 2.15 (s, 3H, CH3, Ac), 2.03-
2.02 (m, 6H, 2x CH3, Ac), 2.01 (s, 3H, CH3, Ac). 13C NMR (126 MHz, CDCl3) δ 171.83 (CO, OAc), 171.13 
(CO, OAc), 170.46 (CO, OAc), 169.81 (CO, OAc), 167.05 (CO, NAc), 165.05 (C-1), δ 94.53 (d, J = 28.7 Hz, 
C-2), 88.35 (d, J = 185.1 Hz, C-3), 70.30 (C-8), 69.96 (C-6), 68.16 (C-7), 61.92 (C-9), 56.59 (d, J = 17.2 Hz, 
C-4), 53.44 (OCH3), 23.47 (CH3, Ac), 20.77 (CH3, Ac), 20.75 (CH3, Ac), 20.66 (CH3, Ac), 20.40 (CH3, Ac). 19F 
NMR (471 MHz, CDCl3) δ -195.34 (dd, J = 48.8, 11.7 Hz). ESI-HRMS calculated for C10H25N5 NaO12, 
557.15072; found 557.15041.  
 
 249 
 
 Methyl 5-(tert-butoxycarbamado)-4,7,8,9-penta-O-acetyl-2,3,5-dideoxy-2-
para-methylthiophenol-D-glycero-β-galacto-non-2-ulopyranosonate (23). As described previously16, 
thiocresol protected NBoc methyl ester sialic acid (8.39 g; 17.2 mmol) was dissolved in Pyr (62 mL; 764 
mmol; 44.4 eq.). Ac2O (36 mL; 382 mmol; 22.2 eq.) was slowly added. After stirring at r.t. for 7 h, the 
mixture was concentrated in vacuo using Tol for co-evaporation. The residue was dissolved in EtOAc 
and washed successively with HCl (0.1 M) and sat. aq. NaHCO3. The organic layer was dried over MgSO4 
and filtered and concentrated in vacuo. Silica gel flash column chromatography (0 → 50% EtOAc in 
Hept) afforded 23 (10.26 g; 15.6 mmol; 91%) as a white foam. TLC: (EtOAc:Hept, 50:50 v/v) Rf = 0.47 
1H NMR (500 MHz, CDCl3) δ 7.32 (d, J = 7.7 Hz, 2H, 2x CH, meta STol), 7.14 (d, J = 7.7 Hz, 2H, 2x CH, 
ortho STol), 5.55 (t, J = 2.6 Hz, 1H, H-7), 5.33 (td, J = 11.1, 4.8 Hz, 1H, H-4), 5.01 (dt, J = 8.5, 2.5 Hz, 1H, 
H-8), 4.55 (dd, J = 10.5, 2.6 Hz, 1H, H-6), 4.51 (dd, J = 12.2, 2.3 Hz, 1H, H-9a), 4.45 (d, J = 10.7 Hz, 1H, 
NH), 4.04 (dd, J = 12.2, 8.5 Hz, 1H, H-9b), 3.79 (q, J = 10.6 Hz, 1H, H-5), 3.61 (s, 3H, OCH3), 2.67 (dd, J = 
13.8, 4.8 Hz, 1H, H-3eq), 2.34 (s, 3H, CH3,STol), 2.10 (s, 3H, CH3,OAc), 2.08 (s, 3H, CH3,OAc), 2.04 (s, 4H, 
H-3ax; CH3,OAc), 1.97 (s, 3H, CH3,OAc), 1.40 (s, 9H, tBu, Boc). 13C NMR (126 MHz, CDCl3) δ 170.98 (CO, 
OAc), 170.61 (CO, OAc), 170.43 (CO, OAc), 169.93 (CO, OAc), 168.48 (C-1), 155.35 (CO, Boc), 140.22 (C-
CH3,STol) 136.38 (2x CH, meta STol), 129.99 (2x CH ortho STol), 125.41 (C-S, STol), 88.87 (C-2), 80.29 
(C(CH3)3, Boc), 73.34 (C-6), 72.90 (C-8), 69.51 (C-4), 69.12 (C-7), 62.92 (C-9), 52.68 (OCH3), 50.96 (C-5), 
37.59 (C-3), 28.28 (tBu, Boc), 21.44 (CH3,STol), 21.21 (CH3,OAc), 20.94 (CH3,OAc), 20.83 (CH3,OAc), 
20.82 (CH3,OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C30H41NNaO13S, 678.21963; found, 
678.21799.  
 
 Methyl 5-(tert-butoxycarbamado]-4,7,8,9-tetra-O-acetyl-2,6-anhydro-3,5-
dideoxy-D-glycero-D-galacto-non-2-enonate (24). To a solution of 23 (2.757 g; 4.22 mmol) in DCM 
(42.2 mL; 0.1 M), slowly Br2 (0.239 mL; 4.64 mmol; 1.1 eq.) was added. After 2.5 h stirring at r.t., the 
reaction was diluted with DCM and washed with 10% Na2S2O3. The milky organic layer was dried over 
MgSO4, filtered and the clear filtrate was extracted once more with 10% Na2S2O3 aq. before drying over 
MgSO4, filtering. The filtrate was concentrated in vacuo, redissolved in DCM (42.0 mL; 0.1 M) and TEA 
(1.699 g; 16.79 mmol; 4 eq.) was added. The reaction was stirred 16 h at r.t. and concentrated in vacuo. 
The residue was dissolved in EtOAc and washed successively with HCl (0.1 M) and sat. aq. NaHCO3. The 
organic layer was dried over MgSO4, filtered and again concentrated in vacuo. Silica gel flash column 
chromatography (0 → 45% EtOAc in Hept) afforded 24 (1.734 g; 3.26 mmol; 78% two steps) as a white 
solid. TLC: (EtOAc:Hept, 60:40 v/v) Rf = 0.62 1H NMR (500 MHz, CDCl3) δ 5.99 (d, J = 3.1 Hz, 1H, H-3), 
5.55 (t, J = 4.3 Hz, 1H, H-7), 5.47 (dd, J = 7.5, 3.1 Hz, 1H, H-4), 5.37 (ddd, J = 6.8, 4.9, 3.4 Hz, 1H, H-8), 
4.65 (d, J = 9.9 Hz, 1H, NH), 4.60 (dd, J = 12.3, 3.4 Hz, 1H, H-9a), 4.33 (dd, J = 9.0, 3.8 Hz, 1H, H-6), 4.19 
(dd, J = 12.2, 6.8 Hz, 1H, H-9b), 4.09 (q, J = 8.9 Hz, 1H, H-5), 3.80 (s, 3H, OCH3), 2.13 (s, 3H, CH3,OAc), 
2.08 (s, 3H, CH3,OAc), 2.06 (s, 3H, CH3,OAc), 1.41 (s, 9H, tBu, Boc). 13C NMR (126 MHz, CDCl3) δ 170.73 
(CO, Ac), 170.68 (CO, Ac), 170.05 (CO, Ac), 169.91 (CO, Ac), 161.78 (C-1), 154.98 (CO, Boc), 145.15 (C-
2), 108.11 (C-3), 80.57 (C(CH3)3, Boc), 76.94 (C-6), 70.58 (C-8), 68.60 (C-4), 67.92 (C-7), 62.10 (C-9), 
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52.66 (OCH3), 48.01 (C-5), 28.27 (tBu, Boc), 20.96 (CH3,OAc), 20.91 (CH3,OAc), 20.85 (CH3,OAc), 20.80 
(CH3,OAc). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C23H33NNaO13, 554.18496; found, 554.18611.
  
 Methyl 5-(tert-butoxycarbamado)-4,7,8,9-penta-O-acetyl-3,5-dideoxy-3-
fluoro-D-glycero-β-galacto-non-2-ulopyranosonate (25). To a solution of 24 (1.724 g; 3.24 mmol) in a 
1:3 mixture of H2O and DMF (32 mL; 0.1 M), Selectfluor (3.45 g; 9.73 mmol; 3 eq.) was added. The 
reaction was stirred at 60 ˚C for 3 h. The mixture was quenched with sat. aq. NaHCO3 and concentrated 
in vacuo- even though conversion was incomplete. The residue was dissolved in EtOAc and washed 
successively with HCl (0.1M) and sat. aq. NaHCO3. The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. Silica gel flash column chromatography (0 → 50% EtOAc in Hept) afforded 25 
(789 mg; 1.39 mmol; 72% based on recovery of starting material) as a white foam. TLC: (EtOAc:Hept, 
60:40 v/v) Rf = 0.47 1H NMR (500 MHz, CDCl3) δ 5.52 (s, 1H, OH), 5.47 (dd, J = 4.4, 2.3 Hz, 1H, H-7), 5.37 
– 5.23 (m, 2H, H-8; H-4), 4.94 (d, J = 10.3 Hz, 1H, NH), 4.92 (dd, J = 49.8, 2.1 Hz, 1H, H-3), 4.81 (dd, J = 
12.3, 2.5 Hz, 1H, H-9a), 4.26 (dd, J = 10.6, 2.3 Hz, 1H, H-6), 4.18 – 4.08 (m, 2H, H-5; H-9b), 3.85 (s, 3H, 
OCH3), 2.16 (s, 3H, CH3,OAc), 2.09 (s, 3H, CH3,OAc), 2.09 (s, 3H, CH3,OAc), 2.04 (s, 3H, CH3,OAc), 1.40 
(s, 9H, tBu, Boc). 13C NMR (126 MHz, CDCl3) δ 171.68 (CO, Ac), 171.48 (CO, Ac), 170.60 (CO, Ac), 170.19 
(CO, Ac), 167.70 (C-1), 155.22 (CO, Boc), 94.45 (d, J = 25.5 Hz, C-2), 87.06 (d, J = 185.1 Hz, C-3), 80.09 
(C(CH3)3, Boc), 71.91 (C-8), 71.46 (C-6), 69.96 (d, J = 17.3 Hz, C-4), 68.63 (C-7), 63.01 (C-9), 53.50 (OCH3), 
46.36 (C-5), 28.31 (tBu, Boc), 21.13 (CH3,OAc), 20.99 (CH3,OAc), 20.85 (CH3,OAc), 20.78 (CH3,OAc). HR-
ESI-TOF/MS (m/z): [M+Na]+ calcd. for C23H34FNNaO14, 590.18610; found, 590.18498. 
 
 
Contributions 
Synthesis and molecular design done by Heise T and his student: Pijnenborg JFA1. The biological testing 
and statistic was performed by Büll C2, Kers-Rebel ED2, Balneger N2 and Elfering H1. 
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8 
Selective Inhibition of 
Haemophilus Influenzae 
Sialic Acid Theft with a 
Sialic Acid-based Inhibitor 
Abrogates Serum 
Resistance  
 
“It is probable that serum acts on bacteria by changing the relations of molecular 
attraction between the bacteria and the surrounding fluid.” 
Jules Bordet (1870-1961), discovered the bacteriolytic effect of serum. 
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Abstract 
Pathogens such as Nontypeable Haemophilus influenzae (NTHi) evade the immune 
system by presenting host-derived sialic acids. NTHi cannot synthesize sialic acid and 
therefore needs to utilize sialic acids originating from host tissue. Here we report 
sialic acid-based probes to visualize and inhibit the transfer of host sialic acids to 
NTHi. Inhibition of sialic acid utilization by NTHi dramatically enhanced serum-
mediated killing. Furthermore, in an in vitro model of the human respiratory tract, we 
demonstrate efficient inhibition of sialic acid transfer from primary human bronchial 
epithelial cells to NTHi using bioorthogonal chemistry.  
 
 Heise T#, Langereis JD*#, Rossing E, De Jonge ML, Adema GJ, Büll C, Boltje TJ*. 
Selective inhibition of sialic acid-based molecular mimicry in Haemophilus 
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Introduction 
Several pathogens that colonize the human host have evolved the ability to engage in 
‘molecular mimicry’, the expression of host-like molecular structures at the cell 
surface. These structures are used by pathogens as a molecular cloak to avoid 
detection and clearance by the host immune system.  A prime example of an 
opportunistic pathogen that uses molecular mimicry is Nontypeable Haemophilus 
influenzae (NTHi). NTHi is a commensal organism in the upper respiratory tract 
microbiome, which can become an opportunistic pathogen mainly in children and 
elderly.1-2 NTHi infections are found in 55-95% of children suffering from otitis media, 
an inflammatory disease that affects 65-300 million people globally and is a major 
cause of hearing loss.1 In addition, NTHi is found in up to 87% of patients with acute 
exacerbation of chronic obstructive pulmonary disease (COPD), a leading cause of 
death worldwide.1 The switch of NTHi from a symbiotic colonizing bacterium to an 
opportunistic pathogen is associated with uptake and expression of host sialic acids. 
Sialic acids are complex nine-carbon sugars abundantly expressed on human 
glycoconjugates3 and can be released by the action of neuraminidases (Figure 1). 
Unbound sialic acids can be taken up by NTHi using a tripartite ATP-independent 
periplasmic (TRAP) transporter system4-5 and enzymatically incorporated into the 
variable outer core of the NTHi lipo-oligosaccharide (LOS, Figure 1).6 LOS sialylation is 
an important NTHi virulence factor that confers resistance to serum killing and 
increases biofilm formation, although the underlying mechanisms are still poorly 
understood.7-8 NTHi strains defective in sialic acid utilization are no longer virulent in 
animal models for otitis media making the sialic acid utilization pathway a promising 
therapeutic target.9  
 
Herein we report a sialic acid-based inhibitor (SiaNAc-3Fax, all sialic acid derivatives 
used are shown in Figure S1) that prevents sialic acid incorporation into NTHi lipo-
oligosaccharide (LOS) at low micromolar concentrations which led to enhanced 
serum-mediated killing of NTHi (Figure 1). Furthermore, we report the use of sialic 
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acid-based probes and bioorthogonal chemistry to visualize the transfer of sialic acids 
from host to NTHi using a model system of the human airway.  
 
 
 
Figure 1. Sialic acid utilization by NTHi, host sialic acids are released by neuraminidases and taken up 
in NTHi via active uptake. Incorporation of sialic acids in NTHi LOS leads to resistance to serum 
mediated killing. 
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Results and Discussion 
To evaluate the efficacy of sialic acid-based inhibitors on LOS sialylation, we 
developed a fast and reliable assay to measure LOS sialylation in NTHi using a 
metabolic sialic acid glycoengineering approach with azidoacetyl (SiaNAz) and 
propargyloxycarbonyl (SiaNPoc) modified sialic acids 9 and 8, respectively (Scheme 
1).10-11,12 A microwave-assisted procedure was chosen to rapidly synthesize known 
thioglycoside 3 and subsequently exchanging the C-5 acetyl to trifluoroacetamide 
4.13-14 This avoids the usual Boc-assisted two step acetyl deprotection. Free amine 
intermediate 5 was directly acquired by basic conditions under microwave radiation. 
Subsequent coupling to the succinimide esters followed by deprotection yielded 
SiaNPoc 8 and SiaNAz 9 (Scheme 1). 
 
Scheme 1. Synthesis of SiaNPoc and SiaNAz. i) Dowex H+, MeOH, 80 °C µW, 60 min; ii) Ac2O, Pyr, r.t., 
16 h; iii) BF3•Et2O, DCM, r.t., 16 h, 82% (three steps). iv) TFAA, ACN, 135 °C µW, 10 min, 74%. v) LiOH, 
MeOH, H2O, 120 °C µW, 30 min, 98%. vi) H2O, ACN, r.t., 16 h, 6: PocOSu, 84%; 7: AzOSu, 75%. vii) I2, 
H2O, r.t., 8: 1 h, 86%; 9: 15 min, 95%. 
 
NTHi bacteria were grown in sialic acid deficient medium supplemented with SiaNAz 
or SiaNPoc and incorporation of these sialic acids analogues into LOS was detected by 
reacting them to biotin-alkyne or -azide, respectively, using copper-catalyzed alkyne 
azide cycloaddition (CuAAC) followed by staining with fluorescent streptavidin (Figure 
2A). Incorporation of SiaNAz and SiaNPoc sialic acid analogues was dose-dependent 
(Figures S2A and S2B) and required a functional TRAP sialic transporter because no 
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labeling was detected for siaP transporter mutant NTHi  (∆siaP) (Figures S2C and 
S2D). To assess whether passive diffusion of sialic acid derivatives over the NTHi 
membrane was possible, we tested the incorporation of the protected (peracetylated 
and methyl-capped acid) sialic acid derivatives Ac5SiaNAz and Ac5SiaNPoc.15-16,17 Both 
Ac5SiaNAz and Ac5SiaNPoc were not incorporated in NTHi LOS (Figures 2B and S2D) 
indicating that they were not able to enter the bacteria via diffusion and also not 
recognized as substrates for the TRAP system. Vice versa, human THP-1 cells utilized 
only protected sialic acid analogues for sialoglycan synthesis, but not the unprotected 
sialic acid analogues (Figure 2C).  
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Figure 2. Visualization and inhibition of sialic acid analogues by NTHi. A) Uptake and inhibition of 
SiaNAz. B) Incorporation of sialic acid analogues by NTHi. C) Incorporation of sialic acid analogues by 
human THP-1 cells. D) IC50 curve of the effect of SiaNAc-3Fax  on the incorporation of SiaNAz by NTHi. 
E) Effect of NTHi Ac5SiaNAc-3Fax on the incorporation of SiaNAz by NTHi. 
 
Having established a fast, robust and selective assay to measure NTHi LOS sialylation, 
we set out to selectively block this process with sialic acid-based inhibitors. Recently 
it has been shown that protected, fluorinated sialic acid can be taken up by passive 
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diffusion and metabolized into CMP-SiaNAc-3Fax, which acts as a competitive inhibitor 
of sialyltransferases in mammalian cells.18-20 We reasoned that unprotected 
fluorinated sialic acid could be actively taken up through the TRAP transporter system 
of NTHi and inhibit NTHi sialyltransferases to prevent LOS sialylation (Figure 2A). 
Therefore, an unprotected fluorinated sialic acid analogue, SiaNAc-3Fax, was 
synthesized (Scheme 2) and its effect on NTHi LOS sialylation was assessed.21  
Using a previously published route, protected inhibitor 11 was synthesized in a three-
step procedure from 2.22 It should be noted that both isomers with equatorial and 
axial fluoride are formed, even though the equatorial fluoride is formed to a lesser 
extent. After deprotection under basic conditions to yield the unprotected bacterial 
inhibitor 12 (SiaNAc-3Fax), only the more abundant axial fluoride 12 was isolated 
(Scheme 2).  
 
 
Scheme 2. Synthesis of SiaNAc-3Fax i) TMSOTf, 0 °C, 4 h, 61%. ii) DMF, H2O, Selectfluor, 50 °C, 16 h; 
iii) Ac2O, Pyr, r.t., (80% two steps). iv) MeOH, H2O, r.t.; 16 h, 51%. 
 
NTHi was grown in defined media containing 100 µM SiaNAz and SiaNPoc and 
increasing concentrations of 3Fax-SiaNAc (0.01 - 100 µM). SiaNAc-3Fax blocked the 
incorporation of SiaNAz and SiaNPoc in a dose-dependent manner (Figures 2D and 
S3A-C) with an IC50 between 90 - 700 nM (Figures 2D and S3C). Even though SiaNAz 
was present in a 100-fold access, 1 µM SiaNAc-3Fax showed over 50% reduction of 
SiaNAz incorporation into LOS (Figure 2D). 
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In line with the findings obtained with protected SiaNAz and SiaNPoc sialic acid 
analogues, no inhibition was observed with the protected fluorinated sialic acid 
(Ac5SiaNAc-3Fax) (Figures 2E and 3D). In human THP-1 cells, however, treatment with 
protected Ac5SiaNAc-3Fax effectively decreased sialic acid expression measured by 
lectins, whereas this was not the case for the non-protected analogue SiaNAc-3Fax 
(Figures S3E and S3F). 
Having demonstrated that SiaNAc-3Fax potently inhibited NTHi LOS sialylation, we 
next investigated the functional consequences on serum-mediated killing. NTHi was 
grown in defined media containing natural sialic acid (SiaNAc) and subjected to a 
killing assay with pooled normal human serum (NHS). With increasing sialic acid 
concentrations, NTHi acquired resistance to serum-mediated killing (Figure 3A). This 
process required a functional sialic transporter, because SiaNAc addition had no 
effect on serum resistance of the ∆siaP mutant (Figure 3B).  
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Figure 3. Promotion and inhibition of serum resistance of NTHi. A) SiaNAc supplement confers serum 
resistance of NTHi. B) Sialic acid uptake requires bacterial Trap-transporter. C) SiaNAc-3Fax inhibits 
serum resistance. D) IC50 curve of the effect of SiaNAc-3Fax. 
 
No difference in factor H binding to NTHi strain 86-028NP and ∆siaP mutant grown 
with or without SiaNAc was detected (Figure S4A) indicating that resistance to serum-
mediated killing is independent of factor H, which is consistent with previous 
findings.23-24 Having established that sialylation increased serum resistance, we 
investigated whether inhibition of LOS sialylation could mitigate this effect. 
Therefore, NTHi was grown in defined media containing 1000 µM SiaNAc as well as 
increasing concentrations of SiaNAc-3Fax (1 - 100 µM) and subjected to serum-
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mediated killing. Increasing concentrations of SiaNAc-3Fax completely abolished sialic 
acid-mediated serum resistance of NTHi in a dose-dependent manner (Figure 3C), 
with an IC50 of 1.2 µM (Figure 3D). On the other hand, no inhibition was observed 
with the protected fluorinated sialic acid inhibitor Ac5SiaNAc-3Fax (Figure S4B).  
 
These results demonstrate that SiaNAc-3Fax effectively inhibits LOS sialylation thereby 
decreasing resistance to serum-mediated killing. However, it remains elusive how 
sialic acid is released from host tissue and transferred to NTHi. Hence, we 
constructed a model system of the respiratory tract to study transfer of host sialic 
acids to NTHi in a physiological setting (Figure 4A). Primary human bronchial 
epithelial cells (PHBECs) which express mucins at the apical side were differentiated 
in a transwell system using basolateral medium supplemented with Ac5SiaNAz or 
Ac5SiaNPoc and incorporation of SiaNPoc into secreted glycoproteins released on the 
apical side of the PHBECs culture was confirmed by western blot analysis (Figure 
S5A). Noteworthy, only protected sialic acid derivatives, but not the unprotected 
versions were incorporated into the secreted proteins (Figure S5A). Subsequently, 
NTHi was grown at the apical side of the transwell for 24 hours and uptake and 
incorporation of SiaNAz or SiaNPoc sialic acids into the LOS was determined using 
CuAAC and flow cytometry (Figure 4B). Incorporation of PHBEC-derived azide sialic 
acids by NTHi was clearly detected when Ac5SiaNAz was added to the PHBEC growth 
medium at the basolateral side (Figure 4B). Similar results were obtained with 
PHBECs grown in the presence of Ac5SiaNPoc, albeit to a remarkably lower extent 
even though Ac5SiaNAz and Ac5SiaNPoc were incorporated with comparable 
efficiency (Figure 2B-C). Recently, we showed that Poc-, but not azide- modified sialic 
acids were largely resistant to cleavage by bacterial neuraminidases (also known as 
sialidase).25 This difference in sensitivity towards release by neuraminidase could 
explain the lower transfer of SiaNPoc compared with SiaNAz.  
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Figure 4. Visualization and inhibition of sialic acid transfer from PHBEC to NTHi. A) Schematic 
presentation of sialic acid transfer from PHBEC to NTHi in the presence of the inhibitors DANA and 
SiaNAc-3Fax. B) Visualization of sialic acid transfer from host to NTHi C) Effect of DANA on sialic acid 
transfer D) Effect of SiaNAc-3Fax on sialic acid transfer to NTHi E) Serum survival of NTHi in the 
presence of SiaNAc-3Fax. 
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To confirm the requirement of neuraminidase activity for sialic acid transfer, 
neuraminidase inhibitor N-acetyl-2,3-dehydro-2-deoxyneuraminic acid (DANA) was 
added 2 days prior to NTHi infection. Treatment with DANA significantly reduced 
transfer from host cell sialic acids to NTHi (Figure 4C). Combined with the reduced 
transfer of SiaPoc, these data strongly suggest that neuraminidase activity is required 
for the transfer of host cell sialic acids to NTHi. So far, neuraminidase activity by 
Haemophilus influenzae has not been conclusively demonstrated,6 therefore it is 
possible that endogenous host neuraminidases contribute to the release of the sialic 
acid derivatives from host cell glycans.  
Next, we determined whether sialic acid transfer could be inhibited with SiaNAc-3Fax. 
NTHi wild-type (WT) and siaP mutant strain were grown at the apical side of the 
transwell both with and without the SiaNAc-3Fax inhibitor for 24 hours and 
subsequently the uptake and incorporation of SiaNAz sialic acid analogues into LOS 
was determined. Clear incorporation of PHBEC-derived SiaNAz sialic acid was 
detected for NTHi wild-type strain, but not for the ΔsiaP mutant strain (Figure 4D) 
while treatment with 1 µM SiaNAc-3Fax completely inhibited SiaNAz incorporation 
into wild-type NTHi. Furthermore, wild-type NTHi grown on PHBECs showed higher 
survival in serum compared to the siaP mutant (Figure 4E). Increased survival was 
also observed for DMSO and Ac5SiaNAz-treated PHBEC cultures, suggesting that both 
normal and azide sialic acids mediate NTHi serum resistance after transfer. 
Importantly, bacterial growth was similar in all conditions and PHBEC viability was not 
significantly affected by NTHi growth (Figure S5B). In accordance with our data 
obtained with defined culture medium, addition of SiaNAc-3Fax abrogated sialic acid-
mediated serum resistance of NTHi (Figure 4E).  
 
  
266 
 
Conclusion 
Pathogens acquire sialic acids to evade the immune system thereby hazarding to not 
only promote the infection but causing autoimmune diseases. To counter the threat 
of long-term damage, it is crucial to counter sialylation rather than just killing the 
pathogen. We have shown that potent sialic acid-based glycotools can be used to 
visualize or inhibit sialic acid utilization in pathogenic NTHi. In a model for the human 
respiratory tract we demonstrated that sialic acids were released by neuraminidases 
and subsequently taken up by NTHi which provides new  insights in the mechanism of 
NTHi sialic acid transfer. Moreover, we demonstrated that pharmacological inhibition 
of NTHi LOS sialylation abolished the resistance to serum-mediated killing, therefore 
enabling NTHi specific therapies. These tools might be used to treat other sialic acid-
dependent pathogens and counter long-term damage caused by sialic acid mimicry.
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Supplementary information 
 
Figure S1. All sialic acid derivatives used. Top: The three unprotected sialic acid derivatives for active uptake 
Bottom: The three acetyl- and methyl-ester protected sialic acids for passive diffusion. Left to right: Derivatives 
with azidoacetyl-, propargyloxycarbonyl - or fluoride respectively. 
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Figure S2. A) NTHi 86-028NP bacteria were grown in RPMI-1640 medium with 1, 10, 100 or 1000 µM 
SiaNPoc. Incorporation of SiaNPoc by NTHi was determined by CuAAC and flow cytometry (n = 4 ± 
SEM). B) NTHi 86-028NP bacteria were grown in RPMI-1640 medium with 1, 10, 100 or 1000 µM 
SiaNAz. Incorporation of SiaNAz by NTHi was determined by CuAAC and flow cytometry (n = 4 ± 
SEM). C) NTHi 86-028NP wild-type (WT) or ∆siaP mutant bacteria were grown in supplemented 
RPMI-1640 medium with 100 µM SiaPoc. Incorporation of SiaPoc by NTHi was determined by CuAAC 
and flow cytometry (n = 4 ± SEM). ). D) NTHi 86-028NP wild-type (WT) or ∆siaP mutant bacteria were 
grown in supplemented RPMI-1640 medium with 100 µM SiaNAz. Incorporation of SiaNAz by NTHi 
was determined by CuAAC and flow cytometry (n = 6 ± SEM). E) NTHi 86-028NP bacteria were grown 
in supplemented RPMI-1640 medium with 100 µM SiaNPoc or Ac5SiaNPoc. LOS was isolated and 
incorporation of SiaNPoc was determined by CuAAC and Western blot.  
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Figure S3. A) NTHi 86-028NP bacteria were grown in RPMI-1640 medium with 100 µM SiaPoc and 
0.01, 0.1, 1, 10 or 100 µM SiaNAc-3Fax. Incorporation of SiaPoc by NTHi was determined by CuAAC 
and flow cytometry (n = 6-10 ± SEM). B) NTHi 86-028NP bacteria were grown in RPMI-1640 medium 
with 100 µM SiaNAz and 0.01, 0.1, 1, 10 or 100 µM SiaNAc-3Fax. Incorporation of SiaNAz by NTHi was 
determined by CuAAC followed by flow cytometric analysis (n = 7 ± SEM). C) IC50 curve of the effect 
of SiaNAc-3Fax inhibitor on the incorporation of SiaNPoc by NTHi. D) NTHi 86-028NP bacteria were 
grown in RPMI-1640 medium with 100 µM SiaNPoc and 1, 10 or 100 µM Ac5SiaNAc-3Fax. 
Incorporation of SiaNPoc by NTHi was determined by CuAAC and flow cytometry (n = 4 ± SEM). E) 
α2,3-linked or F) α2,6-linked sialic acids were detected with MALII or SNA-I, respectively (n = 3 ± 
SEM). One-way ANOVA with Dunnett’s Multiple Comparison Test was used for statistical analysis. NS 
= not significant, ** = p <0.01, *** = p <0.001. 
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Figure S4. A) Serum survival was determined for 1 hour with 20% pooled NHS (n = 7 ± SEM) c) and 
factor H binding was determined by flow cytometry (n = 4). B) NTHi 86-028NP bacteria were grown in 
RPMI-1640 medium with 1000 µM SiaNAc and 1, 10 or 100 µM Ac5SiaNAc-3Fax. Serum survival was 
determined for 1 hour with 20% pooled NHS (n = 3 ± SEM). One-way ANOVA with Dunnett’s Multiple 
Comparison Test (b) or Tukey’s Multiple Comparison Test (a) was used for statistical analysis. NS = 
not significant, * = p <0.05, ** = p <0.01, *** = p <0.001.  
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Figure S5. A) PHBEC were grown with 100 µM SiaNPoc or Ac5SiaNPoc in basolateral medium for 6 
days. Apical side was washed with Dulbecco’s PBS at day 2, 4 and 6. Apical washes were separated by 
SDS-PAGE and visualized by silver staining (right) or transferred to PVDF membrane for Western 
blotting. Incorporation of SiaNPoc into secreted proteins released on the apical side of the PHBECs 
culture was determined by CuAAC and Western blot (left). B) PHBECs were grown with 100 µM 
Ac5SiaNAz and/or 1 µM SiaNAc-3Fax for 3 days. NTHi 86-028NP wild-type (WT) or ∆siaP mutant 
bacteria were grown in Dulbecco’s PBS on the apical side for 24 hours. left: Bacterial CFU count was 
determined after 24 h (n = 4 ±SEM) and right: membrane integrity, as measured by transendothelial 
electrical resistance (TEER), was determined before and after 24 h bacterial growth (n = 4 ± SEM). 
Two-way ANOVA with Bonferroni post-test was used for statistical analysis * = p <0.05, ** = p <0.01, 
*** = p <0.001. 
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Chemical synthesis 
 
General synthetic procedures: 1H and 13C NMR spectra were recorded on a Varian Inova 400 MHz or 
Bruker Avance III 500 MHz spectrometer. Chemical shifts are reported in parts per million (ppm) 
relative to tetramethylsilane (TMS) as the internal standard. NMR data is presented as follows: 
Chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet of 
doublet, dt = doublet of triplet, m = multiplet and/or multiple resonances), integration, coupling 
constant in Hertz (Hz). All NMR signals were assigned on the basis of 1H, 13C, 19F NMR, COSY and 
HSQC experiments. Mass spectra were recorded on a JEOL JMS-T100CS AccuTOF mass spectrometer. 
Automatic column chromatography was performed on Biotage Isolera Spektra One, using SNAP 
cartridges 10-50g filled with normal silica (Biotage, 30-100 μm, 60 Å) or water resistant iatro beads. 
Microwave reactions were perfomed on a Biotage Initiator 4.1.3. TLC analysis was conducted on TLC 
Silicagel, 60, F254, Merck, with detection by UV absorption (254 nm) where applicable, and by 
spraying with 20% sulfuric acid in methanol followed by charring at ~150 °C or by spraying with a 
solution of (NH4)6Mo7O24.H2O (25 g l-1) in 10% sulfuric acid in methanol followed by charring at ~300 
°C. DCM, ACN and Tol were freshly distilled. All reactions were carried out under an argon 
atmosphere. 
List of abbreviations 
Ac2O  Acetic anhydride    
Acet  Acetone 
ACN   Acetonitrile 
AzOSu   Azidoacetic acid hydroxysuccinimide ester 
BF3•Et2O  Boron trifluoride etherate 
CD3OD  Deuterated methanol 
CDCl3  Deuterated chloroform 
D2O  Deuterium oxide 
DMF  N,N-Dimethylformamide 
DCM   Dichloromethane 
EtOAc  Ethyl acetate 
LiOH   Lithium hydroxide 
MeOH   Methanol 
NaOH  Sodium hydroxide 
PocOSu  Propargylcarboxycarbonyl hydroxysuccinimide carbonate 
Pyr  Pyridine 
r.t.  Room temperature 
sat.  Saturated 
TEA  Triethylamine 
TFA  Trifluoroacetic acid 
TFAA   Trifluoroacetic acid anhydride 
TMSOTf Trimethylsilyl trifluoromethanesulfonate 
Tol  Toluene 
SAda  Adamantyl-thiol 
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Methyl (5-acetamido-3,5-dideoxy-5-D-glycero-D-galacto)onate (1). The Dowex H+ 
resin was washed with MeOH three times before adding 0.2 g resin to a solution of N-
acetylneuraminic acid (1 g; 3.24 mmol) in MeOH (20 mL; 0.16 M). After stirring at 80 °C for 1 h under 
microwave radiation, the colorless mixture was filtered. The filtrate was concentrated in vacuo 
affording 1 (1.05 g; 3.24 mmol; quant.) as a white foam. TLC: (H2O:ACN, 20:80 v/v) Rf = 0.39. 1H NMR 
(500 MHz, CD3OD) δ 4.07 – 3.98 (m, 2H, H-4; H-6), 3.85 – 3.79 (m, 2H, H-5; H-9a), 3.78 (s, 3H, OMe), 
3.70 (ddd, J = 8.8, 5.7, 2.8 Hz, 1H, H-8), 3.62 (dd, J = 11.3, 5.7 Hz, 1H, H-9b), 3.48 (dd, J = 9.2, 1.1 Hz, 
1H, H-7), 2.22 (dd, J = 12.9, 4.9 Hz, 1H, H-3eq), 2.02 (s, 3H, Me, Ac), 1.89 (dd, J = 12.8, 11.5 Hz, 1H, H-
3ax). 13C NMR (126 MHz, CD3OD) δ 175.10 (C-1), 171.78 (CO, Ac), 96.65 (C-2), 72.06 (C-6), 71.62 (C-8), 
70.16 (C-7), 67.83 (C-4), 64.82 (C-9), 54.29 (C-5), 53.71 (OMe), 40.68 (C-3), 22.68 (Me, Ac). HR-ESI-
TOF/MS (m/z): [M+Na]+ calcd. for C12H21NNaO9, 346.11140; found, 346.11286. 
 
Methyl (5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-5-D-glycero-D-
galacto)onate (2). To a solution of sialic acid methylester 1 (20.9 g; 64.6 mmol) in Pyr (250 mL; 3.09 
mol; 47.8 eq.), Ac2O (125 mL; 1.59 mol; 24.6 eq.) was slowly added. After stirring at r.t. for 24 h, the 
mixture was concentrated in vacuo with Tol co-evaporation. The residue was dissolved in EtOAc and 
washed successively with HCl (0.1 M) and sat. aq. NaHCO3. The organic layer was dried over MgSO4 
and filtered. The filtrate was concentrated in vacuo affording 2 (34.5 g; 64.6 mmol; quant.) as white 
foam. TLC: (Acet:DCM, 40:60 v/v) Rf = 0.51. 1H NMR (500 MHz, CDCl3, major anomer) δ 5.38 – 5.37 
(m, 1H, H-7), 5.26 (ddt, J = 10.1, 7.5, 4.9 Hz, 1H, H-4), 5.07 (ddd, J = 6.8, 5.1, 2.5 Hz, 1H, H-8), 4.50 (dd, 
J = 12.5, 2.6 Hz, 1H, H-9a), 4.15 – 4.10 (m, 3H, H-9b; H-6; H-5), 3.80 (s, 3H, OMe), 2.55 (dd, J = 13.5, 5.0 
Hz, 1H, H-3eq), 2.15 (s, 3H, Me, OAc), 2.14 (s, 3H, Me, OAc), 2.10 – 2.09 (m, 1H, H-3ax), 2.07 (s, 3H, Me, 
OAc), 2.05 – 2.03 (m, 6H, 2xMe, OAc), 1.90 (s, 3H, Me, NHAc). 13C NMR (126 MHz, CDCl3, major 
anomer) δ 171.15 (CO, Ac), 170.75 (CO, Ac), 170.41 (2x CO, Ac), 170.38 (CO, Ac), 168.37 (C-1), 166.46 
(CO, Ac), 97.65 (C-2), 73.00 (C-6), 71.52 (C-8), 68.44 (C-4), 67.98 (C-7), 62.27 (C-9), 53.35 (OMe), 
49.49 (C-5), 36.05 (C-3), 23.33 (Me, Ac), 21.05 (Me, Ac), 20.99 (Me, Ac), 20.93 (2xMe, Ac) 20.91 (Me, 
Ac). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C22H31NNaO14, 556.16422; found, 556.16487. 
 
Methyl 5-acetamido-4,7,8,9-penta-O-acetyl-2,3,5-tri-deoxy-2-thioadamantyl-
D-glycero-α-galacto-non-2-ulopyranosonate (3). Peracetylated sialic acid 2 (5 g; 9.37 mmol) was 
solved in DCM (60 mL; 0.16 M) and HSAda (1.735 g; 10.31 mmol; 1.1 eq) was added. BF3•Et2O (2.375 
mL; 18.74 mmol; 2 eq) was added slowly and the reaction was stirred at room temperature for 16 h. 
Diluted with DCM and ice-cold sat. aq. NaHCO3. The organic layer was separated, dried with MgSO4 
and filtered. The filtrate was concentrated in vacuo. Silicagel flash column chromatography (0 → 25% 
Acet in DCM) afforded 3 (4.95 g; 9.37 mmol; 82%) as a white foam. TLC: (Acet:DCM, 25:75 v/v) Rf = 
0.46. 1H NMR (500 MHz, CDCl3, major anomer) δ 5.88 (d, J = 10.2 Hz, 1H, NH), 5.43 (dd, J = 2.8, 1.4 
Hz, 1H, H-7), 5.29 – 5.17 (m, 1H, H-4), 5.10 (dt, J = 8.9, 1.7 Hz, 1H, H-8), 4.96 (dd, J = 12.4, 1.8 Hz, 1H, 
H-9a), 4.52 (dd, J = 10.5, 2.7 Hz, 1H, H-6), 4.16 (ddd, J = 11.7, 9.0, 2.4 Hz, 1H, H-9b), 4.01 (d, J = 10.4 
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Hz, 1H, H-5), 3.77 (s, 3H, OMe), 2.48 (dd, J = 13.5, 4.6 Hz, 1H, H-3eq), 2.07 (s, 3H, Me, Ac), 2.03 (s, 3H, 
Me, Ac), 2.01 – 1.78 (m, 19H, 3xMe, Ac; H-3ax; (CH2)3CS, SAda; 3x(CH2CH), SAda), 1.66 – 1.54 (m, 6H, 
3x(CH2CH), SAda). 13C NMR (126 MHz, CDCl3, major anomer) δ 171.33 (CO, Ac), 170.74 (CO, Ac), 
170.29 (CO, Ac), 170.26 (CO, Ac), 170.09 (CO, Ac), 169.80 (C-1), 86.04 (C-2), 74.00 (C-8), 72.57 (C-6), 
69.20 (C-7), 68.91 (C-4), 63.24 (C-9), 52.69 (OMe), 50.36 ((CH2)3CS, SAda), 49.31 (C-5), 43.38 
((CH2)3CH, SAda), 39.84 (C-3), 35.84 (3x(CH2CH), SAda), 29.64 (3x(CH2CH), SAda), 22.99 (Me, Ac), 
20.98 (Me, Ac), 20.75 (Me, Ac), 20.62 (Me, Ac), 20.52 (Me, Ac). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. 
for C30H43NNaO12S, 664.24036; found, 664.23780.  
 
Methyl 5-trifluoroacetamido-4,7,8,9-penta-O-acetyl-2,3,5-tri-deoxy-2-
thioadamantyl-D-glycero-α-galacto-non-2-ulopyranosonate (4). Thioadamantyl sialic acid 3 (100 mg; 
0.156 mmol) was solved in ACN (4 mL; 0.04 M) and TFAA (88 µL; 0.623 mmol; 4 eq.) was added. The 
reaction vessel was sealed and stirred at 135°C and 6 bar for 10 min under microwave radiation. 
After cooling to room temperature, the reaction was quenched by an excess of TEA and MeOH, 
diluted in EtOAc and washed three times with sat. aq. NaHCO3. The organic layer was separated, 
dried with MgSO4 and filtered. The filtrate was concentrated in vacuo. Silicagel flash column 
chromatography (0 → 10% Acet in DCM) afforded 4 (80 mg; 0.12 mmol; 74%) as a white foam. TLC: 
(Acet:DCM, 10:90 v/v) Rf = 0.75. 1H NMR (500 MHz, CDCl3, major anomer) δ 5.48 (t, J = 2.1 Hz, 1H, H-
7), 5.43 (ddd, J = 11.8, 10.4, 4.7 Hz, 1H, H-4), 5.18 (dt, J = 8.7, 1.9 Hz, 1H, H-8), 4.98 (dd, J = 12.3, 1.8 
Hz, 1H, H-9a), 4.75 (dd, J = 10.4, 2.7 Hz, 1H, H-6), 4.25 (dd, J = 12.4, 8.7 Hz, 1H, H-9b), 4.08 (q, J = 10.1 
Hz, 1H, H-5), 3.84 (s, 3H, OMe), 2.59 (dd, J = 13.6, 4.7 Hz, 1H, H-3eq), 2.14 (s, 3H, Me, OAc), 2.10 (s, 
3H, Me, OAc), 2.04 – 1.83 (m, 16H, 2xMe, OAc; H-3ax; (CH2)3CS Sada; 3x(CH2CH), SAda), 1.71 – 1.62 
(m, 6H, 3x(CH2CH), SAda). 13C NMR (126 MHz, CDCl3, major anomer) δ 171.39 (CO, Ac), 170.84 (CO, 
Ac), 170.37 (CO, Ac), 169.80 (CO, Ac), 169.67 (C-1), 157.72 (q, J = 37.8 Hz, COCF3), 115.47 (q, J = 288.3 
Hz, COCF3), 86.03 (C-2), 73.61 (C-8), 71.56 (C-6), 69.11 (C-7), 68.43 (C-4), 63.15 (C-9), 52.81 (OMe), 
50.61 ((CH2)3CH, SAda), 50.34 (C-5), 43.38 ((CH2)3CS, SAda), 39.86 (C-3), 35.84 (3x(CH2CH), SAda), 
29.75 (3x(CH2CH), SAda), 21.04 (Me, Ac), 20.59 (Me, Ac), 20.56 (Me, Ac), 20.53 (Me, Ac). HR-ESI-
TOF/MS (m/z): [M+Na]+ calcd. for C30H40F3NNaO12S, 718.21210; found, 718.21045. 
 
5-amido-2,3,5-tri-deoxy-2-thioadamantyl-D-glycero-α-galacto-non-2-
ulopyranosonate (5). TFA protected sialic acid 4 (1g; 1.437 mmol) was solved in MeOH (10 mL; 0.144 
M) and LiOH (482 mg; 20.12 mmol; 14 eq.) and H2O (5 mL) were added. The reaction vessel was 
sealed and stirred at 120°C and 2 bar for 30 min under microwave radiation. The reaction was 
filtered and silica was added to the filtrate. After concentration in vacuo, the crude product on silica 
was loaded on water-resistant iatro-beads crosslinked-silicagel flash column chromatography (0 → 
20% H2O (+1% TFA) in ACN) afforded 5 (591 mg; 1.1416 mmol; 98%) as a white foam. TLC: (H2O:ACN, 
20:80 v/v) Rf = 0.19. 1H NMR (500 MHz, D2O, major anomer) δ 4.17 (dd, J = 10.0, 1.0 Hz, 1H, H-5), 
3.93 – 3.81 (m, 5H, H-7; H-8; H-5; H-9a; H-4), 3.80 – 3.72 (m, 1H, H-9b), 2.68 (t, J = 9.8 Hz, 1H, H-6), 
2.42 (dd, J = 13.5, 4.6 Hz, 1H, H-3eq), 2.03 – 1.95 (m, 9H, (CH2)3CS, SAda; 3x(CH2CH), SAda), 1.74 – 1.60 
(m, 7H, H-3ax; 3x(CH2CH), SAda). 13C NMR (126 MHz, D2O, major anomer) δ 177.24 (C-1), 88.40 (C-2), 
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73.36 (C-5), 70.14 (C-7), 69.58 (C-8), 68.94 (C-4), 63.32 (C-9), 53.44 (C-6), 49.44 ((CH2)3CS, SAda), 
43.63 (C-3), 43.32 ((CH2)3CS, SAda), 35.66 (3x CH2CH, SAda), 29.68 (3x CH2CH, SAda). HR-ESI-TOF/MS 
(m/z): [M+H]+ calcd. for C19H32NO7S, 418.18995; found, 418.19152. 
 
5-propargyloxycarbamado-2,3,5-tri-deoxy-2-thioadamantyl-D-glycero-α-
galacto-non-2-ulopyranosonate (6) Sialic acid amine 5 (50 mg; 0.12 mmol) was solved in H2O (0.5 
mL). PocOSu (28 mg; 0.144 mmol; 1.2 eq) was solved in ACN (1 mL) and added to the sialic acid 
solution. The reaction was stirred at r.t. for 16 h, diluted with an excess of MeOH and concentrated 
on silica. The product was purified on water-resistant iatro-beads crosslinked-silicagel flash column 
chromatography (0 → 20% H2O (+1% TFA) in ACN) affording 7 (50 mg; 0.12 mmol; 84%) as a white 
foam. TLC: (H2O:ACN, 25:75 v/v) Rf = 0.57. 1H NMR (500 MHz, D2O, major anomer) δ 4.71 (dd, J = 4.8, 
2.4 Hz, 2H, CH2, Poc), 4.30 (d, J = 10.5 Hz, 1H, H-6), 4.04 (ddd, J = 11.9, 10.0, 4.8 Hz, 1H, H-4), 3.91 – 
3.83 (m, 2H, H-8; H-9a), 3.73 (dd, J = 11.8, 5.1 Hz, 1H, H-9b), 3.61 (d, J = 9.2 Hz, 1H, H-7), 3.55 (t, J = 
10.3 Hz, 1H, H-5), 2.92 (t, J = 2.4 Hz, 1H, C≡CH, Poc), 2.50 (dd, J = 13.5, 4.9 Hz, 1H, H-3ax), 2.04 – 1.95 
(m, 9H, (CH2)3CS, SAda; 3x CH2CH, SAda), 1.74 (dd, J = 13.6, 12.0 Hz, 1H, H-3ax), 1.68 (d, J = 2.9 Hz, 6H, 
3x CH2CH, SAda). 13C NMR (126 MHz, D2O) δ 176.82 (C-1), 157.52 (CO, Poc), 88.10 (C≡CH, Poc), 78.52 
(C-2), 75.67 (C≡CH, Poc), 70.99 (C-6), 69.87 (C-8), 68.93 (C-7), 67.39 (C-4), 63.28 (C-9), 54.31 (C-5), 
52.88 (CH2, Poc), 49.46 ((CH2)3CS, SAda), 43.56 (C-3), 43.20 ((CH2)3CH, SAda), 35.59 (3x CH2CH, SAda), 
29.64 (3x CH2CH, SAda). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C23H33NNaO9S, 522.17737; found, 
522.17847.  
 
5-azidoacetamido-2,3,5-tri-deoxy-2-thioadamantyl-D-glycero-α-galacto-non-2-
ulopyranosonate (7) Sialic acid amine 5 (50 mg; 0.12 mmol) was solved in H2O (0.5 mL). AzOSu (31 
mg; 0.156 mmol; 1.3 eq) was solved in ACN (1 mL) and added to the sialic acid solution. The reaction 
was stirred at r.t. for 16 h, diluted with an excess of MeOH and concentrated on silica. The product 
was purified on water-resistant iatro-beads crosslinked-silicagel flash column chromatography (0 → 
20% water (+1% TFA) in ACN) affording 7 (45 mg; 0.09 mmol; 75%) as a white foam. Note: 
Surprisingly, the conversion was not complete - 5 mg amine starting material was retrieved. TLC: 
(H2O:ACN, 25:75 v/v) Rf = 0.50. 1H NMR (500 MHz, D2O, major anomer) δ 4.39 (d, J = 10.6 Hz, 1H, H-
6), 4.17 (ddd, J = 11.8, 10.0, 4.7 Hz, 1H, H-4), 4.11 (s, 2H, CH2, Az), 3.93 (t, J = 10.2 Hz, 1H, H-5), 3.89 – 
3.81 (m, 2H, H-8; H-9a), 3.72 (dd, J = 12.1, 5.2 Hz, 1H, H-9b), 3.54 (d, J = 9.4 Hz, 1H, H-7), 2.52 (dd, J = 
13.6, 4.7 Hz, 1H, H-3eq), 2.06-1.98 (m, 9H, (CH2)3CS, SAda; 3x CH2CH, SAda), 1.91 (dd, J = 13.6, 11.8 Hz, 
1H, H-3ax), 1.68 (d, J = 2.9 Hz, 6H, 3x CH2CH, SAda). 13C NMR (126 MHz, D2O, major anomer) δ 176.47 
(C-1), 175.04 (CO, Az), 86.50 (C-2), 70.78 (C-6), 69.67 (C-8), 68.65 (C-7), 66.56 (C-4), 63.09 (C-9), 52.52 
(C-5), 51.93 (CH2, Az), 50.44 ((CH2)3CS, SAda), 43.10 ((CH2)3CS, SAda), 42.53 (C-3), 35.46 (3x CH2CH, 
SAda), 29.65 (3x CH2CH, SAda). HRMS (m/z): [M+Na]+ calcd for C21H32N4NaO8S, 523.18385; found, 
523.18332. 
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5-propargyloxycarbamado-3,5-dideoxy-D-glycero-α-galacto-non-2-
ulopyranosonate (8) . Sialic acid 6 (55 mg; 0.11 mmol) was solved in H2O (1 mL; 0.11 M) and I2 (31 
mg; 0.121 mmol; 1.1 eq.) was added. The reaction was stirred vigourisly for 30 min and diluted with 
an excess of EtOAc. The reaction was left stirring for 1 min and then washed with water. The water 
layer was lyophilized to yield compound 8 (33 mg; 0.110 mmol; 86%) as a white foam. TLC: (H2O:ACN, 
20:80 v/v) Rf = 0.11. 1H NMR (500 MHz, D2O, major anomer) δ 4.63 (dd, J = 4.1, 2.4 Hz, 2H, CH2, Poc), 
3.98 – 3.88 (m, 2H, H-6; H-4), 3.78 (dd, J = 11.9, 2.7 Hz, 1H, H-9a), 3.69 (ddd, J = 9.2, 6.6, 2.7 Hz, 1H, H-
8), 3.58 (t, J = 10.2 Hz, 1H, H-5), 3.56 – 3.51 (m, 2H, H-7; H-9b), 2.84 (t, J = 2.4 Hz, 1H, C≡CH, Poc), 2.13 
(dd, J = 12.9, 4.9 Hz, 1H, H-3eq), 1.75 (t, J = 12.3 Hz, 1H, H-3ax). 13C NMR (126 MHz, D2O, major 
anomer) δ 176.71 (C-1), 157.47 (CO, Poc), 92.41 (C-2), 78.52 (C≡CH, Poc), 75.66 (C≡CH, Poc), 70.46 (C-
8), 70.27 (C-6) , 68.50 (C-7), 67.37 (C-4), 63.31 (C-9), 53.79 (C-5), 52.87 (CH2, Poc), 39.35 (C-3). HRMS 
(m/z): [M+Na]+ calcd for C13H19NO10, 372.09066; found, 372.09041. 
 
5-azidoacetamido-3,5-dideoxy-D-glycero-α-galacto-non-2-ulopyranosonate (9) 
Sialic acid 7 (6 mg; 0.012 mmol) was solved in H2O (1 mL; 0.012 M) and I2 (9 mg; 0.036 mmol; 3 eq.) 
was added. The reaction was stirred vigourisly for 10 min and diluted with an excess of EtOAc. The 
reaction was left stirring for 1 min and then washed with water. The water layer was lyophilized to 
yield compound 9 (4 mg; 0.011 mmol; 95%) as a white foam. TLC: (H2O:ACN, 20:80 v/v) Rf = 0.09. 1H 
NMR (500 MHz, D2O, major anomer) δ 4.20 – 4.11 (m, 2H, H-4; H-6), 4.11 (s, 2H, CH2, Az), 4.03 (d, J = 
10.3 Hz, 1H, H-5), 3.85 (dd, J = 12.1, 2.7 Hz, 1H, H-9a), 3.81 – 3.73 (m, 1H, H-8), 3.63 (dd, J = 11.9, 6.4 
Hz, 1H, H-9b), 3.57 (d, J = 9.1 Hz, 1H, H-7), 2.32 (dd, J = 13.0, 5.0 Hz, 1H, H-3eq), 1.90 (t, J = 12.2 Hz, 1H, 
H-3ax). 13C NMR (126 MHz, D2O, major anomer) δ 176.47 (C-1), 173.82 (CO, Az), 95.52 (C-2 hardly 
visible) 70.20 (C-8), 68.20 (C-6), 52.17 (C-5), 51.92 (CH2, Az), 38.93 (C-3). HRMS (m/z): [M+Na]+ calcd 
for C11H18N4NaO9, 373.09715; found, 373.09913. 
 
 Methyl (5-acetamido-4,7,8,9-tetra-O-acetyl-3-dehydro-2,3,5-trideoxy-5-β-D-
glycero-D-galacto)onate (10). Peracetylated sialic acid 2 (1.02 g, 1.912 mmol) was dissolved in ACN (4 
mL; 0.478 M) and cooled to 0°C. TMSOTf (1.03 mL; 5.736 mmol; 3 eq.) was added dropwise to the 
solution which turned slightly yellow. After 4 hours, the reaction was diluted with an excess EtOAc 
and washed three times with sat. aqueous NaHCO3 (30 mL). The organic layer was concentrated in 
vacuo and the product was purified on silicagel flash column chromatography (0  30% Acet in 
DCM), and a white solid was obtained (0.552 g, 1.166 mmol, 61% yield as a white foam). TLC: 
(Acet:DCM, 30:70 v/v) Rf = 0.50. 1H NMR (400 MHz, CDCl3) δ 6.05 (d, J = 8.9 Hz, 1H, NH), 5.99 (d, J = 
3.1 Hz, 1H, H-3), 5.54 – 5.48 (m, 2H, H4; H7), 5.35 (ddd, J = 7.5, 4.4, 3.1 Hz, 1H, H-8), 4.65 (dd, J = 
12.3, 3.1 Hz, 1H, H-9a), 4.40 (dd, J = 7.8, 5.1 Hz, 2H, H-6; H-5), 4.20 (dd, J = 12.3, 7.3 Hz, 1H, H-9b), 3.81 
(s, 3H, OMe), 2.13 (s, 3H, Me, Ac), 2.08 (s, 3H, Me, Ac), 2.07 (s, 3H, Me, Ac), 2.06 (s, 3H, Me, Ac), 1.93 
(s, 3H, Me, Ac). 13C NMR (101 MHz, CDCl3) δ 170.82 (CO, Ac), 170.61 (CO, Ac), 170.19 (CO, Ac), 170.17 
(CO, Ac), 161.63 (C-1), 145.06 (C-2), 107.98 (C-3), 76.64 (C-6), 70.85 (C-8), 68.03 (C-7), 67.64 (C-4), 
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61.97 (C-9), 52.57 (OMe), 46.46 (C-5), 23.09 (Me, Ac), 20.85 (Me, Ac), 20.76 (Me, Ac), 20.72 (Me, Ac), 
20.70 (Me, Ac). HRMS (m/z): [M+Na]+ calcd for C20H27NO12, 496.1431; found, 496.1430. 
 
Methyl (5-acetamido-4,7,8,9-tetra-O-acetyl-3-dehydro-3,5-dideoxy-3-fluoro-5-β-
D-glycero-D-galacto)onate (11). Sialic acid glycal 10 (1.5 g, 3.17 mmol) was solved in DMF (23.8 mL) 
and H2O (7.9 mL; 0.1 M). Selectfluor (3.37 g, 9.51 mmol; 3 eq.) was added and the reaction was 
heated to 60°C for 16 hours, then concentrated in vacuo. The compound was redissolved in EtOAc 
washed with sat. aqueous NaHCO3, dried with MgSO4, filtered, concentrated in vacuo. TLC: 
(Acet:DCM, 30:70 v/v) Rf = 0.40. HRMS (m/z): [M+Na]+ calcd for C20H28FNO13, 532.1443; found, 
532.1442. The crude fluorinated alcohol was dissolved in Pyr (14.5 mL) and Ac2O (7.3 ml), stirred for 
16 hours at r.t. and was evaporated in vacuo. The resulting solid dissolved in EtOAc and sat. aqueous 
NaHCO3. The organic phase was separated and the solvent evaporated in vacuo and purified on silica 
flash-column chromatography (0  30% Acet in DCM) affording 11 (1.46 g, 2.54 mmol, 80% yield 
over two steps) as a slightly yellow foam. TLC: (Acet:DCM, 30:70 v/v) Rf = 0.55. 1H-NMR (500 MHz, 
CD3OD, major anomer) δ 5.58 (d, J = 8.9 Hz, 1H, NH), 5.46 (dd, J = 27.9, 10.7 Hz, 1H, H-4), 5.29 (dd, J = 
5.0, 1.8 Hz, 1H, H-7), 5.05 (ddd, J = 6.7, 5.2, 2.5 Hz, 1H, H-8), 4.87 (dd, J = 49.1, 2.5 Hz, 1H, H-3), 4.51 
(dd, J = 12.5, 2.5 Hz, 1H, H-9a), 4.21 – 4.10 (m, 3H, H-9b; H-5; H-6), 3.77 (s, 3H, OMe), 2.12 – 2.09 (m, 
6H, 2xMe, OAc), 2.04 (s, 3H, Me, OAc), 1.98 (s, 3H, Me, OAc), 1.97 (s, 3H, Me, OAc), 1.85 (s, 3H, Me, 
NHAc).; 13C-NMR (126 MHz, CD3OD) δ 170.58 (CO, Ac), 170.56 (CO, Ac), 170.50 (CO, Ac), 170.34 (CO, 
Ac), 167.11 (C-1), 95.16 (d, J = 28.8 Hz, C-2), 86.95 (d, J = 185.3 Hz, C-3), 71.91 (C-6), 71.37 (C-8), 
68.40 (d, J = 17.2 Hz, C-4), 67.93 (C-7), 62.09 (C-9), 53.49 (OMe), 45.53 (C-5), 29.27 (Me, Ac), 20.88 
(Me, Ac), 20.79 (Me, Ac) , 20.74 (Me, Ac), 20.65 (Me, Ac), 20.51 (Me, Ac); HRMS (m/z): [M+Na]+ calcd 
for C22H30FNO14, 574.1548; found, 574.1548. 
 
(5-acetamido-3-dehydro-3,5-dideoxy-3-fluoro-5-β-D-glycero-D-galacto)onate (12). 
Fluorinated sialic acid 11 (150 mg; 0.294 mmol) was solved in a 1 molar solution of NaOH (0.8 g; 0,02 
mol) in MeOH (19 mL) and H2O (1 mL) and stirred at r.t. for 16 h. Silica powder was added to the 
solution before concentrating in vacuo and purification on water-resistant iatro-beads crosslinked-
silicagel flash column chromatography (0% → 20% H2O (+1% TFA) in ACN) to afford 12 (52 mg; 0.15 
mmol; 51%) as a white foam. TLC: (H2O:ACN, 25:75 v/v) Rf = 0.27. 1H NMR (500 MHz, D2O, major 
anomer) δ 4.78 (dd, J = 49.3, 2.5 Hz, 1H, H-3), 4.17 (t, J = 10.6 Hz, 1H, H-5), 4.04 (ddd, J = 30.0, 10.8, 
2.5 Hz, 1H, H-4), 3.97 (d, J = 10.6 Hz, 1H, H-6), 3.86 – 3.75 (m, 3H, H-8; H-9a), 3.57 (dd, J = 12.5, 7.0 Hz, 
1H, H-9b), 3.47 (dd, J = 8.8, 1.1 Hz, 1H, H-7), 1.98 (s, 3H, Me, NHAc). 13C NMR (126 MHz, D2O,) δ 
174.89 (CO, NHAc), 171.43 (C-1), 94.49 (d, J = 26.5 Hz, C-2), 89.59 (d, J = 177.4 Hz, C-3), 70.35 (C-8), 
70.10 (C-6), 68.11 (C-7), 67.69 (d, J = 18.3 Hz, C-4)., 63.10 (C-9), 47.26 (C-5), 22.03 (Me, NHAc). 19F 
NMR (470 MHz, D2O) δ -208.11 (dd, J = 49.3, 30.0 Hz, major anomer), -217.73 (dd, J = 51.3, 30.0 Hz, 
minor anomer). HRMS (m/z): [M+Na]+ calcd for C11H18FNNaO9, 350.08633; found, 350.08670.  
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Biological Procedures 
Bacterial strains and growth conditions. 
NTHi strains used in this study are listed in Table 1. Growth on plates was performed on brain heart 
infusion (BHI) broth (Becton Dickinson) agar plates supplemented with 10 µg/mL hemin (Sigma-
Aldrich) and 2 µg/mL β-nicotinamide adenine dinucleotide (Merck) (sBHI) at 37 °C + 5% CO2. For gene 
deletion mutants, sBHI plates contained 150 µg/mL of spectinomycin (Calbiochem). NTHi was grown 
shaking with 250 rpm at 37 °C in supplemented RPMI-1640 medium as described previously 26. 
Medium was supplemented with SiaNAz, SiaNPoc, SiaNAc-3Fax, Ac5SiaNAz, Ac5SiaNPoc, Ac5SiaNAc-
3Fax or N-acetylneuraminic acid (SiaNAc) (Sigma-Aldrich) for ~8 generations before use in 
experiments. Viable bacterial counts were determined by plating serial dilutions in phosphate-
buffered saline (PBS) on sBHI agar plates.  
Cell culture. 
Human monocytic THP-1 cells (TIB-202, ATCC) were cultured in RRMI-1640 medium (Life 
Technologies) supplemented with 10% FBS (Greiner Bio-one), 2 mM glutamine (Lonza) and antibiotic-
antimycotic solution (Life Technologies) in a humidified CO2 incubator at 37 °C. THP-1 cells were 
cultured 3 days with 100 µM of the sialic acid analogues SiaNAz, SiaNPoc, SiaNAc-3Fax, Ac5SiaNAz, 
Ac5SiaNPoc, Ac5SiaNAc-3Fax or solvent control. PHBECs (Lonza) were cultured in Bronchial Epithelial 
Cell Growth (BEGM) medium (Lonza) containing 50 µg/mL gentamycin (Sigma-Aldrich) and 50 ng/mL 
fungizone (Life technologies) to 70 % confluence in a T75 tissue culture flask in a humidified CO2 
incubator at 37 °C. PHBECs were seeded on 24-wells transwells (Greiner) and grown to confluence in 
PHBEC:DMEM containing 50 µg/mL gentamycin (Sigma-Aldrich) and 50 ng/mL fungizone. PHBECs 
were differentiated on air-liquid interface with BEGM:DMEM medium containing 50 µg/mL 
gentamycin (Sigma-Aldrich) and 50 ng/mL fungizone at the basolateral side. Basolateral medium was 
refreshed and apical side was washed with 200 µL Dulbecco’s PBS (Lonza) every 2-3 days for 3 weeks. 
One week before NTHi growth, antibiotics were omitted. PHBECs were grown with 100 µM 
Ac5SiaNAz or Ac5SiaNPoc for 2-3 days. Neuraminidase inhibitor N-acetyl-2,3-dehydro-2-
deoxyneuraminic acid (DANA) was added 2 days prior to NTHi growth. 1 x 104 NTHi bacteria in 50 µL 
in Dulbecco’s PBS were added to the apical side of PHBEC with or without DANA or SiaNAc-3Fax 
inhibitor and grown for 24 h. After 24 h, 200 µL Dulbecco’s PBS was added to the apical side to 
collect the NTHi bacteria for CFU counts, flow cytometry or serum resistance assay. PHBEC cell layer 
integrity was measured by transendothelial electrical resistance (TEER) before and after NTHi co-
culture (Millipore). 
Generation of 86-028NP∆siaP gene deletion mutants. 
Genomic DNA was isolated from mid-log phase cultures with the Qiagen DNeasy Blood and Tissue Kit 
(Qiagen). Directed R2866∆siaP gene deletion mutant was generated by allelic exchange of the target 
gene with a spectinomycin resistance cassette, as described previously.27 Overlap extension PCR was 
performed, which inserted the spectinomycin resistance cassette amplified from the pGSF8 plasmid 
with primers PBpR412_L and PBpR412_R (Table 1) between the two ~1000-bp flanking sequences 
surrounding the target gene R2866_0441. R2866∆siaP gene deletion mutants were obtained by 
transformation of the final PCR product by previously published methods28 and selected by plating on 
sBHI agar plates containing 150 µg/mL of spectinomycin. Directed 86-028NP∆siaP gene deletion was 
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generated by transformation of a PCR product obtained with primers R2866_0441_L1 + 
R2866_0441_R1 covering the spectinomycin cassette and ~1000-bp flanking sequences from the 
R2866∆siaP mutant. Gene deletion mutants were validated by PCR with primer sets R2866_0441_L1 
+ R2866_0441_C and R2866_0441_L1 + PBMrTn9 that control for the presence of the gene or 
spectinomycin cassette, respectively. Gene deletions were crossed back to the wild-type strain by 
using chromosomal DNA of the mutant strains as donor during transformation. All primers (Biolegio, 
Nijmegen, Netherlands or Integrated DNA technologies Coralville, IA, USA) used in this study are 
listed in Table 1. 
Flow cytometry analysis. 
To detect azide and propargyloxycarbonyl groups at the bacterial and cell surface, the cells were 
reacted for 20 minutes at 37 °C with click buffer (1 x PBS, 250 µM CuSO4, 200 µM L-histidine, 500 µM 
sodium ascorbate) containing 50 µM alkyne-PEG4-biotin conjugate or azide-PEG3-biotin conjugate, 
respectively, and stained with streptavidin-PE (Molecular Probes, Invitrogen) for 10 minutes at room 
temperature. Bacteria or cells were resuspended in 1 x PBS containing 1 % BSA and fluorescence was 
assessed using a LSR II or CyAn ADP flow cytometer (BD Biosciences) followed by analysis with FlowJo 
software (Tree Star Inc.).  
Surface binding of factor H (fH) was performed by incubating bacteria with heat-inactivated (20 min 
56 °C) pooled normal human serum (NHS) (GTI Diagnostics) in Hank’s buffered salt solution (HBSS) 
without phenol red containing Ca2+/Mg2+ for 1 h at 37 °C. Bacteria were fixed in 2 % 
paraformaldehyde, and incubated with 1:100 diluted sheep anti-human fH (Abcam) in HBSS without 
phenol red containing Ca2+/Mg2+ + 5 % FCS for 30 min at 4 °C, followed by an incubation with 1:500 
diluted goat anti-mouse-Alexa488 conjugated antibodies (Invitrogen) in HBSS without phenol red 
containing Ca2+/Mg2+ + 5% FCS 30 minutes at 4 °C. Bacteria were washed and taken up in PBS for flow 
cytometry using a LSR II (BD Biosciences) followed by analysis with FlowJo software (Tree Star Inc.).  
Lectin staining THP-1 cells. 
THP-1 cells were stained for 1 hour with biotinylated MALII (5 µg/ml) or SNA-I (1 µg/ml), recognizing 
α2,3-linked or α2,6-linked sialic acids sialic acids, respectively, in carbo-free blocking solution 
containing 1 mM CaCl2 and 1 mM MgCl2 at 4 °C. The cells were washed in 1 x PBS containing 1% BSA 
and cell-bound biotinylated lectins were conjugated for 10 minutes at 4 °C with 2 µg/ml streptavidin-
PE and analyzed by flow cytometry. Untreated cells stained only with streptavidin-PE were used as 
background control and the percentage lectin binding was calculated by normalizing the mean 
fluorescence intensity values from the bound lectins to the respective control.  
Lipooligosaccharide isolation and SDS-PAGE. 
LOS was isolated as described previously.29 LOS samples were separated on a Tris-Tricine SDS-PAGE 
gel with a Protean II xi cell electrophoresis system (Bio-Rad) and visualized by silver staining or 
transferred to PVDF membrane for Western blotting.  
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Silver staining. 
The Tris-Tricine SDS-PAGE gel was fixed for 1 h (45% MeOH, 10% acetic acid), washed 3 times 20 min. 
with 50% MeOH and incubated 1 min. in sensitizing solution (0.02% sodium thiosulfate). The gel was 
washed 3 times with distilled water and incubated for 20 min. in impregnation solution (0.2% silver 
nitrate, 0.075% formaldehyde). After washing the gel twice with distilled water, it was treated with 
develop solution (6 % sodium carbonate, 0.02% sodium thiosulfate, 0.05% formaldehyde) until the 
bands were clearly visible. Developing was stopped by incubation in 0.1% acetic acid followed by 30 
min. wash with distilled water. 
Western blot analysis. 
Membranes were blocked with 5% BSA in PBS for 1 hour, washed 5 times with PBS. To detect 
SiaNPoc, membrane was reacted for 20 minutes at 37 °C with click buffer (1 x PBS, 250 µM CuSO4, 
500 µM sodium ascorbate) containing 50 µM azide-PEG3-biotin conjugate, followed by 3 washes with 
PBS. Biotin was stained with streptavidin-HRP (Thermo Fisher) for 30 minutes at room temperature, 
followed by 3 washes with PBS. Chemoluminescent signal was detected by ECL plus reagent (GE 
healthcare). 
Serum survival assays. 
Bacteria were washed once with PBS and diluted to an OD620 of 0.1 in HBSS without phenol red 
containing Ca2+/Mg2+ + 0.1 % gelatin (HBSS3+). Samples were finally diluted 10,000-fold in HBSS3+ to 
obtain a concentration of ~20,000 CFU/mL. 50 µL of the bacterial culture were mixed with 50 µL 40 % 
pooled NHS or heat-inactivated (HI)-NHS, diluted in HBSS3+ and incubated 30 min. or 1 h at 37 °C. 
Serial dilutions were plated on sBHI plates and incubated over night at 37 °C in 5 % CO2. Survival was 
determined by dividing the CFU counts in 20 % NHS with the CFU count in 20 % HI-NHS after 
incubation. 
Neuraminidase assay. 
Neuraminidase activity was measured using the substrate 2’-(4-methylumbelliferyl)--D-N-
acetylneuraminic acid (4MU-Neu5Ac) (Sigma-Aldrich). Apical washes of PHBEC were collected with 
200 µL Dulbecco’s PBS and supplemented RPMI-1640 culture medium was collected after overnight 
growth of NTHi 86-028NP. Clostridium perfringens neuraminidase (Sigma-Aldrich) was used as 
positive control. Neuraminidase reactions were performed in 96-wells plate with 180 µL medium, 50 
µM 4MU-Neu5Ac, 10 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer (pH 6.0) or 12.5 mM 
sodium citrate buffer in an total volume of 200 µL. Fluorescence was measured using a Tecan Spark 
10M, excitation 360 nm, emission 460 nm for 15 minutes with 30 seconds interval with a manual gain 
of 25.  
Statistics. 
Statistical analyses were performed with GraphPad Prism version 5.03 for Windows (GraphPad 
Software, Inc.). Differences were considered significant at P = 0.05.  
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9 
Synthesis and Evaluation of 
Fluorinated KDO Analogs as  
Inhibitors of LPS 
Biosynthesis 
 
“In order to pursue chemotherapy successfully we must look for substances which 
possess a high affinity and high lethal potency in relation to the parasites, but have 
a low toxicity in relation to the body, so that it becomes possible to kill the parasites 
without damaging the body to any great extent. We want to hit the parasites as 
selectively as possible. In other words, we must learn to aim and to aim in a 
chemical sense. The way to do this is to synthesize by chemical means as many 
derivatives as possible of relevant substances.” 
Paul Ehrlich (1854-1915), invented the concept of chemotherapy, worked on 
chemical staining (precursor of gram staining), discovered the first effective 
treatment against syphilis and developed an antiserum against diphtheria. 
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Abstract 
Multidrug resistant bacterial infections are an increasing threat to our society. New 
medications are needed, especially against gram-negative bacteria protected by their 
LPS (lipopolysaccharide) layer. While the precise saccharide composition of the LPS 
varies between species, all gram-negative bacteria make use of keto-
deoxyoctulosonate (KDO) to link the polysaccharides to lipid A. Inhibition of KDO 
incorporation could prevent LPS biosynthesis, therefore function as antibiotic. Here 
we report the synthesis of fluorinated KDO inhibitors as lead structures, for antibiotic 
development. We identified bacterial uptake as major obstacle and partly overcame 
the problem by simple acetylation and ester protection, thereby improving growth 
inhibition from none to a high micromolar effective concentration. Inhibition of cell 
growth was shown for various pathogens such as Nontypeable Haemophilus 
influenzae; Moraxella catarrhalis and to a lesser extent in Streptococcus pneumoniae. 
No toxic effect was seen in human A549 cells even when exceeding therapeutic 
concentrations.  
 
 Heise T, Moons P, De Jonge MI, Langereis JD*, Boltje TJ*. Synthesis and 
Evaluation of Fluorinated KDO Analogues as Inhibitors of LPS Biosynthesis 
Manuscript in preparation. 
 
 
 
 
 
 
 
 
 
* Corresponding authors 
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Introduction 
Multidrug resistant (MDR) bacteria are becoming a global threat to humanity with at 
least 2 million infections yearly in the United States alone.1 Recent research estimates 
the number of annual deaths caused by multidrug resistant infections will have risen 
to 10 million by the year 2050.2 Especially the increasing prevalence of life-
threatening infections by gram-negative bacteria such as Enterobacteriaceae, 
Pseudomonas aeruginosa, Acinetobacter, Escherichia coli and Neisseria gonorrhoeae 
are becoming increasingly problematic to treat. With decreasing numbers of last 
resort antibiotics, there is an urgent need for new medication to prevent the so 
termed ‘post-antibiotic era’.3-4 
The impermeability of the gram-negative outer membranes and a range of 
promiscuous multidrug efflux pumps5 lead to higher drug resistance of gram-negative 
compared to gram-positive bacteria.6 The outer membrane is highly stabilized by the 
lipo-oligosaccharide (LPS) complex consisting of Lipid A, the inner core region, the 
outer core and O antigen. Lipid A is anchored in the outer membrane and covalently 
linked to keto-deoxyoctulosonat (KDO), the first saccharide of the core region. KDO 
itself is usually linked to another KDO or heptose therefore covalently linking Lipid A 
to the outer core and O-antigen. While the first KDO and Lipid A are strictly conserved 
throughout all gram-negative bacteria, the proceeding oligosaccharide is highly 
variable.  
 
Inhibition of LPS synthesis would deprive gram-negative bacteria of their major 
defense structure and leave them vulnerable towards the environment. The essential 
KDO subunit needed to link the large polysaccharide to the membrane therefore 
emerged as major pharmaceutical target. Already 30 years ago, first approaches 
towards KDO inhibition were published by substitution of the anomeric hydroxyl 
group by a hydrogen.7 Before incorporation into LPS, KDO is activated by an enzyme 
CMP-3-deoxyoctulosonate-cytidyltransferase attaching a CMP group to the anomeric 
hydroxyl group. Without hydroxyl-group, CMP activation is not possible and results in 
3.9 µM inhibition of the enzyme.7 While highly potent on extracted enzymes, the 
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inhibitor did not show any KDO-inhibition in a bacterial assay.8 This is most likely the 
result of inefficient uptake of the polar KDO derivative. We aimed to solve this by 
peracetylation. Furthermore, we aimed to design a KDO-transferase inhibitor rather 
than inhibiting the previous CMP transferase step which may lead to more potent 
inhibitors which are also more polar and may be less prone to efflux. Again, we were 
inspired by previous research using fluorinated sialic acid analogues9 to prevent the 
oxocarbenium formation which is the transferase transition state (Figure 1). 
 
Figure 1. KDO-F and proposed inhibtion of the LPS layer 
 
Results and Discussion 
We initially envisioned the previously published strategy towards KDO analogues 
including KDO-glycal 1 10-13 as starting point for electrophilic fluorination (Scheme 1).  
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Scheme 1. i) 2nd generation Grubbs catalyst, Tol, 70 °C, 24 h, 89%.10 
 
While synthesis of the KDO glycal 1 proceeded smoothly as expected, fluorination of 
the glycal proved to be challenging. While soft electrophiles like halides could be 
introduced easily, the glycal bond was unreactive towards harder electrophiles like 
protons or electrophilic fluoride. Deprotection of the isopropylidene protecting group 
preceding fluorination did improve the fluorination to some extent. The conversion 
was however still incomplete and low yielding.  
 
A main issue in antibiotic design is the inability of most compounds to reach the 
bacterial cytoplasm.14 Uptake through cell wall and membrane is strictly regulated 
and antibiotics that do not resemble metabolites are usually not taken up. Passive 
uptake is not ideal as it is slow and therefore requires high concentrations but can to 
some extent be facilitated by increasing the lipophilicity of the drug.15 We therefore 
acetylated after fluorination to yield the final peracetylated inhibitor 2 (Scheme 2). 
 
 
Scheme 2. i) AcOH, H2O, 60 °C, 3 h; ii) Selectfluor, DMF, H2O, 70 °C, 16 h; iii) Ac2O, Pyr, r.t., 16 h, 16% 
(three steps). 
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Because of the low yield, it was decided to switch to another synthetic approach. 
Fortunately, an efficient route for large scale KDO-synthesis was recently published 
based on a Horner-Wadsworth-Emmons reaction to extend the mannose core.16 
Based on our experience with the low reactivity of KDO-glycal towards acids we 
reasoned that this open form might be more reactive and would allow for 
fluorination. Known intermediate 3 could be fluorinated and ring closed in a single 
reaction step. (Scheme 3) After synthesis of the previously described Horner-
Wadsworth-Emmons product 3 electrophilic fluorination yielded the protected 
fluorinated KDO-inhibitor 5. To our delight, the fluorination reaction proceeded as 
envisioned in a yield of 31% towards compound 5. The major byproduct 4 did 
surprisingly not lose the TBS protecting group during fluorination. This indicates a 
different mechanism than for the synthesis of non-fluorinated KDO, where TBS 
deprotection creates the free enolate, which subsequently attacks a proton. While 
we cannot completely exclude the partial formation of the free enolate, the TBS-
protected byproduct clearly indicates that fluorination of the double bond can occur 
before TBS deprotection. We therefore proposed a mechanism  with charged 
fluorinated intermediate that might either directly ring-close or lose the TBS group 
first (Scheme 3).  
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Scheme 3. Proposed mechanism of ring-closing-fluorination. i) Selectfluor, DMF, 60 °C, 16 h; ii) TBAF, 
THF, r.t., 16 h, 55%. iii) AcOH, H2O, 90 °C, 1 h, 94%. iv) Ac2O, Pyr, DMAP, r.t., 16 h, 77%. iv) NaOH, 
MeOH, H2O, r.t., 16 h, 84%. 
 
Again, acetylation was used to increase the lipophilicity of non-modified fluorinated 
KDO 6. The ester protection of prodrug 7 was expected to show higher membrane 
diffusion and should be activated by esterases in the bacterial cytoplasm.17 Starting 
from fluorinated intermediate 4, deprotection of the isopropylidene group yielded 6, 
which upon acetylation or saponification produced 7 or 8 respectively (Scheme 3). 
In addition, non-fluorinated control KDO-derivatives were synthesized as previously 
described (Supporting information). All gram-negative bacteria are highly dependent 
on their KDO-based LPS-layer to support their structural integrity. Fluorinated KDO 
analogues were therefore expected to not only inhibit the KDO synthesis but also 
cause bacterial cell-death. To investigate their antibiotic potential, two gram-negative 
and two gram-positive bacterial strains were cultured, treated for 6 hours with 
increasing concentration of KDO analogues and the relative growth was monitored. 
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DMSO was set to 100% and natural KDO was added as control. To assess whether the 
acetyl and ethyl protection of pro-drug 7 would cause any growth inhibition itself, 
non-fluorinated Ac5KDOEt 11 was added as additional control compared to 
fluorinated KDO analogue KDO-3Feq 8 and the protected prodrug Ac5KDO-3Feq 7. NTHi 
(Nontypeable Haemophilus influenzae) and Mc (Moraxella catarrhalis) are both well-
known gram-negative pathogens and therefore KDO dependent whereas Sa 
(Staphylococcus Aureus) and Sp (Streptococcus pneumoniae) are gram-positive 
pathogens and were expected to tolerate KDO inhibition.  
As expected, neither natural KDO nor protected Ac5KDOEt 11 showed a clear effect 
on any strain except for a slight growth reduction for Mc at the highest concentration 
(1000 µM) (Figure 2, 3). NTHi showed a dose dependent growth inhibition upon 
treatment with Ac5KDO-3Feq 7 but not at all with unprotected KDO-3Feq 8 (Figure 2, 
left). This might indicate an inability of unprotected KDO-analogues to cross the 
membrane. A similar result was observed for Mc were inhibition was only seen for 7 
(Figure 2, right). The gram-positive Sa was not at all affected by any concentration of 
KDO-inhibitors, which is in line with the expected KDO independence of most gram 
positive bacteria (Figure 3, left). Surprisingly, the gram positive Sp was affected by 
KDO inhibition even though not to the same extent as the gram-negative strains 
(Figure 3, right). Why Sp should process KDO analogues remains unclear but this 
result might hint to either an unknown function of KDO in Sp or the ability of Sp to 
degrade KDO, which might lead to toxic byproducts. 
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Figure 2. Relative growth of gram-negative NTHi a and Mc b bacteria treated with increasing 
concentrations of fluorinated KDO analogues 7 and 8, control analogue 11 and natural KDO relative 
to DMSO control. Statistical significance determined with 2-way ANOVA with Bonferroni post-tests. 
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Figure 3. Relative growth of gram negative Sa a and Sp b bacteria treated with increasing 
concentrations of fluorinated KDO analogues 7 and 8, control analogue 11 and natural KDO relative 
to DMSO control. Statistical significance determined with 2-way ANOVA with Bonferroni post-tests. 
No significant differences for a. 
 
To further evaluate the effect of the KDO inhibitors in NTHi, the growth was also 
measured by analyzing the optical density (Figure 4, top) and colony-forming counts 
(Figure 4, bottom). Again, the protected fluorinated KDO 7 showed the best effect.  
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Figure 4. Optical density (top) and Count of colony forming units (bottom) with KDO analogues 7 and 
8, control analogue 11, natural KDO and DMSO control. Statistical significance of change to control 
with 1-way ANOVA with Dunnett post-test. Statistical significance in comparison to control. 
 
Next, the toxicity of KDO analogs towards human cells was investigated. As high 
concentrations of the inhibitor are needed to stop the bacterial growth, the major 
concern was to see adverse effects on human cells. We therefore carefully assessed 
the toxicity on human epithelia A549 cells with four different readouts at 0.5 and 2 
mM concentration.  A plasma concentration of 2 mM in a therapeutic setting might 
be considered unrealistically high. This, however depends on the toxicity of the drug.  
The very commonly used pain-killer N-(4-hydroxyphenyl)acetamide e.g. is only 
considered a threat if the plasma concentration exceeds 1.3 mM.18 The metabolites 
of ibuprofen ((RS)-2-(4-(2-methylpropyl)phenyl)propanoic acid) is still safe to use in 
vulnerable patients at plasma concentrations of up to 1.49 mM.19 Commonly used 
antibiotics (amoxicillin, cefepime, cefotaxime, ceftazidime, ceftriaxone, cloxacillin, 
imipenem, meropenem, oxacillin, penicillin G, piperacillin, and ticarcillin), however, 
are used at a far lower concentration not exceed a plasma concentration 0.2 mM.20 It 
was therefore crucial to carefully investigate the KDO analogues to exclude any sign 
of toxicity that would prohibit the use of our inhibitor as antibiotic. 
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First, the membrane integrity was assessed to identify dead cells.  No LDH release 
was detected by 0.5 mM concentration of Ac5KDOEt 7 while a concentration of 2 mM 
showed a slight but not significant increase in fluorescence (Figure 5a). CellTox was 
applied to detect any released DNA after membrane lysis. No fluorescence was 
detected for cells treated with KDO analogues (Figure 5b). Both assays combined 
indicate an intact membrane with no significant sign of toxicity at both 
concentrations. Even though alive, the cells could still be affected by treatment of 
KDO analogues.  
Figure 5. Membrane integrity for toxicity evaluation LDH release a and DNA binding CellTox assay b. 
Statistical significance in comparison to DMSO determined with 1-way ANOVA with Dunnett post-
test. 
 
*** *** *** 
*** *** 
*** 
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Therefore, the number of cells after 24 hours was assessed (Figure 6a). The cell count 
of the batch treated with 0.5 mM Ac5KDOEt 7 was lower than the number of cells in 
the control batch. This however was not seen to the same extent when a higher 
concentration of 2 mM was used, were the same number of cells were counted with 
Ac5KDOEt 7 as with non-fluorinated Ac5KDOEt 11. To investigate whether cells might 
undergo a shift to a quiescent state after treatment, the metabolic activity was 
measured by an MTS assay (Figure 6b). No difference was seen at either 
concentration indicating that cell-metabolism was not affected by inhibitor 
treatment. Combining these results show that while the cell count might be slightly 
affected, neither membrane integrity not metabolic activity was affected, therefore 
demonstrating that even the highest concentrations of KDO analogues were not toxic 
to human cells.  
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Figure 6. Cell count a and metabolic activity measured by MTS assay b. Statistical significance in 
comparison to DMSO determined with 1-way ANOVA with Dunnett post-test (all non-significant). 
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Conclusion 
Fluorinated KDO derivatives were prepared using a novel synthetic strategy. 
Especially the protected fluorinated KDO derivative showed antibiotic activity 
towards gram-negative bacteria, but was not toxic to human cells. However, more 
work is needed to elucidate the exact mechanism of action. Furthermore, high 
concentrations are needed to achieve antibiotic activity which probably indicates that 
the compounds are poorly taken up. Hence, further research should focus on 
increasing the uptake efficiency.  
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Supporting information 
 
 
List of Abbreviations 
Ac2O:  Acetic anhydride 
ACN:   Acetonitrile 
AcOH:  Acetic acid 
aq.  Aqueous 
DCM:  Dichloromethane 
DMF:   Dimethylformamide 
Et  CH2CH3 
EtOAc:  Ethyl acetate 
Hept:  Heptane 
HWE:   Horner-Wadsworth-Emmons 
IP:  Isopropylidene 
KDO:   3-Deoxy-D-manno-2-octulosonic Acid 
KDO-F:   3-Deoxy-3-fluoro-D-manno-2-octulosonic Acid  
LiHMDS: Lithium HexamethylDiSilazide 
Pyr:  Pyridine 
RCM:  Ring Closing Metathesis 
sat.  saturated 
TBAF:   Tetrabutylammonium Fluoride 
TBSCl:  tert-butylchlorodimethylsilane 
TEA:  Triethylamine 
TMS  Trimethylsilane 
Tol:  Toluene 
 
 
General Procedures: 1H and 13C NMR spectra were recorded on a Varian Inova 400 MHz or Bruker 
Avance III 500 MHz spectrometer. Chemical shifts are reported in parts per million (ppm) relative to 
TMS as the internal standard. NMR data is presented as follows: Chemical shift, multiplicity (s = 
singlet, bs = broad singlet, d = doublet, t = triplet, dd = doublet of doublet, dt = doublet of triplet, m = 
multiplet and/or multiple resonances), integration, coupling constant in Hertz (Hz). All NMR signals 
were assigned on the basis of 1H, 13C, 19F NMR, COSY and HSQC experiments. Stereochemistry was 
assigned using gated 1H-decoupling 13C-NMR, HMBC, 1D- and 2D-TOCSY and NOESY experiments. 
Mass spectra were recorded on a JEOL JMS-T100CS AccuTOF mass spectrometer. Automatic column 
chromatography was performed on Biotage Isolera Spektra One, using SNAP cartridges 10-50 g filled 
with normal silica (Biotage, 30-100 μm, 60 Å) or water resistant iatro beads. TLC analysis was 
conducted on TLC Silicagel, 60, F254, Merck, with detection by UV absorption (254 nm) where 
applicable, and by spraying with 20% sulfuric acid in methanol followed by charring at ~150 °C or by 
spraying with a solution of (NH4)6Mo7O24.H2O (25 g l-1) in 10% sulfuric acid in methanol followed by 
charring at ~300 °C. DCM, ACN and Tol were freshly distilled. All reactions were carried out under an 
argon atmosphere. 
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 Methyl (3aR,7aR)-4-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyl-3a,7a-
dihydro-4H-[1,3]dioxolo[4,5-c]pyran-6-carboxylate (1) According to literature procedure, the RCM 
precursor13 (550 mg, 1.61 mmol, 1 eq.) and second generation Grubbs catalyst (136 mg, 0.16 mmol, 
0.1 eq.) were solved in Tol (15 mL) and stirred at reflux (70 °C) for 24 h, concentrated in vacuo, 
redissolved in EtOAc and washed with aqueous NaHCO3, dried with Na2SO4, filtered and 
concentrated in vacuo. The crude product was purified by silica chromatopgraphy (0  30% EtOAc in 
Hept) to yield KDO glycal 1 (18.28 g, 51.6 mmol, 89%). TLC: (EtOAc:Hept, 30:70 v/v) Rf = 0.37. 1H NMR 
(500 MHz, CDCl3) δ 5.99 (d,1H, H-3),  4.78 (dd, 1H, H-4), 4.45 (m, 2H, H-5; H-7), 4.19 (m, 2H, H-8a, H-
8b), 3.82 (d, 1H, H-6), 3.79 (s, 3H, OCH3), 1.46 (s, 3H, CH3, IP), 1.42-1.43 (m, 9H, 3x CH3, IP); 13C NMR 
(126 MHz, CDCl3) δ 162.45 (C-1), 143.88 (C-2), 111.02 (C(CH3)2, IP), 110.38 (C-3), 109.63 (C(CH3)2, IP), 
76.38  (C-6), 73.79 (C-5), 71.17 (C-7), 68.68 (C-4), 66.68 (C-8), 52.30 (OCH3), 28.03 (CH3, IP), 26.89 
(CH3, IP), 26.66 (CH3, IP), 25.28 (CH3, IP). 
 
 Methyl [2,4,5,7,8-O-acetyl]-3-deoxy-3-fluoro-D-manno-2-octulopyranosonate (2) 
Compound 1 (150 mg; 0.47 mmol) was solved in AcOH (5 mL) and H2O (5 mL) and stirred at  60 °C for 
3 h before concentrating in vacuo  and redissolving in a mixture of DMF (1.5 mL) and H2O: (0.5 mL). 
Selectfluor (676 mg;  1.109 mmol; 4 eq.) was added and the reaction was stirred at 70 °C for 16 h 
before diluting with an excess of Pyr (30 mL) and Ac2O (15 mL) and stirring at r.t. for 16 h. The 
reaction was concentrated in vacuo, redissolved in EtOAc and washed with 1M HCl aq. and aqueous 
NaHCO3. The organic layer was dried Na2SO4, filtered and the crude product was purified on silica 
column (0  30% EtOAc in Hept) to yield acetylated fluorinated KDO 2 (36 mg, 0.075 mmol, 16%)) 
TLC: (EtOAc:Hept, 50:50 v/v) Rf = 0.55. 1H NMR (500 MHz, CDCl3, major isomer) δ 5.52 (td, J = 3.2, 1.4 
Hz, 1H, H-5), 5.46 (ddd, J = 11.1, 10.0, 3.6 Hz, 1H, H-4), 5.22 (ddd, J = 9.8, 3.5, 2.2 Hz, 1H, H-7), 4.81 
(dd, J = 49.3, 10.0 Hz, 1H, H-3), 4.45 (dd, J = 12.4, 2.3 Hz, 1H, H-8a), 4.19 (dd, J = 9.9, 1.5 Hz, 1H, H-6), 
4.09 (dd, J = 12.5, 3.6 Hz, 1H, H-8b), 3.86 (s, 3H, OCH3), 2.23 (s, 3H, CH3, OAc), 2.13 (s, 3H, CH3, OAc), 
2.06 (s, 3H, CH3, OAc), 2.05 (s, 3H, CH3, OAc), 1.98 (s, 3H, CH3, OAc). 13C NMR (126 MHz, CDCl3, major 
isomer) δ 170.16 (CCH3, OAc), 170.14 (CCH3, OAc), 169.88 (CCH3, OAc), 169.36 (CCH3, OAc), 
167.43(CCH3, OAc), 164.49 (C-1), 95.50 (d, J = 18.7 Hz, C-2), 86.19 (C-3), 68.86 (C-6), 68.50 (C-4),  
66.47 (C-5), 53.58 (OCH3), 61.82 (C-8), 20.70 (CH3, OAc), 20.64 (CH3, OAc), 20.59 (CH3, OAc), 20.55 
(CH3, OAc), 20.52 (CH3, OAc). 19F NMR (471 MHz, CDCl3) δ -197.88 (dd, J = 50.3, 17.3 Hz, axial β-
anomer), -208.29 (ddd, J = 49.7, 10.6, 2.8 Hz, equatorial β-anomer), -208.71 (ddd, J = 49.9, 11.3, 3.4 
Hz, major: equatorial α-anomer), -210.25 (dd, J = 52.4, 23.5 Hz, axial α-anomer). HR-ESI-TOF/MS 
(m/z): [M+Na]+ calcd. for C19H25FO13Na, 503.11769; found, 503.117 
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Ethyl ester (diethoxyphosphinyl) glycolate t-Butyldimethylsilyl ether (HWE reagent)16 Diethyl 
phosphonate (8.25 mL, 64.5 mmol, 1.25 eq.) was dissolved in dry Tol (30 mL, 2.15 M). The solution 
was cooled to 0 °C and TEA (20.5 mL, 147 mmol, 2.86 eq.) was added. The mixture was stirred for 
two h, after which ethyl 2-oxoacetate (10.5 mL, 51.6 mmol, 1.00 eq) and dry Tol (60 mL, 0.86 M) 
were added. The solution was stirred at r.t. for 7 h. The solution was evaporated in vacuo to yield a 
yellow oil. The oil and imidazole (1.9 eq, 6.68 g, 98 mmol) were dissolved in DMF (50 mL), followed 
by the addition of TBSCl (1.5 eq, 11.7 g, 78 mmol). The mixture was stirred overnight at r.t. and then 
evaporated in vacuo. The residue was dissolved in EtOAc (80 mL) and washed with aqueous 0.1M 
HCl. The aqueous layer was again extracted with EtOAc and the combined organic layers were dried 
with MgSO4, filtered and concentrated in vacuo. The resulting orange oil was purified using silica-
flash column chromatography (0  50% EtOAc in Hept) to yield the HWE reagent. (18.28 g, 51.6 
mmol, 100%). TLC: (EtOAc:Hept, 75:25 v/v) Rf = 0.68. 1H-NMR (500 MHz, CDCl3): δ 4.52 (d, J = 18.0 Hz, 
1H, CH), δ 4.34-4.08 (m, 6H, CH2, COOEt; 2x CH2, POOEt), δ 1.31-1.22 (m, 9H, CH3, COOEt; 2x CH3, 
POOEt), δ 0.86 (s, 9H, C(CH3)3, TBS), 0.05 (d, J = 4.3 Hz, 6H, Si(CH3)2, TBS); 13C-NMR (126 MHz, CDCl3): 
δ 168.36 (CO), 70.65 (d, J = 161.5 Hz, CH), 63.44 (CH2, COOEt), 61.53 (2x CH2, POOEt), 25.42 (C(CH3)3, 
TBS), 18.23 (C(CH3)3, TBS), 16.27 (CH3, COOEt), 13.98 (CH3, POOEt),  -5.46 (SiCH3, TBS), -5.61 (SiCH3, 
TBS); HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C14H31O6PSiNa, 377.15252; found, 377.15275.  
 
 
Ethyl 2-t-Butyldimethylsilyl ether-4,5:7,8-di-O-isopropylidene-3-deoxy-D-manno-2-
octulopyranosonate (3) HWE reagent (2.44 g, 6.89 mmol, 1.53 eq.) was dissolved in a Tol:THF (9:1 
v/v, 4 mL, 1.7 M). The solution was cooled to 0 °C and LiHMDS (5.5 mL, 5.50 mmol, 1.21 eq.) was 
added. The mixture was left stirring on ice for 30 min, subsequently 2,3:5,6-Di-O-isopropylidene-α-D-
mannofuranose (1.18 g, 4.52 mmol, 1.00 eq) dissolved in Tol:THF (9:1 v/v, 12.0 mL, 0.4 M) was 
added. The solution was stirred at 70 °C for 16 h, concentrated in vacuo and redissolved in EtOAc (80 
mL). The organic layer was washed with sat., aq. NaHCO3 and brine. The aqueous layer was extracted 
with EtOAc. The combined organic layers were dried with MgSO4 and filtrated. The filtrate was 
evaporated in vacuo and the resulting yellow oil was purified using silica-flash column 
chromatography (0  30% EtOAc in Hept) to yield compound 3 as pale yellow oil (1.81 g, 3.91 mmol, 
87%).  
E-isomer: TLC: (EtOAc:Hept, 33:67 v/v) Rf = 0.57 1H-NMR (500 MHz, CDCl3): δ 5.73 (d, J = 7.2 Hz, 1H, 
H-3), 5.48 (t, J = 7.4 Hz, 1H, H-4), 4.65 (dd, J = 7.7, 1.1 Hz, 1H, H-5), 4.26 – 4.15 (m, 2H, CH2, OEt), 4.10 
– 4.03 (m, 1H, H-8a), 4.03 – 3.94 (m, 2H, H-7; H-8b), 3.36 (ddd, J = 9.1, 7.0, 1.1 Hz, 1H, H-6), 2.05 (d, J = 
9.3 Hz, 1H, OH), 1.52 (s, 3H, CH3, IP), 1.40 (s, 3H, CH3, IP), 1.37 (s, 3H, CH3,IP), 1.35-1.30 (m, 6H, CH3, 
IP; CH3, OEt) 0.96 (s, 9H, C(CH3)3, TBS), 0.18 (d, J = 1.1 Hz, 6H, Si(CH3)2, TBS); 13C-NMR (126 MHz, 
CDCl3): δ 164.22 (C-1), 141.59 (C-2), 122.78 (C-3), 109.21 (C(CH3)2, IP), 108.25 (C(CH3)2, IP), 77.01 (C-
5), 76.52 (C-7), 74.11 (C-4), 70.09 (C-6), 66.92 (C-8), 61.13 (CH2, OEt), 26.80 (CCH3, IP), 26.62 (CCH3, 
P), 25.53 (C(CH3)3, TBS), 25.34 (CCH3, IP), 24.03 (CCH3, IP), 18.16 (C(CH3)3, TBS), 14.11 (CH3, OEt), -4.88 
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(SiCH3, TBS), -4.95 (SiCH3, TBS); HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C22H40O8SiNa, 483.23901; 
found, 483.23802.  
Z-isomer: TLC: (EtOAc:Hept, 33:67 v/v) Rf = 0.61. 1H-NMR (500 MHz, CDCl3): δ 6.22 (t, J = 7.3 Hz, 1H, 
H-3), 5.31 (1H, t, J = 7.7 Hz, H-4), 4.45 (dd, J = 7.5, 1.4 Hz, 1H, H-5), 4.32 – 4.24 (m, 2H, CH2, OEt), 4.23 
– 4.15 (m, J = 7.1, 7.1 Hz, 1H, CH2, OEt), 4.08 (td, J = 8.0, 2.7 Hz, 1H, H-8a), 4.01 (dt, J = 7.5, 5.2 Hz, 2H, 
H-7, H-8b), 3.40 (t, J = 6.5 Hz, 1H, H-6), 2.12 (d, J = 8.4 Hz, 1H, OH), 1.53 (s, 3H, CH3, IP), 1.40 (s, 3H, 
CH3, IP), 1.38 (s, 3H, CH3, IP), 1.34 (s, 3H, CH3, IP), 1.31 (t, J = 7.1 Hz, 3H, CH3, OEt), 0.96 (s, 9H, C(CH3)3, 
TBS), 0.21 (s, 3H, SiCH3, TBS), 0.19 (s, 3H, SiCH3, TBS); 13C-NMR (126 MHz, CDCl3) δ 163.98 (C-1), 
143.48 (C-2), 116.17 (C-3), 109.26 (C(CH3)2, IP), 108.64 (C(CH3)2, IP), 76.46 (C-5), 76.06 (C-7), 72.09 (C-
4), 70.74 (C-6), 66.88 (C-8), 61.48 (CH2, OEt), 26.78 (CCH3, IP), 26.55 (CCH3, IP), 25.84 (C(CH3)3, TBS), 
25.24 (CCH3, IP), 24.26 (CCH3, IP), 18.60 (C(CH3)3, TBS), 14.18 (CH3, OEt), -4.10 (Si(CH3)2, TBS), -4.35 
(Si(CH3)2, TBS); HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C22H40O8SiNa, 483.23901; found, 483.23802.  
 
 
Ethyl 4,5:7,8-di-O-isopropylidene-3-deoxy-3-fluoro-D-manno-2-octulopyranosonate (5)  
Procedure A (4+5): 
Selectfluor (4.4856 g, 12,66 mmol, 3.01 eq.) was added to a flame-dried round-bottom flask under 
schlenk conditions. Compound 3 (1,935 g, 4.20 mmol, 1.00 eq.) and DMF (25 mL, 0.17 M) were added 
to the flask. The solution was gradually heated to 60°C and stirred over night, after which an orange 
solution was observed. The mixture was co-evaporated in vacuo with Tol. The resulting oil was 
dissolved in EtOAc and washed with sat., aqueous NaHCO3 and brine. The aqueous layer was 
extracted twice with EtOAc. The combined organic layers were dried with MgSO4, filteredand 
concentrated in vacuo. The resulting yellow oil was purified using silica-flash column chromatography 
(0  40% EtOAc in Hept) to yield compound 4 (570 mg, 1.191 mmol, 28.4%). and compound 5 (477.1 
mg, 1.309 mmol, 31.2%) 
Procedure B (5): 
Selectfluor (232 mg, 0.66 mmol, 3.0 eq.) was added to a flame-dried round-bottom flask under 
schlenk conditions. Compound 3 (100 mg, 0.22 mmol, 1.0 eq.) and DMF (1.3 mL, 0.17 M) were added 
to the flask. The solution was gradually heated to 60°C and stirred over night, after which an orange 
solution was observed. The mixture was co-evaporated in vacuo with Tol. The resulting oil was 
dissolved in EtOAc and washed with sat., aqueous NaHCO3 and brine. The aqueous layer was 
extracted twice with EtOAc. The combined organic layers were dried with MgSO4 and filtered. The 
filtrate was evaporated in vacuo and redissolved in THF (2.6 mL, 0.085 M) and a solution of 1M TBAF 
in THF (251 µl, 251 mmol, 1.2 eq.) was added. The mixture was stirred at r.t. for 16 h and 
concentrated in vacuo, dissolved in EtOAc and washed with sat., aq. NaHCO3. The organic layer was 
dried with MgSO4, filtered and purified using silica-flash column chromatography (0  40% EtOAc in 
Hept) to yield compound 5 (44 mg, 0.012 mmol, 55%). 
 
Compound 4: α-anomer – major: TLC: (EtOAc:Hept, 33:67 v/v) Rf = 0.71.1H-NMR (500 MHz, CDCl3): δ 
4.80 (1H, dd, J = 49.2, 6.6 Hz, H-3), 4.42 – 4.34 (m, 3H, H-4, H-5, H-7), 4.31 (dq, J = 10.8, 7.2 Hz, 1H, 
CH2, OEt), 4.21 (1H, dq, J = 10.8, 7.1 Hz, CH2, OEt), 4.14 (1H, dd, J = 8.2, 2.4 Hz, H-6), 4.04 (2H, d, J = 
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5.0 Hz, H-8a; H-8b), 1.54 (s, 3H, CH3, IP), 1.41-1.40 (m, 6H, 2x CH3, IP), 1.37 (s, 3H, CH3, IP), 1.32 (t, J = 
7.1 Hz, 3H, CH3, OEt), 0.92 (s, 9H, C(CH3)3, TBS), 0.24 (s, 3H, SiCH3, TBS), 0.17 (s, 3H, SiCH3, TBS); 13C-
NMR (126 MHz, CDCl3): δ 166.68 (C-1), 109.74 (C(CH3)2, IP), 109.15 (C(CH3)2, IP), 95.03 (C-2), 94.86 (C-
2), 91.03 (C-3), 89.53 (C-3), 74.62 (C-4), 74.43 (C-4), 73.86 (C-7), 73.16 (C-5), 73.11 (C-5), 69.29 (C-6), 
66.34 (C-8), 61.99 (CH2, OEt), 27.67 (CCH3, IP), 26.83 (CCH3, IP), 25.99 (CCH3, IP), 25.89 (C(CH3)3, TBS), 
25.34 (CCH3, IP), 18.87 (C(CH3)3, TBS), 13.80 (CH3, OEt), -3.75 (SiCH3, TBS), -3.88 (SiCH3, TBS); 19F-NMR 
(500 MHz, CDCl3) δ -201.87.  
β-anomer - minor: TLC: (EtOAc:Hept, 33:67 v/v) Rf = 0.71.1H-NMR (500 MHz, CDCl3): δ 4.66 (ddd, J = 
15.3, 6.7, 5.1 Hz, 1H, H-4), 4.54 (dd, J = 46.4, 5.1 Hz, 1H, H-3), 4.38 – 4.35 (m, 1H, H-5), 4.30 (ddd, J = 
7.8, 6.1, 4.2 Hz, 1H, H-7), 4.27 – 4.16 (m, 3H, H-8a; CH2, OEt), 4.09 (dd, J = 8.6, 6.3 Hz, 1H, H-8b), 3.82 
(dt, J = 8.3, 1.9 Hz, 1H, H-6), 1.53 (s, 3H, CH3, IP), 1.42 (s, 3H, CH3, IP), 1.39 (s, 3H, CH3, IP), 1.37 (s, 3H, 
CH3, IP), 1.32 (t, J = 7.1 Hz, 3H, CH3, OEt), 0.90 (s, 9H, C(CH3)3, TBS), 0.13 (s, 3H, SiCH3, TBS), 0.10 (s, 
3H, SiCH3, TBS); 13C-NMR (126 MHz, CDCl3): δ 167.64 (C-1), 109.74 (C(CH3)2, IP), 109.15 (C(CH3)2, IP), 
97.06 (C-2), 96.85 (C-2), 93.28 (C-3), 74.05 (C-4), 73.55 (C-7), 72.53 (C-6), 71.79 (C-5), 66.79 (C-8), 
61.40 (CH2, OEt), 26.79 (CCH3, IP), 26.28 (CCH3, IP), 26.16 (CCH3, IP), 25.39 (C(CH3)3, TBS), 25.00 (CCH3, 
IP), 17.73 (C(CH3)3, TBS), 13.95 (CH3, OEt), -2.90 (SiCH3, TBS), -4.11 (SiCH3, TBS); 19F-NMR (500 MHz, 
CDCl3): δ -196.88. HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C22H39FO8SiNa, 501.22959; found, 
501.22859. 
 
Compound 5: TLC: (EtOAc:Hept, 33:67 v/v) Rf = 0.40. 1H-NMR (500 MHz, CDCl3): δ 4.72 (dd, J = 49.6, 
7.3 Hz, 1H, H-3), 4.40 – 4.28 (m, 4H, H-4; H-5; H-6; CHH, OEt), 4.24 (dq, J = 10.7, 7.1 Hz, 1H, CHH, 
OEt), 4.12 (dd, J = 8.0, 2.5 Hz, 1H, H-7), 3.97 (dd, J = 8.9, 6.1 Hz, 1H, H-8a), 3.90 (dd, J = 8.9, 4.6 Hz, 1H, 
H-8b), 1.51 (s, 3H, CH3, IP), 1.35 (s, 3H, CH3, IP), 1.34 (s, 3H, CH3, IP), 1.30 (s, 3H, CH3, IP), 1.28 (t, J = 
7.2 Hz, 3H, CH3, OEt); 13C-NMR (126 MHz, CDCl3): δ 168.43 (C-1), 110.38 (C(CH3)2, IP), 109.80 (C(CH3)2, 
IP), 93.65 (d, J = 22.8 Hz, C-2), 90.21 (d, J = 189.0 Hz), C-3), 74.92 (d, J = 21.8 Hz, C-4), 74.10 (C-6), 
74.05 (C-5), 70.15 (C-7), 67.07 (C-8), 63.95 (CH2, OEt), 28.52 (CCH3, IP), 27.22 (CCH3, IP), 26.65 (CCH3, 
IP), 25.76 (CCH3, IP), 14.28 (CH3, OEt); 19F-NMR (500 MHz, CDCl3) δ -202.83; HR-ESI-TOF/MS (m/z): 
[M+Na]+ calcd. for C16H25FO8Na, 387.14312; found, 387.14076.  
 
 
Ethyl 3-deoxy-3-fluoro-D-manno-2-octulopyranosonate (6) Compound 5 (113.8 mg, 0.312 mmol) 
was dissolved in AcOH (4.5ml) and H2O (0.5 mL) and gradually heated to 90 °C. The solution was 
stirred for 1 h and cooled down to r.t.. The solution was evaporated in vacuo to yield compound 6 as 
a yellow oil (83.1 mg, 0.292 mmol, 94%). TLC: (MeOH:DCM, 20:80 v/v) Rf = 0.33. 1H NMR (400 MHz, 
CD3OD): δ 4.95 (1H, dd, J = 50.1, 9.7 Hz, H-3), 4.27 (2H, dddd, J = 17.9, 10.8, 7.1, 3.6 Hz, CH2, OEt), 
4.15 (1H, td, J = 3.6, 1.2 Hz, H-5), 4.00 (1H, ddd, J = 12.1, 9.6, 3.4 Hz, H-4), 3.92 (1H, dd, J = 8.8, 1.3 Hz, 
H-6), 3.89 – 3.81 (1H, m, H-7), 3.71 (1H, dd, J = 11.6, 2.9 Hz, H-8a), 3.56 (1H, dd, J = 11.6, 5.2 Hz, H-8b), 
1.31 (3H, t, J = 7.1 Hz, CH3, OEt); 13C-NMR (100 MHz, CD3OD): δ 169.66 (C-1), 95.79 (d, J = 20.8 Hz, C-
2), 90.79 (d, J = 187.2 Hz, C-3), 72.44 (C-6), 70.63 (C-5), 70.52 (C-7), 70.46 (d, J = 12.7 Hz, C-4), 64.49 
(C-8), 63.27 (CH2, OEt), 14.32 (CH3, OEt); 19F-NMR (400 MHz, CD3OD) δ -211.85; 
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Ethyl [2,4,5,7,8-O-acetyl]-3-deoxy-3-fluoro-D-manno-2-octulopyranosonate (7) Compound 6 (27.7 
mg, 0.097 mmol) was dissolved in a solution of Pyr and Ac2O (2:1, 1 mL, 0.097 M) and a catalytic 
amount of DMAP (1 mg, 0.01 mmol, 0.1 eq.) was added and the solution was left stirring at r.t. for 16 
h before being concentrating in vacuo, redissolving in EtOAc (15 mL) and washed with aq. 0.1M HCl 
dried with MgSO4 and filtered. The filtrate was evaporated in vacuo and the resulting residue was 
purified using silica-flash column chromatography (0  40% EtOAc in Hept) to yield compound 7 
(37.3 mg, 0.075 mmol, 77%). TLC: (EtOAc:Hept, 50:50 v/v) Rf = 0.50. 1H-NMR (500 MHz, CDCl3): δ 5.54 
– 5.44 (m, 2H, H-4, H-5), 5.23 (ddd, J = 9.7, 3.5, 2.3 Hz, 1H, H-7), 4.80 (dd, J = 49.4, 10.0 Hz, 1H, H-3), 
4.45 (dd, J = 12.5, 2.3 Hz, 1H, H-8a), 4.37 – 4.26 (m, 2H, CH2, OEt), 4.19 (dd, J = 9.9, 1.4 Hz, 1H, H-6), 
4.09 (dd, J = 12.4, 3.5 Hz, 1H, H-8b), 2.23 (s, 3H, CH3, OAc), 2.13 (s, 3H, CH3, OAc), 2.06 (s, 3H, CH3, 
OAc), 2.05 (s, 3H, CH3, OAc), 1.98 (s, 3H, CH3, OAc), 1.31 (t, J = 7.1 Hz, 3H, CH3, OEt); 13C-NMR (101 
MHz, CDCl3): δ 170.19 (CO, OAc), 170.15 (CO, OAc), 169.89 (CO, OAc), 169.39 (CO, OAc), 167.37 (CO, 
OAc), 163.97 (C-1), 95.57 (d, J = 18.9 Hz, C-2), 85.47 (d, J = 200.8 Hz, C-3), 68.80 (C-7), 68.40 (d, J = 
19.2 Hz, C-4), 66.47 (C-5), 62.96 (CH2, OEt), 61.85 (C-8), 20.73 (CH3, OAc), 20.61 (CH3, OAc), 20.57 (2x 
CH3, OAc), 20.54 (CH3, OAc), 13.91 (CH3, OEt); 19F-NMR (500 MHz, CDCl3) δ -208.71; HR-ESI-TOF/MS 
(m/z): [M+Na]+ calcd. for C20H27FO13Na, 517.13334; found, 517.13270. 
 
 
3-Deoxy-3-fluoro-D-manno-2-octulosonic Acid, ammonium salt (8) Compound 6 (49 mg,  0.172 
mmol) was dissolved in MeOH (1.5 mL,  0.145 M), after which 0.3 M aqueous NaOH (3 mL) was 
added until a pH of 11-13 was reached. The solution was allowed to stir for 1 h, followed by the 
addition of ion-exchange resin (Dowex). The mixture was stirred for additional 1 h and then filtered. 
Concentrated ammonium hydroxide (28%, 4 mL) was added to obtain a solution with a pH of 11. The 
mixture was stirred for 1 h, after which the solution was evaporated in vacuo to provide compound 8 
as a yellow oil. TLC: (H2O:ACN, 20:80 v/v) Rf = 0.12. 1H-NMR (500 MHz, CD3OD): δ 4.92 (dd, J = 49.9, 
9.9 Hz, 1H, H-3), 4.11 (t, J = 3.6 Hz, 1H, H-5), 3.98 (ddd, J = 13.0, 9.8, 3.4 Hz, 1H, H-4), 3.92 (dd, J = 8.8, 
1.2 Hz, 1H, H-6), 3.88 – 3.83 (m, 1H, H-7), 3.72 (dd, J = 11.7, 3.0 Hz, 1H, H-8a), 3.57 (dd, J = 11.7, 5.2 
Hz, 1H, H-8b);  13C-NMR (126 MHz, CD3OD): δ 171.55 (C-1), 95.71 (d, J = 21.42 Hz, C-2), 90.92 (d, J = 
186 Hz, C-3), 72.48 (C-6), 70.80 (C-5), 70.60 (C-7), 70.50 (d, J = 18 Hz, C-4), 64.56 (C-8); 19F-NMR (400 
MHz, CD3OD): δ -207.52; HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C8H13FO8Na, 279.04921; found, 
279.05176. 
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Ethyl 4,5:7,8-di-O-isopropylidene-3-deoxy-D-manno-2-octulopyranosonate (9) 
Compound 3 (921.0 mg, 1.999 mmol) was dissolved in THF (6 mL, 0.33 M). The solution was cooled 
down to 0°C. AcOH/H2O (20%, 4 mL) was added, followed by the addition of TBAF (4 mL, 4 mmol, 2 
eq.). The solution was stirred on ice for 5 h. The reaction was quenched with sat., aqueous NaHCO3 
solution (4 mL). The solution was concentrated in vacuo. The remaining mixture was dissolved in 
EtOAc and washed with sat., aqueous NaHCO3 solution. The aqueous layers were extracted with 
EtOAc. The combined organic layers were dried with MgSO4 and filtered. The filtrate was evaporated 
in vacuo and the resulting yellow oil was purified using silica-flash column chromatography (0  35% 
EtOAc in Hept) to yield compound 9 (355.3 mg, 1.025 mmol, 51.3%)  
α-anomer: TLC: (EtOAc:Hept, 33:67 v/v) Rf = 0.23. 1H-NMR (500 MHz, CDCl3): δ 4.51 (td, J = 6.4, 4.8 
Hz, 1H, H-4), 4.35 (ddd, J = 8.0, 6.1, 4.5 Hz, 1H, H-7), 4.30 – 4.23 (m, 3H, H-5; CH2, OEt,), 4.11 - 4.05 
(m, 1H, H-8a), 4.03 - 3.98 (m, 1H, H-8b), 3.90 (dd, J = 7.9, 2.3 Hz, 1H, H-6), 3.74 (s, 1H, OH), 2.49 (dd, J 
= 14.5, 6.5 Hz, 1H, H-3eq), 1.89 (dd, J = 14.5, 4.9 Hz, 1H, H-3ax), 1.46 (s, 3H, CH3, IP), 1.42 (s, 3H, CH3, 
IP), 1.37 (s, 3H, CH3, IP), 1.36 (s, 3H, CH3, IP), 1.32 (t, J = 7.1 Hz, 3H, CH3, OEt). 13C-NMR (126 MHz, 
CDCl3): δ 169.95 (C-1), 109.66 (C(CH3)2, IP), 109.50 (C(CH3)2, IP), 94.69 (C-2), 74.26 (C-7), 71.62 (C-5), 
70.91 (C-6), 70.22 (C-4), 67.17 (C-8), 62.68 (CH2, OEt), 32.61 (C-3), 27.41 (CCH3, IP), 27.25 (CCH3, IP), 
26.04 (CCH3, IP), 25.71 (CCH3, IP), 14.34 (CH3, OEt). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for 
C16H26O8Na, 369.15254; found, 369.15275. 
β-anomer: TLC: (EtOAc:Hept, 50:50 v/v) Rf = 0.42. 1H-NMR (500 MHz, CDCl3): δ 4.77 (s, 1H, OH), 4.75 
(dt, J = 8.0, 2.9 Hz, 1H, H-4), 4.44 (dd, J = 8.0, 1.8 Hz, 1H, H-7), 4.30 – 4.23 (m, 3H, H-5; CH2, OEt), 4.11 
- 4.05 (m, 1H, H-8a), 4.03 - 3.98 (m, 1H, H-8b), 3.45 (dd, J = 8.6, 1.8 Hz, 1H, H-6), 2.34 (d, J = 2.9 Hz, 2H, 
H-3eq, H-3ax), 1.57 (s, 3H, CH3, IP), 1.42 (s, 3H, CH3, IP), 1.39 (s, 3H, CH3, IP), 1.36 (s, 3H, CH3, IP), 1.34 
(t, J = 7.1 Hz, 3H, CH3, OEt). 13C-NMR (126 MHz, CDCl3): δ 169.18 (C-1), 109.90 (C(CH3)2, IP), 109.88 
(C(CH3)2, IP), 95.85 (C-2), 74.19 (C-6), 73.64 (C-5), 72.67 (C-7), 70.99 (C-4), 67.46 (C-8), 62.31 (CH2, 
OEt), 31.25 (C-3), 27.39 (CCH3, IP), 26.38 (CCH3, IP), 25.40 (CCH3, IP), 24.57 (CCH3, IP), 14.45 (CH3, 
OEt). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C16H26O8Na, 369.15254; found, 369.15275. 
 
 
Ethyl 3-deoxy-D-manno-2-octulopyranosonate (10) Compound 9 (427.1 mg, 1.233 mmol) was 
dissolved in AcOH (0.9 mL) and H2O (0.1 mL) and heated to 90°C for 1 h. The solution was cooled 
down to r.t., evaporated in vacuo and the resulting yellow oil was purified using silica-flash column 
chromatography (0%  10% MeOH in DCM) to yield compound 10 (284.0 mg, 1.067 mmol, 87%).  
Major anomer: TLC: (MeOH:DCM, 20:80 v/v) Rf = 0.33. 1H-NMR (500 MHz, CD3OD): δ 4.31 – 4.19 (m, 
2H, CH2, OEt), 4.05 – 3.99 (m, 2H, H-4, H-5), 3.94 – 3.84 (m, 2H, H-6, H-7), 3.77 (dd, J = 11.7, 3.1 Hz, 
1H, H-8a), 3.64 (dd, J = 11.7, 5.0 Hz, 1H, H-8b), 2.18 – 2.11 (m, 1H, H-3eq), 1.87 (dd, J = 12.6, 4.2 Hz, 1H, 
H-3ax), 1.38 – 1.24 (m, 3H, CH3, OEt), 13C-NMR (500 MHz, CD3OD): δ 172.01 (C-1), 95.34 (C-2), 71.48 
(C-6), 69.37 (C-7), 66.54 (C-5), 66.09 (C-4), 63.34 (C-8), 61.52 (CH2, OEt), 33.31 (C-3), 13.04 (CH3, OEt); 
HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C10H18O8Na, 289.08994; found, 289.08993.  
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Ethyl [2,4,5,7,8-O-acetyl]-3-deoxy-D-manno-2-octulopyranosonate (11) Compound 10 (113.4 mg, 
0.426 mmol) was dissolved in a solution of pyr and Ac2O (2:1, 9 mL, 0.047 M). The solution was 
stirred overnight at r.t., after it was evaporated in vacuo. The residue was dissolved in EtOAc and 
washed with aqueous 1M HCl. The aqueous mixture was extracted with EtOAc. The combined 
organic layers were dried with MgSO4, filtered and evaporated  to yield compound 11 (191.2 mg, 
0.401 mmol, 94%). HR-ESI-TOF/MS (m/z): [M+Na]+ calcd. for C20H28O13Na, 499.14276; found, 
499.14185; 
α-anomer: TLC: (EtOAc:Hept, 50:50 v/v) Rf = 0.50. 1H-NMR (500 MHz, CDCl3): δ 5.43 – 5.37 (m, 1H, H-
6), 5.28 – 5.19 (m, 1H, H-7), 5.14 (ddd, J = 7.2, 2.5, 1.6 Hz, 1H, H-4), 4.58 (t, J = 2.8 Hz, 1H, H-5), 4.43 – 
4.34 (m, 1H, H-8a), 4.29 – 4.17 (m, 3H, H-8b; CH2, OEt), 2.89 – 2.77 (m, 1H, H-3eq), 2.52 – 2.45 (m, 1H, 
H-3ax), 2.16 – 1.99 (m, 15H, 5x CH3, OAc), 1.38 – 1.22 (m, 3H, CH3, OEt); 13C-NMR (126 MHz, CDCl3): δ 
170.82 – 165.40 (m, 5x CH3, OAc; C-1), 104.08 (q, J = 4.4 Hz, C-2), 86.19 – 84.83 (m, C-5), 74.24 (dt, J = 
157.5, 4.7 Hz, C-4), 70.50 (dq, J = 149.8, 3.2 Hz, C-7), 69.99 (d, J = 148.5 Hz, C-6), 63.67 – 61.09 (m, 
CH2, OEt),61.46 (tt, J = 149.9, 3.1 Hz, C-8), 40.41 (dd, J = 140.1, 133.5 Hz, C-3), 23.88 – 19.00 (m, 5x 
CH3, OAc), 13.98 (CH3, OEt). 
β-anomer: TLC: (EtOAc/Hept, 50%/50%): Rf=0.50; 1H-NMR (500 MHz, CDCl3) δ 5.36 – 5.30 (m, 1H, H-
6), 5.28 – 5.19 (m, 2H, H-4; H-7), 4.51 (dd, J = 5.9, 4.2 Hz, 1H, H-5), 4.46 (dd, J = 12.3, 2.3 Hz, 1H, H-8a), 
4.29 – 4.17 (m, 2H, CH2, OEt), 4.12 (dd, J = 12.4, 3.9 Hz, 1H, H-8b), 2.89 – 2.77 (m, 1H, H-3eq), 2.52 – 
2.45 (m, 1H, H-3ax), 2.16 – 1.99 (m, 15H, 5x CH3, OAc), 1.38 – 1.22 (m, 3H, CH3, OEt); 13C-NMR (126 
MHz, CDCl3) δ 170.82 – 165.40 (m, 5x CH3, OAc; C-1), 106.15 (t, J = 4.7 Hz, C-2), 85.06 – 83.70 (m, C-
5), 73.03 (dt, J = 157.3, 5.8 Hz, C-4), 70.34 (d, J = 149.7 Hz, C-6), 67.37 (ddd, J = 150.0, 6.0, 2.4 Hz, C-
7), 66.02 (dq, J = 148.5, 5.9 Hz, C-6), 63.67 – 61.09 (m, CH2, OEt), 62.19 (t, J = 149.9, 2.2 Hz, C-8), 
42.02 (dd, J = 139.0, 135.1 Hz, C-3), 23.88 – 19.00 (m, 5x CH3, OAc), 13.98 (CH3, OEt).  
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Statistical Analysis 
* = p <0.05, ** = p <0.01, *** = p <0.001 
Figures 2 and 3: 2-way ANOVA with Bonferroni post-tests  
Figures 4: 1-way ANOVA with Dunnett post-test. Statistical significance in comparison to control. 
Figures 5 and 6: 1-way ANOVA with Dunnett post-test to DMSO. 
 
 
Contributions 
Synthesis and molecular design done by Heise T and his student: Moons P1. The biological testing 
and statistic was performed by Langereis JD2. 
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Part 4 
 
Summary, Conclusion and 
Perspectives 
 
 
“Who can say which great gift imparted to mankind may not be misused and turned 
to destructive purposes? The danger lurks not only in scientific things. Who has not 
seen the benign gifts of literature, history, and, one might add, journalism so 
travestied or construed as to lash emotional peoples to fury? Each gift assumes in 
the user a beneficent sense of responsibility. What less can we ask?” 
Norman Haworth (1883-1950), famous for his work  
on carbohydrates and vitamin C. 
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Summary 
The introduction started by giving background information on sialic acids in general. 
From a chemical perspective, sialic acid monosaccharides seem to be rather simple 
structures. They however tend to surprise with a long list of synthetic challenges that 
make sialic acid monosaccharides sometimes harder to handle than far larger 
molecules such as oligosaccharides. Low alcohol reactivity, high polarity, generally 
difficult purifications, intrinsic instability under basic or acidic conditions, 
decarboxylation under heat, at least six chiral centers that might change upon alcohol 
modification and multiple positions prone to elimination reactions are only a few 
challenges. Ways were discovered to circumvent these challenges, some examples are 
listed in Chapter 1. While the first chapter of the introduction focused on the chemical 
methods to alter sialic acids with small modifications, the second Chapter 2 discussed 
the effect of those modifications in a biological setting by describing their increased 
binding affinity towards Siglecs. To study the biological effect of small chemical 
alterations of sialic acid molecules, new tools and synthetic routes were needed and in 
this thesis several new and reliable routes for sialic acid modification are described.  
The second part focused on metabolic engineering. Direct modifications of sialic acids 
were found to be highly beneficial even though synthetically more challenging 
compared to the usually used mannosamine modifications. The simple and 
reproducible synthesis of C-5 Poc delivered multiple grams of a new metabolic 
engineering reagent which was more efficient than the frequently used N-
acetylmannosamine derivatives. Also we found that mannosamines can sometimes be 
less selective than sialic acid derivatives for MOE and we used our new SiaNPoc for the 
detection of a genetic disease (Chapter 3). SiaNPoc was further used for chemical 
engineering of the cell surface or secreted proteins to provoke functional effects. The 
on-cell synthesis of high affinity Siglec ligands (Chapter 4) showed the potency of 
metabolic engineering in creating living microarrays. We found several new ligands by 
rational design and showed that the on-cell ligands could be used to inhibit in trans 
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immune activation. The simplicity of this approach that allowed high-throughput 
screening was a major advantage compared to available microarrays. The synthesis of 
C-9, C-7, C-4 and C-3 azide sialic acids (Chapter 5) was the crucial first step to prepare 
a way for high-affinity Siglecs on other sialic acid positions than C-5. We were only 
beginning to investigate all new metabolic labeling reagents, but the preliminary data 
already showed promising results. Modifications on all positions except C-2 were 
tolerated by the biosynthetic machinery and the chemical group attached, e.g. 
acetamides or carbamates, was found to have a high impact on incorporation and 
therefore on enzyme recognition. We discovered that this difference was not restricted 
to biosynthetic enzymes but affected neuraminidases as well. The Poc linkage seemed 
to confer neuraminidase resistance to cells (Chapter 6). The biological consequence 
was demonstrated by trapping neuraminidase-dependent influenza virus.  
While the second part mainly focused on the beneficial effects of sialylation, sialylation 
was found to be disadvantageous in cancer or pathogenic infections. The third part 
therefore concentrated on glycosylation-inhibition. The previous chapters made it 
obvious that recognition of sialic acids by the biosynthetic machinery highly depends 
on the chemical groups at the carbon skeleton. We therefore modified the previously 
known fluorinated sialic acid inhibitor at the C-4, C-5 and C-9 position and found C-5 
carbamates to be more potent inhibitors of sialylation than the reported C-5 acetamide 
(Chapter 7). This led to an increase in potency, especially on cancer cells, which was in 
line with our findings for labeling. In order to apply sialic acid labeling and inhibition in 
non-human settings, deprotected versions of our sialic acids were synthesized that 
could be actively taken up by bacteria such as NTHi (Chapter 8). This enabled the 
monitoring of sialic acid transfer from human to bacterial cells and use of the inhibitor 
as indirect antibiotic by decreasing sialic acid dependent serum resistance. We applied 
the inhibition strategy for the bacterial saccharide KDO that forms the basis of every 
gram-negative membrane. Fluorination was envisioned to yield a KDO-based inhibitor 
that could serve as antibiotic against gram-negative infections by blocking LPS 
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synthesis (Chapter 9). While successfully applied, the KDO inhibitor suffered from 
lower uptake compared to sialic acid derivatives. 
 
Conclusion 
One overall-conclusion that might be demonstrated by all these different results 
including efficient cell labeling, autoimmune-suppression, cancer therapeutics, viral 
resistance and antibacterial agents is the variety of applications enabled by modified 
sialic acids. This tremendous diversity of functions led me to a personal conclusion that 
sialic acids are one of the most underestimated molecules in life and that they hold 
immense potential as lead structure for therapeutics. 
More specifically: metabolic engineering with carbamate functionalities did not seem 
to have any adverse effects in vivo (Chapter 3). While the perfect modification might 
not have been found yet, it was clearly demonstrated in vitro that modified sialic acids 
were beneficial in cases of undesired immune activity (Chapter 4). Interestingly, the 
carbamate functionality did lead to neuraminidase resistance and showed viral 
resistance (Chapter 6). The neuraminidase resistance also inhibited sialic acid transfer 
to NTHi (Chapter 8). Still, more investigation is needed to compare the effect of 
modifications at different positions of sialic acid, as their biological impact seemed to 
differ (Chapter 5). All of these results were in line with the current theory that humans 
evolved to present acetyl instead of glycolyl sialic acids to avoid some pathogenic 
infections even though sacrificing some of the sialic acid immune inhibition.1 The 
difference in recognition at C-5 did show a higher affinity of the sialic acid biosynthetic 
machinery towards carbamates over acetamides for glycoengineering (Chapter 3) as 
well as for sialylation inhibition (Chapter 7). While it is likely that this difference reflects 
a higher affinity towards sialyltransferases, this cannot be definitely proven by the 
experiments performed. The experiments on KDO demonstrated that some of the 
principles applied for sialic acids may be used for other saccharides as well (Chapter 9) 
and might result in different classes of inhibitor-based antibiotics.  
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Perspectives 
In the near future, the number of metabolic engineering reagents should be expanded. 
Not every position of sialic acid has been investigated with different chemical groups 
yet. While not possible due to time restrains, with a synthetic procedure as described 
in Chapter 5 it should be possible to test all sialic acid positions for other chemical 
groups such as carbamates, but also for groups not evaluated yet e.g. thiourea- or 
guanidyl-groups. This of course includes the same modifications on fluorinated sialic 
acids. All Siglec experiments should be repeated with other to search for new, perhaps 
more selective Siglec-ligands. While time restraints only allowed more complex in vitro 
experiments for Chapter 4, it would be interesting to investigate whether the Siglec 
attenuation would hold in a therapeutic setting against autoimmune-diseases. 
Experiments to use whole cells or sialylated proteins like mucins or polysialic acid are 
currently underway towards this goal. The KDO inhibitor in Chapter 9 was 
unfortunately only effective at high concentrations; we were challenged by the low 
permeability of the bacterial membrane, which clearly needs improvement in form of 
active uptake. A combination with other sugars, actively taken up by bacteria might 
increase the efficiency. Sialic acids however were successfully taken up by bacteria and 
could be used as Siglec-ligands as well. It would be interesting to see, if their serum 
resistance could be enhanced via glycoengineering. The potential of Poc-sialic acid or 
its successors for metabolic glycoengineering is, however, not fully exploited. Given its 
beneficial Siglec-binding, neuraminidase resistance and antiviral potential could be 
used to speed up evolution. The last evolutionary change from glycolyl to acetyl sialic 
acid helped humans against viral attack, but left them prone to autoimmune diseases.1 
While it might have been a beneficial evolution, the viral proteins have adapted to the 
change. A change towards artificial sialic acids might render humans (or other 
mammals) immune to viral attack, provide higher resistance against some bacteria and 
would increase Siglec binding therefore reduce oxidative stress and even decrease 
aging.2 This is however a perspective for the far future and should be carefully 
investigated before humans take their sialic acid evolution into their own hands. 
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Commonly used abbreviations
Ac  Acetyl 
Ac2O  Acetic anhydride  
Acet  Acetone 
ACN   Acetonitrile 
AIBN  Azobisisobutyronitrile 
Alloc  Allyloxycarbonyl 
aq.  Aqueous 
Az  Azido acetyl 
Azeoc  2-azidoethanyloxycarbonyl 
AzOSu   Azidoacetic acid -
hydroxysuccinimide ester 
BCR B-Cell antigen receptor 
BF3•Et2O  Boron trifluoride etherate 
Boc  Tert-butyloxycarbonyl 
BPA  Biphenyl acetyl 
BPC   Biphenyl carbonyl 
bpy  Bipyridyl 
Bz  Benzoyl 
CAN  Cerum ammonium nitrate 
Cbz  Carboxybenzyl 
CD3OD  Deuterated methanol 
CDCl3  Deuterated chloroform 
CMAS  CMP-Sia synthetase 
CMP  Cytidine monophosphate 
COPD chronic obstructive pulmonary 
disease 
Cp  Cyclopentadienyl 
CSA  Camphorsulfonic acid 
CuAAC  Copper-catalyzed azide–alkyne 
cycloaddition 
D2O  Deuterium oxide 
DABCO 1,4-Diazabicyclo[2.2.2]octane 
DAMP  Danger-associated molecular 
patterns 
DANA  Acetyl-2,3-dehydro-2-
deoxyneuraminic acid 
DBU  1,8-Diazabicyclo(5.4.0)undec-
7-ene 
DCM   Dichloromethane 
DCM   Dichloromethane 
DCs Dendritic cells 
DDQ  2,3-Dichloro-5,6-dicyano-1,4-
benzochinone 
DEAD  Diethyl azodicarboxylate 
Diox  Dioxane 
DiPEA  Diisopropylethylamine 
DMAP  Dimethylaminopyridine 
DMF  N,N-Dimethylformamide 
DMP  Dess-Martin periodinane 
DMSO  Dimethylsulfoxide 
EtOAc  Ethyl acetate 
Gc Glycolyl 
GFP Green fluorescent protein 
GMP  Guanosine monophosphate 
GNE  UDP-GlcNAc 2-Epimerase/ 
ManNAc Kinase 
GVHD  Graft-Versus-Host Disease  
HDMS  Bis(trimethylsilyl)amine 
IP  Isopropylidene 
iPr  Isopropyl 
ITIM Immunoreceptor tyrosine-
based inhibition motif 
IVA Influenza virus strain A 
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KDN  2-Keto-3-deoxy-D-glycero-D-
galactonononic acid 
KDO Keto-deoxyoctulosonate 
LiHMDS: Lithium hexamethyldisilazide 
LPS Lipopolysaccharide 
MAG Myelin-associated 
glycoprotein 
MAL  Maackia Amurensis  
MCPBA  Meta-chloroperoxybenzoic 
acid 
MDR Multidrug resistant 
MeOH   Methanol 
MOE Metabolic oligosaccharide 
engineering 
MsCl  Methanesulfonyl chloride 
NANS Sialic acid synthase 
NBS  N-Bromosuccinimide 
Neu5Ac N-acetylneuraminic acid 
NIS  N-Iodosuccinimide 
NKs Natural killer cells 
NMR  Nuclear magnetic resonance 
NPC  Nuclear pore complex 
NTHi Nontypeable Haemophilus 
influenzae 
OSu   Hydroxysuccinimide 
PDC  Pyridinium dichromate 
Ph  Phenyl 
PMB  4-Methoxybenzyl ether 
PNA  Peanut agglutinin 
Poc  Propargylcarboxycarbonyl 
Pyr  Pyridine 
r.t.  Room temperature 
SAda  Adamantyl-thiol 
SAM  Sialic Acid Mimetic 
sat.  Saturated 
SIAE  Sialic acid acetylesterase 
Siglec  Sialic acid-binding 
immunoglobulin like lectin 
SNA  Sambucus nigra 
ST  Sialic acid transferase 
STD  Saturation transfer-difference 
STol  4-methylthiophenol 
Su  Succinimide 
TBAB  Tetrabutylammoniumbromide  
TBAF  Tetrabutylammoniumfluoride 
TBS  tert-Butyldimethylsilyl 
TBTA  Tris(benzyltriazolyl 
methyl)amine 
tBu  tert-butyl 
TCBC  2,4,6-Trichlorobenzoic acid 
TEA  Triethylamine 
TEMPO  2,2,6,6-
Tetramethylpiperidinyloxyl 
Tf  Triflate 
TFA  Trifluoroacetic acid 
TFA  Trifluoroacetic acid 
TFAA   Trifluoroacetic acid anhydride 
THF  Tetrahydrofuran 
TMS  Trimethylsilyl 
TMSOTf Trimethylsilyl 
trifluoromethanesulfonate 
Tol  Toluene 
TRAP Tripartite ATP-independent 
periplasmic 
Troc  2,2,2 trichloroethoxycarbonyl 
TsCl  Toluenesulfonyl chloride 
TTBP  2,4,6-Tri-tert-butylpyrimidine 
TTMS  Tris(trimethylsilyl)silane 
UDP  Uridine diphosphate 
 
 
  
316 
 
 
Acknowledgements 
 
Research can never be carried out alone and I would like to thank everyone that helped 
me during the four year journey of my PhD.  
Floris: I admire your incredible knowledge about chemistry and was happy to learn 
from you already during my study but also during my PhD. Despite of having so many 
tasks to perform, you did not hesitate to offer help when help was needed most.  
Thomas: We have been on a long journey together that now comes to an end. Being 
your first student when you started your postdoc was my first contact with glyco-
chemistry and I had the chance to learn a lot from you. I think we shared success and 
challenges and I would like to thank you for this opportunity. I wish you good fortune 
for the times to come.  
Also I would like to thank the doctoral thesis committee consisting of Prof. Dr. Rita 
Gerardy-Schahn, Prof. Dr. Roeland J.M. Nolte and Prof. Dr. Steven Verhelst for taking 
their time to read my thesis. 
Before continuing, I would like to highlight the incredible work done by my students. 
Not all of your work has found its way into this thesis and only a small part can be 
published but you all can be sure, that it is not forgotten. The supervision of students, 
thinking about new projects and teaching them how to realize these projects was the 
part of my PhD that I valued most. I enjoyed having you and sincerely hope that you 
learned from me as much as I learned from you. I secretly think, that I have played a 
bigger role in your future careers then you might realize now. I am proud to have 
helped so many great upcoming scientists on their way and I am sure to hear or read 
about you in the future. I would like to thank all of my students for their work and the 
next section describes their work chronologically: 
317 
 
 
Wobbe: I can imagine that your first internship under my strict supervision must have 
been an overwhelming task but you managed it. While your approach in KDO synthesis 
might not have led to the desired outcome, I hope you have learned a lot, not only 
about KDO but about organic chemistry in general. 
Guido: Your work on fluorinated heptoses was unfortunately never completed and is 
therefore not mentioned in this thesis. However, I do not think this will bother you too 
much, because you already had a very clear picture of your future in mind and it was 
not in academia. While you are now happily doing something quite different, I still hope 
that your internship was a useful experience. 
Victor: You accompanied me for quite a while being my first bachelor and master 
student and now you even joined the group as PhD-student. With two publications 
carrying your name, I think we can objectively say that you had a successful internship 
(Chapter 4). I enjoyed having you as a student not only because of your scientific 
qualities but also because of your kind and generous nature. I saw your abilities grow 
over the years and I am sure, that you will successfully finish your PhD in a few years, 
without any troubles and even more publications carrying your name. 
Johan: I had a good time with our little Heise-subgroup and while not all our ideas 
worked out as planned, I am sure you are proud of your achievements and rightly so. 
Initially quite stubborn you tried your own routes during your bachelor even against 
advice and failed. But you tried, failed and learned, which is probably the most 
important ability of a scientist. Not at all discouraged, you stayed with me for your 
master internship and (even though you might not have noticed yourself) learned to 
follow mine, and eventually to support your own ideas. You were rewarded with at 
least one article and even a patent (Chapters 4 & 7). I say at least because I am sure 
that your second article will be accepted soon with many of your own to follow. While 
other routes like selective inhibitors or the C-9 modifications were less fruitful, you 
now have the opportunity to continue and improve those ideas. You, Emiel and Sam 
318 
 
 
were chosen to follow up my project and of course expand it. I could not think of better 
students to challenge this task and wish you good luck for the future! 
Emiel: Being a smart and hard worker I sometimes thought you might be disappointed 
to see so few of your work being published. Our idea to synthesize the unprotected 
glycoengineering tools and inhibitors enzymatically was unfortunately less successful. 
I think we both learned from this that enzymes in the hand of a chemist are less reliable 
and sometimes just stop working. In the end, chemical synthesis was faster than the 
enzymatic approach. Still, you can be proud of at least one, hopefully two good articles 
by now (Chapters 6 & 8). I would really have liked to show more of your work to give 
you credit for all of your projects but as you know, most of them did not reach the final 
stage. Still, I would like to mention our work on the synthesis of UDP sugars, I hope 
someone can use them. While I have (as usually) no idea how far our colleagues have 
come with their MS tools, I am sure they will not forget your work on isotope-labeled 
sugars. I always liked discussing new ideas with you as you were usually  most 
enthusiastic about it and ready to take the ideas into the lab. While our on-cell 
dendrimers may stay an idea in our heads, your C-5 modified sialic acid labeling tools 
will surely be used and published someday and can already be seen in Chapter 5. Last 
but not least, we both regret that the on-cell boronic acid click did not work out as 
planned but I guess that this is how science works. As said before, you, Johan and Sam 
will surely continue my project with great enthusiasm and ability and I have no doubt 
that good results will follow.  
Peter: Challenged with the task to synthesize KDO inhibitors and even more challenged 
in your life outside of the lab you managed to deal with all problems and your work 
can now be read in Chapter 9. You can be proud of what you achieved. Your talent in 
organizing and planning might not have accelerated your research but I am sure it will 
help you in your future career and hopefully, your first article will be published soon. 
You are a smart and skilled scientist. While we might not have worked in your most 
319 
 
 
pleasant time of life I still hope you enjoyed working for me and learned something for 
your future. 
Lotte: Being the fourth out of four students that came to me for their bachelor 
internship and continued to stay with me for their master internship I can't have been 
the most terrible supervisor. That does not take away the fact that you at times were 
quite unlucky with the task that I gave you during your master. Starting with the 
synthesis of different azide ligands during your bachelor, you managed to synthesize 
an impressive library and were rewarded with your name on our article (Chapter 4). 
You may not have imagined how challenging the route to a few modified sialic acids 
could be. Synthesis that looked good on paper became surprisingly difficult and the 
sialic acids just did not behave as they should. However, after months of hard work you 
managed to produce one and nearly both of your target products eventually during the 
last days of your internship. I hope, I did not only teach you how tedious and frustrating 
science can be but also how you can stick to a problem and in the end solve it. With 
the knowledge of today we could probably have synthesized the product in a few 
weeks but instead of being frustrated about this we should just call it a scientific 
advance. You did find a way that will help others and your results can be found in 
Chapter 5 were you synthesized C-7, -8 and -9 modified sialic acids. Besides being a 
good student, I was really glad to have you around to listen to my daily struggles, fights 
with chemistry or other matters. I am sure that your assertiveness will even grow and 
help you to find your way in your career and your life in general. 
Jordi: While synthesis was not always easy, your results on selective or response 
triggered glycoengineering as well as your work on fucose will surely find some 
application or publication in the future. Unfortunately, as the biological data had not 
been gathered by the time of writing or was regarded confidential, the chapter about 
fucose did not make it into the thesis. I know that you would have liked to see it here 
but I am sure that other opportunities will follow. Your unshakeable optimism and 
enthusiasm about science will help you in your career and the success will come. 
320 
 
 
Of course I would like to specially thank my paranymphs Ivan and Rens, we will stay in 
touch! 
Rens: It has been a long way but we are at the finish! Difficult reactions, teaching the 
practical courses and correcting exams were part of it but also traveling around the 
world for conferences, games and success. Actually, we can be happy to still be here, 
with the taxi driver falling asleep on a mountain-street and all those reactions which 
could have gone wrong but luckily didn't. Standing together in the lab for four years 
we have seen good and bad things happen and helped us through the challenges of 
the PhD. I was happy to have you around. 
Ivan: You have been there to share thoughts and of course our lunch-meal when we 
walked to the Refter or hospital. It  was happy to have a friendly ear to talk to and give 
advice when needed. I am still puzzled that you can eat your soup, main-dish and fancy 
cake faster than I can eat a single dish by the way. Jumping between crazy and very 
serious, it is never boring to have you around. Good luck in finishing your thesis! 
I could write multiple pages here for everyone but in order to keep the page limit I have 
to summarize a little bit.  
The Boltje-Boys (and girls): We had fun-times like on the Christmas-market in Cologne, 
several symposia and of course ongoing gaming-evenings. When reactions were not as 
successful as hoped you helped with advice or motivation. In the end, we agreed to 
disagree about our music choice and neither "Gebroeder Scooter" nor "Schlagermusik" 
or "Jodelgesang" will ever become my favorite music but I did learn to tolerate it. 
Unfortunately the general interest in chess matches declined but if someone wants to 
try again, I'm still happy to accept the challenge. ;) We will surely see each other in the 
future and I'm looking forward to do so, perhaps at the next Heise-barbeque? 
Sam: I should not forget to thank you for writing your literature thesis. You will see, 
that some of it has found its way into Chapter 1 and will hopefully become a review 
someday. While I cannot claim that I share your taste in music, I sometimes count you 
321 
 
 
a little bit as my student. Even though Rens might disagree. You did not only write a 
literature thesis about sialic acids, but will continue my project together with Johan 
and Emiel as well. I wish you success with that!  
Hidde: Your little voyage into biology shall not be forgotten, the inhibitors that you 
tested are mentioned in Chapter 7. I would say, that your PhD will go smooth and 
without any troubles but why stating something that you know already? We will surely 
have a Dominion rematch soon. 
I would like to thank the rest and former members of the Boltje-group for the great 
time: Daan, Elko, Femke, Jeroen, Joëlle, Kim, Laura, Maik, Maurits, Nathalie, Nick,  
Oscar, Sander, Stijn, Stephanie, Tim, Timo, Wilke.  
Christian: I am glad for our collaboration that enabled so many interesting projects and 
you really built a bridge across the street connecting our synthesis with the pure 
biologists. I did learn a lot from your experience not only how to handle cells in the lab 
and do click chemistry on-cells or how to attach lectins and Siglecs, but you also taught 
me a little bit how biologists think. Besides work, we should really continue our Skat/ 
Durak club and I enjoyed our trips to Australia and the USA.   
Niek, Estel, Daniëlle: As Christians students you really did a wonderful work in building 
computational models and growing cells for our compounds. Thanks for your work! 
Gosse: I learned a lot from you. Maybe only small pieces of your immunological 
expertise but also how science works, tactics and strategies to deal with manuscripts. 
You also helped me to understand how biologists see our research and taught me to 
see different perspectives. 
Alejandra: Who would have thought that four years pass by so quickly? I still haven't 
found to time to learn Spanish (and I do admit your German has become much better).  
Thanks for helping me with many things and of course to lend me an ear now and then. 
Good luck with the last tasks of your own PhD! 
322 
 
 
Dani: You really are the helping hand for anyone in trouble. Whatever problem it is, 
people would come to you and expect you to solve it. This might sometimes become 
tedious but I think you should be proud of the trust everyone has in you. Anyway, I 
would like to thank you for your help. 
I would like to thank the rest of the Rutjes- and van Hest-group: Abbas (you are always 
so kind and make the best Iraqi soup that I know), Anika, Annika, Bastiaan, Bram, 
Britta, Caroline, Daniël, Danny, David, Eduardo, Fleur, Freek, Imke, Joep, Julia, Lise, 
Lianne, Marcel, Maria, Matthijs, Nanda, Paloma, Pascal, Peter, René, Ruud, Saskia, 
Selma, Stefan and also the secretaries and technical staff-members: Jacky, Marieke, 
Desiree, Paula, Peter vD, Jan, Peter vG, Helene, Ad, Paul S. and of course Paul W (I 
miss your NMR-knowledge already!). Thanks to our mass-spec collaboration: Angel, 
Dirk, Esther H, Monique R, Monique vS and Walinka. Again I would like to thank Tom 
for the pictures used in my thesis. (Still frames taken and modified from “Glycoscience: 
illuminating the secret world of your glycans”, produced by Sensu on behalf of Utrecht 
University.) Also special thanks to all people that I forgot to mention!  
Being so caught up in my research for such a long period and not having time for much 
else is not always easy for the loved ones and I would therefore like to end this section  
by thanking  Sarah for enduring all my moods after failed reactions, rejected articles 
and various challenges. The same holds for my family Günther, Elisabeth, Gunnar, 
Daniela, Jana, Olga and Enya as well as my in-laws family Manfred, Edith, Helmut und 
Adele. 
 
 
  
323 
 
 
About the Author 
 
Torben Heise was born on the 25th of August, 1986 in Bünde, Germany. After school 
education at “Gymnasium am Markt” he served in civilian service followed by 
community service in Lukas-hospital (department of trauma surgery). Continuing in the 
medical direction he completed the pre-semester course medicine at the IFBM, 
Cologne, in 2008 before studying Molecular Life Science at the Radboud University. 
Being selected for the Radboud Honours Academy, he and his colleagues wrote a 
research proposal for cancer therapy “Crossing the Blood-Brain Barrier with 
Polymersomes for Targeted Drug Delivery Against Brain Cancer”. Financed by the 
Radboud Honours Academy he was allowed to implement his own research proposal 
“Development of new Peptoid based Antibiotics to target Multi-resistant Bacteria” in 
the lab of Prof. Jan van Hest and continued the project at New York University, United 
States in the lab of Prof. Kent Kirshenbaum. After his first master internship 
“Development of a General Modular Strategy towards Sialylated Glycans” in the lab of 
Prof. Floris Rutjes and under the supervision of Dr. Thomas Boltje, he continued his 
master at the Ruprecht-Karls-Universität Heidelberg, Germany, under the supervision 
of Dr. Christoph Nitsche with the project “Synthesis of Peptide-based Inhibitors of 
Dengue Virus NS3 Protease” in the lab of Prof. Christian Klein. After his master in 2013 
he continued in academia as PhD-student, joining the newly formed Boltje-research 
group as sub-group of the Rutjes synthetic organic chemistry lab. Since December 
2017, he joined the Chemical Biology and Drug Discovery group of Prof. Roland Pieters 
at Utrecht University as postdoctoral researcher. 
  
324 
 
 
List of publications 
 
1. Boltje TJ*, Heise T, Rutjes FPJT, van Delft FL. A Divergent Method to Prepare 5-
Amino-, 5-N-Acetamido-, and 5-N-Glycolylsialosides. European Journal of 
Organic Chemistry, 2013, 24, 5257-5261 
 
2. Riemersma M, Sandrock J, Boltje TJ, Büll C, Heise T, Ashikov A, Adema GJ, van 
Bokhoven H, Lefeber DJ. Disease mutations in CMP-sialic acid transporter 
SLC35A1 result in abnormal alpha-dystroglycan O-mannosylation, independent 
from sialic acid. Human Molecular Genetics, 2014, 24, 2241-2246 
 
3. Heise T#, Büll C#, Beurskens DM, Riemersma M, Ashikov A, Rutjes FPJT, van 
Kuppevelt TH, Lefeber DJ, den Brok MH, Adema GJ*, Boltje TJ*. Sialic Acid 
Glycoengineering Using an Unnatural Sialic Acid for the Detection of Sialoglycan 
Biosynthesis Defects and On-Cell Synthesis of Siglec Ligands. ACS chemical 
biology, 2015, 10, 2353-2363 
 
4. Heise T#, Büll C#, Adema GJ*, Boltje TJ*. Sialic Acid Mimetics to Target the Sialic 
Acid-Siglec Axis. Trends in Biochemical Sciences, 2016, 41, 519-531 
 
5. van Karnebeek CD, Bonafé L, Wen XY, Tarailo-Graovac M, Balzano S, Royer-
Bertrand B, Ashikov A, Garavelli L, Mammi I, Turolla L, Breen C, Donnai D, 
Cormier V, Heron D, Nishimura G, Uchikawa S, Campos-Xavier B, Rossi A, Hennet 
T, Brand-Arzamendi K, Rozmus J, Harshman K, Stevenson BJ, Girardi E, Superti-
Furga G, Dewan T, Collingridge A, Halparin J, Ross CJ, van Allen MI, Rossi A, 
Engelke UF, Kluijtmans LA, van der Heeft E, Renkema H, de Brouwer A, Huijben 
K, Zijlstra F, Heise T, Boltje T, Wasserman WW, Rivolta C, Unger S, Lefeber DJ, 
Wevers RA, Superti-Furga A. NANS-mediated synthesis of sialic acid is required 
for brain and skeletal development. Nature Genetics, 2016, 48, 777-784 
 
6. Büll C, Collado-Camps E, Kers-Rebel ED, Heise T, Søndergaard JN, den Brok MH, 
Schulte BM, Boltje TJ, Adema GJ. Metabolic sialic acid blockade lowers the 
activation threshold of moDCs for TLR stimulation. Immunology and Cell 
Biology, 2017, 95, 408-415 
 
 
 
325 
 
 
7. Heise T#, Büll C#, van Hilten N, Pijnenborg JF, Bloemendal VRLJ, Gerrits L, Kers-
Rebel ED, Ritschel T, den Brok MH, Adema GJ*, Boltje TJ*. Steering Siglec-Sialic 
Acid Interactions on Living Cells using Bioorthogonal Chemistry. Angewandte 
Chemie, Int. Ed., 2017, 56, 3309-3313 
 
8. Heise T#, Büll C#, Beurskens DM, Rossing E, de Jonge MI, Adema GJ, Boltje TJ*, 
Langereis JD*. Metabolic Oligosaccharide Engineering with Alkyne Sialic Acids 
Confers Neuraminidase Resistance and Inhibits Influenza Reproduction. 
Bioconjugate chemistry, 2017, 28, 1811-1815 
 
9. Büll C, Boltje TJ#, Balneger N#, Weischer S, Wassink M, van Gernst J, Bloemendal 
VRLJ, Boon L, van der Vlag J, Heise T, den Brok MH, Adema GJ. Sialic acid 
blockade suppresses tumor growth by enhancing T cell-mediated tumor 
immunity. Cancer Research, 2018. 
 
10. Heise T#, Langereis JD*#, Rossing E, De Jonge ML, Adema GJ, Büll C, Boltje TJ*. 
Selective inhibition of sialic acid-based molecular mimicry in Haemophilus 
influenzae abrogates serum resistance. Cell chemical biology, CELL-CHEMICAL-
BIOLOGY-D-17-00411R2. 
 
 
 
 
Other publications or patents 
  
11. Heise T#, Büll C#, Boltje TJ*, Adema GJ*. Hitting the sweet spot: Sialic acid sugars 
for the treatment of immune diseases and other disorders? Atlas of Science, 
2016. 
 
12. Boltje TJ, Heise T, Pijnenborg JFA, Büll C, Adema GJ. NEW POTENT 
SIALYLTRANSFERASE INHIBITORS. European patent, Date of filing 29.01.18, 
P6068109EP 
 
 
 
  
326 
 
 
Manuscripts submitted or in preparation 
 
13. van den Bijgaart RJE, Kroesen M, Wassink M, Brok IC, Kers-Rebel ED, Boon L, 
Heise T, Boltje TJ, den Brok MH, Hoogerbrugge PM, Büll C, Adema GJ*. 
Combined sialic acid and HDAC inhibitor treatment upregulates the 
neuroblastoma antigen GD2. Under review, JBC-ID: JBC/2018/002763. 
 
14. Heise T, Pijnenborg JFA, Büll C, Kers-Rebel ED, Balneger N, Elferink H, Adema GJ, 
Boltje TJ*. Potent Metabolic Sialyltransferase Inhibitors Based on C-5 Modified 
Sialic Acid Derivatives. Under review,  J.Med.Chem.-ID: jm-2018-00531d. 
 
15. Heise T; Moons S; Boltje TJ. Recent Advances in the Chemical Modification of 
Sialic Acid. Manuscript in preparation. 
 
16. Heise T, Gerrits L, Rossing E, Büll C, Adema GJ, Boltje TJ*. Synthesis and 
Evaluation of Sialic Acid Derivatives for Metabolic Glycoengineering.  
Manuscript in preparation.  
 
17. Heise T, Langereis JD, Moons P, De Jonge MI, Boltje TJ*. Synthesis and 
Evaluation of Fluorinated KDO Analogs as Inhibitors of LPS Biosynthesis. 
Manuscript in preparation. 
 
 
#  Shared authorship, * (co)corresponding author  
 
 
 
 
 
 
 
